<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="review-article" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Bioeng. Biotechnol.</journal-id>
<journal-title>Frontiers in Bioengineering and Biotechnology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Bioeng. Biotechnol.</abbrev-journal-title>
<issn pub-type="epub">2296-4185</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">1191327</article-id>
<article-id pub-id-type="doi">10.3389/fbioe.2023.1191327</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Bioengineering and Biotechnology</subject>
<subj-group>
<subject>Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Nanomedical research and development in Spain: improving the treatment of diseases from the nanoscale</article-title>
<alt-title alt-title-type="left-running-head">Fern&#xe1;ndez-G&#xf3;mez et al.</alt-title>
<alt-title alt-title-type="right-running-head">
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fbioe.2023.1191327">10.3389/fbioe.2023.1191327</ext-link>
</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Fern&#xe1;ndez-G&#xf3;mez</surname>
<given-names>Paula</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="fn" rid="fn1">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2279159/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>P&#xe9;rez de la Lastra Aranda</surname>
<given-names>Carmen</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="fn" rid="fn1">
<sup>&#x2020;</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tosat-Bitri&#xe1;n</surname>
<given-names>Carlota</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2254333/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bueso de Barrio</surname>
<given-names>Jes&#xfa;s Alejandro</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2276533/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Thompson</surname>
<given-names>Sebasti&#xe1;n</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2256082/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sot</surname>
<given-names>Bego&#xf1;a</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2277882/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Salas</surname>
<given-names>Gorka</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2274230/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Somoza</surname>
<given-names>&#xc1;lvaro</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/768571/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Espinosa</surname>
<given-names>Ana</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff7">
<sup>7</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1478191/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Castellanos</surname>
<given-names>Milagros</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Palomo</surname>
<given-names>Valle</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1381849/overview"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Instituto Madrile&#xf1;o de Estudios Avanzados en Nanociencia (IMDEA Nanociencia)</institution>, <addr-line>Madrid</addr-line>, <country>Spain</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Centro de Investigaciones Biol&#xf3;gicas Margarita Salas-CSIC</institution>, <addr-line>Madrid</addr-line>, <country>Spain</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas (CIBERNED)</institution>, <institution>Instituto de Salud Carlos III</institution>, <addr-line>Madrid</addr-line>, <country>Spain</country>
</aff>
<aff id="aff4">
<sup>4</sup>
<institution>Centro de Investigaciones Energ&#xe9;ticas</institution>, <institution>Medioambientales y Tecnol&#xf3;gicas (CIEMAT)</institution>, <institution>Unidad de Innovaci&#xf3;n Biom&#xe9;dica</institution>, <addr-line>Madrid</addr-line>, <country>Spain</country>
</aff>
<aff id="aff5">
<sup>5</sup>
<institution>Advanced Therapies Unit</institution>, <institution>Instituto de Investigaci&#xf3;n Sanitaria Fundaci&#xf3;n Jim&#xe9;nez D&#xed;az (IIS-FJ UAM)</institution>, <addr-line>Madrid</addr-line>, <country>Spain</country>
</aff>
<aff id="aff6">
<sup>6</sup>
<institution>Unidad Asociada al Centro Nacional de Biotecnolog&#xed;a (CSIC)</institution>, <addr-line>Madrid</addr-line>, <country>Spain</country>
</aff>
<aff id="aff7">
<sup>7</sup>
<institution>Instituto de Ciencia de Materiales de Madrid</institution>, <institution>ICMM-CSIC</institution>, <addr-line>Madrid</addr-line>, <country>Spain</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1275488/overview">Yuce Li</ext-link>, Sungkyunkwan University, Republic of Korea</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/854081/overview">Leopoldo Sitia</ext-link>, University of Milan, Italy</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1996023/overview">Wooram Um</ext-link>, Pukyong National University, Republic of Korea</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Valle Palomo, <email>valle.palomo@imdea.org</email>
</corresp>
<fn fn-type="equal" id="fn1">
<label>
<sup>&#x2020;</sup>
</label>
<p>These authors share first authorship</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>21</day>
<month>07</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="collection">
<year>2023</year>
</pub-date>
<volume>11</volume>
<elocation-id>1191327</elocation-id>
<history>
<date date-type="received">
<day>21</day>
<month>03</month>
<year>2023</year>
</date>
<date date-type="accepted">
<day>23</day>
<month>05</month>
<year>2023</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2023 Fern&#xe1;ndez-G&#xf3;mez, P&#xe9;rez de la Lastra Aranda, Tosat-Bitri&#xe1;n, Bueso de Barrio, Thompson, Sot, Salas, Somoza, Espinosa, Castellanos and Palomo.</copyright-statement>
<copyright-year>2023</copyright-year>
<copyright-holder>Fern&#xe1;ndez-G&#xf3;mez, P&#xe9;rez de la Lastra Aranda, Tosat-Bitri&#xe1;n, Bueso de Barrio, Thompson, Sot, Salas, Somoza, Espinosa, Castellanos and Palomo</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>The new and unique possibilities that nanomaterials offer have greatly impacted biomedicine, from the treatment and diagnosis of diseases, to the specific and optimized delivery of therapeutic agents. Technological advances in the synthesis, characterization, standardization, and therapeutic performance of nanoparticles have enabled the approval of several nanomedicines and novel applications. Discoveries continue to rise exponentially in all disease areas, from cancer to neurodegenerative diseases. In Spain, there is a substantial net of researchers involved in the development of nanodiagnostics and nanomedicines. In this review, we summarize the state of the art of nanotechnology, focusing on nanoparticles, for the treatment of diseases in Spain (2017&#x2013;2022), and give a perspective on the future trends and direction that nanomedicine research is taking.</p>
</abstract>
<kwd-group>
<kwd>nanoparticles</kwd>
<kwd>therapy</kwd>
<kwd>Spain</kwd>
<kwd>nanotechnology</kwd>
<kwd>nanomedicine</kwd>
</kwd-group>
<contract-num rid="cn001">PID2021-128340OA-I00 PID2020-119352RB-I00 RYC2019-027489-I CEX2020-001039-S</contract-num>
<contract-num rid="cn002">S2022/BMD-7403 RENIM-CM Talento program 2018-T1/IND-1005</contract-num>
<contract-num rid="cn003">grant agreement No 685795</contract-num>
<contract-num rid="cn004">LCF/PR/HA21/52350003</contract-num>
<contract-num rid="cn005">IDEAS21989THOM</contract-num>
<contract-num rid="cn006">FPU18/06310</contract-num>
<contract-sponsor id="cn001">Ministerio de Ciencia e Innovaci&#xf3;n<named-content content-type="fundref-id">10.13039/501100004837</named-content>
</contract-sponsor>
<contract-sponsor id="cn002">Comunidad de Madrid<named-content content-type="fundref-id">10.13039/100012818</named-content>
</contract-sponsor>
<contract-sponsor id="cn003">Horizon 2020 Framework Programme<named-content content-type="fundref-id">10.13039/100010661</named-content>
</contract-sponsor>
<contract-sponsor id="cn004">&#x201c;la Caixa&#x201d; Foundation<named-content content-type="fundref-id">10.13039/100010434</named-content>
</contract-sponsor>
<contract-sponsor id="cn005">Fundaci&#xf3;n Cient&#xed;fica Asociaci&#xf3;n Espa&#xf1;ola Contra el C&#xe1;ncer<named-content content-type="fundref-id">10.13039/501100002704</named-content>
</contract-sponsor>
<contract-sponsor id="cn006">Ministerio de Educaci&#xf3;n y Formaci&#xf3;n Profesional<named-content content-type="fundref-id">10.13039/501100020636</named-content>
</contract-sponsor>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Biomaterials</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="s1">
<title>1 Introduction</title>
<p>Nanoparticles (NPs) are small particles usually around 10&#x2013;100&#xa0;nm in size, that can be obtained from a broad class of materials, (<xref ref-type="bibr" rid="B149">Khan et al., 2019</xref>), and are classified according to their nature (<xref ref-type="fig" rid="F1">Figure 1</xref>). Materials have different properties at a nanometric scale, such as higher reactivity, singular optical or magnetic properties, among others. These properties can be used as warheads against pathological conditions (<xref ref-type="bibr" rid="B96">Fratila et al., 2019</xref>), (<xref ref-type="bibr" rid="B134">Guisasola et al., 2018a</xref>). Nanomedicine takes advantage of these unique features, offering a new set of therapeutic and diagnostic tools. For example, in NP-mediated hyperthermia, each NP acts as a heat source, increasing the temperature specifically at localized areas, damaging specific tumor cells in a controlled manner and reducing side effects in healthy tissues (in contrast with the bulk heating of conventional hyperthermia) (<xref ref-type="bibr" rid="B305">Vilaboa et al., 2017</xref>), (<xref ref-type="bibr" rid="B262">Sanz et al., 2017</xref>). A rise in temperature to 41&#xb0;C&#x2013;50&#xb0;C induces cell death via necrosis and/or apoptosis, especially for the more thermosensitive cancer cells (<xref ref-type="bibr" rid="B31">Bass et al., 1978</xref>), (<xref ref-type="bibr" rid="B266">Sapareto and Dewey, 1984</xref>). In addition, hyperthermia increases blood irrigation preferentially within tumors (<xref ref-type="bibr" rid="B76">Elming et al., 2019</xref>), modifies the extracellular matrix of tumor tissue (<xref ref-type="bibr" rid="B152">Kolosnjaj-Tabi et al., 2017</xref>), and activates immunological responses by increasing the surface display of tumor antigens (<xref ref-type="bibr" rid="B161">Lee et al., 2018</xref>).</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>Main types of NPs and the therapeutic areas in which they are used in the articles included in this review.</p>
</caption>
<graphic xlink:href="fbioe-11-1191327-g001.tif"/>
</fig>
<p>The shape, size, and surface of NPs are important properties to consider when using them for biological applications, since they determine the biocompatibility, biodistribution, cell-targeting, and uptake efficiency. NPs can be surface-modified with different biomolecules, including small proteins, antibodies, aptamers, oligonucleotides, oligosaccharides, polymers, or drugs. Therefore, by selecting suitable molecules, NPs can be tailored for the desired biological applications (<xref ref-type="bibr" rid="B147">Jindal, 2017</xref>), (<xref ref-type="bibr" rid="B72">Dolai et al., 2021</xref>), (<xref ref-type="bibr" rid="B113">Gatoo et al., 2014</xref>). In addition, the nanoformulation protects the cargo from degradation and improves its distribution in physiological media, facilitating oral administration and improving cell entry (<xref ref-type="bibr" rid="B151">Kim et al., 2021</xref>). Coating NPs with PEG, shields the surface from aggregation, opsonization, and phagocytosis, prolonging systemic circulation time and reducing their immunogenicity (<xref ref-type="bibr" rid="B272">Shi et al., 2021</xref>). Thus, different functionalization strategies make possible to enhance the pharmacokinetic properties of NPs, boosting the efficacy of therapy (<xref ref-type="bibr" rid="B59">Dacoba et al., 2017</xref>).</p>
<p>Another fundamental aspect is the protein corona formed on the surface of NPs, which plays a crucial role in the biological identity of NPs as it affects cytotoxicity, body distribution, endocytosis into specific cells, and biodegradation (<xref ref-type="bibr" rid="B283">Stepien et al., 2018</xref>), (<xref ref-type="bibr" rid="B105">Garcia-Alvarez and Vallet-Regi, 2021</xref>; <xref ref-type="bibr" rid="B321">Fleury et al., 2021</xref>). For these reasons, the proper identification and characterization of protein corona are essential in developing NPs-based therapeutics (<xref ref-type="bibr" rid="B240">Ritz et al., 2015</xref>; <xref ref-type="bibr" rid="B322">Di Silvio et al., 2018</xref>), (<xref ref-type="bibr" rid="B8">Alfranca et al., 2019</xref>).</p>
<p>NPs have a significant application as drug delivery systems (<xref ref-type="bibr" rid="B188">Miron-Barroso et al., 2021</xref>). Targeted therapies have at least three main advantages: reaching the target site specifically, not affecting other healthy organs, and reducing the dose needed to have the same therapeutic effect to the free drug. Biological barriers such as the blood-brain barrier (BBB) or mucus have a protective nature, hindering the simple diffusion of some therapeutic molecules, and a specific NP-mediated delivery can improve the permeability of therapeutic agents (<xref ref-type="bibr" rid="B199">Mulvihill et al., 2020</xref>), (<xref ref-type="bibr" rid="B175">Martin-Rapun et al., 2017</xref>). Finally, the possibility to encapsulate more than one drug that could provide synergistic effects showcases NPs versatility for delivery.</p>
<p>A significant example of the success of NPs as carriers is the drug Abraxane<sup>&#xae;</sup>. This nanomedicine, which comprises the chemotherapeutic paclitaxel (PTX) bound to albumin, has been approved for the treatment of metastatic breast cancer, advanced non-small cell lung cancer, late-stage pancreatic cancer, and metastatic triple-negative breast cancer. In several studies, it has increased patient survival and response rate significantly (<xref ref-type="bibr" rid="B63">De Luca et al., 2019</xref>).</p>
<p>Moreover, nanotechnology has also acquired a great interest in the immunological field. Vaccines are an extremely effective strategy to prevent several diseases, however their generation can be challenging since it is necessary to finely regulate the immunogenicity and the use of adjuvants as immunostimulatory agents can be critical to produce the desired effect. NPs have importance in vaccine generation because they are easily recognized by immune cells as they have a similar size to pathogens, and molecules can be anchored to their membrane to improve their recognition. In addition, new routes of administration, such as oral and nasal, can be used, and the possibility of multivalency enhances their activity (<xref ref-type="bibr" rid="B188">Miron-Barroso et al., 2021</xref>), (<xref ref-type="bibr" rid="B121">Gonzalez-Aramundiz et al., 2018</xref>).</p>
<p>Spain has emerged as a prominent player in the field of nanomedicine research in recent years. With numerous cutting-edge research centers and groups dedicated to this field, the country has made significant strides in the development of advanced treatments. Our review aims to provide a comprehensive overview of the latest breakthroughs in nanomedicine treatments in Spain over the past 5&#xa0;years. By highlighting the capabilities of various research centers and groups, we hope to shed light on the role that Spain plays in advancing this exciting field.</p>
</sec>
<sec id="s2">
<title>2 Inorganic nanoparticles</title>
<p>Inorganic NPs encompass the nanoformulations that mainly contain inorganic elements. They include magnetic, metallic, gold, silver NPs and metallic quantum dots, among others, and have been studied as therapeutic systems against various diseases. For example, the plasmonic and optical properties of inorganic NPs have enabled to undertake innovative approaches to treat diseases, serving as improved contrast agents or thermo-photo-induced sources (<xref ref-type="bibr" rid="B144">Jaque et al., 2014</xref>), (<xref ref-type="bibr" rid="B150">Kim et al., 2018</xref>), (<xref ref-type="bibr" rid="B40">Borzenkov et al., 2019</xref>). Their tunable morphological properties and advantageous stability have promoted great promises in their nanomedical use. However, the long-term effects of the administration of these NPs in the human body still needs exhaustive characterization, which has resulted in a slower clinical translation of these NPs in comparison to their organic counterparts (<xref ref-type="bibr" rid="B219">Paul et al., 2020</xref>). In this review, recent advances in silica, magnetic, gold, and silver NPs, are summarized. At the end of each section, the studies are summarized in tables and categorized by NP type highlighting their purpose, therapeutic area, agent and functionalization strategy.</p>
<sec id="s2-1">
<title>2.1 Mesoporous silica nanoparticles</title>
<p>Mesoporous silica NPs (MSNs) present several advantages that have qualified them as ideal carriers for drug delivery (<xref ref-type="bibr" rid="B172">Manzano and Vallet-Regi, 2019</xref>), (<xref ref-type="bibr" rid="B171">Manzano and Vallet-Regi, 2018</xref>), (<xref ref-type="bibr" rid="B142">Iturrioz-Rodriguez et al., 2019</xref>). They have large pores (0.6&#x2013;1&#xa0;cm<sup>3</sup>) to encapsulate molecules of different sizes (including proteins), an easily modifiable surface that allows controlling drug loading and release, a very high surface-to-volume ratio, and good biocompatibility (<xref ref-type="bibr" rid="B309">Villegas et al., 2018</xref>), (<xref ref-type="bibr" rid="B301">Vallet-Regi et al., 2022</xref>). In addition, they can be prepared at different sizes (50&#x2013;200&#xa0;nm) and present a large surface area (<xref ref-type="bibr" rid="B297">Vallet-Regi et al., 2017</xref>). The group of Vallet-Reg&#xed; was the first one to report the use of ordered mesoporous silica for drug delivery using the mesoporous material MCM-41 for the controlled release of ibuprofen using a simulated body fluid (<xref ref-type="bibr" rid="B300">Vallet-Regi et al., 2001</xref>). After that, tailored strategies have been developed for an efficient and smart delivery of therapeutic molecules, mainly for cancer treatment. For example, MSNs can be tuned to be responsive to a specific pH through an acid-sensitive linker, increasing tumor selectivity and efficacy, (<xref ref-type="bibr" rid="B178">Martinez-Carmona et al., 2018</xref>), and they can also be tuned to target specific organelles (<xref ref-type="table" rid="T1">Table 1</xref>) (<xref ref-type="bibr" rid="B116">Gisbert-Garzaran et al., 2020</xref>).</p>
<table-wrap id="T1" position="float">
<label>TABLE 1</label>
<caption>
<p>Summary of MSNs with their therapeutic area and functionalization strategy.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="center">NP Type</th>
<th align="center">Purpose</th>
<th align="center">Therapeutic area</th>
<th align="center">Therapeutic agent</th>
<th align="center">Functionalization strategy</th>
<th align="center">Ref.</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="center">Gated MSNs</td>
<td rowspan="7" align="center">Delivery</td>
<td align="center">Antimicrobial</td>
<td align="center">Essential Oils</td>
<td align="center">Lactose as molecular gate</td>
<td align="center">
<xref ref-type="bibr" rid="B228">Poyatos-Racionero et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="center">Multifunctional MSNs</td>
<td rowspan="4" align="center">Cancer</td>
<td rowspan="2" align="center">DOX</td>
<td align="center">Layer by layer functionalization with benzimidazole and &#x3b2;-cyclodextrin gold NPs as pH sensitive gate</td>
<td align="center">
<xref ref-type="bibr" rid="B146">Jimenez-Falcao et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="center">MSNs</td>
<td align="center">Galacto-oligosaccharides covered MSNs to target senescent tumoral cells</td>
<td align="center">
<xref ref-type="bibr" rid="B200">Munoz-Espin et al. (2018)</xref>
</td>
</tr>
<tr>
<td align="center">Nanovehicle MSNs</td>
<td align="center">Camptothecin and DOX</td>
<td align="center">pH responsive PEG linker</td>
<td align="center">
<xref ref-type="bibr" rid="B166">Llinas et al. (2018)</xref>
</td>
</tr>
<tr>
<td align="center">MCM-41/Pt</td>
<td align="center">Ru(Bpy)<sub>3</sub>Cl<sub>2</sub>/DOX</td>
<td align="center">Catalytic self-propulsion and oligoethylenglycol containing a disulfide element as redox dependent gating system</td>
<td align="center">
<xref ref-type="bibr" rid="B70">Diez et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="center">TNFR-Dex-MSN</td>
<td align="center">Pulmonary diseases</td>
<td align="center">Dexamethasone</td>
<td align="center">Functionalized with a peptide targeting TNFR1 that avoids cargo release. After internalization and peptide hydrolysis, the cargo is released</td>
<td align="center">
<xref ref-type="bibr" rid="B107">Garcia-Fernandez et al. (2021a)</xref>, <xref ref-type="bibr" rid="B106">Garcia-Fernandez et al. (2021b)</xref>
</td>
</tr>
<tr>
<td align="center">Monodisperse silica spheres</td>
<td align="center">-</td>
<td align="center">-</td>
<td align="center">Particles were functionalized with carbon nanotubes and linked to fluorophores</td>
<td align="center">
<xref ref-type="bibr" rid="B143">Iturrioz-Rodriguez et al. (2017)</xref>
</td>
</tr>
<tr>
<td align="center">Au-MSNs Janus</td>
<td align="center">Development of an enzyme-controlled NP to release DOX in cancer cells</td>
<td rowspan="3" align="center">Cancer</td>
<td rowspan="2" align="center">DOX</td>
<td align="center">MSNs capped with a thiol sensitive gate and glutathione reductase on the gold face, that controls cargo release</td>
<td align="center">
<xref ref-type="bibr" rid="B183">Mayol et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="center">MSN loaded with iron oxide</td>
<td align="center">Synergy of hyperthermia and drug delivery</td>
<td align="center">SPIONS in MSNs covered with small PEG chains and a shell of polymer sentitive to temperature</td>
<td align="center">
<xref ref-type="bibr" rid="B133">Guisasola et al. (2018b)</xref>
</td>
</tr>
<tr>
<td align="center">Janus MSNs</td>
<td align="center">Improve controlled targeting and current nanomedicines</td>
<td align="center">Topotecan</td>
<td align="center">Asymmetrically functionalized with two targeting moieties, folic acid and triphenylphosphine to target tumor cells and mitochondria respectively</td>
<td align="center">
<xref ref-type="bibr" rid="B167">Lopez et al. (2017)</xref>
</td>
</tr>
<tr>
<td align="center">MSNs</td>
<td align="center">Overcoming biofilm barrier</td>
<td rowspan="3" align="center">Antibacterial</td>
<td rowspan="2" align="center">Levofloxacin</td>
<td align="center">Concanavalin A was attached to carboxylic groups grafted on the MSNs surface forming covalent amide bonds</td>
<td align="center">
<xref ref-type="bibr" rid="B177">Martinez-Carmona et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="center">AuNR@MSNs-SNO</td>
<td align="center">Develop NIR activated MSNs combinade with photothermal and antimicrobial ccapabilities</td>
<td align="center">Gold nanorods were covered in a silica shell functionalized with PEG and thiol groups to be attached to tert-butylnitrite</td>
<td align="center">
<xref ref-type="bibr" rid="B102">Garc&#xed;a et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="center">MSNs</td>
<td align="center">Induce biofilm disaggregation</td>
<td align="center">Moxifloxacin, rifampicin</td>
<td align="center">Gelatin/colistin coated MSNs to avoid premature antibiotic release</td>
<td align="center">
<xref ref-type="bibr" rid="B2">Aguilera-Correa et al. (2022a)</xref>
</td>
</tr>
<tr>
<td align="center">MSNs-AgBr and AG@MSNs</td>
<td align="center">Improve AgNPs effect</td>
<td align="center">Tuberculosis</td>
<td align="center">-</td>
<td align="center">-</td>
<td align="center">
<xref ref-type="bibr" rid="B191">Montalvo-Quiros et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="center">MSNs@PEI</td>
<td align="center">Silence genes to stimulate bone regeneration</td>
<td rowspan="2" align="center">Bone regeneration</td>
<td align="center">Osteostatin</td>
<td align="center">Polyethylenimine grafted MSNs on phosphonate-modified MSNs</td>
<td align="center">
<xref ref-type="bibr" rid="B193">Mora-Raimundo et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="center">MSNs</td>
<td align="center">Induce osteogenesis and bone repair</td>
<td rowspan="3" align="center">Ipriflavone</td>
<td align="center">Spherical NPs with a porous core-shell structure synthesized by double template method</td>
<td align="center">
<xref ref-type="bibr" rid="B14">Arcos et al. (2022)</xref>
</td>
</tr>
<tr>
<td rowspan="2" align="center">Mesoporous nanospheres</td>
<td align="center">Promote vascularization</td>
<td align="center">Tissue regeneration</td>
<td align="center">-</td>
<td align="center">
<xref ref-type="bibr" rid="B47">Casarrubios et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="center">Study NPs effects on osteoprogenitor cells</td>
<td align="center">Periodontal</td>
<td align="center">-</td>
<td align="center">
<xref ref-type="bibr" rid="B46">Casarrubios et al. (2020)</xref>
</td>
</tr>
<tr>
<td align="center">MSNs</td>
<td align="center">Vaccine development</td>
<td align="center">Tuberculosis</td>
<td align="center">-</td>
<td align="center">MSNs loaded with immunomodulatory proteins</td>
<td align="center">
<xref ref-type="bibr" rid="B192">Montalvo-Quiros et al. (2020)</xref>
</td>
</tr>
<tr>
<td align="center">SiO<sub>2</sub>@ShTxB:FITC and Fe<sub>3</sub>O<sub>4</sub>@SiO<sub>2</sub>:RBITC@ShTxB</td>
<td align="left"/>
<td align="center">Head and Neck Cancer</td>
<td align="center">-</td>
<td align="center">Particles were functionalized with fluorophores and with the protein through sonication methodology</td>
<td align="center">
<xref ref-type="bibr" rid="B202">Navarro-Palomares et al. (2021)</xref>
</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>The delivery of the specific agent of MSNs can be controlled in different manners (<xref ref-type="bibr" rid="B301">Vallet-Regi et al., 2022</xref>). For example, Poyatos-Racionero et al. prepared MSNs loaded with essential oil components and covered by lactose that functioned as a molecular gate. They explored the properties of these particles loaded with different active agents in cellular and animal models, confirming the potential of this strategy for controlled delivery (<xref ref-type="bibr" rid="B228">Poyatos-Racionero et al., 2021</xref>). With regard to toxicity, mesoporous silica rods (MSR) have been less investigated in terms of biodistribution, biocompatibility, and cellular uptake, however in this case they presented improved characteristics when compared to their spherical counterparts in animal models. In this scenario, MSRs were functionalized with magnetic and fluorescent elements for diagnosis and treatment of fibrotic liver diseases (<xref ref-type="bibr" rid="B131">Grzelak et al., 2022</xref>).</p>
<p>Jimenez-Falcao et al. brought further the strategy of on-command delivery engineering loaded MSNs with a layer-by-layer supramolecular architecture, each with a specific role. The particles were first functionalized by benzimidazole and &#x3b2;-cyclodextrin gold NPs that act as a pH-sensitive gate. Then, a final coating was performed with glucose oxidase modified with an adamantine moiety linked to the free cyclodextrins. In that manner, these conjugates delivered their cargo upon the addition of glucose and were able to reduce HeLa cell viability (<xref ref-type="bibr" rid="B146">Jimenez-Falcao et al., 2019</xref>). A different delivery strategy was developed by Mu&#xf1;oz-Esp&#xed;n et al. to target senescent cells. They used MSNs coated with galacto-oligosaccharides, taking advantage of the high activity of lysosomal &#x3b2;-galactosidase activity in senescent cells. The nanoconjugates showed a preferential accumulation in senescent cells in animal models, improving tumor regression in mice and reducing the side effect of toxic drugs (<xref ref-type="bibr" rid="B200">Munoz-Espin et al., 2018</xref>).</p>
<p>To enhance delivery and exploit different ways of cellular entry, Navarro-Palomares et al. took advantage of cytoplasmatic entry of the toxic Shiga protein. They prepared fluorescent MSNs conjugated to a safe fragment of the protein that enabled to deliver the NPs intracellularly by a non-canonical pathway and thus avoiding the endolysosomal entry and its associated degradation (<xref ref-type="bibr" rid="B202">Navarro-Palomares et al., 2021</xref>).</p>
<p>Llinas et al. prepared a pH responsive nanosystem to deliver several drugs. First, they developed a nanosystem capable of delivering camptothecin (CPT) and doxorubicin (DOX) (<xref ref-type="bibr" rid="B166">Llinas et al., 2018</xref>), and, in a further step, they developed a new system for the delivery of CPT, DOX, and zinc (II) phthalocyanine (Pc). They labelled (Pc-CPT)@MSN-hyd-PEG-hyd-DOX, which sequentially releases DOX, linked on the MSNs surface through a pH-sensitive PEG linker that gradually delivers the Pc-CPT conjugate loaded inside the MSNs. In this manner, they combined chemotherapy and photosensitizers for photodynamic therapy (PDT). Upon irradiation of the samples, the Pc phototoxicity enhances the chemotoxicity of DOX and CPT (<xref ref-type="bibr" rid="B179">Martinez-Edo et al., 2021</xref>).</p>
<p>In a further step, self-propelled NPs also enable a more efficient manner to reach their target site without the need for external stimuli. Diez et al. designed MSNs coupled with platinum nanodendrites as a self-propulsion element (<xref ref-type="fig" rid="F2">Figure 2</xref>). The particles were designed with an oligoethylenglycol containing a disulfide element that acts as a gating system that can be opened under specific redox conditions. This is a successful proof of concept of a nanomaterial that can autonomously reach its target and deliver the cargo upon specific and controllable conditions (<xref ref-type="bibr" rid="B70">Diez et al., 2021</xref>).</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>Design of Janus Pt-MSN motors. Reprinted from Diez et al. (<xref ref-type="bibr" rid="B70">Diez et al., 2021</xref>), and licensed under the Creative Commons Attribution.</p>
</caption>
<graphic xlink:href="fbioe-11-1191327-g002.tif"/>
</fig>
<p>Another complicated site for drug delivery are the lungs, which present several pulmonary barriers that prevent the effective delivery of traditional drugs. In this regard, Garc&#xed;a-Fern&#xe1;ndez et al. addressed this issue using MSNs (<xref ref-type="bibr" rid="B107">Garcia-Fernandez et al., 2021a</xref>), (<xref ref-type="bibr" rid="B106">Garcia-Fernandez et al., 2021b</xref>). In this case, the nanostructures were loaded with dexamethasone, which is the standard corticoid used for the treatment of this disease, and decorated with a peptide with a dual objective, targeting TNFR1 receptors and avoiding the release of the cargo. TNFR1 receptors are expressed in pro-inflammatory macrophages, and indeed the particles showed a selective uptake by these cells and released the drug. The conjugates were also effective in animal models, demonstrating lung accumulation and the reduction of the damage.</p>
<p>As seen by now, the versatility of NP development with therapeutic approaches enables infinite combinations of coatings, particle size, shape, and biomolecule incorporation. In addition, one can combine several NPs into new assemblies that enable to take advantage of several properties simultaneously (<xref ref-type="bibr" rid="B236">Redolfi Riva et al., 2017</xref>). When NPs display two or more physical properties divided on their surface, they are called Janus particles, due to their asymmetric geometry. They can also be prepared with the combination of different kinds of NPs that enable them to take advantage of both materials, and even unlock undiscovered synergistic effects. Mayo et al. developed mesoporous silica-gold Janus NPs linked to glutathione reductase. These assemblies resulted highly efficient in delivering their cargo when presented with NADPH and glutathione disulfide as triggers (<xref ref-type="bibr" rid="B183">Mayol et al., 2021</xref>).</p>
<p>Similarly, Guisasola et al. developed innovative MSNs loaded with iron oxide NPs coated with a polymer sensitive to temperature. Upon the application of alternating magnetic fields (AMF), DOX was effectively released in animal models without increasing global tissue temperature, provoking a synergistic effect of drug and hyperthermia antitumoral activities (<xref ref-type="bibr" rid="B133">Guisasola et al., 2018b</xref>). In another example of Janus-type MSNs, Lopez et al. designed particles selective for tumor cells that, once internalized, specifically targeted mitochondria organelles, showcasing the utility of this strategy (<xref ref-type="bibr" rid="B167">Lopez et al., 2017</xref>).</p>
<p>Bacterial resistance to common antimicrobials is growing, and many efforts are being dedicated to the development of new antibiotic tools. Biofilm formation is especially problematic because it requires much higher antibiotic doses. MSNs can be designed to deliver antimicrobials in a localized and efficient way (<xref ref-type="bibr" rid="B36">Bernardos et al., 2019</xref>), (<xref ref-type="bibr" rid="B298">Vallet-Regi et al., 2019</xref>), (<xref ref-type="bibr" rid="B54">Colilla and Vallet-Regi, 2020</xref>). This approach has been used in MSNs functionalized with concanavalin A, which promotes the internalization of the NPs into the biofilm matrix to deliver levofloxacin (<xref ref-type="bibr" rid="B177">Martinez-Carmona et al., 2019</xref>). Also, in a sophisticated example, the release of levofloxacin and nitric oxide in biofilms was enhanced by near-infrared (NIR) irradiation using core-shell Au-MSN NPs (<xref ref-type="bibr" rid="B102">Garc&#xed;a et al., 2021</xref>). Aguilera-Correa et al. developed gelatin/colistin coated MSNs to treat osteomyelitis, a bone infection with poor prognosis. The functional coating prevented premature antibiotic release and induced biofilm disaggregation, showing the potential of these NPs to treat bone infections (<xref ref-type="bibr" rid="B2">Aguilera-Correa et al., 2022a</xref>). Finally, Montalvo-Quir&#xf3;s et al. explored the antimicrobial activity of MSNs loaded with silver bromide NPs and silver NPs with a mesoporous silica shell, confirming the great potential of MSNs for this application (<xref ref-type="bibr" rid="B191">Montalvo-Quiros et al., 2021</xref>).</p>
<p>Another prominent field of nanomedicine is the use of MSNs in bone regeneration. Mora-Raimundo et al. engineered particles to simultaneously deliver siRNA, to silence genes that inhibit osteoblasts differentiation, and osteostatin, which stimulates bone regeneration in animal models, taking advantage of the high loading capacity of MSNs (<xref ref-type="bibr" rid="B193">Mora-Raimundo et al., 2019</xref>). Further, Arcos et al. developed a methodology to inject MSNs loaded with an antiosteoporotic drug, ipriflavone, for the first time in rabbits, by suspending them in a hyaluronic acid hydrogel. The particles induced osteogenesis and bone repair (<xref ref-type="bibr" rid="B14">Arcos et al., 2022</xref>). In the same field, Casarrubios et al. decided to take advantage of the essential role that angiogenesis plays in vascularization and tissue regeneration. They loaded mesoporous nanospheres with ipriflavone, showing its release in endothelial cells by the increase of VEGFR2 expression indicating angiogenesis (<xref ref-type="bibr" rid="B47">Casarrubios et al., 2021</xref>). In another publication, the authors explored the potential of ipriflavone MSNs for periodontal treatment. They confirmed the clathrin-mediated entrance of the NPs, showing an osteogenesis activity (<xref ref-type="bibr" rid="B46">Casarrubios et al., 2020</xref>).</p>
<p>An original manner to deliver NPs was developed by Iturrioz-Rodriguez et al. that coated silica NPs with carbon nanotubes that enabled a cytoplasmic delivery and opens an innovative pathway to reach the cytoplasm of cells (<xref ref-type="bibr" rid="B143">Iturrioz-Rodriguez et al., 2017</xref>).</p>
<p>Finally, MSNs have also ideal properties to become a platform for vaccine development. Montalvo-Quir&#xf3;s et al. engineered MSNs loaded with immunomodulatory proteins that showed to have protective effects against infection of tuberculosis, (<xref ref-type="bibr" rid="B192">Montalvo-Quiros et al., 2020</xref>), and that could be used for dual delivery of immunomodulatory proteins and antitubercular drugs.</p>
</sec>
<sec id="s2-2">
<title>2.2 Magnetic nanoparticles</title>
<p>Magnetic NPs (MNPs) are an exceptional tool for biomedical treatment. They can deeply internalize in tissues, and have magnetic-heating capability. The most explored MNPs for nanomedicine are, by far, superparamagnetic iron oxide NPs (SPIONs) and related ferrites (<xref ref-type="bibr" rid="B241">Roca et al., 2019</xref>), (<xref ref-type="bibr" rid="B215">Pardo et al., 2020</xref>), (<xref ref-type="bibr" rid="B184">Mazario et al., 2012</xref>), (<xref ref-type="bibr" rid="B110">Garcia-Soriano et al., 2020</xref>), (<xref ref-type="bibr" rid="B246">Rubia-Rodriguez et al., 2021a</xref>). In clinical practice and biomedical research, they are used as iron supplements, contrast agents, and magnetic hyperthermia therapeutics (<xref ref-type="bibr" rid="B226">Polo et al., 2018</xref>), (<xref ref-type="bibr" rid="B62">de la Presa et al., 2012</xref>). Through the later application, localized heat is generated, which increases gene expression (<xref ref-type="bibr" rid="B196">Moros et al., 2019</xref>), particularly of the heat shock protein family, and the formation of reactive oxygen species (ROS), while inducing apoptosis and several cellular stresses such as endoplasmic reticular stress or mitochondrial damage. Interestingly, cancer cells are more sensitive to heat than healthy ones, and therefore, this approach can present reduced toxicity in healthy cells and tissues. On the other hand, the requirement to use this therapy is the application of an alternating magnetic field (AMF), which has a high penetration and negligible effect on the tissues, compared with other antitumoral techniques that present toxic side effects for nearby healthy cells and tissues. Finally, magnetic hyperthermia can be used to promote drug release and therefore it can be used alone or in combination with drugs, for synergistic combinatory therapy, or with specific molecules for active targeting (<xref ref-type="table" rid="T2">Table 2</xref>). For example, Fe<sub>3</sub>O<sub>4</sub> NPs were synthesized by a seed growth method with defined shapes and sizes and were functionalized with an arginine-glycine-aspartate (RGD)-type peptide to target &#x3b1;v&#x3b2;3 integrin receptors over-expressed in angiogenic cancer cells. NPs showed a good heating response, lower toxicity and better biocompatibility with improved magnetic properties (<xref ref-type="bibr" rid="B21">Arriortua et al., 2018</xref>). Sanz et al. extensively studied and compared conventional hyperthermia and the therapeutic advantage of using MNPs, confirming the improved effectiveness of the nanoheaters (<xref ref-type="bibr" rid="B262">Sanz et al., 2017</xref>). In case of other type of hyperthermia, Lozano-Pedraza et al. explored the optical heat losses using iron oxide NPs and identified the parameters that influence the NIR-heating effects for therapeutic purposes (<xref ref-type="bibr" rid="B168">Lozano-Pedraza et al., 2021</xref>).</p>
<table-wrap id="T2" position="float">
<label>TABLE 2</label>
<caption>
<p>Summary of MNPs with their therapeutic area and functionalization strategy.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="center">NP Type</th>
<th align="center">Purpose</th>
<th align="center">Therapeutic area</th>
<th align="center">Therapeutic agent</th>
<th align="center">Functionalization strategy</th>
<th align="center">Ref.</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td rowspan="16" align="center">Iron oxide (magnetite/maghemite)</td>
<td align="center">Study of cell internalization and effects of IONPs</td>
<td rowspan="4" align="center">Cancer</td>
<td align="center">-</td>
<td align="center">Citric acid-coated IONPs</td>
<td align="center">
<xref ref-type="bibr" rid="B41">Cabrera et al. (2018)</xref>
</td>
</tr>
<tr>
<td align="center">MHT: cytotoxicity study</td>
<td align="center">-</td>
<td align="center">3-aminopropyl-triethoxysilane and dimercaptosuccinic acid coated MNPs</td>
<td align="center">
<xref ref-type="bibr" rid="B186">Mejias et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="center">MHT control</td>
<td align="center">DOX</td>
<td align="center">Silica coated MNPs functionalized with hydroxyl groups</td>
<td align="center">
<xref ref-type="bibr" rid="B98">Fuentes-Garc&#xed;a et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="center">MHT with 3D cultures</td>
<td align="center">-</td>
<td align="center">MNPs coated with poly(maleic anhydride-alt-1-octadecene) modified with TAMRA functionalized with glucose</td>
<td align="center">(<xref ref-type="bibr" rid="B33">Beola et al., 2018</xref>), (<xref ref-type="bibr" rid="B34">Beola et al., 2020</xref>)</td>
</tr>
<tr>
<td align="center">MHT: conditions for improving treatment effectiveness <italic>in vivo</italic>
</td>
<td align="center">Pancreatic cancer</td>
<td align="center">-</td>
<td align="center">MNPs coated with poly(maleic anhydride-alt-1-octadecene) modified with carboxytetramethylrhodamine functionalized with glucose</td>
<td align="center">
<xref ref-type="bibr" rid="B35">Beola et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="center">Multi-Hot-Spot magnetic inductive nanoheating</td>
<td align="center">Selective regulation of multienzymatic reactions</td>
<td align="center">-</td>
<td align="center">Dimercaptosuccinic acid, poly(maleic anhydride-alt-1-octadecene) or poly(acrylic acid) coated MNPs</td>
<td align="center">
<xref ref-type="bibr" rid="B210">Ovejero et al. (2021b)</xref>
</td>
</tr>
<tr>
<td align="center">MHT in mice. Study on the reliability of NP synthesis and how to control T increase</td>
<td align="center">Pancreatic cancer</td>
<td align="center">-</td>
<td align="center">Dextran or starch coated MNPs</td>
<td align="center">
<xref ref-type="bibr" rid="B169">Luengo et al. (2022)</xref>
</td>
</tr>
<tr>
<td align="center">MHT: chemotherapeutic synergy with drug delivery</td>
<td align="center">Cancer</td>
<td align="center">Gemcitabine</td>
<td align="center">N6L ligand and gemcitabine functionalized on albumin coated MNPs</td>
<td align="center">
<xref ref-type="bibr" rid="B6">Aires et al. (2017)</xref>
</td>
</tr>
<tr>
<td align="center">MHT and chemotherapeutic drug nanocarriers</td>
<td align="center">Breast cancer</td>
<td align="center">DOX</td>
<td align="center">Dimercaptosuccinic acid coated MNPs functionalized with DOX using three different linkers-disulfide, imine or both</td>
<td align="center">
<xref ref-type="bibr" rid="B158">Lazaro-Carrillo et al. (2020)</xref>
</td>
</tr>
<tr>
<td align="center">Selective multimodal treatment of pancreatic cancer</td>
<td align="center">Pancreatic cancer</td>
<td align="center">Gemcitabine</td>
<td align="center">Dimercaptosuccinic acid coated MNPs functionalized with Gemcitabine and anti-CD47 antibody</td>
<td align="center">
<xref ref-type="bibr" rid="B295">Trabulo et al. (2017)</xref>
</td>
</tr>
<tr>
<td align="center">Antiproliferative properties</td>
<td align="center">Cancer</td>
<td align="center">Crocin</td>
<td align="center">Dextran and crocin coated MNPs</td>
<td align="center">
<xref ref-type="bibr" rid="B267">Saravani et al. (2020)</xref>
</td>
</tr>
<tr>
<td align="center">Cell retention to improve cell therapy, EMF</td>
<td rowspan="3" align="center">Cell therapy in cancer</td>
<td align="center">-</td>
<td align="center">Dimercaptosuccinic acid, 3-aminopropyl-triethoxysilane or dextran coated MNPs</td>
<td align="center">
<xref ref-type="bibr" rid="B264">Sanz-Ortega et al. (2019a)</xref>
</td>
</tr>
<tr>
<td align="center">Adoptive T cell-transfer, EMF<xref ref-type="fn" rid="fn2"/>
</td>
<td align="center">Antibodies</td>
<td align="center">3-aminopropyl-triethoxysilane coated MNPs functionalized with antibodies</td>
<td align="center">
<xref ref-type="bibr" rid="B263">Sanz-Ortega et al. (2019b)</xref>
</td>
</tr>
<tr>
<td align="center">Improve adoptive cell transfer therapy, EMF</td>
<td align="center">-</td>
<td align="center">Dimercaptosuccinic acid, 3-aminopropyl-triethoxysilane or dextran coated MNPs</td>
<td align="center">
<xref ref-type="bibr" rid="B265">Sanz-Ortega et al. (2019c)</xref>
</td>
</tr>
<tr>
<td align="center">Gene transfection, pro-inflammation, magnetic targeting and anti-angiogenesis</td>
<td rowspan="2" align="center">Cancer</td>
<td align="center">Polyethylenimine</td>
<td align="center">Polyethylenimine-coated SPIONs</td>
<td align="center">
<xref ref-type="bibr" rid="B198">Mulens-Arias et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="center">Smart miRNA delivery system for immunotherapy</td>
<td align="center">miRNA155, miRNA125b and miRNA146a</td>
<td align="center">Dextran, carboxymethyldextran or dimercaptosuccinic acid coated NPs</td>
<td align="center">
<xref ref-type="bibr" rid="B153">Lafuente-Gomez et al. (2022)</xref>
</td>
</tr>
<tr>
<td rowspan="2" align="center">Iron oxide (magnetite/maghemite)</td>
<td align="center">PTT using iron oxide NPs</td>
<td align="center">Cancer</td>
<td align="center">-</td>
<td align="center">IONPs with different sizes and coatings for biocompatibility</td>
<td align="center">
<xref ref-type="bibr" rid="B168">Lozano-Pedraza et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="center">PEI-MNPs</td>
<td align="center">Cancer</td>
<td align="center">-</td>
<td align="center">Polymer coated NPs (PEI)</td>
<td align="center">
<xref ref-type="bibr" rid="B262">Sanz et al. (2017)</xref>
</td>
</tr>
<tr>
<td align="center">Iron oxide (magnetite) NPs and iron oxyhydroxide NPs</td>
<td align="center">Prophylactic or therapeutic treatments for SARS-CoV-2</td>
<td align="center">SARS-CoV-2</td>
<td align="center">-</td>
<td align="center">Dimercaptosuccinic acid, 3-aminopropyl-triethoxysilane or carboxydextran coated IONPs and sucrose coated iron oxyhydroxy NPs</td>
<td align="center">
<xref ref-type="bibr" rid="B65">DeDiego et al. (2022)</xref>
</td>
</tr>
<tr>
<td rowspan="3" align="center">Ferrites M<sub>x</sub>Fe<sub>3-x</sub>O<sub>4</sub> (M &#x3d; metal other than iron)</td>
<td align="center">Develop microswimmers with MHT capacity</td>
<td align="center">Sarcoma (collagen-rich ECM)</td>
<td align="center">-</td>
<td align="center">PLL and collagenase coated polystyrene particles containing manganese ferrite NPs</td>
<td align="center">
<xref ref-type="bibr" rid="B234">Ramos-Docampo et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="center">Describe MHT and NPs uptake in cancer cells</td>
<td align="center">Glioblastoma</td>
<td align="center">-</td>
<td align="center">cRGD peptide conjugation in dimercaptosuccinic acid manganese ferrite NPs</td>
<td align="center">
<xref ref-type="bibr" rid="B66">Del Sol-Fernandez et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="center">Promote heterogeneous catalysis for ROS production</td>
<td align="center">Cancer</td>
<td align="center">-</td>
<td align="center">Copper-iron oxide spinel NPs. BSA templated synthesis with ethylene glycol</td>
<td align="center">
<xref ref-type="bibr" rid="B39">Bonet-Aleta et al. (2022a)</xref>, <xref ref-type="bibr" rid="B38">Bonet-Aleta et al. (2022b)</xref>
</td>
</tr>
<tr>
<td colspan="6" align="left">Hybrid magnetic nanomaterials<xref ref-type="table-fn" rid="Tfn1">
<sup>1</sup>
</xref>
</td>
</tr>
<tr>
<td align="center">&#x2003;Iron oxide-MnO<sub>2</sub>
</td>
<td align="center">Intracellular response for switchable MRI contrast and magnetic hyperthermia</td>
<td align="center">Cancer</td>
<td align="center">-</td>
<td align="center">Core-shell NPs with a tunable Mn oxide shell growth over iron oxide NPs</td>
<td align="center">
<xref ref-type="bibr" rid="B111">Garcia-Soriano et al. (2022)</xref>
</td>
</tr>
<tr>
<td rowspan="4" align="center">Iron oxide-gold</td>
<td align="center">Multifunctional photothermal therapy (PTT)</td>
<td rowspan="4" align="center">
</td>
<td align="center">-</td>
<td align="center">Gold suprashells around dextran coated SPIONS</td>
<td align="center">
<xref ref-type="bibr" rid="B218">Paterson et al. (2017)</xref>
</td>
</tr>
<tr>
<td align="center">Multimodal cancer theranostics</td>
<td align="center">-</td>
<td align="center">Iron oxide-gold nanoflowers with PEGylated ligand</td>
<td align="center">
<xref ref-type="bibr" rid="B51">Christou et al. (2022)</xref>
</td>
</tr>
<tr>
<td align="center">PTT, MHT and magneto-photothermal treatment with Janus NPs</td>
<td align="center">-</td>
<td align="center">Polyvinylpyrrolidone-coated iron oxide-gold magnetic Janus nanostars</td>
<td align="center">
<xref ref-type="bibr" rid="B83">Espinosa et al. (2020)</xref>
</td>
</tr>
<tr>
<td align="center">PTT, MHT and magneto-photothermal treatment</td>
<td align="center">-</td>
<td align="center">Au-coated rod-shaped magnetite NPs in agarose hydrogels</td>
<td align="center">
<xref ref-type="bibr" rid="B239">Rincon-Iglesias et al. (2022)</xref>
</td>
</tr>
<tr>
<td rowspan="2" align="center">Iron oxide-silver</td>
<td align="center">Synergy between Ag and MHT</td>
<td align="center">Antibacterial</td>
<td align="center">-</td>
<td align="center">&#x3b3;-Fe<sub>2</sub>O<sub>3</sub>-Ag nanocomposites</td>
<td align="center">
<xref ref-type="bibr" rid="B170">Luengo et al. (2020)</xref>
</td>
</tr>
<tr>
<td align="center">MHT <italic>in vivo</italic> real time feedback</td>
<td align="center">Cancer</td>
<td align="center">-</td>
<td align="center">Phospholipid encapsulated Iron oxide-Ag<sub>2</sub>S nanocomposites</td>
<td align="center">
<xref ref-type="bibr" rid="B314">Ximendes et al. (2021)</xref>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="Tfn1">
<label>
<sup>1</sup>
</label>
<p>Hybrid here refers to nanostructures combining two types of inorganic materials in which both are clearly distinguishable (e.g., core-shell, aggregates/encapsulates of individual NPs of both materials) and both provide a relevant function for the application (i.e., are not used just as a coating or as a platform).</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Remarkably, iron oxide and other NPs can be obtained in a wide variety of morphologies and anisometric properties (<xref ref-type="fig" rid="F3">Figure 3</xref>) (<xref ref-type="bibr" rid="B241">Roca et al., 2019</xref>) including, rods, cubes, stars, rings or as flower-shaped NPs among others (<xref ref-type="bibr" rid="B114">Gavil&#xe1;n et al., 2017</xref>). It is worth mentioning that the biological properties (e.g., internalization, toxicity) and response to AMF vary upon specific morphology (<xref ref-type="bibr" rid="B211">Ovejero et al., 2021a</xref>), (<xref ref-type="bibr" rid="B275">Simeonidis et al., 2016</xref>).</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>Different shapes and morphologies of iron oxide and other NPs. Scanning and transmission electron microscopy images on the upper part and morphology representation on the lower part. <bold>(A)</bold> nanorod, <bold>(B)</bold> nanohusk, <bold>(C)</bold> distorted cubes, <bold>(D)</bold> nanosheets, <bold>(E)</bold> distorted cubes, <bold>(F)</bold> porous spheres, <bold>(G)</bold> self-oriented flowers, <bold>(H)</bold> prismatic IONPs, <bold>(I)</bold> nanostar, <bold>(J)</bold> nanodiscs, <bold>(K)</bold> nanorings and <bold>(L)</bold> nanotubes. <bold>(A, B, C, E, F, G)</bold> adapted from <xref ref-type="bibr" rid="B269">Sayed and Polshettiwar (2015)</xref>, <bold>(D)</bold> adapted from <xref ref-type="bibr" rid="B50">Chin et al. (2007)</xref>, <bold>(I)</bold> adapted from <xref ref-type="bibr" rid="B319">Becerril-Castro et al. (2022)</xref>, <bold>(J)</bold> adapted from <xref ref-type="bibr" rid="B320">Qu et al. (2021)</xref>, <bold>(H)</bold> adapted from <xref ref-type="bibr" rid="B233">Ramirez-Jimenez et al. (2020)</xref>, <bold>(K)</bold> adapted from <xref ref-type="bibr" rid="B145">Jia et al. (2008)</xref>, <bold>(L)</bold> adapted from <xref ref-type="bibr" rid="B318">Zhang et al. (2016)</xref>. Licensed under a Creative Commons Attribution.</p>
</caption>
<graphic xlink:href="fbioe-11-1191327-g003.tif"/>
</fig>
<p>MNPs can be also combined with other nanostructures to yield nanostructures with additional properties. In this regard, Paterson et al. engineered self-assembled gold suprashells around dextran-coated SPION cores, which allowed them to obtain nanostructures with plasmonic and magnetic properties. The use of magnetic fields can be used to promote the accumulation of these nanostructures in cancer cells, and then exploit the plasmonic properties to induce heat by a light source, leading to the death of the tumoral cells (<xref ref-type="bibr" rid="B218">Paterson et al., 2017</xref>). In another work, MNPs were functionalized with dextran and crocin, which has antiproliferative properties. Crocin-coated dextran-MNPs showed greater anti-tumor effects and a higher rate of early apoptosis on MCF-7 breast tumor cells than free crocin was obtained, suggesting an effective alternative to traditional cancer treatments (<xref ref-type="bibr" rid="B267">Saravani et al., 2020</xref>).</p>
<p>Mejias et al., have worked in hyperthermia that improves tumor antigen presentation, activation of dendritic cells and natural killer cells, and leukocyte trafficking through endothelium. Probably due to NP aggregation, the contact of MNPs with cells could affect the heating capacity, highlighting the importance of NP coating to avoid cell-induced aggregation (<xref ref-type="bibr" rid="B186">Mejias et al., 2019</xref>). Similarly, Cabrera et al. studied intracellular MNP clustering, that led to a reduction of the magnetic hyperthermia ability. This work allowed to predict the magnetic thermal response of several NPs sizes in the cellular media (<xref ref-type="bibr" rid="B41">Cabrera et al., 2018</xref>).</p>
<p>Beola et al. investigated MNPs activity in 3D cell cultures, showing that magnetic hyperthermia can trigger necrosis or disruption of the extracellular matrix depending if the MNPs are inside or outside the cells (<xref ref-type="bibr" rid="B33">Beola et al., 2018</xref>). They studied the cell death mechanisms and the influence of the number of internalized particles to the cytotoxic effect testing several concentrations up to 7.5&#xa0;pg Fe/cell. They showed that different apoptotic routes are triggered depending on the number of internalized NPs (<xref ref-type="bibr" rid="B34">Beola et al., 2020</xref>). In another work, they selected the conditions that caused the largest effect in cell viability for testing the NPs in animal models (<xref ref-type="bibr" rid="B35">Beola et al., 2021</xref>). AMF promoted MNPs migration into the tumor and confirmed that NP biodistribution is essential for hyperthermia effectiveness, and is affected by surface coating, playing the protein corona a significant role (<xref ref-type="bibr" rid="B283">Stepien et al., 2018</xref>).</p>
<p>Also employing 3D cell cultures, the group of V. Salgueiri&#xf1;o and co-workers described the assembly of magnetic microswimmers, composed of 500&#xa0;nm polystyrene particles containing ferrite NPs. The motion of the self-propelled microswimmers was triggered by calcium, and they were able to penetrate spheroid models for heat delivery under AMF (<xref ref-type="bibr" rid="B234">Ramos-Docampo et al., 2019</xref>).</p>
<p>Luengo et al. synthesized maghemite NPs with different coatings to determine the best properties to use in clinical applications. The NPs were injected into animals with pancreatic cancer, and the results determined that modulating the field intensity can control the temperature rise during magnetic hyperthermia protocols in animal models (<xref ref-type="bibr" rid="B169">Luengo et al., 2022</xref>).</p>
<p>The combination of experimental and simulation approaches might be a useful tool for better engineering NPs. In this regard, a model has provided quantitative predictions to fit the properties of iron NPs, including a targeting agent and a drug. Particularly, it allowed the design of NPs with a pseudopeptide Nucant-6L, which induced a significant accumulation in tumors. The studies revealed the synergy of Nucant-6L, the chemotherapeutic drug gemcitabine, and the NPs, together with the importance of fine tuning the functionalization (<xref ref-type="bibr" rid="B6">Aires et al., 2017</xref>).</p>
<p>Christou et al. developed a seed-assisted methodology for the synthesis of gold and iron oxide nanoflowers. The particles were functionalized with PEG, greatly enhancing the colloidal stability of the conjugates. The nanoflowers performed highly as contrast agents and exhibited a considerable conversion of energy to heat, having ideal properties to be used as theragnostic agents (<xref ref-type="bibr" rid="B51">Christou et al., 2022</xref>).</p>
<p>Del Sol-Fernandez et al. also developed flowerlike manganese iron oxide cRGD-functionalized NPs that, when exposed to the appropriate AMF conditions, induced intracellular magnetic hyperthermia resulting in <italic>hsp70</italic> transcription and strong ROS production leading to cell death in a glioblastoma cell line (<xref ref-type="bibr" rid="B66">Del Sol-Fernandez et al., 2019</xref>).</p>
<p>Espinosa et al. developed Janus magneto-plasmonic NPs, using gold nanostars and iron oxide nanospheres subjected to an external magnetic field and NIR light. With this strategy, a synergistic cytotoxic effect on cancer cells was achieved based on the combination of the two thermal effects into a magneto-photothermal modality. Moreover, experiments in animal models confirmed the high efficiency of magnetically enhanced photothermal therapy (PTT) that led to tumor growth inhibition, and the delivery was highly improved by magnetic targeting (<xref ref-type="bibr" rid="B83">Espinosa et al., 2020</xref>). Another type of magneto-plasmonic materials that display magneto- and photothermal anisotropic transductions for cancer ablation has been proposed by Rincon- Iglesias et al., that incorporated Fe<sub>3</sub>O<sub>4</sub>@Au nanorods in an agarose hydrogel, resulting in free-standing anisotropic materials (<xref ref-type="bibr" rid="B239">Rincon-Iglesias et al., 2022</xref>).</p>
<p>Mulens-Arias et al., investigated the modulation of angiogenesis as an antitumor therapy. They used MNPs and a magnetic field for this approach. PEI-SPIONs, (SPIONs coated with polyethylenimine) showed anti-angiogenic and antitumoral effects as these NPs were able to reduce tumor vessel numbers and promoted intratumor macrophage infiltration in a tumor model after administration and application of magnetic field (<xref ref-type="bibr" rid="B198">Mulens-Arias et al., 2019</xref>). As another strategy against cancer, Sanz Ortega et al. developed NPs-based drug delivery systems to increase immunotherapy effectiveness. They showed that MNPs and the use of AMF can guide and retain T lymphocytes to a target region of interest and can be magnetically retained there (<xref ref-type="bibr" rid="B264">Sanz-Ortega et al., 2019a</xref>), (<xref ref-type="bibr" rid="B263">Sanz-Ortega et al., 2019b</xref>). In addition, they took advantage of the role of natural killer cells in antitumor immunity by binding MNPs coated with 3-aminopropyl triethoxysilane (APTES) to the surface of natural killer cells. They reported the retention of the cells at the specific target site by using external magnetic fields as the magnetic guiding effect (<xref ref-type="bibr" rid="B265">Sanz-Ortega et al., 2019c</xref>).</p>
<p>While hyperthermia has been exploited using several conjugates, an unsolved problem in this field is the lack of real time information on the temperature achieved locally, which complicates a fine control of therapeutic parameters <italic>in situ</italic>. Ximendes et al. combined in a recent work MNPs with infrared nanothermometers of Ag<sub>2</sub>S NPs that provided an efficient solution to this problem by monitoring the subcutaneous temperatures in real time, to build 2D thermal maps, which were used to accurately assess the therapeutic effect of the MNPs (<xref ref-type="bibr" rid="B314">Ximendes et al., 2021</xref>). Alternatively, the temperature at the surface of AMF-activated MNPs was also obtained with fluorescence probes by J. Ovejero et al. (<xref ref-type="bibr" rid="B210">Ovejero et al., 2021b</xref>). Moreover, to guarantee an efficient thermal treatment in tumors in a safe window of applicability in the clinical practice, a modelling of the heat distribution in tissues (<italic>in silico</italic> studies) is crucial. Rubia-Rodriguez et al. have explored collateral heating effects on prostheses that can affect the safety and efficiency of magnetic hyperthermia treatments of localized tumors (<xref ref-type="bibr" rid="B247">Rubia-Rodriguez et al., 2021b</xref>).</p>
<p>Luengo et al. enhanced the antibacterial properties of silver NPs in combination with iron oxide and its magnetic hyperthermia properties. The authors showed how the introduction of silver in the iron oxide particles had bactericidal activity against <italic>Staphylococcus aureus</italic> and <italic>Escherichia coli</italic>, and in addition, how the external magnetic fields enhanced this activity, demonstrating the synergistic properties of both materials when used in the same composite (<xref ref-type="bibr" rid="B170">Luengo et al., 2020</xref>).</p>
<p>In a recent study, MNPs were coated by a sonochemical method with a mesoporous silica surface in which the drug, DOX, could be loaded. The release of the drug used was dependent on pH, which showed effectiveness at acidic pH, proving the ultrasound synthesis as successful (<xref ref-type="bibr" rid="B98">Fuentes-Garc&#xed;a et al., 2021</xref>). In another strategy for DOX delivery, Lazaro-Carrillo et al. engineered a release mechanism based on iron oxide MNPs controlled by pH. The reductive environment of the cell was critical to diminish the side effects of the chemotherapy, increasing the effect against cancer cells (<xref ref-type="bibr" rid="B158">Lazaro-Carrillo et al., 2020</xref>).</p>
<p>Trabulo et al. developed a nanoformulation of MNPs with gemcitabine (chemotherapeutic drug) and anti-CD47 (adjuvant). The anti-CD47 antibody formulation showed efficient induction of apoptosis in cancer cells compared to free antibodies. In addition, the NPs were covered with BSA and polyethylene glycol (PEG) avoiding their rapid clearance and leading to a better efficacy (<xref ref-type="bibr" rid="B295">Trabulo et al., 2017</xref>).</p>
<p>MNPs can also be employed as smart delivery system for miRNAs. Lafuente-G&#xf3;mez et al. developed maghemite core NPs loaded with immunomodulatory miRNA that induced a pro-inflammatory response in macrophages due to their load and specific coating (<xref ref-type="bibr" rid="B153">Lafuente-Gomez et al., 2022</xref>).</p>
<p>A promising strategy against cancer delivered by NPs is heterogeneous catalysis, which aims to target key chemical species of the tumor and generate <italic>in situ</italic> harmful biomolecules. Bonet-Aleta et al. engineered copper-iron oxide spinel NPs that effectively reduced glutathione levels and increased ROS and apoptotic pathways in cancer cells (<xref ref-type="bibr" rid="B39">Bonet-Aleta et al., 2022a</xref>). Furthermore, they investigated in depth the selective homo- and heterogenous catalytic processes undergoing in the tumor microenvironment, in which the higher glutathione levels are the main driving factor (<xref ref-type="bibr" rid="B38">Bonet-Aleta et al., 2022b</xref>). Glutathione is in a much higher concentration inside the cells than on the outside and it is largely responsible of the redox environment of the intracellular medium. This has also been exploited using iron oxide-MnO<sub>2</sub> core-satellite shell NPs that undergo a chemical dissolution of the manganese dioxide shell when they are internalized by cells (<xref ref-type="bibr" rid="B111">Garcia-Soriano et al., 2022</xref>). This stimuli-responsive behavior changes the MRI contrast mode of the NPs and, at the same time, the iron oxide cores preserve their ability to kill cells through magnetic hyperthermia.</p>
<p>Another interesting property of MNPs is their antiviral activity, de Diego et al. showed that iron oxide NPs impair SARS-CoV-2 infection, highlighting their repurposing value as prophylactic agents against this viral infection (<xref ref-type="bibr" rid="B65">DeDiego et al., 2022</xref>).</p>
<p>Finally, the ultimate goal of research in nanomedical development is to reach clinical trials and improve current therapies. In this regard, it is worth highlighting the work done within the European project NoCanTher, where several Spanish institutions were involved. The consortium has been able to test the magnetic hyperthermia approach at Vall d&#x2019;Hebron hospital (Barcelona) for the treatment of locally advanced pancreatic cancer. These types of studies are essential to make nanomaterial-based treatments a reality in the near future (<xref ref-type="bibr" rid="B201">Nanoscience, 2020</xref>).</p>
</sec>
<sec id="s2-3">
<title>2.3 Gold nanoparticles</title>
<p>Gold NPs (AuNPs) are especially relevant due to their ease of preparation, surface reactivity and unique optical properties (<xref ref-type="bibr" rid="B104">Garcia, 2011</xref>), (<xref ref-type="bibr" rid="B117">Goesmann and Feldmann, 2010</xref>; <xref ref-type="bibr" rid="B313">Wolfram and Ferrari, 2019</xref>). The small size of AuNPs, their biocompatibility, low toxicity and the possibility of simultaneous assembly of different molecular functionalities are attractive for biomedical use in therapy and sensing (<xref ref-type="bibr" rid="B115">Giner-Casares et al., 2016</xref>), (<xref ref-type="bibr" rid="B250">Saha et al., 2012</xref>), (<xref ref-type="bibr" rid="B90">Fabrizio et al., 2016</xref>), (<xref ref-type="bibr" rid="B12">Amendola et al., 2017</xref>), (<xref ref-type="bibr" rid="B280">Sperling et al., 2008</xref>), (<xref ref-type="bibr" rid="B276">Soenen et al., 2015</xref>). They are excellent candidates for PTT, biological imaging and optical sensing applications based on the localized surface plasmon resonance (LSPR) phenomenon, in terms of intrinsic properties as well as loading of different molecules, and they can also serve as contrast agents in computed tomography. Here we give an overview of the field given some examples of different AuNPs types but focusing on spherical colloids (<xref ref-type="table" rid="T3">Table 3</xref>).</p>
<table-wrap id="T3" position="float">
<label>TABLE 3</label>
<caption>
<p>Summary of AuNPs with their therapeutic area and functionalization strategy.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="center">Purpose</th>
<th align="center">Cargo</th>
<th align="center">Therapeutic area</th>
<th align="center">Functionalization strategy</th>
<th align="center">Ref.</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td rowspan="4" align="center">Improve NP&#x2019;s properties</td>
<td align="center">Increase the cellular attachment</td>
<td align="center">-</td>
<td align="center">Gelation with polyoxometalates for encapsulation of Gold Nanorods into mucoadhesive hydrogel, allowing the attachment to the cytoplasmic membranes</td>
<td align="center">
<xref ref-type="bibr" rid="B23">Artiga et al. (2018)</xref>
</td>
</tr>
<tr>
<td align="center">Enhance Adenovirus cellular uptake, distribution and therapeutic effect via surface modification with NPs</td>
<td align="center">Cancer</td>
<td align="center">Adenovirus decoration with PEGylated AuNPs carrying quaternary ammonium groups and RGD-motifs</td>
<td align="center">
<xref ref-type="bibr" rid="B127">Gonzalez-Pastor et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="center">To gain control over protein corona formation</td>
<td align="center">-</td>
<td align="center">Zwitterionic ligands based on oligocationic cages and negatively charged pyranine</td>
<td align="center">
<xref ref-type="bibr" rid="B197">Mosquera et al. (2020)</xref>
</td>
</tr>
<tr>
<td align="center">Study physicochemical changes by tracking the spectral signatures using Hyperspectral-enhanced dark field microscopy</td>
<td align="center">-</td>
<td align="center">Polymer-coated gold/copper sulfide NPs</td>
<td align="center">
<xref ref-type="bibr" rid="B317">Zamora-Perez et al. (2021)</xref>
</td>
</tr>
<tr>
<td rowspan="2" align="center">Enhance biological processes</td>
<td align="center">Enhance immune response</td>
<td align="center">HIV infection</td>
<td align="center">AuNPs dually conjugated with IgG anti-HIVgp120 and IgG anti-human CD16, bringing together virus and NK cells to reinforce the immune response against virus</td>
<td align="center">
<xref ref-type="bibr" rid="B24">Astorga-Gamaza et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="center">Activation and expansion of T cells against tumors</td>
<td align="center">Cancer</td>
<td align="center">Nanostructured surfaces functionalized with the stimulating anti-CD3 antibody and the RGD peptide, plus costimulatory agents</td>
<td align="center">
<xref ref-type="bibr" rid="B132">Guasch et al. (2018)</xref>
</td>
</tr>
<tr>
<td rowspan="4" align="center">Control hyperthermia</td>
<td align="center">Monitor light-to-heat conversion of gold nanorods</td>
<td align="center">-</td>
<td align="center">Encapsulation of gold nanorods together with Nd-doped fluorescent NPs in a PLGA polymer</td>
<td align="center">
<xref ref-type="bibr" rid="B242">Rocha et al. (2016)</xref>
</td>
</tr>
<tr>
<td align="center">Control local heating and nanothermometry</td>
<td align="center">Brain cancer</td>
<td align="center">Gold Nanostars (photothermal) combined with CaF<sub>2</sub>:Nd<sup>3&#x2b;,</sup>Y<sup>3</sup> luminescence NPs (thermometer)</td>
<td align="center">
<xref ref-type="bibr" rid="B232">Quintanilla et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="center">Nanothermometry Method</td>
<td rowspan="2" align="center">-</td>
<td align="center">Gold nanorods and gold-iron oxide magnetic nanostars</td>
<td align="center">
<xref ref-type="bibr" rid="B82">Espinosa et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="center">Intercellular trafficking of gold nanostars as photothermal agents in cancer therapy</td>
<td align="center">Gold nanostars functionalized with PEG-SH</td>
<td align="center">
<xref ref-type="bibr" rid="B5">Ahijado-Guzman et al. (2020)</xref>
</td>
</tr>
<tr>
<td rowspan="3" align="center">Sustainable synthesis</td>
<td rowspan="3" align="center">Green synthesis of NPs for different purposes</td>
<td align="center">Antimicrobial</td>
<td align="center">Au and Ag NPs stabilized with &#x201c;safely-obtained&#x201d; biosurfactants</td>
<td align="center">
<xref ref-type="bibr" rid="B120">Gomez-Grana et al. (2017)</xref>
</td>
</tr>
<tr>
<td align="center">Antiproliferative and Immunostimulative</td>
<td align="center">Synthesis using an extract of <italic>Saccorhiza polyschides</italic> conferring a protective NP environment</td>
<td align="center">
<xref ref-type="bibr" rid="B123">Gonzalez-Ballesteros et al. (2021a)</xref>
</td>
</tr>
<tr>
<td align="center">Cancer</td>
<td align="center">Green synthesis of AuNPs with carrageenan from seaweed</td>
<td align="center">
<xref ref-type="bibr" rid="B124">Gonzalez-Ballesteros et al. (2021b)</xref>
</td>
</tr>
<tr>
<td align="center">Hyperthermia-triggered gene expression</td>
<td align="center">Generation of cellular scaffolds and controlled gene expression</td>
<td align="center">Cell therapy</td>
<td align="center">AuNPs coated with poly-L-lysine through COOH-PEG-SH as covalent linker and thrombin to generate photothermal matrices</td>
<td align="center">
<xref ref-type="bibr" rid="B81">Escudero-Duch et al. (2019)</xref>
</td>
</tr>
</tbody>
</table>
<table>
<thead>
<tr>
<th align="center">Purpose</th>
<th align="center">Cargo</th>
<th align="center">Therapeutic area</th>
<th align="center">Functionalization strategy</th>
<th align="center">Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td rowspan="5" align="center">Drug delivery</td>
<td align="center">Horseradish peroxidase</td>
<td rowspan="3" align="center">
</td>
<td align="center">Covalent functionalization with horseradish peroxidase which oxidizes the prodrug indole-3-acetic acid (IAA) to release toxic oxidative species</td>
<td align="center">
<xref ref-type="bibr" rid="B311">Vivo-Llorca et al. (2022)</xref>
</td>
</tr>
<tr>
<td align="center">Gemcitabine/gapmers</td>
<td align="center">Combination of PEG, PEI and oligonucleotides electrostatically bound and released in reducing ambient</td>
<td align="center">
<xref ref-type="bibr" rid="B108">Garcia-Garrido et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="center">DOX</td>
<td align="center">DOX into Gold Nanorods loaded-HSA NPs prepared through desolvation</td>
<td align="center">
<xref ref-type="bibr" rid="B78">Encinas-Basurto et al. (2018a)</xref>
</td>
</tr>
<tr>
<td align="center">Docetaxel and DOX</td>
<td rowspan="2" align="center">Cancer</td>
<td align="center">HSA/Chitosan NPs to encapsulate docetaxel and DOX-gold nanorods for chemotherapy and photothermal therapy</td>
<td align="center">
<xref ref-type="bibr" rid="B306">Villar-Alvarez et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="center">Antivascular drugs</td>
<td align="center">Gold nanorods coated with mesoporous silica functionalized with aminopropyl groups and coupled to ICG photosensitizer. PEGylation with NHS-PEG-RGD</td>
<td align="center">
<xref ref-type="bibr" rid="B216">Paris et al. (2020)</xref>
</td>
</tr>
<tr>
<td rowspan="3" align="center">
</td>
<td align="center">DOX</td>
<td rowspan="3" align="center">
</td>
<td align="center">Nanorods coated with PSS DOX/PLL/human serum albumin layer-by-layer for chemotherapy and photothermal therapy</td>
<td align="center">
<xref ref-type="bibr" rid="B307">Villar-Alvarez et al. (2018)</xref>
</td>
</tr>
<tr>
<td align="center">DOX</td>
<td align="center">Fibrin hydrogel imbibing AuNPs and thermosensitive liposomes with DOX</td>
<td align="center">
<xref ref-type="bibr" rid="B176">Martin-Saavedra et al. (2017)</xref>
</td>
</tr>
<tr>
<td align="center">DOX and SN38</td>
<td align="center">Albumin-stabilized gold nanoclusters modified with drugs</td>
<td align="center">
<xref ref-type="bibr" rid="B156">Latorre et al. (2019)</xref>
</td>
</tr>
<tr>
<td rowspan="5" align="center">Drug delivery</td>
<td align="center">miRNA and SN38</td>
<td rowspan="2" align="center">Cancer</td>
<td align="center">Conjugation of therapeutic oligonucleotides and SN38 using thiol moieties on AuNPs</td>
<td align="center">
<xref ref-type="bibr" rid="B187">Milan Rois et al. (2018)</xref>
</td>
</tr>
<tr>
<td align="center">NK-Extracellular vesicles miRNAs</td>
<td align="center">AuNPs functionalized with miRNAs via thiol modifications</td>
<td align="center">
<xref ref-type="bibr" rid="B73">Dosil et al. (2022)</xref>
</td>
</tr>
<tr>
<td align="center">Calcein</td>
<td align="center">-</td>
<td align="center">Listeriolysin conjugated to the surface of AuNPs by functionalization with nitrile acetic acid</td>
<td align="center">
<xref ref-type="bibr" rid="B225">Plaza-Ga et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="center">Amikacin</td>
<td align="center">Microbicidal</td>
<td align="center">Gold nanostars functionalized with mercapto-poly(ethylene glycol)amino by ligand exchange and loaded with amikacin</td>
<td align="center">
<xref ref-type="bibr" rid="B1">Aguilera-Correa et al. (2022b)</xref>
</td>
</tr>
<tr>
<td align="center">siRNA</td>
<td align="center">Viral infection</td>
<td align="center">AuNPs with cationic carbosilane dendrone coating</td>
<td align="center">
<xref ref-type="bibr" rid="B222">Pena-Gonzalez et al. (2017)</xref>
</td>
</tr>
<tr>
<td rowspan="6" align="center">Smart delivery</td>
<td align="center">Plasmid DNA</td>
<td align="center">Gene therapy</td>
<td align="center">Plasmonic PEGylated gold nanostars and gemini cationic lipoplexes</td>
<td align="center">
<xref ref-type="bibr" rid="B252">Sanchez-Arribas et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="center">Proteins</td>
<td align="center">Biological therapy</td>
<td align="center">PEGylated gold nanorods functionalized with a fluorescently labelled BSA cell penetrating peptide, and mixed with therapeutic proteins</td>
<td align="center">
<xref ref-type="bibr" rid="B103">Garcia et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="center">Antibodies</td>
<td align="center">Cell-based therapies</td>
<td align="center">Cell-derived NPs containing PEGylated gold nanorods for intracellular delivery of antibodies</td>
<td align="center">
<xref ref-type="bibr" rid="B278">Soprano et al. (2020)</xref>
</td>
</tr>
<tr>
<td align="center">DOX</td>
<td rowspan="3" align="center">Cancer</td>
<td align="center">Janus gold nanostars-mesoporous silica NP functionalized with a thiolated photolabile molecule</td>
<td align="center">
<xref ref-type="bibr" rid="B138">Hernandez Montoto et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="center">DOX in combination with PTT</td>
<td align="center">Gold nanorods coated with silica and a thermosensitive polymer for drug delivery on demand upon irradiation</td>
<td align="center">
<xref ref-type="bibr" rid="B308">Villaverde et al. (2018)</xref>
</td>
</tr>
<tr>
<td align="center">Bisbenzimide molecules</td>
<td align="center">Thermoresponsive gold nanostars coated with ZIF-8 in combination with an amphiphilic polymer</td>
<td align="center">
<xref ref-type="bibr" rid="B44">Carrillo-Carrion et al. (2019)</xref>
</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>The group of Liz-Marzan is a recognized reference in the synthesis of gold-based nanomaterials for multiple biomedical applications, including sensing, photothermia, and preparation of 3D scaffolds (<xref ref-type="bibr" rid="B109">Garcia-Lojo et al., 2019</xref>). For instance, they systematically investigated the synthesis of gold-branched nanostructures, such as nanostars with interesting optical properties related to LSPR and surface-enhanced spectroscopies, as excellent candidates for biomedical purposes (<xref ref-type="bibr" rid="B30">Barbosa et al., 2010</xref>). They are considered state-of-the-art NPs to be used as efficient agents for photothermal treatment at the NIR range employed as a single modality or combination with other therapeutic functionalities (<xref ref-type="bibr" rid="B232">Quintanilla et al., 2019</xref>), (<xref ref-type="bibr" rid="B84">Espinosa et al., 2016</xref>), (<xref ref-type="bibr" rid="B308">Villaverde et al., 2018</xref>).</p>
<p>In order to enhance the cellular adherence of AuNPs, some strategies have been explored. For instance Artiga et al. encapsulated AuNPs inside a mucoadhesive chitosan hydrogel using polyoxometalates and phosphotungstic acid, showing that these containers can adhere to the cytoplasmic membrane of cells, enabling the thermoablating effect of the AuNPs without the need of cellular internalization (<xref ref-type="bibr" rid="B23">Artiga et al., 2018</xref>) (<xref ref-type="fig" rid="F4">Figure 4</xref>). Gonzalez-Pastor et al. explored an interesting modification of Adenoviral vectors (Ad) for improving their uptake in resistant cells and their biodistribution. The authors proposed a strategy based on the modification of the Ad surface with 14&#xa0;nm PEGylated AuNPs with quaternary ammonium groups and arginine-glycine-aspartic acid peptide motifs (or RGD-motif (<xref ref-type="bibr" rid="B9">Alipour et al., 2020</xref>)) to promote the attachment to cells via alternative cellular surface receptors, helped by the increase in positive charges. Modified vectors were tested in cellular models and in mice demonstrating their biocompatibility, high transduction efficiency, and antitumor activity (<xref ref-type="bibr" rid="B127">Gonzalez-Pastor et al., 2021</xref>).</p>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption>
<p>Synthesis of AuNR@CS hydrogel. Reprinted from <xref ref-type="bibr" rid="B23">Artiga et al. (2018)</xref>and licensed under the Creative Commons Attribution.</p>
</caption>
<graphic xlink:href="fbioe-11-1191327-g004.tif"/>
</fig>
<p>As highlighted in MNPs, the shape of AuNPs also affects their biological behavior and therapeutic properties, and therefore a controlled synthesis with optimized purification methodologies is critical to obtain homogeneous NPs. Ram&#xed;rez-Mart&#xed;nez et al. developed an efficient method to synthesize gold nanoprisms that showed reduced non-specific interactions with cells (<xref ref-type="bibr" rid="B233">Ramirez-Jimenez et al., 2020</xref>).</p>
<p>Enzyme prodrug therapy consists of selectively delivering an enzyme that activates a nontoxic prodrug into an active agent. Vivo-Llorca et al. functionalized the NPs with horseradish peroxidase, able to oxidize indole-3-acetic acid into toxic agents, and showed that this strategy presented high activity in 3D tumor models in which the three components on their own exhibit no therapeutic action (<xref ref-type="bibr" rid="B311">Vivo-Llorca et al., 2022</xref>).</p>
<p>Garcia-Garrido et al. studied drug delivery systems based on gold NPs tailored with low molecular weight polymers branched polyethylenimine and PEG. The system was able to deliver Gapmers targeting p53, reducing the chemoresistance to gemcitabine in mutant p53 cancer cells (<xref ref-type="bibr" rid="B108">Garcia-Garrido et al., 2021</xref>).</p>
<p>As is the case with every NP, the protein corona formed around NPs in biological media, modulates several key properties, including cellular internalization or clearance. Therefore, it is essential to study its formation, stability, and composition to understand NPs dynamics in cell and animal experiments. In this regard, Barbero et al. have studied the impact of common cell culture media elements in the formation of protein corona, and the mechanisms behind cellular penetration (<xref ref-type="bibr" rid="B28">Barbero et al., 2019</xref>), (<xref ref-type="bibr" rid="B29">Barbero et al., 2017</xref>), (<xref ref-type="bibr" rid="B27">Barbero et al., 2022</xref>). In this same subject, Mosquera et al. developed a strategy to control protein corona formation. The authors used AuNPs covered by an anionic dye (pyranine), which disrupts protein binding when a positively charged macromolecular cage is present. Zwitterionic surface ligands containing positive and negative charges will favor the formation of a protective hydration layer around the NPs. The authors demonstrate the reversibility of the system, which allows the control of corona formation through external additives. Applying this strategy the authors also increased (30-fold) the cellular uptake due to a synergistic effect between corona suppression and the charge switch from negative to positive at the NP surface. Finally, they explored its use in PTT, exploiting the conditional and enhanced cellular uptake of the system, this time using gold nanorods, with promising results (<xref ref-type="bibr" rid="B197">Mosquera et al., 2020</xref>).</p>
<p>Given the advantages of hybrid NPs, Encinas-Basurto et al. used DOX with gold NPs for PTT using human serum albumin NPs. When HeLa cells were treated with HSA-AuNR-DOX NPs, the cell viability was lower than the nanoplatform without DOX decreasing even further when the cells were irradiated (<xref ref-type="bibr" rid="B78">Encinas-Basurto et al., 2018a</xref>). Villar-Alvarez et al. also developed an hybrid nanocarrier based on human serum albumin/chitosan NPs that encapsulated free docetaxel and DOX-modified gold nanorods (DOX-GNRs) aiming to combine the chemotherapeutic properties of docetaxel and DOX with the plasmonic optical properties of GNRs for plasmonic-based PTT. This nanoformulation produced high cytotoxicity in breast cancer cells, and PTT enhances the cytostatic efficacy, with apoptosis being the main activated pathway (<xref ref-type="bibr" rid="B306">Villar-Alvarez et al., 2019</xref>). In a similar approach, Paris et al. engineered gold nanorods coated with a mesoporous silica shell to deliver two antivascular drugs with different mechanisms of action. The NPs also released heat and ROS through photothermal and PDT upon NIR light irradiation yielding remarkable results in a chicken embryo xenograft model (<xref ref-type="bibr" rid="B216">Paris et al., 2020</xref>).</p>
<p>In order to combine therapeutic plasmonic hyperthermia and DOX chemoaction, nanotransporters consisting of gold nanorods coated with poly(sodium-4-styrenesulfonate) (PSS)/DOX/hydrolyzed polylysine (PLL)/hyaluronic acid and (PSS/DOX/PLL)2/hyaluronic acid were developed by Villar-Alvarez et al. Hyaluronic acid targets CD44 receptors, which are overexpressed in some cancers. PTT induced cell necrosis, and apoptosis was promoted by DOX, resulting in a significant synergistic effect provided by a nano-based platform of targeted and multimodal controlled delivery (<xref ref-type="bibr" rid="B307">Villar-Alvarez et al., 2018</xref>). Astorga-Gamaza et al. also developed the synthesis of multivalent bispecific AuNPs to enhance the immune response towards HIV-expressing cells. They developed a cooperative adsorption methodology that allows the production of NPs with a 50:50 conjugation with two different antibodies that recognize the HIV gp120 protein and the CD16 receptor of natural killer cells. They performed a thorough characterization of the particles, which were able to promote specific cell-to-cell contact and induce a potent cytotoxic response (<xref ref-type="bibr" rid="B24">Astorga-Gamaza et al., 2021</xref>).</p>
<p>Martin-Saavedra et al. designed an hydrogel to incorporate AuNPs and thermosensitivie liposomes loaded with DOX. Upon NIR irradiation, the temperature rose locally releasing active DOX, whose delivery was dependent on the hydrogel composition and irradiation characteristics. Finally, the authors refined the system by incorporating copper sulfide NPs to create an easily biodegradable composite (<xref ref-type="bibr" rid="B176">Martin-Saavedra et al., 2017</xref>).</p>
<p>With the aim of controlling and monitoring the temperature of NPs reached during photothermal procedures in the tumor environment and, therefore, minimizing collateral effects during thermal treatments, plasmonic-mediated intracellular hyperthermia generated by Au nanomaterials has been tracked by nanothermometry methods. For instance, Rocha et al. have used Nd-doped Infrared-emitting NPs to monitor the light-to-heat conversion of Au nanorods during PTT (<xref ref-type="bibr" rid="B242">Rocha et al., 2016</xref>). Quintanilla et al. designed a hybrid probe for simultaneous plasmonic heating and NIR nanothermometry in glioma cells (<xref ref-type="bibr" rid="B232">Quintanilla et al., 2019</xref>). Finally, X-rays were also used to probe the local temperature of photoexcitated Au-based nanomaterials under NIR light for PTT, revealing significant nanothermal gradients (<xref ref-type="bibr" rid="B82">Espinosa et al., 2021</xref>).</p>
<p>Guasch et al., also investigated adoptive T cell therapy as a treatment for cancer, in an attempt to overcome the challenge of activating and expanding primary human T cells <italic>in vitro</italic>. They performed a method for activating primary human CD4<sup>&#x2b;</sup> T cells <italic>in vitro</italic> functionalizing nanostructured surfaces. These surfaces consist of covalently functionalized RGD on rigid TiO<sub>2</sub> surfaces decorated with arrays of AuNPs cell-linked to the stimulating antibody anti-CD3. They demonstrated that the combination of prestimulatory steps, nanostructure surfaces, and costimulatory compounds has an effect on the activation and proliferation of cells (<xref ref-type="bibr" rid="B132">Guasch et al., 2018</xref>).</p>
<p>Multidrug resistance is one of the problems of chemotherapy that reduces the efficacy of treatment, and nanocarriers can be used to enhance permeability and retention effect at the target site. Latorre et al. selected two chemotherapeutic drugs, DOX and the camptothecin analogue (CPT) SN38, for the functionalization of albumin-stabilized gold nanoclusters (AuNCs) using tailored linkers. The drugs were released when exposed to different stimuli, such as glutathione and acid pH, leading to a potent antitumor activity. Furthermore, this system showed antineoplastic activity against cancer stem cells (<xref ref-type="bibr" rid="B156">Latorre et al., 2019</xref>).</p>
<p>Recently, there has been wide interest in the nanomaterials community to synthesize NPs in a sustainable manner, reducing the use of toxic chemicals and solvents. In this regard, Gomez-Gra&#xf1;a et al. explored the possibility of synthesizing gold and silver NPs using a lipopeptide biosurfactant extracted from corn steep liquor. The silver NPs showed antimicrobial properties against <italic>Escherichia coli</italic> that was greater than similar citrate-stabilized NPs, enhancing the application of sustainable methodologies in NP synthesis (<xref ref-type="bibr" rid="B120">Gomez-Grana et al., 2017</xref>). Gonzalez-Ballesteros et al. also synthesized gold and silver NPs in bionanofactories, aiming at developing environmentally friendly processes for NPs synthesis. They characterized the NPs obtained and demonstrated that the particles showed antiproliferative properties and could also serve as immunostimulant agents (<xref ref-type="bibr" rid="B123">Gonzalez-Ballesteros et al., 2021a</xref>). In another related work, Gonzalez-Ballesteros and colleagues performed a green synthesis of AuNPs that were decorated with carrageenan extracted from red seaweed. The NPs showed relevant antioxidant and antitumoral properties, highlighting the beneficial effect of NP loading of the active compound (<xref ref-type="bibr" rid="B124">Gonzalez-Ballesteros et al., 2021b</xref>).</p>
<p>Regarding delivery, AuNPs have demonstrated to be effective carriers for a wide variety of oligonucleotides. For example, siRNAs are interesting molecules capable of modulating gene expression. One of the critical factors for this strategy to be effective is choosing an optimal strategy to link the siRNA to the AuNPs, and several chemistries have been developed to form stable complexes with proven activity in cellular and animal models (<xref ref-type="bibr" rid="B294">Tortiglione and de la Fuente, 2019</xref>). S&#xe1;nchez-Arribas et al. developed a strategy combining plasmonic gold nanostars and gemini cationic lipoplexes to release plasmid DNA upon irradiation (<xref ref-type="bibr" rid="B252">Sanchez-Arribas et al., 2021</xref>). Interestingly, this strategy exploits the release of a DNA plasmid &#x201c;on demand&#x201d; upon external stimuli.</p>
<p>Similarly, Milan-Rois et al., developed a strategy for the delivery of four miRNA downregulated in uveal melanoma, and other cancers, in combination with SN38, a topoisomerase I inhibitor. The study showed a synergistic effect between the four oligonucleotides and chemotherapeutic drug conjugated to the AuNPs (<xref ref-type="bibr" rid="B187">Milan Rois et al., 2018</xref>). In the same pathology, Ahijado-Guzman et al. explored the potential of gold nanostars as efficient plasmonic PTT using a non-harmful laser irradiation (<xref ref-type="bibr" rid="B5">Ahijado-Guzman et al., 2020</xref>). Their results show how these cancer cells can release and uptake the NPs achieving effective PTT even in non-preloaded cells.</p>
<p>Dosil et al. have demonstrated how AuNP-based delivery of specific NK-extracellular vesicles-miRNAs regulates immune responses related to Th1 and recapitulated this phenomenon in animal models. Th1 cells directly killed tumor cells via the release of cytokines that activate death receptors on the tumor cell surface, representing a potential immunomodulatory strategy against diseases (<xref ref-type="bibr" rid="B73">Dosil et al., 2022</xref>).</p>
<p>Endosomal escape of the transported cargo is another important feature of NP delivery, to guarantee active functionality in the cytosol. In a recent work, Plaza Ga et al. (<xref ref-type="bibr" rid="B225">Plaza-Ga et al., 2019</xref>), explored a mechanism used by the bacterial pathogen <italic>Listeria monocytogenes</italic> through a toxin called Listeriolysin O. They conjugated this protein to the surface of AuNPs and observed how upon endosomal acidification, the protein disassembles from the NPs to form a pore in the endosomal lipid bilayer enabling the escape of NPs. Within the same focus, and to improve the delivery of proteins, Garcia et al. developed gold nanorods modified with a cell-penetrating peptide that, upon NIR irradiation in the safe second biological window, releases the protein cargo in a controlled spatial and temporal manner (<xref ref-type="bibr" rid="B103">Garcia et al., 2021</xref>).</p>
<p>Smart delivery or delivery after external stimuli offers exciting methodologies for delivering cargo into the cytosol on demand. Soprano et al. developed cell-derived NPs that contained gold nanorods in their structure that enabled the release of non-permeant antibodies into the cytosol of cells. The nanocarriers were responsive to NIR irradiation, which proved safe for cells at the conditions needed for cytosolic delivery (<xref ref-type="bibr" rid="B278">Soprano et al., 2020</xref>).</p>
<p>Escudero-Duch and collaborators developed a NIR responsive hydrogel based on fibrin, and hollow poly-L-lysine covered gold NPs. The <italic>in-situ</italic> polymerization of fibrin upon NIR irradiation yields a hydrogel potentially suitable for its use as a scaffold in regenerative medicine. This hydrogel tested in cellular and animal models showed good biocompatibility and allowed the spatial patterning of transgene expression triggered by heat (<xref ref-type="bibr" rid="B81">Escudero-Duch et al., 2019</xref>).</p>
<p>Hern&#xe1;ndez-Montoto et al. prepared Janus gold nanostars MSNs loaded with DOX, and equipped with a cyclodextrin supramolecular gatekeeper. NIR light triggered the release of succinic acid that enabled gate opening and cargo delivery. This strategy enables to use AuNPs as photochemical transducers able to release a chemical messenger upon NIR irradiation. The Janus NPs showed a reduction in cell viability, proving their potential as smart delivery materials (<xref ref-type="bibr" rid="B138">Hernandez Montoto et al., 2019</xref>).</p>
<p>In an attempt to improve the available treatments for melanoma, which is highly resistant to cytotoxic agents after metastasis, Villaverde et al. engineered gold nanorods coated with silica and a thermosensitive polymer conjugated to NAPamide, a selective targeting agent for alpha melanocytes. Thus, these NPs exerted a synergistic effect of the cytotoxic DOX and PTT (<xref ref-type="bibr" rid="B308">Villaverde et al., 2018</xref>).</p>
<p>Carrillo-Carri&#xf3;n et al. investigated the combination of gold nanostars with metal organic frameworks based on zeolitic imidazole and an amphiphilic polymer to afford thermoresponsive nanocomposites. They demonstrated their stability and the release of cargo inside cells (<xref ref-type="bibr" rid="B44">Carrillo-Carrion et al., 2019</xref>).</p>
<p>Zamora-P&#xe9;rez et al. employed Hyperspectral-Enhanced Dark Field Microscopy (HEDFM) to test the dynamics of Au/CuS NPs directly, based on the changes in the scattering of the nanomaterial in different physiological conditions. Changes in the scattering profiles of NPs could be used as indicators of their performance as photothermal probes. The authors demonstrated how the combination of plasmonic NPs with HEDFM informs of the behavior of intracellular NPs to optimize their functionality for nanomedical applications (<xref ref-type="bibr" rid="B317">Zamora-Perez et al., 2021</xref>).</p>
<p>Aguilera-Correa et al. also developed gold nanostars and tested their antimicrobial properties alone and loaded with a potent and widely used antibiotic. The gold nanostars <italic>per se</italic> did not show antimicrobial activity, however in combination with amikacin inhibited the growth of bacterial biofilm of carbapenem-resistant <italic>Klebsiella pneumoniae</italic> strain, suggesting that the NPs facilitate the entrance of the therapeutic agent into the biofilm (<xref ref-type="bibr" rid="B1">Aguilera-Correa et al., 2022b</xref>).</p>
<p>Finally, Pe&#xf1;a-Gonzalez et al. engineered AuNPs and AgNPs with a cationic carbosilane dendrone coating that improved their delivering capabilities, and characterized their interactions with erythrocytes, platelets, and peripheral blood mononuclear cells. The NPs showed to have a safe profile in these systems and proved successful in cell delivery of siRNA against HIV (<xref ref-type="bibr" rid="B222">Pena-Gonzalez et al., 2017</xref>).</p>
</sec>
<sec id="s2-4">
<title>2.4 Silver nanoparticles</title>
<p>Similar to gold NPs, silver NPs (AgNPs) have unique and useful properties and are being used in several consumer products such as textiles or home appliances (<xref ref-type="bibr" rid="B4">Ahamed et al., 2010</xref>). The antibacterial properties of silver have been known for centuries (<xref ref-type="bibr" rid="B185">McGillicuddy et al., 2017</xref>), and colloidal silver has been used by humans for more than 150 years for the treatment of wounds and infections (<xref ref-type="bibr" rid="B237">Reidy et al., 2013</xref>). Interestingly, this biological activity is gaining significant interest among researchers due to the resistance developed by different pathogens to current antibiotics. In this regard, some developments carried out by Spanish scientists are mentioned below (<xref ref-type="table" rid="T4">Table 4</xref>).</p>
<table-wrap id="T4" position="float">
<label>TABLE 4</label>
<caption>
<p>Summary of AgNPs with their therapeutic area and functionalization strategy.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="center">NP Type</th>
<th align="center">Purpose</th>
<th align="center">Therapeutic area</th>
<th align="center">Therapeutic agent</th>
<th align="center">Functionalization strategy</th>
<th align="center">Ref</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td rowspan="6" align="center">AgNPs</td>
<td align="center">Anti-amoebic contact lens solution</td>
<td align="center">Keratitis</td>
<td align="center">-</td>
<td align="center">Commercially available AgNPs</td>
<td align="center">
<xref ref-type="bibr" rid="B137">Hendiger et al. (2021)</xref>, (<xref ref-type="bibr" rid="B136">Hendiger et al. (2020)</xref>
</td>
</tr>
<tr>
<td align="center">Anti-amoebic contact lens solution</td>
<td align="center">Keratitis, encephalitis</td>
<td align="center">Tannic acid</td>
<td align="center">Tannic acid-modified AgNPs</td>
<td align="center">
<xref ref-type="bibr" rid="B212">Padzik et al. (2018)</xref>
</td>
</tr>
<tr>
<td align="center">Prevention of implant-associated infection</td>
<td align="center">Antibacterial</td>
<td align="center">-</td>
<td align="center">AgNPs were synthesized by laser ablation in de-ionized water</td>
<td align="center">
<xref ref-type="bibr" rid="B224">Perez-Tanoira et al. (2022)</xref>
</td>
</tr>
<tr>
<td align="center">Low cost antitumor tool</td>
<td align="center">Cancer</td>
<td align="center">Acetogenin rich extracts</td>
<td align="center">Extracts from leaves and peel of <italic>A. muricata</italic> were used to synthesize AgNPs</td>
<td align="center">
<xref ref-type="bibr" rid="B128">Gonzalez-Pedroza et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="center">Anti-biofilm treatments in chronic wound infections</td>
<td align="center">Antibacterial</td>
<td align="center">Enzymes (&#x3b1;-amylase, cellulose, DNase I and proteinase K)</td>
<td align="center">Enzyme-coated AgNPs</td>
<td align="center">
<xref ref-type="bibr" rid="B248">Rubio-Canalejas et al. (2022)</xref>
</td>
</tr>
<tr>
<td align="center">Combination of two antibacterial agents (probiotics and AgNPs)</td>
<td align="center">Antibacterial (topical)</td>
<td align="center">Probiotics</td>
<td align="center">Probiotics and AgNPs in a matrix as bacterial cellulose</td>
<td align="center">
<xref ref-type="bibr" rid="B249">Sabio et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="center">GSH-Ag NPs</td>
<td align="center">Improve efficacy for multidrug resistant bacteria</td>
<td rowspan="2" align="center">Antibacterial</td>
<td align="center">-</td>
<td align="center">Glutathione for stabilization</td>
<td align="center">
<xref ref-type="bibr" rid="B274">Silvan et al. (2018)</xref>
</td>
</tr>
<tr>
<td align="center">AgNP@nanoMOF</td>
<td align="center">Combating bacterial biofilms</td>
<td align="center">-</td>
<td align="center">Silver impregnated nanoMOF thin film functionalized with DNase I</td>
<td align="center">
<xref ref-type="bibr" rid="B17">Arenas-Vivo et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="center">Silver nanorings</td>
<td align="center">Study a novel type of AgNPs as an antimicrobial therapy</td>
<td align="center">Antifungal, antiamoebic</td>
<td align="center">-</td>
<td align="center">Silver nanorings which have a filament diameter of 80&#xa0;nm and a ring diameter of between 12 and 18&#xa0;&#xb5;m</td>
<td align="center">
<xref ref-type="bibr" rid="B125">Gonzalez-Fernandez et al. (2022)</xref>
</td>
</tr>
<tr>
<td align="center">PLGA@Ag<sub>2</sub>S and PLGA@Ag<sub>2</sub>S@SPION</td>
<td align="center">Hybrid system for chemotherapy</td>
<td align="center">Cancer</td>
<td align="center">Maslinic acid</td>
<td align="center">Combination of Ag<sub>2</sub>S NPs and SPIONs by electrospraying into a PLGA matrix loaded with maslinic acid (PLGA@Ag2S@maslinic acid)</td>
<td align="center">
<xref ref-type="bibr" rid="B10">Alvear-Jimenez et al. (2022)</xref>
</td>
</tr>
<tr>
<td align="center">AgNPs and AuNPs</td>
<td align="center">Nanoparticles as delivery systems for cancer cells</td>
<td rowspan="2" align="center">Cancer</td>
<td align="center">Raltitrexed</td>
<td align="center">AuNPs and AuNPs functionalized with raltitrexed</td>
<td align="center">
<xref ref-type="bibr" rid="B195">Morey et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="center">AgNPs nanofluid</td>
<td align="center">Photothermal agent acting as nanothermometer</td>
<td align="center">-</td>
<td align="center">AgNPs were functionalized with HS-PEG-OMe</td>
<td align="center">
<xref ref-type="bibr" rid="B323">Mendez-Gonzalez et al. (2022)</xref>
</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>Silvan et al. designed AgNPs stabilized with glutathione and evaluated their efficacy against multidrug-resistant <italic>Campylobacter</italic> strains that were extracted from chicken samples. While the NPs were able to inhibit bacterial growth, the mean minimal inhibitory concentration resulted cytotoxic for three different human intestinal cell lines tested. This effect highlights the importance of further safety experiments to assess the practical potential of AgNPs therapeutic effects (<xref ref-type="bibr" rid="B274">Silvan et al., 2018</xref>).</p>
<p>Sabio et al. designed a two-sided material combining AgNPs on one side and living probiotics on the other, with antibacterial capacity against <italic>Pseudomonas aeruginosa</italic> (<xref ref-type="bibr" rid="B249">Sabio et al., 2021</xref>). AgNPs have also been explored for their anti-amoebotic properties against pathogens responsible for keratitis. In this regard, Hendiger et al. evaluated the activity, cytotoxicity, and anti-adhesive properties of AgNPs included in contact lens solutions against the <italic>Acanthamoeba castellanii Neff</italic> strain (<xref ref-type="bibr" rid="B137">Hendiger et al., 2021</xref>), (<xref ref-type="bibr" rid="B136">Hendiger et al., 2020</xref>). The presence of the AgNPs showed a significant increase in anti-amoebic activity, without increasing the overall cytotoxicity, decreasing the risk of <italic>Acanthamoeba keratitis</italic> infection. Padzik et al. also employed AgNPs conjugated with tannic acid as potential agents against <italic>Acanthamoeba spp</italic> (<xref ref-type="bibr" rid="B212">Padzik et al., 2018</xref>).</p>
<p>In the case of peri-implantitis due to biofilm deposits, P&#xe9;rez-Tanoira et al. immobilized AgNPs in titanium, demonstrating its beneficial effect in reducing the biofilms stablished by <italic>S. aureus</italic> and by mixed oral bacterial flora (<xref ref-type="bibr" rid="B224">Perez-Tanoira et al., 2022</xref>). Other anti-biofilm strategies involve the use of silver-containing nanoscaled Metal Organic Frameworks (MOFs) against <italic>S. aureus</italic> biofilm. Arenas-Vivo et al. demonstrated the use of AgNPs functionalized with DNase I decreasing the <italic>S. aureus</italic> biofilm viability more than using the antibiotics alone (<xref ref-type="bibr" rid="B17">Arenas-Vivo et al., 2019</xref>). Rubio-Canalejas et al. pointed out that clinical treatment combining antibiofilm enzymes and antibiotics may be essential to eliminating chronic wound infections (<xref ref-type="bibr" rid="B248">Rubio-Canalejas et al., 2022</xref>). Finally, Gonz&#xe1;lez-Fern&#xe1;ndez et al. demonstrated how silver nanorings are capable of totally inhibiting the germination of <italic>A. castellanii</italic> cysts (<xref ref-type="bibr" rid="B125">Gonzalez-Fernandez et al., 2022</xref>).</p>
<p>In regards to drug delivery, the formation of hybrid Ag<sub>2</sub>S NPs with poly(lactic-co-glycolic acid) (PLGA) by electrospray allows for the encapsulation of drugs such as maslinic acid (MA). The anticancer drug showed an efficient encapsulation and controlled release in cellular models (<xref ref-type="bibr" rid="B10">Alvear-Jimenez et al., 2022</xref>).</p>
<p>Morey et al., modified silver and gold NPs using cysteine to bind raltitrexed to the surface of NPs and tested them in A549 and HTC-116 cells lines. Silver raltitrexed NPs inhibited cancer cell viability (<xref ref-type="bibr" rid="B195">Morey et al., 2021</xref>). Other modifications, such as the functionalization of AgNPs with <italic>Annona muricata</italic> plant antitumoral extracts, have been prepared and tested by Gonz&#xe1;lez-Pedroza et al. as promising antitumoral nanoformulations (<xref ref-type="bibr" rid="B128">Gonzalez-Pedroza et al., 2021</xref>).</p>
<p>Finally, AgNPs can be used as luminescent biofluids capable of acting as photothermal agents and nanothermometers. Mendez-Gonzalez et al. showed how a nanofluid containing AgNPs had improved properties compared to a combination with magnetic nanoflowers and showcases their use for hyperthermia in brain tumors (<xref ref-type="bibr" rid="B323">Mendez-Gonzalez et al., 2022</xref>).</p>
</sec>
</sec>
<sec id="s3">
<title>3 Organic nanoparticles</title>
<p>Organic NPs have synthetic or natural organic components such as carbohydrates, proteins, peptides, or lipids (<xref ref-type="bibr" rid="B245">Romero et al., 2012</xref>). Their biodegradable composition, together with the relatively simple encapsulation of drugs, make them the preferred drug delivery systems. The current advances in the use of protein, polysaccharide, polymeric and lipid NPs carried out in Spanish institutions are discussed below, and summarized in tables at the end of each section.</p>
<sec id="s3-1">
<title>3.1 Protein nanoparticles</title>
<p>Protein NPs are of great interest in nanomedicine due to the intrinsic properties of proteins, such as their biocompatibility and biodegradability. Proteins possess different functional groups located in the side chains of amino acids that can be exploited for chemical conjugation. They also contain hydrophilic and hydrophobic regions that can be used to interact with hydrosoluble or insoluble compounds. Finally, they have tunable structures that can be obtained by protein engineering, expanding their applications (<xref ref-type="table" rid="T5">Table 5</xref>).</p>
<table-wrap id="T5" position="float">
<label>TABLE 5</label>
<caption>
<p>Summary of protein NPs with their therapeutic area and synthesis strategy.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="center">Protein</th>
<th align="center">Purpose</th>
<th align="center">Therapeutic area</th>
<th align="center">Therapeutic Agent</th>
<th align="center">Synthesis/Encapsulation strategy</th>
<th align="center">Ref</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td rowspan="4" align="center">Albumin</td>
<td align="center">Drug delivery/smart release</td>
<td align="center">Cancer</td>
<td align="center">DOX</td>
<td align="center">NPs stabilized by redox crosslinker to increase drug release in cancer cells</td>
<td align="center">
<xref ref-type="bibr" rid="B229">Prajapati et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="center">Increase efficacy and biodisponibility of AZD8055</td>
<td align="center">Uveal melanoma</td>
<td align="center">AZD8055</td>
<td align="center">Gold nanoculsters stabilized by albumin. Cargo conjugation by disulfide bonds</td>
<td align="center">
<xref ref-type="bibr" rid="B155">Latorre et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="center">Increase selectivity of nanoparticle delivery against tumor</td>
<td rowspan="2" align="center">Cancer</td>
<td align="center">PTX</td>
<td align="center">Folate-targeted NPs based on BSA and alginate and stabilized by amide bonds using ethylenediamine</td>
<td align="center">
<xref ref-type="bibr" rid="B182">Martinez-Relimpio et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="center">Develop tumor-targeted BSA NPs</td>
<td align="center">-</td>
<td align="center">BSA NPs functionalized with chlorosydnone to click with anti-PD-L1 antibodies with dibenzocyclooctyne moeities</td>
<td align="center">
<xref ref-type="bibr" rid="B324">Gerke et al. (2022)</xref>
</td>
</tr>
<tr>
<td rowspan="2" align="center">Protamine</td>
<td align="center">Insulin oral delivery</td>
<td align="center">Diabetes</td>
<td align="center">Insulin</td>
<td align="center">Nanocarriers with oily core and protamine/PSA shell</td>
<td align="center">
<xref ref-type="bibr" rid="B291">Thwala et al. (2018)</xref>
</td>
</tr>
<tr>
<td align="center">Vaccine adjuvant</td>
<td align="center">Influenza</td>
<td align="center">Different antigens</td>
<td align="center">Nanocarriers with oily core and protamine shell</td>
<td align="center">
<xref ref-type="bibr" rid="B122">Gonzalez-Aramundiz et al. (2017)</xref>, <xref ref-type="bibr" rid="B121">Gonzalez-Aramundiz et al. (2018)</xref>
</td>
</tr>
<tr>
<td align="center">Polyarginine</td>
<td align="center">Oral peptide delivery</td>
<td rowspan="3" align="center">Diabetes</td>
<td align="center">Insulin and oleic acid</td>
<td align="center">Nanocapsules with oily core and polyarginine shell</td>
<td align="center">
<xref ref-type="bibr" rid="B206">Niu et al. (2017)</xref>
</td>
</tr>
<tr>
<td rowspan="2" align="center">Zein</td>
<td rowspan="2" align="center">Insulin delivery</td>
<td rowspan="2" align="center">Insulin</td>
<td align="center">Zein NPs coated with PEG and synthetic polymers</td>
<td align="center">
<xref ref-type="bibr" rid="B235">Reboredo et al. (2021)</xref>, <xref ref-type="bibr" rid="B141">Inchaurraga et al. (2020)</xref>
</td>
</tr>
<tr>
<td align="center">Zein NPs coated with PEG and Gantrez AN-PEG</td>
<td align="center">
<xref ref-type="bibr" rid="B180">Martinez-Lopez et al. (2021)</xref>
</td>
</tr>
<tr>
<td rowspan="5" align="center">Engineered peptides</td>
<td rowspan="5" align="center">Toxic proteins delivery</td>
<td rowspan="5" align="center">Cancer</td>
<td align="center">Diphteria and <italic>P.aeruginosa</italic> toxins</td>
<td rowspan="5" align="center">Toxic peptides self-assembled in NPs with specific targeting regions</td>
<td align="center">
<xref ref-type="bibr" rid="B256">Sanchez-Garcia et al. (2018)</xref>, <xref ref-type="bibr" rid="B312">Volta-Duran et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="center">29 amino acid-segment of the helix &#x3b1;5 from the human BAX protein</td>
<td align="center">
<xref ref-type="bibr" rid="B255">Sanchez-Garcia et al. (2020)</xref>
</td>
</tr>
<tr>
<td align="center">Exotoxin A from <italic>P.aeruginosa</italic>
</td>
<td align="center">
<xref ref-type="bibr" rid="B91">Falgas et al. (2020)</xref>
</td>
</tr>
<tr>
<td align="center">Diphteria toxin</td>
<td align="center">
<xref ref-type="bibr" rid="B213">Pallares et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="center">Monometyl Auristatin E (MMAE)</td>
<td align="center">
<xref ref-type="bibr" rid="B214">Pallares et al. (2020)</xref>
</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>Several proteins have been used to create NPs for their use in nanomedicine, being albumin one of the most successful ones. It is naturally present in the blood, so it can avoid immunogenic reactions, increasing the circulation time of their cargoes. It is a natural vehicle especially suited for the interaction with hydrophobic molecules. Furthermore, human cells present albumin receptors, namely, gp60 and SPARC (<xref ref-type="bibr" rid="B230">Prajapati and Somoza, 2021</xref>). As these receptors are overexpressed in cancer cells, albumin NPs can be used to target tumor sites. This strategy has been successfully used in the formulation of Abraxane, which has been approved for the treatment of several tumors (<xref ref-type="bibr" rid="B295">Trabulo et al., 2017</xref>). Albumin is a monomeric protein unable to form NPs by itself, therefore several methods have been used to form albumin nanostructures, being desolvation the most common one. For example, Prajapati et al. used this method to encapsulate DOX, a drug limited by its toxicity. Its encapsulation inside of NPs enabled to target tumor cells specifically, increased the drug efficacy, and decreased its toxicity. Furthermore, they stabilized the NPs employing several cross-linkers, showing that a redox-dependent crosslinker (SPDP, N-succinimidyl 3-(2-pyridyldithio) propionate) increased drug release in cancer cells, due to their enhanced redox environment compared to non-cancer cells. Their nanoformulation showed toxicity in breast cancer cells and a negligible effect in non-tumoral cells, presenting a potential use for the treatment of breast cancer (<xref ref-type="bibr" rid="B229">Prajapati et al., 2021</xref>) (<xref ref-type="fig" rid="F5">Figure 5</xref>). The same group also used albumin-based nanostructures for uveal melanoma treatment. In another article, they studied the use of albumin to deliver AZD8055, a potent inhibitor of the mTOR pathway that is overexpressed in the pathology and is critical in tumorgenesis. They produced gold nanoclusters stabilized by albumin, while the drug was conjugated externally using disulphide bonds. The lately thiol-dependent conjugation of the drug allowed its specific release in the cytoplasm of cancer cells. The authors showed that their nanostructures had anti-tumoral activity in mice models, using a dose 23-fold lower than previously reported (<xref ref-type="bibr" rid="B155">Latorre et al., 2021</xref>). The conjugation of folate to NPs based on BSA and alginate as an active targeting strategy for the delivery of PTX was showed by Martinez-Relimpio et al. which resulted in an increased uptake of the NPs by cancer cell lines, as there is an overexpression of folate receptors (<xref ref-type="bibr" rid="B182">Martinez-Relimpio et al., 2021</xref>). To exploit BSA NPs delivery possibilities Gerke et al. developed a simple methodology with clickable anti-PD-L1 antibodies, showcasing the versatility of this bioorthogonal design (<xref ref-type="bibr" rid="B324">Gerke et al., 2022</xref>).</p>
<fig id="F5" position="float">
<label>FIGURE 5</label>
<caption>
<p>Albumin NPs synthesis. Reprinted from <xref ref-type="bibr" rid="B229">Prajapati et al. (2021)</xref> and licensed under the Creative Commons Attribution.</p>
</caption>
<graphic xlink:href="fbioe-11-1191327-g005.tif"/>
</fig>
<p>Hydrophilic proteins with multiple arginine residues, such as protamine and polyarginine, are widely used to form NPs as their positive charge confers membrane-translocation properties (<xref ref-type="bibr" rid="B291">Thwala et al., 2018</xref>). Similarly to albumin, it does not form NPs by itself, so a solvent displacement method must be used to create protamine nanocapsules. NPs contain an oily core and a protamine coating. Thwala et al. used them for the delivery of insulin, a highly used protein that cannot be administered orally. The authors used a protamine/PSA shell that controls the release of insulin from the moment the NPs are administered orally until reaching the intestine (<xref ref-type="bibr" rid="B291">Thwala et al., 2018</xref>). Furthermore, the insulin transport across mucus layers can be increased by incorporating in the formulation penetration enhancers such as oleic acid (<xref ref-type="bibr" rid="B206">Niu et al., 2017</xref>). The same group used protamine nanocapsules loaded with antigens as an alternative to vaccine adjuvants. This system can load multiple antigens, be lyophilized, and trigger the immune response. These properties have been shown in particles loaded with influenza hemagglutinin antigen, and particles containing hepatitis B virus surface antigen (<xref ref-type="bibr" rid="B122">Gonzalez-Aramundiz et al., 2017</xref>; <xref ref-type="bibr" rid="B121">Gonzalez-Aramundiz et al., 2018</xref>). According to the results, the protamine nanocapsules showed the ability to enter macrophages without toxicity and produced an important immune response against influenza (<xref ref-type="bibr" rid="B122">Gonzalez-Aramundiz et al., 2017</xref>).</p>
<p>Zein is a small hydrophobic protein that, in contrast to albumin and protamine, can easily self-assemble, forming colloidal NPs in the aqueous phase. Zein NPs coated with PEG and Gantrez AN-thiamine have been used to deliver insulin. They have an enhanced permeation within the mucus and intestinal absorption, which decreases the glucose level in blood (<xref ref-type="bibr" rid="B141">Inchaurraga et al., 2020</xref>; <xref ref-type="bibr" rid="B235">Reboredo et al., 2021</xref>). In particular, the Gantrez conjugate reduced the accumulated fat in <italic>Caenorhabditis elegans</italic> (<xref ref-type="bibr" rid="B180">Martinez-Lopez et al., 2021</xref>). Given this promising results a double blind clinical trial has been designed by Cl&#xed;nica Universidad de Navarra to determine whether this particles are able to provide glycemic control in patients (NT: 05560412) (<xref ref-type="bibr" rid="B53">Clinica Universidad de Navarra UdN, 2022b</xref>).</p>
<p>Another interesting kind of proteins are the ones considered self-delivered nanoscale drugs that, at the same time, can self-assemble in NPs. With this in mind, Sanchez-Garc&#xed;a et al. fused bacterial toxin peptides to a N-terminal cationic T22 peptide and a C-terminal region with 6 histidines. These engineered peptides self-assemble in nanostructures by the interaction of the N- and C-terminal regions. T22 peptide can recognize CXCR4, a receptor overexpressed in cancer cells, providing specific tumor targeting, while the toxin peptide promotes general cell death (<xref ref-type="bibr" rid="B256">Sanchez-Garcia et al., 2018</xref>). The bacterial toxins can be exchanged for human pro-apoptotic peptides with similar results (<xref ref-type="bibr" rid="B255">Sanchez-Garcia et al., 2020</xref>). These nanostructures were successfully applied to several cancer models in mice, such as colon, (<xref ref-type="bibr" rid="B256">Sanchez-Garcia et al., 2018</xref>), lymphoma, (<xref ref-type="bibr" rid="B91">Falgas et al., 2020</xref>), and leukemia (<xref ref-type="bibr" rid="B213">Pallares et al., 2021</xref>). Volta-Duran et al. (<xref ref-type="bibr" rid="B312">Volta-Duran et al., 2021</xref>) designed a method to deliver anticancer drug pairs that consist of a tumor-targeted protein NP based on two microbial toxins, exotoxin A and diphtheria toxin, chemically coupled with oligo-floxuridine and monomethyl auristatin E respectively. These nanoformulations were able to internalize into target cells and had a biological impact. Unfortunately, the chemical conjugation annulled the activity of the toxins. Pallares et al. synthesized a nanoconjugate that contained GFP instead of a bacterial toxin, covalently labelled with auristatin, a potent antimitotic agent. With this treatment, they were able to significantly reduce and control myeloid leukemia dissemination (<xref ref-type="bibr" rid="B214">Pallares et al., 2020</xref>).</p>
</sec>
<sec id="s3-2">
<title>3.2 Polysaccharide nanoparticles</title>
<p>Polysaccharides are biomacromolecules formed by sugars found in every living organism. They are non-toxic or immunogenic and are a better biocompatible alternative to synthetic polymers. In addition, they are highly versatile, varying in molecular weight, branch degree, and functional groups, and can be tuned to deliver different cargo (<xref ref-type="bibr" rid="B270">Serrano-Sevilla et al., 2019</xref>; <xref ref-type="bibr" rid="B273">Shokrani et al., 2022</xref>). In Spain, many polysaccharides have been used to form nanostructures with biomedical applications, such as chitosan, hyaluronic acid or cellulose as reviewed here (<xref ref-type="table" rid="T6">Table 6</xref>).</p>
<table-wrap id="T6" position="float">
<label>TABLE 6</label>
<caption>
<p>Summary of polysaccharide NPs with their therapeutic area and synthesis strategy.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="center">Saccharide</th>
<th align="center">Purpose</th>
<th align="center">Therapeutic area</th>
<th align="center">Therapeutic Agent</th>
<th align="center">Synthesis/Encapsulation strategy</th>
<th align="center">Ref.</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td rowspan="4" align="center">Chitosan</td>
<td align="center">Drug delivery</td>
<td align="center">Wnt signaling</td>
<td align="center">Alsterpaullone</td>
<td align="center">Oily core chitosan NPs formed by nanoemulsion</td>
<td align="center">
<xref ref-type="bibr" rid="B11">Ambrosone et al. (2020)</xref>
</td>
</tr>
<tr>
<td align="center">Drug delivery to brain</td>
<td align="center">Neurodegenerative diseases</td>
<td align="center">PH797804</td>
<td align="center">Oily core chitosan NPs formed by nanoemulsion</td>
<td align="center">
<xref ref-type="bibr" rid="B45">Casadome-Perales et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="center">Delivery to vaginal mucosa</td>
<td align="center">Microbicidal</td>
<td align="center">Peptide</td>
<td align="center">NPs formed by inotropic gelation of chitosan with TPP method</td>
<td align="center">
<xref ref-type="bibr" rid="B173">Marciello et al. (2017)</xref>
</td>
</tr>
<tr>
<td align="center">Nanovaccine</td>
<td align="center">HIV</td>
<td align="center">HIV antigen</td>
<td align="center">NPs formed by ionic complexation of positive chitosan with negative hyaluronic acid or dextran</td>
<td align="center">
<xref ref-type="bibr" rid="B60">Dacoba et al. (2019)</xref>, <xref ref-type="bibr" rid="B61">Dacoba et al. (2020a)</xref>
</td>
</tr>
<tr>
<td align="center">Mannose dendrons</td>
<td align="center">Tolerance for allergens</td>
<td align="center">Immune response modulation</td>
<td align="center">Prup3 allergen peptide</td>
<td align="center">Prup3 peptide bound to a mannose dendron structure (D<sub>1</sub>ManPrup3 and D<sub>4</sub>ManPrup3)</td>
<td align="center">
<xref ref-type="bibr" rid="B243">Rodriguez et al. (2019)</xref>
</td>
</tr>
<tr>
<td rowspan="5" align="center">Hyaluronic acid</td>
<td align="center">Tumor penetration</td>
<td align="center">Cancer</td>
<td align="center">Docetaxel</td>
<td align="center">Hyaluronic acid modified with maleimide and with peptide tLyp1 on the shell</td>
<td align="center">
<xref ref-type="bibr" rid="B286">Teijeiro-Valino et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="center">Drug delivery</td>
<td align="center">Cancer</td>
<td align="center">Docetaxel</td>
<td align="center">Hyaluronic acid functionalized by hydrophobic side chains</td>
<td align="center">
<xref ref-type="bibr" rid="B43">Cadete et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="center">Intraocular Drug delivery</td>
<td align="center">Ocular inserts</td>
<td align="center">Ferulic acid and peptide &#x3b5;-polylysine</td>
<td align="center">Electrospunned Hyaluronic acid by using PVP as excipient</td>
<td align="center">
<xref ref-type="bibr" rid="B130">Grimaudo et al. (2020)</xref>
</td>
</tr>
<tr>
<td align="center">Drug delivery</td>
<td align="center">Inflammatory joint diseases</td>
<td align="center">Anti-inflammatory drugs</td>
<td align="center">Hydrogels formed by Hyaluronic acid and fibrin with Hyaluronic acid NPs</td>
<td align="center">
<xref ref-type="bibr" rid="B284">Storozhylova et al. (2020)</xref>
</td>
</tr>
<tr>
<td align="center">Drug delivery at infection site</td>
<td align="center">Antibacterial</td>
<td align="center">Clarithromycin</td>
<td align="center">Clarithromycin-loaded papain-modified ureido-conjugated thiolated hyaluronic acid-co-oleic acid (CLR-PAP-Ur-thHyaluronic acid-co-OA) nanomicelles</td>
<td align="center">
<xref ref-type="bibr" rid="B231">Qaiser et al. (2022)</xref>
</td>
</tr>
<tr>
<td align="center">Cellulose</td>
<td align="center">Drug delivery</td>
<td align="center">Cancer</td>
<td align="center">DOX</td>
<td align="center">CNC modified with APTES and functionalized with FA, followed by incorporating Carbon dots and DOX</td>
<td align="center">
<xref ref-type="bibr" rid="B71">Do et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="center">Cyclodextrin</td>
<td align="center">Delivery of DNA to spleen</td>
<td align="center">Gene therapy</td>
<td align="center">DNA</td>
<td align="center">Cyclodextrin-based molecular NPs through covalent dimerization</td>
<td align="center">
<xref ref-type="bibr" rid="B101">Gallego-Yerga et al. (2018)</xref>
</td>
</tr>
<tr>
<td align="center">Inulin</td>
<td align="center">Improve lymphatic accumulation</td>
<td align="center">Nanovaccine development</td>
<td align="center">-</td>
<td align="center">Small and negatively charged inulin nanocapsules</td>
<td align="center">
<xref ref-type="bibr" rid="B57">Crecente-Campo et al. (2019)</xref>
</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>Chitosan is a derivative of the natural polysaccharide chitin, which is the second most abundant polysaccharide in the world after cellulose. Chitosan has many interesting properties, including biocompatibility, biodegradability, antibacterial effect, and muco-adhesion, and it is widely used in food, cosmetics, and biomedical applications. Chitosan has a high concentration of reactive amino groups along its backbone, conferring a high positive charge that promotes its interaction with biological tissues (<xref ref-type="bibr" rid="B97">Frigaard et al., 2022</xref>). The excellent properties of chitosan NPs for intracellular delivery have been exploited by Ambrossone et al. They showed that oily core chitosan nanocapsules synthesized by nanoemulsion efficiently delivered alsterpaullone, a Wnt signaling agonist, into the model organism <italic>Hydra vulgaris</italic>. They also studied the characteristics of the intracellular delivery with Nile red-loaded NPs. Their methodology resulted in a more efficient manner of activating Wnt pathway than free alsterpaullone at the same concentration (<xref ref-type="bibr" rid="B11">Ambrosone et al., 2020</xref>). Similarly, Montero et al. developed chitosan-BSA NPs and studied their potential as vehicles with different combinations, demonstrating their potential for drug delivery (<xref ref-type="bibr" rid="B325">Montero et al., 2019</xref>).</p>
<p>Chitosan NPs also enable the transportation of agents into the brain, given the difficulty to target this organ. As a proof of concept, Casadom&#xe9;-Perales et al. demonstrated the inhibition of p38 MAPK, an enzyme that is commonly dysregulated in several neurodegenerative diseases. They encapsulated PH797804, an inhibitor of this enzyme, in NPs with a nanoemulsion core. The intranasal delivery of the NPs enabled the inhibition in different parts of the brain in animal models, showing that it could be an efficient strategy for brain delivery (<xref ref-type="bibr" rid="B45">Casadome-Perales et al., 2019</xref>).</p>
<p>Marciello et al. used chitosan NPs to deliver a model peptide through vaginal mucosa, given the interest of microbicides delivery for the prevention and treatment of sexually transmitted diseases. The NPs contained chitosan and ascorbate, with insulin as the model cargo. Then, the NPs were incorporated in sponge-like cylinders made of mannitol, sucrose, and gelatin B to control their release in the vaginal environment (<xref ref-type="bibr" rid="B173">Marciello et al., 2017</xref>).</p>
<p>The fact that chitosan NPs can encapsulate peptides opens the possibility of their use as nanovaccines. As mentioned previously, using NPs as vaccines improves both the administration and the activation of the targeted immune cells, which results in greater efficacy. The role of chitosan in these formulations has shown to enhance the activation of the adaptive immune response (<xref ref-type="bibr" rid="B194">Moran et al., 2018</xref>).</p>
<p>The generation of an effective HIV vaccine is still an important health challenge, to which several nanotechnological approaches are being developed. According to previous works, the peptide sequences around the protease cleavage sites have been proposed as a target for HIV vaccines. Dacoba et al. developed different chitosan NPs loaded with the HIV peptide PCS5. The NPs were formed by ionic complexation, mixing the positive polysaccharide chitosan with negative ones like Hyaluronic acid or dextran. Furthermore, they tested if the presence of poly (I:C), an immunomodulatory molecule, had any effect. All the NPs were able to induce humoral responses against the antigen (<xref ref-type="bibr" rid="B60">Dacoba et al., 2019</xref>). However, they showed that the binding of the antigen, the presence of poly (I:C), and the nature of the polysaccharides influence the type of immune response, such as the kinetics of the effector T cell responses. The results suggest the possibility of developing a nanovaccine against HIV and its translation into clinical trials (<xref ref-type="bibr" rid="B61">Dacoba et al., 2020a</xref>). The same group showed that NPs made of chitosan and the anionic carboxymethyl-&#x3b2;-glucan, which accumulate in the lymph nodes, promoted the accumulation of the NPs in draining lymph nodes and exerted an immune response. The NPs were formed using the ionic complexation method, and loaded with ovalbumin (<xref ref-type="bibr" rid="B97">Frigaard et al., 2022</xref>).</p>
<p>Polysaccharide NPs loaded with antigens can also be used to induce tolerance for allergens. Rodriguez et al. explored the capabilities of several mannose nanostructures to serve as an efficient platform to generate specific recognition without the need for additional adjuvants. In this particular case the treatment developed prolonged protection against allergen exposure without any sign of anaphylaxis (<xref ref-type="bibr" rid="B243">Rodriguez et al., 2019</xref>).</p>
<p>Hyaluronic acid is an anionic polysaccharide, a glycosaminoglycan, consisting of disaccharide repeating units of &#x3b2;-1,4-D-glucuronic acid-&#x3b2;-1,3-N-acetyl-D-glucosamine. It has a high binding affinity towards the CD44 receptor, highly expressed in cancer cells (<xref ref-type="bibr" rid="B164">Liu and Huang, 2022</xref>). It can be used as shell in oil-based NPs, by the solvent displacement technique. Teijeiro-Valino et al. used this kind of NPs for the encapsulation of the anti-cancer drug docetaxel. Furthermore, they decorated the hyaluronic acid shell with the tumor homing peptide tLyp1. Their formulation increased penetration in the tumor and anti-cancer activity in lung and pancreatic cancer mice models (<xref ref-type="bibr" rid="B286">Teijeiro-Valino et al., 2019</xref>).</p>
<p>Cadete et al. used a modification of hyaluronic acid consisting of the addition of hydrophobic side chains, like dodecyl, to promote the self-assembly of NPs without the use of surfactants. This strategy decreased the cytotoxicity of the NPs, while showing an improved intracellular drug delivery (<xref ref-type="bibr" rid="B43">Cadete et al., 2019</xref>).</p>
<p>Delivery of drugs on the eye surface can be achieved by flexible electrospun nanofibers, which are able to adapt and persist on the eye surface whilst the drug is released. Grimaudo et al. overcame the incapability of hyaluronic acid to be electrospunned, by using PVP as an excipient. This resulted in creating hyaluronan nanofibers, capable of delivering the antioxidant ferulic acid and the antimicrobial peptide &#x3b5;-polylysine at the same time (<xref ref-type="bibr" rid="B130">Grimaudo et al., 2020</xref>).</p>
<p>In another study, Storozhylova et al. engineered hydrogels formed by Hyaluronic acid and fibrin, with hyaluronic acid nanocapsules loaded with anti-inflammatory drugs. They were used to improve intra-articular administration, showing a rapid efflux of the administered drugs. This system could relieve the inflammatory conditions of large joints (<xref ref-type="bibr" rid="B284">Storozhylova et al., 2020</xref>).</p>
<p>Qaiser et al. developed three types of nanomicelles formulations to synthesize a targeted, mucoadhesive and mucopenetrating drug delivery system. The goal was to encapsulate clarithromycin, an antibacterial drug, to improve its residence time at the <italic>Helicobacter pylori</italic> infection site. They concluded that clarithromycin-loaded papain-modified ureido-conjugated thiolated hyaluronic acid-co-oleic acid (CLR-PAP-Ur-thHA-co-OA) nanomicelles could be used as nanocarriers for the treatment of <italic>H. pylori</italic> infection, due to their mucopenetration, mucoadhesion properties, stability, and extended drug release (<xref ref-type="bibr" rid="B231">Qaiser et al., 2022</xref>).</p>
<p>Cellulose is the world&#x2019;s most abundant polysaccharide. It is a linear polymer composed of repeating units of two anhydroglucose rings. Its abundance and biocompatibility make nanocellulose a good candidate for biomedical applications (<xref ref-type="bibr" rid="B203">Nicu et al., 2021</xref>). Recently, Do et al. developed a modified cellulose nanocrystal (CNC) for the delivery of anti-cancer drugs. They engineered nanoplatforms based in modified CNCs with APTES to improve their dispersibility. These CNCs were covalently functionalized with folic acid (FA), followed by the incorporation of Carbon dots and the drug DOX, by electrostatic interaction. These CNCs may be promising nanoplatforms to be used both in chemotherapy and PTT against cancer (<xref ref-type="bibr" rid="B71">Do et al., 2021</xref>).</p>
<p>Gallego-Yerga et al. prepared DNA-cyclodextrin NPs to improve gene therapy. They controlled the morphology of the complexes to study how the shape affects the transfection properties. They found several complexes that exhibited highly efficient transgene expression and were able to deliver DNA to the spleen in a tissue-specific manner in animal models (<xref ref-type="bibr" rid="B101">Gallego-Yerga et al., 2018</xref>).</p>
<p>Finally, inulin is a fructan that has high structural flexibility and good biodegradability, which allows for its use as a drug delivery system. In a study comparing chitosan with inulin for drug delivery, the small inulin NPs showed less toxicity and a higher accumulation in the lymphatic nodes (<xref ref-type="bibr" rid="B57">Crecente-Campo et al., 2019</xref>).</p>
</sec>
<sec id="s3-3">
<title>3.3 Polymeric nanoparticles</title>
<p>The potential of polymeric NPs relies on their highly versatile structure, which can be altered depending on the therapeutic application, cargo, or type of administration. Moreover, the chemical reactivity of the polymers can be exploited for the controlled release of drugs at different pH or thermal environments. These properties in addition to good biocompatibility, make polymeric NPs great candidates in the biomedicine field (<xref ref-type="table" rid="T7">Table 7</xref>) (<xref ref-type="bibr" rid="B77">Elsabahy and Wooley, 2012</xref>; <xref ref-type="bibr" rid="B268">Sartaj et al., 2021</xref>).</p>
<table-wrap id="T7" position="float">
<label>TABLE 7</label>
<caption>
<p>Summary of polymeric NPs with their therapeutic area and functionalization strategy.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="center">Polymer type</th>
<th align="center">Purpose</th>
<th align="center">Therapeutic area</th>
<th align="center">Therapeutic Agent</th>
<th align="center">Functionalization strategy</th>
<th align="center">Ref.</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="center">Arginine based</td>
<td align="center">Macrophages polarization from M2 to M1 profiles</td>
<td rowspan="2" align="center">Cancer</td>
<td rowspan="2" align="center">Toll-like receptor 3 agonist poly(I:C)</td>
<td align="center">Poly(I:C) arginine-rich polypeptide was enveloped with an anionic polymeric layer by film hydration or incubation</td>
<td align="center">
<xref ref-type="bibr" rid="B58">Dacoba et al. (2020b)</xref>
</td>
</tr>
<tr>
<td align="center">Polyethylemine</td>
<td align="center">Intratumoral immunotherapy</td>
<td align="center">Nanoplexed formulation of Poly I:C complexed with polyethylenimine</td>
<td align="center">
<xref ref-type="bibr" rid="B25">Aznar et al. (2019)</xref>
</td>
</tr>
<tr>
<td rowspan="3" align="center">Polyglutamic acid</td>
<td align="center">Enhance the efficacy of first-line chemotherapeutics</td>
<td align="center">Cancer (Triple negative breast cancer)</td>
<td align="center">DOX</td>
<td align="center">Nanogel particles were formed by Cu catalyzed azide-alkyne cycloaddition of polyglutamic acid and subsequently loaded with DOX</td>
<td align="center">
<xref ref-type="bibr" rid="B75">Duro-Castano et al. (2021a)</xref>
</td>
</tr>
<tr>
<td align="center">Improve treatment of unresectable cancer by controlled release</td>
<td align="center">Cancer</td>
<td align="center">Gemcitabine</td>
<td align="center">The low molecular weight nanogel N4-Octanoyl-2-deoxycytidine was loaded with hyaluronic acid and polyglutamic acid nanocapsules prepared by a self-emulsifying method</td>
<td align="center">
<xref ref-type="bibr" rid="B282">Staka et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="center">To develop zwitterionic pDNA delivery systems</td>
<td align="center">-</td>
<td align="center">Plasmid DNA delivery</td>
<td align="center">Derivatization with oligoaminoamide residues for an efficient assembly containing five units of succinyl tetraethylene pentamine to develop a zwitterionic nonviral vectors</td>
<td align="center">
<xref ref-type="bibr" rid="B204">Nino-Pariente et al. (2017)</xref>
</td>
</tr>
<tr>
<td align="center">Polyglutamate</td>
<td align="center">Develop multimodal NPs for AD</td>
<td align="center">Neurodegenerative diseases</td>
<td align="center">Bisdemethoxycurcumin or Genistein</td>
<td align="center">80&#x2013;100&#xa0;nm sphere-like cross-linked self-assembled star-shaped Polyglutamic acid functionalized with Angiopep-2 to promote BBB permeation</td>
<td align="center">
<xref ref-type="bibr" rid="B74">Duro-Castano et al. (2021b)</xref>
</td>
</tr>
<tr>
<td align="center">Tert-Ser polyacetal</td>
<td align="center">pH dependent and controlled release of drug</td>
<td align="center">Cancer (prostate)</td>
<td align="center">PTX</td>
<td align="center">PTX was incorporated to the side-chains of the pH-susceptible and biodegradable tert-serinol polymer by a one-pot synthetic procedure</td>
<td align="center">
<xref ref-type="bibr" rid="B93">Fernandez et al. (2022)</xref>
</td>
</tr>
<tr>
<td rowspan="3" align="center">Polyarginine</td>
<td align="center">Delivery of two therapeutic agents for reverting MDSC-mediated immunosuppression</td>
<td align="center">Cancer immunotherapy</td>
<td align="center">RNAi and CCL2 chemokine</td>
<td align="center">RNAs were associated to the nanocapsules through the RNA condensing capacity of the polyarginine shell. The chemokine was encapsulated in the aqueous domains of a glyceryl-monooleate (GMO)-based liquid-crystal core where</td>
<td align="center">
<xref ref-type="bibr" rid="B160">Ledo et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="center">miRNA delivery to the hippocampus</td>
<td align="center">Neurodegenerative diseases</td>
<td align="center">Specific miRNA mimic, miR-132</td>
<td align="center">D-octaarginine was covalently conjugated to lauric acid and subsequently to RNA through electrostatic interactions of interest. Finally, the nanocomplexes were enveloped with protective polymers such as polyethyleneglycol - polyglutamic acid or hyaluronic acid to enhance stability and diffusion through the olfactory nasal mucosa</td>
<td align="center">
<xref ref-type="bibr" rid="B251">Samaridou et al. (2020)</xref>
</td>
</tr>
<tr>
<td align="center">Oral delivery of insulin</td>
<td align="center">Diabetes</td>
<td align="center">Insulin</td>
<td align="center">Polyarginine NPs were coated with PEGylated polyaminoacids to protect insulin</td>
<td align="center">
<xref ref-type="bibr" rid="B205">Niu et al. (2018)</xref>
</td>
</tr>
<tr>
<td align="center">Poly(N-vinyl caprolactam)</td>
<td align="center">Develop microgels for drug delivery</td>
<td align="center">Cancer</td>
<td align="center">DOX</td>
<td align="center">(PVCL)-based thermoresponsive microgels prepared by copolymerization of N-vinylcaprolactam monomer and ethylene glycol dimethacrylate stabilized by a reactive [poly(2-(acryloyloxy)ethyl]trimethylammonium chloride) cationic shell and loaded with DOX</td>
<td align="center">
<xref ref-type="bibr" rid="B87">Etchenausia et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="center">Chitosan, polyarginine, and carboxymethyl-&#x3b2;-glucan</td>
<td align="center">Improve targeting specific immune cells in the lymphatics</td>
<td align="center">Vaccine development</td>
<td rowspan="2" align="center">-</td>
<td align="center">Chitosan nanocapsulse were functionalized with positively charged (polyarginine) and negatively charged (carboxymethyl-beta-glucan) polymeric shells</td>
<td align="center">
<xref ref-type="bibr" rid="B55">Cordeiro et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="center">Polyanionic carbosilane dendrimers</td>
<td align="center">Inhibits the infection of human cytomegalovirus</td>
<td align="center">Antiviral therapy</td>
<td align="center">Polyanionic carbosilane dendrimers that present several sulfonate or sulfate groups in their periphery</td>
<td align="center">
<xref ref-type="bibr" rid="B238">Relano-Rodriguez et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="center">Nanocapsules with a polymeric shell</td>
<td align="center">Development of intranasal vaccination against <italic>Mycobacterium tuberculosis</italic>
</td>
<td rowspan="2" align="center">Vaccine development</td>
<td align="center">Imiquimod and a fusion protein formed by two antigens of <italic>Mycobacterium tuberculosis</italic>
</td>
<td align="center">Imiquimod was encapsulated in the oily core of the nanocapsules together with a fusion protein. Nanocapsules were functionalized with a polymer shell made of chitosan or inulin/polyarginine</td>
<td align="center">
<xref ref-type="bibr" rid="B69">Diego-Gonzalez et al. (2020)</xref>
</td>
</tr>
<tr>
<td align="center">Poly(&#x3b2;-amino esters)</td>
<td align="center">Improve vaccine development</td>
<td align="center">mRNA</td>
<td align="center">mRNA NPs based on poly(beta aminoester) polymers</td>
<td align="center">
<xref ref-type="bibr" rid="B94">Fornaguera et al. (2021)</xref>
</td>
</tr>
<tr>
<td rowspan="9" align="center">Poly(lactic-co-glycolic acid)</td>
<td rowspan="2" align="center">Improve BBB permeability and pharmacokinetics of compounds</td>
<td rowspan="2" align="center">Neurodegenerative diseases</td>
<td align="center">PDE7 inhibitor</td>
<td align="center">NPs were prepared in two different manners, by single emulsion and nanoprecipitation</td>
<td align="center">
<xref ref-type="bibr" rid="B208">Nozal et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="center">CDC7 inhibitor</td>
<td align="center">Polymeric NPs were prepared by nanoprecipitation</td>
<td align="center">
<xref ref-type="bibr" rid="B244">Rojas-Prats et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="center">Enhance BBB penetration</td>
<td align="center">Stroke</td>
<td align="center">-</td>
<td align="center">Functionalized with supramagnetic iron oxide NPs</td>
<td align="center">
<xref ref-type="bibr" rid="B129">Grayston et al. (2022)</xref>
</td>
</tr>
<tr>
<td align="center">Improve antiretroviral therapy</td>
<td rowspan="2" align="center">HIV</td>
<td rowspan="2" align="center">HIV-1 peptide inhibitor</td>
<td align="center">PLGA NPs were covered by glycol-chitosan to enhance delivery</td>
<td align="center">
<xref ref-type="bibr" rid="B19">Ariza-Saenz et al. (2017)</xref>
</td>
</tr>
<tr>
<td align="center">Improve the delivery of bioactive peptides to inhibit HIV infection</td>
<td align="center">PLGA NPs coated with glycol chitosan</td>
<td align="center">
<xref ref-type="bibr" rid="B20">Ariza-Saenz et al. (2018)</xref>
</td>
</tr>
<tr>
<td align="center">Provide an efficient oral peptide administration</td>
<td align="center">Diabetes</td>
<td align="center">Hydrophobically modified insulin</td>
<td align="center">Nanoemulsions and micelles formed by MPEG-2000-DSPE sodium tauocholate, Miglyol 812N and Polaxamer 407</td>
<td align="center">
<xref ref-type="bibr" rid="B260">Santalices et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="center">Improve pharmacokinetic properties of Licochalcone A</td>
<td align="center">Ocular inflammation</td>
<td align="center">Licochalcone A</td>
<td align="center">PLGA was covalently bound to cell penetrating peptides through maleimide-PEG amine</td>
<td align="center">
<xref ref-type="bibr" rid="B99">Galindo et al. (2022)</xref>
</td>
</tr>
<tr>
<td align="center">Deliver miRNA and atorvastatin simultaneously</td>
<td align="center">Atherosclerosis</td>
<td align="center">miRNA 124a and atorvastatin</td>
<td align="center">Atorvastatin was loaded in PLGA NPs in the single emulsion synthesis, that were subsequently covered by chitosan to promote electrostatic interactions with the miRNA and finally functionalized with anti-VCAM and H4A3 antibodies</td>
<td align="center">
<xref ref-type="bibr" rid="B159">Leal et al. (2022)</xref>
</td>
</tr>
<tr>
<td align="center">Improve tumor targeting</td>
<td align="center">Cancer</td>
<td align="center">Allyl-isothiocyanate</td>
<td align="center">NPs were functionalized with an anti-EGFR antibody</td>
<td align="center">
<xref ref-type="bibr" rid="B79">Encinas-Basurto et al. (2018b)</xref>
</td>
</tr>
<tr>
<td align="center">1-vinylimidazole</td>
<td align="center">Obtain a synergistic anti-inflammatory effect</td>
<td rowspan="2" align="center">Inflammation autoimmune diseases</td>
<td align="center">Ketoprofen and dexamethasone</td>
<td align="center">Copolymers were self-assembled by nanoprecipitation, and NPs presented a hydrophobic core formed by covalently linked ketoprofen and a hydrophilic shell mainly formed by vinylimidazole</td>
<td align="center">
<xref ref-type="bibr" rid="B85">Espinosa-Cano et al. (2020a)</xref>, <xref ref-type="bibr" rid="B86">Espinosa-Cano et al. (2020b)</xref>
</td>
</tr>
<tr>
<td align="center">1-vinylimidazole and methacrylic derivative</td>
<td align="center">Study the synergistic anti-inflammatory effect</td>
<td align="center">Dexamethasone and naproxen</td>
<td align="center">Polymeric NPs were self assembled incorporating covalently-linked naproxen and physically entrapped dexamethasone</td>
<td align="center">
<xref ref-type="bibr" rid="B86">Espinosa-Cano et al. (2020b)</xref>
</td>
</tr>
<tr>
<td align="center">CaCO<sub>3</sub> core stabilized by poly(vinylsulfonic acid)</td>
<td align="center">Optimize <italic>in vivo</italic> delivery specificity</td>
<td align="center">Acute ischemic stroke</td>
<td align="center">Thrombolytic serine protease</td>
<td align="center">Layer-by-layer structure of CaCO<sub>3</sub> cores later removed and stabilized by poly(vinylsulfonic acid). After macromolecule entrapment alternate layer of charged polyelectrolyte poly(sodium 4-styrenesulfonate) and poly(diallyldimethylammonium chloride) are added. Finally a coating with a layer of doped iron oxide NP or gelatin is performed</td>
<td align="center">
<xref ref-type="bibr" rid="B56">Correa-Paz et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="center">Polyethylene and propylene glycol and ribose</td>
<td align="center">Develop fuel-free propulsion NPs activatable by NIR</td>
<td align="center">-</td>
<td align="center">-</td>
<td align="center">Micelles formed by polyethyleneglycol, polypropylenglycol copolymer and sodium oleate and then ribose was polymerized on the surface at high temperature yielding a bottle-structured particles</td>
<td align="center">
<xref ref-type="bibr" rid="B316">Xuan et al. (2018)</xref>
</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>Given their versatility, several anti-cancer strategies have been accomplished. Aznar et al. have studied the immunotherapeutic profile of BO-112, a nanoplexed form of Poly I:C coupled to polyethylemine that prevents its degradation from proteases. Poly I:C is a synthetic analog of double stranded RNA that activates innate immune receptors and several formulations with different polymers have been tested in the clinic. BO-112 was locally injected, leading to the death of tumoral cells. Also, this nanoplexed Poly I:C showed an antitumoral activity through the induction of type I Interferon and CD8 T-cell infiltrates in the tumor (<xref ref-type="bibr" rid="B25">Aznar et al., 2019</xref>). These promising results motivated the development of two clinical trials of BO-112 in combination with antiPD-1 therapies or with pembrolizumab showing encouraging clinical benefits in cancer patients. Dacoba et al. developed an arginine-based poly (I:C) nanocomplex that induces the accumulation of endosomal toll-like receptor 3 agonists, which affect the polarization of the profile M2 to M1 (pro-inflammatory and antitumoral) in endosomal compartments. This strategy has been explored in cancer, where the polarization to M1 profile of tumor-associated macrophages could be a promising approach against tumors (<xref ref-type="bibr" rid="B58">Dacoba et al., 2020b</xref>). Another study was based on the study of intratumoral immunotherapy.</p>
<p>Poly amino acid nanogels are also an interesting strategy in the delivery of cancer treatment. Interestingly, these agents can be developed to release the cargo specifically in the tumor microenvironment as pH responsive particles (<xref ref-type="bibr" rid="B22">Arroyo-Crespo et al., 2018</xref>). Duro-Castano et al. engineered polyglutamic acid nanogels loaded with DOX as an effective strategy for the treatment of triple-negative breast cancer metastases, which effectively reduced lung and lymph node metastases (<xref ref-type="bibr" rid="B75">Duro-Castano et al., 2021a</xref>). In another strategy, Fern&#xe1;ndez et al. developed a tert-Ser polyacetal loaded with PTX forming NPs of 10&#x2013;70&#xa0;nm, which showed a controlled release of drug dependent on pH. The nanomedicine thus inhibited an early release and reduced primary tumors in animal models while also inhibiting metastasis (<xref ref-type="bibr" rid="B93">Fernandez et al., 2022</xref>).</p>
<p>Staka et al. developed a low molecular weight hydrogel formed by a nucleoside (N4-octanoyl-2-deoxycytidine). The gel accommodated multiple polymeric NPs loaded with gemcitabine, a chemotherapeutic drug. The gel released the encapsulated drug for a month, which could be used as a treatment for unresectable cancer (<xref ref-type="bibr" rid="B282">Staka et al., 2019</xref>).</p>
<p>Myeloid-derived suppressor cells are a target in adoptive T cells transfer. Ledo et al. developed multilayer polymer nanocapsules to co-deliver two drugs: RNAi polynucleotides and chemokine CCL2. These NPs may help modulate the activity of myeloid derived suppressor cells (<xref ref-type="bibr" rid="B160">Ledo et al., 2019</xref>).</p>
<p>Etchenausia et al. studied poly(N-vinyl caprolactam) (PVCL)-based thermoresponsive microgels with polymer brushes as potential drug delivery nanocarriers. These microgels were biocompatible on HeLa and RAW cells. They tested DOX-loaded microgels and determined a sustained release of DOX from microgels as well as increased cell viability compared to free DOX, confirming the suitability of these microgels as safe drug delivery nanocarriers (<xref ref-type="bibr" rid="B87">Etchenausia et al., 2019</xref>).</p>
<p>Cordeiro et al. designed synthetic and natural polymer NPs and nanocapsules for antigen delivery. They observed that small-size cationic nanoclusters showed high accumulation in the lymph nodes and concluded that by modifying the physicochemical properties and composition of the nanocapsules, modulation of lymphatic uptake and biodistribution would be possible (<xref ref-type="bibr" rid="B55">Cordeiro et al., 2019</xref>).</p>
<p>Relano-Rodr&#xed;guez et al. worked on human cytomegalovirus (HCMV), which infects and replicates in a wide variety of cells. They focused on the study of polyanionic carbosilane dendrimers (PCD). They tested two PCDs, G2-S16 and G2-S24P, which, alone or with current treatments, seemed to be a good tool against HCMV (<xref ref-type="bibr" rid="B238">Relano-Rodriguez et al., 2021</xref>) (<xref ref-type="fig" rid="F6">Figure 6</xref>).</p>
<fig id="F6" position="float">
<label>FIGURE 6</label>
<caption>
<p>Dendrimer strategy as antiviral therapy. Reprinted from <xref ref-type="bibr" rid="B238">Relano-Rodriguez et al. (2021)</xref> and licensed under the Creative Commons Attribution.</p>
</caption>
<graphic xlink:href="fbioe-11-1191327-g006.tif"/>
</fig>
<p>Polymeric nanocapsules are promising carriers for various antigens against different pathogens whose immunogenicity can be improved by including immunostimulatory molecules, improving current vaccines. Imiquimod (IMQ) has been described as a good modulator of innate immunity and activator of the Th1 immune response, which is the target of most vaccines. Previous work showed that encapsulation of IMQ in chitosan (CS) NC induced protective antibody levels against recombinant hepatitis B surface antigen (HB) in mice immunized intranasally. In this work, two different IMQ-loaded NPs with a CS or inulin/pArg polymeric shell were synthesized for the development of a model vaccine containing a recombinant fusion protein (RFP) derived from the ESAT-6 antigen and CFP-10 from Mtb. The vaccine containing INU:pArg:Ag nanocapsules was the most immunogenic prototype against the ECH fusion protein (<xref ref-type="bibr" rid="B69">Diego-Gonzalez et al., 2020</xref>). The use of mRNA in vaccination has achieved great success in preventing the acute effects of COVID-19 after SARS-Cov-2 infection. Fornaguera et al. developed and described a protocol for the preparation of poly(&#x3b2;-amino esters) and their conjugation to mRNA and studies in cellular models (<xref ref-type="bibr" rid="B94">Fornaguera et al., 2021</xref>).</p>
<p>Poly amino acid particles are also excellent carriers able to cross the BBB when conjugated to brain penetrant peptides, demonstrating interesting properties in treating central nervous system disorders such as Alzheimer&#x2019;s disease (<xref ref-type="bibr" rid="B74">Duro-Castano et al., 2021b</xref>). Octaarginine conjugated with lauric acid forms a hydrophobic complex that can protect labile molecules by electrostatic and hydrophobic interactions, improving miRNA delivery in the hippocampus (<xref ref-type="bibr" rid="B251">Samaridou et al., 2020</xref>). Poly-I-glutamic acid complexes are also an efficient and non-toxic strategy to deliver oligonucleotides or DNA. Ni&#xf1;o-Pariente et al. developed nanocomplexes with a poly-I-glutamic acid backbone that was derivatized with oligoaminoamide residues to efficiently assemble and deliver plasmid DNA (<xref ref-type="bibr" rid="B204">Nino-Pariente et al., 2017</xref>). Using PLGA-based polymeric NPs, Nozal et al., enhanced BBB permeation of NPs loaded with S14, a phosphodiesterase 7 (PDE7) inhibitor with great potential to treat Parkinson&#x2019;s disease. According to the studies, S14-loaded PLGA-NPs showed improved pharmacokinetic properties of S14 in animal models, as well as enhanced safety of this inhibitor (<xref ref-type="bibr" rid="B208">Nozal et al., 2021</xref>). The same group also encapsulated PHA-767491, a potent cell division cycle 7 (CDC7) kinase inhibitor in PLGA-NPs improving its permeability and CNS delivery properties (<xref ref-type="bibr" rid="B244">Rojas-Prats et al., 2021</xref>).</p>
<p>Grayston et al. tested biocompatible PLGA nanocapsules functionalized with superparamagnetic iron oxide NPs and Cy7.5 to improve brain targeting of drugs after stroke. According to the results, the intra-arterial route for the cerebral administration of new treatments showed an extraordinary advantage (<xref ref-type="bibr" rid="B129">Grayston et al., 2022</xref>).</p>
<p>Another active area of research belongs to anti-inflammatory agents. Interleukin-12 and interleukin-23 have a high interest as therapeutic targets to treat autoimmune/inflammatory diseases and chronic inflammatory diseases where T cells are the primary cells that are dysfunctional. Espinosa-Cano et al. prepared anti-inflammatory polymeric NPs that combine ketoprofen and dexamethasone (14Dx-KT), which are one of the most efficient cyclooxygenase-inhibitors. According to the results, a long-term treatment with 14Dx-KT NPs reduced the expression of Il12b and IL23a to normal cellular levels. The results suggest that the ketoprofen-based systems present an anti-inflammatory activity reducing the basal levels of pro-inflammatory markers and increasing the gene expression of anti-inflammatory cytokines (<xref ref-type="bibr" rid="B85">Espinosa-Cano et al., 2020a</xref>). Recent studies demonstrate the anti-inflammatory capacity of dexamethasone and naproxen. However, their use is limited by the rapid clearance of free drug. Espinosa-Cano et al. used polymeric NPs to administer these drugs in order to accumulate in pathological tissue, increasing the drugs&#x2019; activity and reducing their adverse effects. The prepared naproxen-containing polymeric NPs loaded with dexamethasone were able to repress Il12b transcript levels, which would be an interesting treatment of autoimmune/anti-inflammatory diseases in which IL12 and IL23 are overexpressed (<xref ref-type="bibr" rid="B86">Espinosa-Cano et al., 2020b</xref>).</p>
<p>Oral delivery of insulin is also an attractive application for this type of NPs, since the acidity of intestinal fluids increases the risk of degradation. For instance, coating polyarginine insulin NPs with PEGylated polyaminoacids, protects insulin until it reaches the intestinal mucus (<xref ref-type="bibr" rid="B205">Niu et al., 2018</xref>), achieving the highest insulin uptake ever recorded in cellular models. Despite not resulting in a significantly increased systemic insulin uptake, the system showed a great potential for the delivery of peptides through the intestine mucosa. Santalices et al. also aimed at orally delivering hydrophobically modified insulin. They developed and extensively characterized nanoemulsions with selected components with improved properties on permeation, stability and mucodiffusion, such as miglyol, PEGylated phospholipids and poloxamer. The nanocomplexes showed promising results in cellular models and a moderate but significant hypoglycemic response in animals, highlighting key steps to take into consideration to overcome intestinal barriers (<xref ref-type="bibr" rid="B260">Santalices et al., 2021</xref>).</p>
<p>Similarly, Ariza-Saenz et al. used polymeric NPs of PLGA particles coated with glycol-chitosan (<xref ref-type="bibr" rid="B19">Ariza-Saenz et al., 2017</xref>) to enhance the delivery of a peptide inhibitor of the HIV-1 fusion protein that demonstrated to have enhanced permeability and efficacy of the peptide alone (<xref ref-type="bibr" rid="B20">Ariza-Saenz et al., 2018</xref>; <xref ref-type="bibr" rid="B257">Sanchez-Lopez et al., 2021</xref>).</p>
<p>As already showcased, polymeric NPs have been widely studied for the delivery of active compounds with poor pharmacokinetic properties. Here the delivery of licochalcone A was investigated using PLGA NPs and cell-penetrating peptides Tet and B6. Galindo et al. showed how the nanoconjugates with B6 showed increased activity for the treatment of ocular inflammation (<xref ref-type="bibr" rid="B99">Galindo et al., 2022</xref>).</p>
<p>Since combining drugs with miRNAs within a nanocarrier is a promising treatment for atherosclerosis, Leal et al., have developed polymeric PLGA NPs that simultaneously encapsulate and deliver miRNA-124a and the statin atorvastatin (ATOR). This combination reduced levels of proinflammatory cytokines and ROS. In addition, the dual-loaded NPs proved to be non-toxic to cells and prevent the accumulation of low-density lipoproteins inside macrophages and morphological changes, showing promise as a treatment for these types of diseases (<xref ref-type="bibr" rid="B159">Leal et al., 2022</xref>).</p>
<p>Encinas-Basurto et al., have developed allyl-isothiocyanate (AITC)-loaded PLGA NPs that target epithelial carcinoma cells due to anti-EGFR antibody binding to the surface. These NPs showed better anti-cancer properties compared to the free drug, suggesting that receptor-ligand binding could be used to target the NPs to tumor cells for improved drug delivery (<xref ref-type="bibr" rid="B79">Encinas-Basurto et al., 2018b</xref>).</p>
<p>In another attempt to generate smart-delivery NPs, Correa-Paz et al. engineered polymeric templated CaCO<sub>3</sub> NPs with a layer-by-layer structure. The NPs were loaded with a fragile thrombolytic serine protease, labelled fluorescently and tagged with iron oxide NPs. The particles proved to efficiently release their protease cargo upon ultrasound application in cellular and animal models and maintained the activity after its delivery (<xref ref-type="bibr" rid="B56">Correa-Paz et al., 2019</xref>).</p>
<p>In another example of smart drug delivery using nanomaterials, Xuan et al. developed nanobottles formed from polyethylene glycol and ribose with a soft-template-based polymerization methodology. Using NIR light, the inner fluid of the bottle can be heated, resulting in its propulsion. The authors studied the trajectories, velocity and explosion events of the motors that could be controlled by modulating the NIR source and analyzed them through finite element analysis. This work is paving the road for the discovery and synthesis of new fuel-free based nanomotors (<xref ref-type="bibr" rid="B316">Xuan et al., 2018</xref>).</p>
</sec>
<sec id="s3-4">
<title>3.4 Lipid nanoparticles</title>
<p>Lipid NPs (LNPs) range from liposomes to solid LNPs (SLNs) and quatsomes (QS). The potential of these formulations relies on their stable structure and ability to cross biological barriers. LNPs constitute a good vehicle to transport both hydrophobic and hydrophilic drugs, providing protection for its cargo. For example, the complexation of lipids with nucleic acids allows their transport and prevents their degradation. They can be divided into four major types: liposomes, niosomes, SLNs, and nanostructured lipid carriers (NLCs) (<xref ref-type="bibr" rid="B68">Dhiman et al., 2021</xref>). SLNs and NLCs overcome liposomes and niosome due to their better performance under pH- and enzyme-dependent degradation. All of these formulations have been of research interest in Spain (<xref ref-type="table" rid="T8">Table 8</xref>) (<xref ref-type="bibr" rid="B303">Vargas-Nadal et al., 2020</xref>), (<xref ref-type="bibr" rid="B287">Tenchov et al., 2021</xref>)</p>
<table-wrap id="T8" position="float">
<label>TABLE 8</label>
<caption>
<p>Summary of LNPs with their therapeutic area and functionalization strategy.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="center">NP Type</th>
<th align="center">Purpose</th>
<th align="center">Therapeutic area</th>
<th align="center">Therapeutic Agent</th>
<th align="center">Functionalization strategy</th>
<th align="center">Ref.</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td rowspan="17" align="center">Solid lipid NPs (SLNs)</td>
<td align="center">Edelfosine oral administration</td>
<td rowspan="4" align="center">Cancer</td>
<td rowspan="2" align="center">Edelfosine</td>
<td align="center">NPs prepared with the homogenization and ultrasonication method</td>
<td align="center">
<xref ref-type="bibr" rid="B126">Gonzalez-Fernandez et al. (2018)</xref>
</td>
</tr>
<tr>
<td align="center">Biodistribution study of edelfosine oral, intravenous and intraperitoneal administration</td>
<td align="center">Edelfosine-LNS labeled with Technetium-99m</td>
<td align="center">
<xref ref-type="bibr" rid="B154">Lasa-Saracibar et al. (2022)</xref>
</td>
</tr>
<tr>
<td align="center">Maslinic acid oral administration</td>
<td align="center">Maslinic acid</td>
<td align="center">Poloxamer407 (PMA), dicarboxylic acid-Poloxamer407 (PCMA) or Hialuronic Acid (Hyaluronic acid)-coated PCMA shell</td>
<td align="center">
<xref ref-type="bibr" rid="B3">Aguilera-Garrido et al. (2022)</xref>
</td>
</tr>
<tr>
<td align="center">Improve the efficiency and the specificity of the SLN-loaded drug</td>
<td align="center">Trans retinoic acid</td>
<td align="center">SLNs composed of stearic acid, Epikuron 200 and sodium taurodeoxycholate coated with PE-PEG</td>
<td align="center">
<xref ref-type="bibr" rid="B13">Arana et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="center">Pulmonary administration</td>
<td align="center">Tuberculosis</td>
<td align="center">Rifabutin</td>
<td align="center">RFB-loaded SLN based on glyceryl debehenate or glyceril tristearate</td>
<td align="center">
<xref ref-type="bibr" rid="B112">Gaspar et al. (2017)</xref>
</td>
</tr>
<tr>
<td align="center">Drug administration</td>
<td align="center">Tuberculosis</td>
<td align="center">Bedaquiline</td>
<td align="center">Chitosan-based nanocapsules with PEG layer</td>
<td align="center">
<xref ref-type="bibr" rid="B64">De Matteis et al. (2018)</xref>
</td>
</tr>
<tr>
<td align="center">Local administration</td>
<td align="center">Hearing loss</td>
<td align="center">Dexamethasone and hydrocortisone</td>
<td align="center">Stearic acid-based SLNs loaded with glucocorticoids</td>
<td align="center">
<xref ref-type="bibr" rid="B48">Cervantes et al. (2019)</xref>
</td>
</tr>
<tr>
<td rowspan="2" align="center">Oral drug delivery</td>
<td align="center">Inflammatory bowel disease</td>
<td align="center">Polyphenol oleuropein (OLE)</td>
<td align="center">Olive oil-based NLCs</td>
<td align="center">
<xref ref-type="bibr" rid="B140">Huguet-Casquero et al. (2020)</xref>
</td>
</tr>
<tr>
<td align="center">Antiparasitic (<italic>Leishmania</italic>)</td>
<td align="center">Ammonium iodide derivative C6I</td>
<td align="center">Glycerol tripalmitate and glyrerol tristearate SLNs obtained by emulsi&#xf3;n-solvent evaporation method</td>
<td align="center">
<xref ref-type="bibr" rid="B92">Fern&#xe1;ndez et al. (2021)</xref>
</td>
</tr>
<tr>
<td rowspan="2" align="center">Nucleic acid delivery</td>
<td rowspan="2" align="center">-</td>
<td align="center">Circular DNA and linear RNA</td>
<td align="center">Combination of cationic and ionizable lipids</td>
<td align="center">
<xref ref-type="bibr" rid="B89">Fabregas et al. (2017)</xref>
</td>
</tr>
<tr>
<td align="center">mRNA and pDNA</td>
<td align="center">Combination of ionizable and cationic lipids (DOTAP)</td>
<td align="center">
<xref ref-type="bibr" rid="B119">Gomez-Aguado et al. (2020)</xref>
</td>
</tr>
<tr>
<td align="center">Ocular drug delivery</td>
<td align="center">Keratoconus</td>
<td align="center">Lactoferrin</td>
<td align="center">Double emulsion/solvent evaporation method</td>
<td align="center">
<xref ref-type="bibr" rid="B302">Varela-Fernandez et al. (2022)</xref>
</td>
</tr>
<tr>
<td align="center">Gene therapy</td>
<td rowspan="2" align="center">Eye disease</td>
<td align="center">IL-10</td>
<td align="center">SLNs combined con protamine, dextran or hyaluronic acid and formulated with PVA.</td>
<td align="center">
<xref ref-type="bibr" rid="B304">Vicente-Pascual et al. (2020)</xref>
</td>
</tr>
<tr>
<td align="center">Production of IL-10 in corneal cells</td>
<td align="center">mRNA-based nanomedicinal products</td>
<td align="center">Eye drops containing mRNA formulated in SLNs</td>
<td align="center">
<xref ref-type="bibr" rid="B118">Gomez-Aguado et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="center">Nucleic acid delivery (gene-silencing therapy)</td>
<td align="center">-</td>
<td align="center">siRNA</td>
<td align="center">Cholesterol derivative cholesteryl oleate SLNs</td>
<td align="center">
<xref ref-type="bibr" rid="B285">Sune-Pou et al. (2018)</xref>
</td>
</tr>
<tr>
<td align="center">Liver lipopolysaccharide-binding protein (LBP) downregulation</td>
<td align="center">Obesity</td>
<td align="center">Modified LBP siRNA</td>
<td align="center">Four different lipid combination that interact with RNA and form non-charged NPs</td>
<td align="center">
<xref ref-type="bibr" rid="B157">Latorre et al. (2022)</xref>
</td>
</tr>
<tr>
<td align="center">Downregulate metalloproteinase 9 (MPP-9)</td>
<td align="center">Eye disease</td>
<td align="center">Short-hairpin RNA (shRNA)</td>
<td align="center">Nanocarriers formed by protamine, dextran and plasmids</td>
<td align="center">
<xref ref-type="bibr" rid="B293">Torrecilla et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="center">Nanostructured lipid carriers (NLCs)</td>
<td align="center">Characterization of IMT-loaded NLCs</td>
<td align="center">Gastrointestinal stromal tumors</td>
<td align="center">Imatinib</td>
<td align="center">NLCs containing imatinib by emulsification-sonication methods</td>
<td align="center">
<xref ref-type="bibr" rid="B135">Gundogdu et al. (2022)</xref>
</td>
</tr>
<tr>
<td align="center"/>
<td align="center">Develop, characterize and assay Tripalm-NPs-PTX</td>
<td align="center">Breast and Lung cancer</td>
<td align="center">PTX</td>
<td align="center">Glycerin tripalmitate NLCs loaded with PTX</td>
<td align="center">
<xref ref-type="bibr" rid="B162">Leiva et al. (2017)</xref>
</td>
</tr>
<tr>
<td align="center">
</td>
<td align="center">Induce cancer cell death by apoptosis</td>
<td align="center">Cancer</td>
<td align="center">Apo2L/TRAIL</td>
<td align="center">Binding TRAIL on a lipid nanoparticle surface</td>
<td align="center">
<xref ref-type="bibr" rid="B100">Gallego-Lleyda et al. (2018)</xref>
</td>
</tr>
<tr>
<td align="center">
</td>
<td align="center">Provide effective NLCs formulations for intramuscular or intraperitoneal administration</td>
<td align="center">Resistant bacteria</td>
<td align="center">Sodium colistumethate (SCM) and amikacin (AMK)</td>
<td align="center">NLC formulations using trehalose and dextran as cryoprotectants and positive charged chitosan as coating</td>
<td align="center">
<xref ref-type="bibr" rid="B296">Vairo et al. (2020)</xref>
</td>
</tr>
<tr>
<td align="center">
</td>
<td align="center">Compare the efficacy of NLC-colistin vs. free colistin</td>
<td align="center">Colistin-resistant <italic>Pseudomonas aeruginosa</italic> biofilm</td>
<td align="center">Colistin</td>
<td align="center">Hot melt homogenization technique. Precirol&#xae;ATO 5 and Miglyol 812 core mixed with colistin sulfate</td>
<td align="center">
<xref ref-type="bibr" rid="B259">Sans-Serramitjana et al. (2017a)</xref>
</td>
</tr>
<tr>
<td align="center">Nanostructured lipid carriers (NLCs)</td>
<td align="center">Develop safer cationic NLCs using machine learning algorithms</td>
<td align="center">Glioblastoma</td>
<td align="center">Atorvastatin Coumarin</td>
<td align="center">Glycerol based lipids NLCs produced by high-shear homogenization-ultrasonication</td>
<td align="center">
<xref ref-type="bibr" rid="B32">Basso et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="center">
</td>
<td align="center">Drug oral administration</td>
<td align="center">Antiparasitic (<italic>Leishmania</italic>)</td>
<td align="center">Diselenide</td>
<td align="center">Glyceryl palmitostearate and diethylene glycol monoethyl ether-based NLCs loaded with Diselenide</td>
<td align="center">
<xref ref-type="bibr" rid="B88">Etxebeste-Mitxeltorena et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="center">
</td>
<td align="center">Increase EGFR gene expression</td>
<td align="center">Cell culture and tissue engineering</td>
<td align="center">Recombinant human epithelial growth factor (rhEGF)</td>
<td rowspan="2" align="center">NLCs prepared by hot melt homogenization</td>
<td align="center">
<xref ref-type="bibr" rid="B49">Chato-Astrain et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="center">
</td>
<td align="center">Pulmonary and intramuscular administration</td>
<td align="center">Respiratory infections</td>
<td align="center">Sodium colistimethate</td>
<td align="center">
<xref ref-type="bibr" rid="B217">Pastor et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="center"/>
<td align="center">Drug delivery across BBB</td>
<td align="center">Neurodegenerative diseases</td>
<td align="center">Growth factors</td>
<td align="center">Polyunsaturated fatty acids-based NLC modulated with chitosan and TAT</td>
<td align="center">
<xref ref-type="bibr" rid="B139">Hernando et al. (2022)</xref>
</td>
</tr>
<tr>
<td align="center">Liposomes</td>
<td align="center">Increase the granulysin concentration at the site of contact with the target cell</td>
<td align="center">Cancer</td>
<td align="center">Granulysin</td>
<td align="center">Binding granulysin to the LNP surface through the complex formed by histidine tail of the protein and Ni<sup>2&#x2b;</sup> of a quelant lipid</td>
<td align="center">
<xref ref-type="bibr" rid="B277">Soler-Agesta et al. (2022)</xref>
</td>
</tr>
<tr>
<td align="center">Quatsomes and liposomes</td>
<td align="center">Delivery</td>
<td align="center">Fabry disease</td>
<td align="center">&#x3b1;-galactosidase A</td>
<td align="center">Incorporation of the cationic miristalkonium chloride (MKC) surfactant to nanoformulations</td>
<td align="center">
<xref ref-type="bibr" rid="B292">Tomsen-Melero et al. (2021)</xref>
</td>
</tr>
<tr>
<td rowspan="3" align="center">Quatsomes</td>
<td align="center">Parenteral administration</td>
<td align="center">Cancer</td>
<td align="center">Myristalkonium chloride (MKC) and cholesterol</td>
<td align="center">Quatsomes prepared by depressurization on an expanded liquid organic solution-suspension method</td>
<td align="center">
<xref ref-type="bibr" rid="B303">Vargas-Nadal et al. (2020)</xref>
</td>
</tr>
<tr>
<td align="center">Drug delivery</td>
<td align="center">Chagas disease</td>
<td align="center">Benznidazole</td>
<td align="center">Quatsomes and LNPs prepared using CO<sub>2</sub> in a one-step procedure. Cyclodextrins by antisolvent precipitation</td>
<td align="center">
<xref ref-type="bibr" rid="B310">Vinuesa et al. (2017)</xref>
</td>
</tr>
<tr>
<td align="center">miRNAs delivery</td>
<td rowspan="3" align="center">Cancer</td>
<td align="center">miRNAs</td>
<td align="center">Quatsomes composed of Chol and/or DC-Chol and quaternary ammonium surfactants</td>
<td align="center">
<xref ref-type="bibr" rid="B37">Boloix et al. (2022)</xref>
</td>
</tr>
<tr>
<td rowspan="3" align="center">Lipoplexes</td>
<td rowspan="2" align="center">Cellular transfection</td>
<td rowspan="2" align="center">siRNA</td>
<td align="center">Histidine-based gemini cationic lipids</td>
<td align="center">
<xref ref-type="bibr" rid="B254">Sanchez-Arribas et al. (2020a)</xref>
</td>
</tr>
<tr>
<td align="center">Double-chain cationic lipid based on the argnine</td>
<td align="center">
<xref ref-type="bibr" rid="B253">Sanchez-Arribas et al. (2020b)</xref>
</td>
</tr>
<tr>
<td align="center">pDNA delivery</td>
<td align="center">-</td>
<td align="center">pDNA</td>
<td align="center">Mixture of a Gemini-Bolaamphiphilic Hybrid Lipid and DOPE</td>
<td align="center">
<xref ref-type="bibr" rid="B181">Martinez-Negro et al. (2018)</xref>
</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>LNPs are vastly used to treat cancer. Mitxelena-Iribarren et al. tested the effectiveness of nanoencapsulated methotrexate against human bone osteosarcoma cells U2OS using microfluidic platforms that allow cell culture and incubation under highly controlled dynamic conditions (<xref ref-type="bibr" rid="B189">Mitxelena-Iribarren et al., 2017</xref>; <xref ref-type="bibr" rid="B190">Mitxelena-Iribarren et al., 2021</xref>). Cacicedo et al. combined bacterial cellulose hydrogel (BC) and NLC, including cationic or neutral DOX as a drug model and tested in human breast adenocarcinoma MDA-MB-231 cells and orthotopic breast cancer mouse model. These carriers showed a significant reduction in tumor growth, metastasis incidence and local drug toxicities (<xref ref-type="bibr" rid="B42">Cacicedo et al., 2018</xref>). Gonz&#xe1;lez-Fern&#xe1;ndez et al. tested the oral administration of edelfosine encapsulated SLNs in osteosarcoma cancer cell lines and animal models. They found that oral administration had a better effect against primary osteosarcoma tumors and successfully prevented the metastatic spread of cancer cells from the primary tumor to the lungs. In addition, Lasa-Sarac&#xed;bar et al. labelled these SLNs with Tc and studied their biodistribution in mice after intraperitoneal and intravenous administration. Results showed that the drug could reach circulation and provide a more constant blood concentration after intraperitoneal administration (<xref ref-type="bibr" rid="B126">Gonzalez-Fernandez et al., 2018</xref>; <xref ref-type="bibr" rid="B154">Lasa-Saracibar et al., 2022</xref>) (<xref ref-type="fig" rid="F7">Figure 7</xref>). Aguilera-Garrido et al. tested the delivery maslinic acid using SLNs with three different shell compositions: Poloxamer 407 (PMA), dicarboxylic acid-Poloxamer 407 (PCMA), and Hyaluronic acid-coated PCMA (PCMA-HA) in Caco-2/HT29-MTX co-cultures. Interestingly, they found that the SLNPs improved the solubility of MA up to 7.5&#xa0;mg/mL, stable in a wide range of pH, and increased the bioaccessibility of MA after gastrointestinal digestion in a cellular model (<xref ref-type="bibr" rid="B3">Aguilera-Garrido et al., 2022</xref>). Arana et al. studied how different amounts of phosphatidylethanolamine polyethylene glycol (PE&#x207b;PEG) influence SLNs composed of stearic acid, Epikuron 200, and sodium taurodeoxycholate. They observed that the presence of PE&#x207b;PEG improved active cell internalization of the NPs in an oral adenocarcinoma cell line, reducing non-specific internalization mechanisms. Furthermore, they also tested the effect of surface coating on the efficiency of incorporated drugs finding that PE&#x207b;PEG coated SLN increases its chemotoxic effect compared to non-coated SL (<xref ref-type="bibr" rid="B13">Arana et al., 2019</xref>). Gundogdu et al. rigorously studied the physical characteristics of imatinib-containing NLC for the treatment of gastrointestinal stroma tumors. They found that these NPs revealed a Korsmeyer-Peppas drug release model of 53% at 8&#xa0;h with above 90% of cell viability. They also found an IC<sub>50</sub> of 23.61 &#x03BC;M and induction of apoptosis in CRL-1739 cell lines (<xref ref-type="bibr" rid="B135">Gundogdu et al., 2022</xref>). Leiva et al. tested glyceryl tripalmitate NLCs loaded with PTX. The NPs-PTX significantly enhanced PTX antitumor activity in human breast (MCF7, MDAMB231, SKBR3, and T47D) and lung (A549, NCI-H520, and NCI-H460) cancer cells. They also decreased the volume of breast and lung multicellular tumor spheroids (<xref ref-type="bibr" rid="B162">Leiva et al., 2017</xref>).</p>
<fig id="F7" position="float">
<label>FIGURE 7</label>
<caption>
<p>Distribution of LNPs loaded with edelfosine. Reprinted from <xref ref-type="bibr" rid="B154">Lasa-Saracibar et al. (2022)</xref>, and licensed under the CReative Commons Attribution.</p>
</caption>
<graphic xlink:href="fbioe-11-1191327-g007.tif"/>
</fig>
<p>To induce apoptosis in cancer cells, Gallego-Leyda et al. employed SLNs decorated with TNF-related apoptosis-inducing ligand (TRAIL). They found that the decorated NPs were more cytotoxic than soluble TRAIL in A673 cells, RD cells and HT-1080 cells (<xref ref-type="bibr" rid="B100">Gallego-Lleyda et al., 2018</xref>). Similarly, Solar-Agesta et al. developed LNPs whose surfaces can bind granulysin as an antitumoral treatment, increasing the concentration at the site of contact with the target cell. Granulysin binding to the liposomes significantly increased the cytotoxic potency, produced mainly by apoptosis (<xref ref-type="bibr" rid="B277">Soler-Agesta et al., 2022</xref>).</p>
<p>NLC can overcome the toxicity of some antibiotics with a current limited use. Vairo et al. encapsulated antibiotics in different NLC formulations through high pressure homogenization, and showed that negatively charged SCM-NLC, with trehalose as cryoprotectant, had the best efficacy in several bacteria strains (<xref ref-type="bibr" rid="B296">Vairo et al., 2020</xref>). With a similar aim, Vinuesa et al. explored different lipid nanoformulation options for benznidazole, a commercially available drug currently used for the treatment of Chagas disease with a high toxicity, finding balanced conjugates of activity/toxicity (<xref ref-type="bibr" rid="B310">Vinuesa et al., 2017</xref>).</p>
<p>LNPs are also used to destroy biofilms. Sans-Serramitjana et al. studied the viability of <italic>P. aeruginosa</italic> biofilms treated with both free and nanoencapsulated colistin finding a more rapid killing of <italic>P. aeruginosa</italic> bacterial biofilms by nanostructure lipid carrier-colistin than by free colistin (<xref ref-type="bibr" rid="B259">Sans-Serramitjana et al., 2017a</xref>). The same group investigated the encapsulation of Tobramycin and its effect on planktonic and biofilm forms of <italic>Pseudomonas</italic>. They found that the nanoencapsulation of tobramycin did not improve its efficacy against planktonic <italic>P. aeruginosa</italic> but did improve its ability to eradicate <italic>P. aeruginosa</italic> biofilms (<xref ref-type="bibr" rid="B258">Sans-Serramitjana et al., 2017b</xref>).</p>
<p>Machine learning algorithms can be used to unravel hidden patterns in NP. In this work by Basso et al., the effects of two novel glycerol-based lipids, GLY1 and GLY2, on the architecture and performance of NLC were evaluated. Results showed that GLY1 circumvents the intrinsic cytotoxicity, is effective at increasing glioblastoma uptake, and exhibits encouraging anticancer activity (<xref ref-type="bibr" rid="B32">Basso et al., 2021</xref>).</p>
<p>Diselenide loaded in NLCs were developed by Etxebeste-Mitxeltorena et al. to treat visceral leishmaniasis. In this work, Diselenide (2m), a trypanothione reductase inhibitor, was loaded in glyceryl palmitostearate and diethylene glycol monoethyl ether-based NLCs. They found that diselenide 2m-NLCs drastically enhanced its intestinal permeability and provided plasmatic levels higher than its effective concentration (IC<sub>50</sub>). In <italic>Leishmania infantum</italic>-infected BALB/c mice, 2m-NLC reduced the parasite burden in the spleen, liver, and bone marrow by at least 95% after 5 doses (<xref ref-type="bibr" rid="B88">Etxebeste-Mitxeltorena et al., 2021</xref>).</p>
<p>SLNs can also be included in microspheres of appropriate size through a spray-drying technique. Gaspar et al. encapsulated SLNs containing rifabutin (pulmonary antibiotic) and tested their antimycobacterial activity in a murine model of infection with <italic>Mycobacterium tuberculosis</italic> (<xref ref-type="bibr" rid="B112">Gaspar et al., 2017</xref>). Moreover, tuberculosis was also treated using Bedaquiline encapsulation in SLNs and chitosan nanocapsules in a work performed by Matteis et al. The authors encapsulated this drug and found no cytotoxicity at the concentration needed to kill bacteria, (<xref ref-type="bibr" rid="B64">De Matteis et al., 2018</xref>), highlighting the great potential of this approach (<xref ref-type="bibr" rid="B26">Baranyai et al., 2021</xref>).</p>
<p>Another interesting application of SLNs was developed by Cervantes et al. to protect auditory cells from cisplatin-induced ototoxicity. SLNs were loaded with glucocorticoids (dexamethasone and hydrocortisone) and they were efficiently incorporated by auditory HEI-OC1. Their results showed that the encapsulation in SLNs increased the protective effect of low-doses of hydrocortisone and lengthened the survival of HEI-OC1 cells treated with cisplatin (<xref ref-type="bibr" rid="B48">Cervantes et al., 2019</xref>).</p>
<p>NLCs were also used to treat inflammatory bowel disease. Huguet-Casquero et al. loaded NLCs with polyphenol (antioxidant/antiinflammatory) oleuropein (OLE). NLC-OLE showed to be more effective in decreasing the TNF-&#x3b1; secretion and intracellular ROS by activated macrophages (J774) compared to the conventional form of OLE in a murine model (<xref ref-type="bibr" rid="B140">Huguet-Casquero et al., 2020</xref>)</p>
<p>Fernandez et al. developed a SLN to deliver N-iodomethyl-N, N-Dimethyl-N-(6,6-diphenylhex-5-en-1-yl) ammonium iodide (C6I). The SLNs were obtained by emulsion&#x2013;solvent evaporation method. They were made of glycerol tripalmitate and glyceryl tristearate. They compared their performance with PLGA NPs. Although SLNs performed better than the free C6I, the SLNs were not capable of overcoming the performance of PLGA (<xref ref-type="bibr" rid="B92">Fern&#xe1;ndez et al., 2021</xref>).</p>
<p>Oligonucleotides are one of the biomolecules that reach their site of action less effectively. Thus, Fabregas et al. characterized the main physicochemical characteristics and binding capabilities of SLNs to oligonucleotides. They optimized the formulation of the NPs to efficiently transfect circular DNA and linear RNA molecules into cells (<xref ref-type="bibr" rid="B89">Fabregas et al., 2017</xref>). Gomez-Aguado et al. developed different SLNs by the combination of cationic and ionizable lipids, to deliver mRNA and pDNA. They evaluated their performance in human retinal pigment epithelial cells (ARPE-19) and human embryonic kidney cells (HEK-293). The results showed that SLNs containing only DOTAP (1,2-dioleoyl-3-trimethylammonium-propane) were the most promising formulations for nucleic acid delivery (<xref ref-type="bibr" rid="B119">Gomez-Aguado et al., 2020</xref>).</p>
<p>Similarly, Sanchez-Arribas et al. developed a strategy for siRNA delivery using cationic lipoplexes (<xref ref-type="bibr" rid="B254">Sanchez-Arribas et al., 2020a</xref>) enabling moderate to high gene lockdown levels. The authors also characterized the protein corona formed around these lipoplexes, that could have an influence on the silencing activity of these agents (<xref ref-type="bibr" rid="B253">Sanchez-Arribas et al., 2020b</xref>). Delivery of siRNAs was also performed by Su&#xf1;&#xe9;-Pou et al. The authors incorporated the cholesterol derivative cholesteryl oleate to produce SLN&#x2013;nucleic acid complexes with reduced cytotoxicity and more efficient cellular uptake. They found that intermediate concentrations of cholesteryl oleate exhibited good stability and spherical structures with no aggregation (<xref ref-type="bibr" rid="B285">Sune-Pou et al., 2018</xref>). Latorre J. et al. generated a LNP containing a siRNA with a chemically modified lipopolysaccharide-binding protein in order to reduce the levels of fat accumulated in the liver. The NPs showed to be effective <italic>in vivo,</italic> stressing the potential of this therapy against fatty liver disease (<xref ref-type="bibr" rid="B157">Latorre et al., 2022</xref>). In another work, Torrecillas et al. developed a SLN-based shRNA delivery system. This system was designed to downregulate metalloproteinase 9 (MMP-9), a proangiogenic factor, in corneal cells for the treatment of corneal neovascularization associated with inflammation. The non-viral vectors based on SLNs were able to downregulate the MMP-9 expression in HCE-2 cells via gene silencing, and, consequently, to inhibit cell migration and tube formation (<xref ref-type="bibr" rid="B293">Torrecilla et al., 2019</xref>).</p>
<p>Martinez-Negro et al. developed a multidisciplinary approach using a nanocarrier built with gemini-bolaamphiphilic hybrid lipids. This strategy resulted in a non-cytotoxic delivery of DNA plasmids in cellular models (<xref ref-type="bibr" rid="B181">Martinez-Negro et al., 2018</xref>). With the same goal, nanovesicles have proven to be effective carriers of miRNA in a recent work from Bloix et al. They engineered quatsomes, for the delivery of miRNAs and other small RNAs into the cytosol of tumor cells. The miRNAs delivered by this methodology were able to reach their target destination and thus providing a potential platform for the delivery of these molecules (<xref ref-type="bibr" rid="B37">Boloix et al., 2022</xref>).</p>
<p>LNPs have also been employed to cross the BBB to deliver drugs to the brain. Hernando et al. developed polyunsaturated fatty acids (PUFA)-based NLCs, namely, DHAH-NLC. The carriers were modulated with BBB-permeating compounds such as CS and trans-activating transcriptional activator (TAT) from HIV-1. They quantitatively assessed the permeability of DHAH-NLCs in endothelial cells (BMECs). Successfully, they reported that TAT-functionalized DHAH-NLCs successfully crossed the BBB in a cellular model (<xref ref-type="bibr" rid="B139">Hernando et al., 2022</xref>).</p>
<p>Improving ocular drug delivery is a milestone that can greatly impact the treatment of eye disorders. Varela-Fernandez et al. designed, developed and performed the physicochemical characterization of lactoferrin-loaded NLCs as a new therapeutic alternative for the keratoconus treatment. Based on the preclinical base obtained, they concluded that NLCs were stable, non-toxic and showed mucoadhesive properties (<xref ref-type="bibr" rid="B302">Varela-Fernandez et al., 2022</xref>). Vicente-Pascal et al. designed SLN-based eye drops as gene delivery system to induce the expression of interleukin 10 (IL-10). Two kinds of SLNs combined with different ligands (protamine, dextran, or hyaluronic acid) and formulated with polyvinyl alcohol (PVA) were prepared and tested in cellular and animal models. SLN-based vectors were capable of transfecting corneal epithelial cells. Animal model experiments show that IL-10 could reach even the endothelial layer (<xref ref-type="bibr" rid="B304">Vicente-Pascual et al., 2020</xref>; <xref ref-type="bibr" rid="B118">Gomez-Aguado et al., 2021</xref>).</p>
<p>To generate human keratinocyte primary cell cultures with potential in tissue engineering Chato-Astrain et al. developed EGF-loaded NLCs. After testing in skin keratinocytes and cornea epithelial cells, and in two epithelial cancer cell lines, gene expression analysis showed that the NLCs were able to increase EGFR gene expression (<xref ref-type="bibr" rid="B49">Chato-Astrain et al., 2021</xref>). Tomsen-Melero et al. investigated the potential of nanovesicles as carriers of &#x3b1;-galactosidase A, specifically quatsomes and hybrid liposomes. These structures provided improved colloidal stability in comparison to nanoliposomes and the conditions to preserve &#x3b1;-galactosidase A activity were also characterized, thus resulting in promising nanostructures for the delivery of this enzyme (<xref ref-type="bibr" rid="B292">Tomsen-Melero et al., 2021</xref>). In another study, MKC-Quatsomes formed by cholesterol and myristalkonium chloride were highly stable in different media and remained unaltered in human plasma for 24&#xa0;h. After studying their biodistribution in a xenograft colorectal model they accumulated in tumors, liver, spleen, and kidneys (<xref ref-type="bibr" rid="B303">Vargas-Nadal et al., 2020</xref>). In fact, given their stability, they have also been used to efficiently incorporate different fluorophores (<xref ref-type="bibr" rid="B16">Ardizzone et al., 2018a</xref>), including diketopyrrolopyrroles, which promoted their photophysical properties and were used for imaging experiments in Saos-2 osteosarcoma cell line (<xref ref-type="bibr" rid="B15">Ardizzone et al., 2018b</xref>).</p>
<p>Pasto et al. prepared sodium colistimethate-loaded NLCs to treat respiratory infections (multiresistant <italic>P. aeroginosa</italic>). Biodistribution assessments showed a mild systemic absorption after nebulization and a notorious absorption after intramuscular route (<xref ref-type="bibr" rid="B217">Pastor et al., 2019</xref>).</p>
</sec>
</sec>
<sec id="s4">
<title>4 Perspective</title>
<p>In this review, we aimed to provide an overview of the nanomedical research currently being performed in Spain. We organized the literature based on NP type and the most common materials employed in their preparation. There is a large number of researchers devoted to engineering NPs with nanomedical applications, and although here we have only focused on NPs with therapeutic applications, there is also a substantial amount of scientists engineering NPs for diagnostic purposes (<xref ref-type="bibr" rid="B209">Ortgies et al., 2016</xref>; <xref ref-type="bibr" rid="B148">Jornet-Martinez et al., 2019</xref>; <xref ref-type="bibr" rid="B227">Portela et al., 2020</xref>). Similarly, the thorough study of NPs and their properties is fundamental to future applications of these therapeutic agents. Here, we have reviewed a fraction of the work, due to space limitations, on the more popular nanoformulations and their therapeutic applications (<xref ref-type="table" rid="T9">Table 9</xref>). It is important to highlight the diverse applications of every type of NPs, that showcase the versatility of these nanomedical materials and their potential (<xref ref-type="bibr" rid="B7">Alfranca et al., 2016</xref>; <xref ref-type="bibr" rid="B223">Perez-Hernandez et al., 2017</xref>; <xref ref-type="bibr" rid="B299">Vallet-Regi, 2022</xref>).</p>
<table-wrap id="T9" position="float">
<label>TABLE 9</label>
<caption>
<p>Summary of NPs classified by therapeutic area.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="center">Therapeutic area</th>
<th align="center">Purpose</th>
<th align="center">NP type</th>
<th align="center">Agent</th>
<th align="center">Main results</th>
<th align="center">Ref.</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td rowspan="2" align="center">Antiamoebical activity <italic>(A. castellani</italic>)</td>
<td rowspan="2" align="center">Develop of anti-amoebic contact lens solution</td>
<td rowspan="2" align="center">AgNPs</td>
<td align="center">-</td>
<td align="center">A significant increase in anti-amoebic activity was observed</td>
<td align="center">
<xref ref-type="bibr" rid="B137">Hendiger et al. (2021)</xref>, <xref ref-type="bibr" rid="B136">Hendiger et al. (2020)</xref>
</td>
</tr>
<tr>
<td align="center">Tannic acid</td>
<td align="center">AgNPs conjugated with tannic acid showed potential as an anti-amoebic agent</td>
<td align="center">
<xref ref-type="bibr" rid="B212">Padzik et al. (2018)</xref>
</td>
</tr>
<tr>
<td align="center">Antimicrobial activity</td>
<td align="center">Lactose-gated delivery</td>
<td rowspan="2" align="center">MSNs</td>
<td align="center">Essential Oil cinnamaldehyde</td>
<td align="center">Improved delivery by decreasing volatility of compound and increasing its local concentration</td>
<td align="center">
<xref ref-type="bibr" rid="B228">Poyatos-Racionero et al. (2021)</xref>
</td>
</tr>
<tr>
<td rowspan="2" align="center">Antibacterial activity</td>
<td rowspan="2" align="center">Overcome biofilm barrier</td>
<td rowspan="2" align="center">Levofloxacin</td>
<td align="center">Therapeutic efficacy of levofloxacin was increased</td>
<td align="center">
<xref ref-type="bibr" rid="B177">Martinez-Carmona et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="center">AuNR@MSN</td>
<td align="center">NIR activated MSNs with photothermal and antimicrobial properties</td>
<td align="center">
<xref ref-type="bibr" rid="B102">Garc&#xed;a et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="center">Antibacterial activity</td>
<td align="center">Provide effective NLCs formulations for intramuscular or intraperitoneal administration against resistant bacteria</td>
<td align="center">Nanostructured lipid carriers (NLCs)</td>
<td align="center">Sodium colistumethate (SCM) and amikacin (AMK)</td>
<td align="center">NLC showed equal activity to the free drug. Intraperitoneal administration was observed to be superior than the intramuscular route</td>
<td align="center">
<xref ref-type="bibr" rid="B296">Vairo et al. (2020)</xref>
</td>
</tr>
<tr>
<td align="center">Antibacterial activity (Colistin-resistant <italic>P. aeruginosa</italic> biofilm)</td>
<td align="center">Compare the efficacy of NLC-colistin vs. free colistin</td>
<td align="center">Nanostructured lipid carriers (NLCs)</td>
<td align="center">Colistin</td>
<td align="center">Time dependent study of biofim viability upon treatment, showing colistin-NLC a more rapid biofilm killing with similar cellular death activity to the free drug</td>
<td align="center">
<xref ref-type="bibr" rid="B259">Sans-Serramitjana et al. (2017a)</xref>
</td>
</tr>
<tr>
<td align="center">Antibacterial activity (osteomyelitis)</td>
<td align="center">Improve therapeutic effect</td>
<td align="center">MSNs</td>
<td align="center">Moxifloxacin, rifampicin</td>
<td align="center">NPs treatment prevented the premature release of the antibiotics and induced biofilm disaggregation</td>
<td align="center">
<xref ref-type="bibr" rid="B2">Aguilera-Correa et al. (2022a)</xref>
</td>
</tr>
<tr>
<td rowspan="3" align="center">Antibacterial activity (tuberculosis)</td>
<td align="center">Pulmonary administration</td>
<td align="center">SLNs</td>
<td align="center">Rifabutin</td>
<td align="center">Biodistribution study confirmed that pulmonary administered rifabutin NPs reached organs in 15&#x2013;30&#xa0;min timeframe, exerting their therapeutic activity</td>
<td align="center">
<xref ref-type="bibr" rid="B112">Gaspar et al. (2017)</xref>
</td>
</tr>
<tr>
<td align="center">Drug administration</td>
<td align="center">SLNs</td>
<td align="center">Bedaquiline</td>
<td align="center">NP encapsulation reduced drug toxicity while maintaining therapeutic activity</td>
<td align="center">
<xref ref-type="bibr" rid="B64">De Matteis et al. (2018)</xref>
</td>
</tr>
<tr>
<td align="center">Drug delivery</td>
<td align="center">MSNs-AgBr and Ag@MSNs</td>
<td rowspan="2" align="center">-</td>
<td align="center">Good antimycobacterial capacity of both types of NPs was found <italic>in vitro</italic>
</td>
<td align="center">
<xref ref-type="bibr" rid="B191">Montalvo-Quiros et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="center">Antibacterial activity (<italic>E. coli</italic> infection)</td>
<td align="center">Treatment of <italic>E. coli</italic> infection</td>
<td rowspan="2" align="center">AuNPs</td>
<td align="center">Inhibition of <italic>E. coli</italic> infection was observed after treatment with the biosurfactant stabilized NPs</td>
<td align="center">
<xref ref-type="bibr" rid="B120">Gomez-Grana et al. (2017)</xref>
</td>
</tr>
<tr>
<td align="center">Antibacterial activity (<italic>K. pneumoniae</italic>)</td>
<td align="center">Drug delivery</td>
<td align="center">Amikacin</td>
<td align="center">The combination of AuNPs and the antiobiotic evidenced a synergistic effect representing a potential anti-bacterial nanomaterial</td>
<td align="center">
<xref ref-type="bibr" rid="B1">Aguilera-Correa et al. (2022b)</xref>
</td>
</tr>
<tr>
<td align="center">Antibacterial activity (<italic>Campylobacter</italic>)</td>
<td align="center">Improve drug efficacy against multidrug resistant strains</td>
<td align="center">GSH-Ag NPs</td>
<td rowspan="2" align="center">-</td>
<td align="center">Results evidenced that these NPs are highly effective against the infection of multidrug resistant strains</td>
<td align="center">
<xref ref-type="bibr" rid="B274">Silvan et al. (2018)</xref>
</td>
</tr>
<tr>
<td align="center">Antibacterial activity (<italic>S. aureus</italic> and <italic>E. coli</italic>)</td>
<td align="center">Treatment against bacterial infection by <italic>S. aureus</italic> and <italic>E. coli</italic>
</td>
<td align="center">Hybrid &#x3b3;-Fe<sub>2</sub>O<sub>3</sub>/Ag nanocomposites</td>
<td align="center">Synergistic properties between AgNPs and IONPs were found for the treatment of bacterial infection of <italic>S. aureus</italic> and <italic>E. coli</italic>
</td>
<td align="center">
<xref ref-type="bibr" rid="B170">Luengo et al. (2020)</xref>
</td>
</tr>
<tr>
<td align="center">Antibacterial activity (<italic>P. aeruginosa</italic>)</td>
<td align="center">Treatment against bacterial infection by <italic>P. aeruginosa</italic>
</td>
<td rowspan="2" align="center">AgNPs</td>
<td align="center">Probiotics</td>
<td align="center">Combination of AgNPs with living probiotics showed anti-bacterial activity against <italic>P. aeruginosa</italic>
</td>
<td align="center">
<xref ref-type="bibr" rid="B249">Sabio et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="center">Antibacterial activity (peri-implantitis)</td>
<td align="center">Prevention of implant associated infection (<italic>S. aureus</italic> and mixed oral bacteria flora infection)</td>
<td rowspan="2" align="center">-</td>
<td align="center">NPs prevented the formation of bacterial biofilms proving their potential to be used in dental implants to prevent pre-implantitis</td>
<td align="center">
<xref ref-type="bibr" rid="B224">Perez-Tanoira et al. (2022)</xref>
</td>
</tr>
<tr>
<td align="center">Antibacterial activity (<italic>S. aureus</italic>)</td>
<td align="center">Anti-biofilm treatment</td>
<td align="center">AgNP@nanoMIL-125(Ti)NH<sub>2</sub>
</td>
<td align="center">Results showed a significant bacterial inhibition, proposing this composite as an active coating biofilm treatment</td>
<td align="center">
<xref ref-type="bibr" rid="B17">Arenas-Vivo et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="center">Antibacterial activity (<italic>S. aureus</italic> and <italic>P.aeruginosa</italic>)</td>
<td align="center">Improve antibiotic treatment of <italic>S. aureus</italic> and <italic>P.aeruginosa</italic> infection</td>
<td align="center">AgNPs</td>
<td align="center">Enzymes (&#x3b1;-amylase, cellulose, DNase I and proteinase K)</td>
<td align="center">A potent anti-biofilm activity was found decreasing bacterial infection in combination with antibiotics</td>
<td align="center">
<xref ref-type="bibr" rid="B248">Rubio-Canalejas et al. (2022)</xref>
</td>
</tr>
<tr>
<td align="center">Antimicrobial activity (anti-fungal and anti-amoebic)</td>
<td align="center">Treatment for fungal and amoebic infection</td>
<td align="center">AgNRs and AgNws</td>
<td align="center">-</td>
<td align="center">AgNPs showed activity agains various fungals and <italic>A. castellanii</italic> infection</td>
<td align="center">
<xref ref-type="bibr" rid="B125">Gonzalez-Fernandez et al. (2022)</xref>
</td>
</tr>
<tr>
<td rowspan="2" align="center">Antiparasitic (<italic>Leishmania</italic>)</td>
<td align="center">Oral drug delivery</td>
<td align="center">Solid lipid NPs (SLNs)</td>
<td align="center">Ammonium iodide derivative C6I</td>
<td align="center">Several NPs were tested in macrophages and PLGA based nanoformulationms improved antui&#xf1;lieshmanial activity on intracellular amastigotes</td>
<td align="center">
<xref ref-type="bibr" rid="B92">Fern&#xe1;ndez et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="center">Drug oral administration</td>
<td align="center">Nanostructured lipid carriers (NLCs)</td>
<td align="center">Diselenide</td>
<td align="center">NLCs increased intestinal permeability providing higher plasmatic drug levels and reducing parasite burden after oral administration</td>
<td align="center">
<xref ref-type="bibr" rid="B88">Etxebeste-Mitxeltorena et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="center">Chagas disease</td>
<td align="center">Drug delivery</td>
<td align="center">Quatsomes</td>
<td align="center">Benznidazole</td>
<td align="center">NPs enabled a safer administration of the drug without losing therapeutic activity</td>
<td align="center">
<xref ref-type="bibr" rid="B310">Vinuesa et al. (2017)</xref>
</td>
</tr>
<tr>
<td align="center">Antiviral activity (SARS-CoV-2)</td>
<td align="center">Treat or prevent SARS-CoV-2 infection</td>
<td align="center">Iron oxide NPs and iron oxyhydroxide NPs</td>
<td align="center">
<bold>-</bold>
</td>
<td align="center">IONPs and IOHNPs might be repurposed as a therapeutic treatment for SARS-CoV-2 infection</td>
<td align="center">
<xref ref-type="bibr" rid="B65">DeDiego et al. (2022)</xref>
</td>
</tr>
<tr>
<td rowspan="4" align="center">Antiviral activity (HIV)</td>
<td align="center">Enhance immune response in HIV infection</td>
<td rowspan="2" align="center">AuNPs</td>
<td align="center">
<bold>-</bold>
</td>
<td align="center">AuNPs coated with two different antibodies that recognize HIV protein and natural killer cells, promoting specific cell-to-cell contact and induced a potent cytotoxic response</td>
<td align="center">
<xref ref-type="bibr" rid="B24">Astorga-Gamaza et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="center">Drug delivery</td>
<td align="center">siRNA-Nef</td>
<td align="center">AuNPs were used for gene delivery against the HIV</td>
<td align="center">
<xref ref-type="bibr" rid="B222">Pena-Gonzalez et al. (2017)</xref>
</td>
</tr>
<tr>
<td align="center">Improve antiretroviral therapy</td>
<td rowspan="2" align="center">Poly(lactic-co-glycolic acid)</td>
<td align="center">HIV-1 Peptide inhibitor</td>
<td align="center">NPs were successfully loaded with inhibitory peptides, permeated through the mucus reaching the vaginal epithelium and released the cargo</td>
<td align="center">
<xref ref-type="bibr" rid="B19">Ariza-Saenz et al. (2017)</xref>
</td>
</tr>
<tr>
<td align="center">Improve the delivery of bioactive peptides to inhibit HIV infection</td>
<td align="left"/>
<td align="center">NPs successfully permeated vaginal tissue and released inhibitory peptides</td>
<td align="center">
<xref ref-type="bibr" rid="B20">Ariza-Saenz et al. (2018)</xref>
</td>
</tr>
<tr>
<td align="center">Antiviral therapy</td>
<td align="center">Inhibits the infection of human cytomegalovirus</td>
<td align="center">Polyanionic carbosilane dendrimers</td>
<td align="center">-</td>
<td align="center">Dendrimers reduced HCMV infection and enhanced the activity of ganciclovir</td>
<td align="center">
<xref ref-type="bibr" rid="B238">Relano-Rodriguez et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="center">Cancer</td>
<td rowspan="2" align="center">Delivery</td>
<td align="center">Multifunctional MSNs</td>
<td rowspan="2" align="center">DOX</td>
<td align="center">Increase the efficacy of glucose dependent cargo delivery</td>
<td align="center">
<xref ref-type="bibr" rid="B146">Jimenez-Falcao et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="center">
</td>
<td align="center">MSNs</td>
<td align="center">A drug encapsulation system was designed using galacto-oligosaccharides to coat a silica scaffold containing the drug of interest, which is preferentially released in tissues with senescent cells</td>
<td align="center">
<xref ref-type="bibr" rid="B200">Munoz-Espin et al. (2018)</xref>
</td>
</tr>
<tr>
<td align="center">
</td>
<td rowspan="2" align="center">Delivery</td>
<td align="center">Nanovehicle MSNs</td>
<td align="center">Camptothecin and DOX, Zn, and phtalocyanine</td>
<td align="center">A pH-triggered nanovehicle with regioselectively bifunctionalized MSNs for the dual release of DOX and camptothecin was developed</td>
<td align="center">
<xref ref-type="bibr" rid="B166">Llinas et al. (2018)</xref>
</td>
</tr>
<tr>
<td align="center">
</td>
<td align="center">MCM-41/Pt</td>
<td align="center">Ru(Bpy)<sub>3</sub>Cl<sub>2</sub>/DOX</td>
<td align="center">Pt-MSNs nanomotors with stimuli-response drug release capabilities have been designed, synthetized and characterized</td>
<td align="center">
<xref ref-type="bibr" rid="B70">Diez et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="center">
</td>
<td align="center"/>
<td align="center">Au-MSNs Janus NPs</td>
<td rowspan="2" align="center">DOX</td>
<td align="center">A nanodevice was designed for the autonomous release of DOX in specific cells triggered by NADPH and glutathione disulfide</td>
<td align="center">
<xref ref-type="bibr" rid="B183">Mayol et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="center">
</td>
<td align="center">Synergy of hyperthermia and drug delivery</td>
<td align="center">MSNs loaded with iron oxide NPs</td>
<td align="center">The synergic effect of the intracellular hyperthermia and chemotherapy significantly reduced <italic>in vivo</italic> tumor growth without a global temperature rise of the tissue</td>
<td align="center">
<xref ref-type="bibr" rid="B133">Guisasola et al. (2018b)</xref>
</td>
</tr>
<tr>
<td align="center">
</td>
<td align="center">Photothermal therapy</td>
<td align="center">Gold suprashells assembled around SPIONs</td>
<td align="center">-</td>
<td align="center">Development of multifunctional gold suprashell that can be magnetically accumulated and used for controlled plasmonic heat generation</td>
<td align="center">
<xref ref-type="bibr" rid="B218">Paterson et al. (2017)</xref>
</td>
</tr>
<tr>
<td align="center">
</td>
<td align="center">Delivery (drug nanocarrier)</td>
<td rowspan="3" align="center">Iron Oxide (magnetite) NPs</td>
<td align="center">Crocin</td>
<td align="center">Drug nanocarrier enhance therapy in comparison to free drug</td>
<td align="center">
<xref ref-type="bibr" rid="B267">Saravani et al. (2020)</xref>
</td>
</tr>
<tr>
<td align="center">
</td>
<td align="center">Magnetic hyperthermia (MHT) cytotoxicity</td>
<td rowspan="3" align="center">-</td>
<td align="center">Cytotoxic effects caused by magnetic hyperthermia are reduced by the cell-promoted NP aggregation</td>
<td align="center">
<xref ref-type="bibr" rid="B186">Mejias et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="center">
</td>
<td align="center">Cell internalization of IONPs</td>
<td align="center">Magnetic thermal response can be predicted based on the type and size of the NP in the cellular media</td>
<td align="center">
<xref ref-type="bibr" rid="B41">Cabrera et al. (2018)</xref>
</td>
</tr>
<tr>
<td align="center">
</td>
<td align="center">Study of MHT in 3D cultures and a murine model</td>
<td align="center"/>
<td align="center">Localization of NPs inside or outside the cells can trigger different apoptotic routes. Best therapeutic conditions were tested in an animal model</td>
<td align="center">
<xref ref-type="bibr" rid="B33">Beola et al. (2018)</xref>, <xref ref-type="bibr" rid="B34">Beola et al. (2020)</xref>, <xref ref-type="bibr" rid="B35">Beola et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="center">
</td>
<td align="center">To develop computational models to effectively design nanomedicine</td>
<td align="center">Iron Oxide (maghemite) NPs</td>
<td align="center">Gemcitabine</td>
<td align="center">Rational design was successfully used to develop multifunctional NPs</td>
<td align="center">
<xref ref-type="bibr" rid="B6">Aires et al. (2017)</xref>
</td>
</tr>
<tr>
<td align="center">
</td>
<td align="center">Therasnotic agent</td>
<td align="center">Au@Fe nanoflowers</td>
<td align="center">-</td>
<td align="center">Nanoflowers could be used as promising tools for diagnostics and hyperthermia therapy</td>
<td align="center">
<xref ref-type="bibr" rid="B51">Christou et al. (2022)</xref>
</td>
</tr>
<tr>
<td align="center">
</td>
<td align="center">MHT and NP uptake in cancer cells</td>
<td align="center">Manganese ferrite nanoflowers</td>
<td rowspan="6" align="center">-</td>
<td align="center">Improvement heating efficiency of magnetic NPs in a glioma cellular model</td>
<td align="center">
<xref ref-type="bibr" rid="B66">Del Sol-Fernandez et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="center">
</td>
<td align="center">PTT, MHT and magneto-photothermal treatment</td>
<td align="center">Gold-iron oxide Janus magnetic nanostars</td>
<td align="center">A synergistic cytotoxic effect on cancer cells and in an animal model was observed</td>
<td align="center">
<xref ref-type="bibr" rid="B83">Espinosa et al. (2020)</xref>
</td>
</tr>
<tr>
<td align="center">
</td>
<td align="center">PTT, MHT and magneto-photothermal treatment</td>
<td align="center">Gold coated magnetite nanorods</td>
<td align="center">Proof of concept of the generation of free-standing anisotropic materials for magneto and photothermia applications</td>
<td align="center">
<xref ref-type="bibr" rid="B239">Rincon-Iglesias et al. (2022)</xref>
</td>
</tr>
<tr>
<td align="center">
</td>
<td align="center">Modulation of angiogenesis as an antitumor therapy</td>
<td align="center">Super paramagnetic Iron oxide (maghemite) NPs</td>
<td align="center">Anti-angiogenic and an-tumoral effects were observed after treatment with NPs</td>
<td align="center">
<xref ref-type="bibr" rid="B198">Mulens-Arias et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="center">
</td>
<td align="center">Targeted cell therapy</td>
<td align="center">Iron oxide (maghemite) NPs</td>
<td align="center">Cell retention was favoured improving cell-based therapy for cancer treatment</td>
<td align="center">
<xref ref-type="bibr" rid="B264">Sanz-Ortega et al. (2019a)</xref>
</td>
</tr>
<tr>
<td align="center">
</td>
<td align="center">Targeted adoptive T-cell transfer therapy and EMF</td>
<td align="center">Iron oxide NPs</td>
<td align="center">T cells modified with the magnetic NPs were retained in lymph nodes after the use of an EMF despite their lower number</td>
<td align="center">
<xref ref-type="bibr" rid="B263">Sanz-Ortega et al. (2019b)</xref>, <xref ref-type="bibr" rid="B265">Sanz-Ortega et al. (2019c)</xref>
</td>
</tr>
<tr>
<td align="center">
</td>
<td align="center">MHT <italic>in vivo</italic> feedback</td>
<td align="center">Ag<sub>2</sub>S-based NPs, Fe<sub>3</sub>O<sub>4</sub> MNPs</td>
<td align="center"/>
<td align="center">Therapeutic effect of the MNPs was more accurately evaluated</td>
<td align="center">
<xref ref-type="bibr" rid="B314">Ximendes et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="center">Cancer</td>
<td align="center">Drug delivery, controlled release and MHT</td>
<td align="center">MNP@mSiO<sub>2</sub>
</td>
<td align="center">DOX</td>
<td align="center">Drug was released at acidic pH showing promising results</td>
<td align="center">
<xref ref-type="bibr" rid="B98">Fuentes-Garc&#xed;a et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="center">
</td>
<td align="center">Drug delivery, controlled release and MHT</td>
<td align="center">MF66 iron oxide NPs</td>
<td align="center"/>
<td align="center">Drug release was controlled by pH reducing side effects of chemotherapy and increasing their therapeutic effect</td>
<td align="center">
<xref ref-type="bibr" rid="B158">Lazaro-Carrillo et al. (2020)</xref>
</td>
</tr>
<tr>
<td align="center">
</td>
<td align="center">Delivery</td>
<td align="center">Iron oxide (maghemite) NPs</td>
<td align="center">miRNA155, miRNA125b and miRNA146a</td>
<td align="center">A pro-inflammatory response was induced after treatment with the loaded NPs</td>
<td align="center">
<xref ref-type="bibr" rid="B153">Lafuente-Gomez et al. (2022)</xref>
</td>
</tr>
<tr>
<td align="center">
</td>
<td align="center">Heterogeneous catalysis</td>
<td align="center">Copper-iron oxide spinel NPs</td>
<td align="center">-</td>
<td align="center">NPs reduced the levels of glutathione and increased ROS and apoptotic pathways in cancer cells</td>
<td align="center">
<xref ref-type="bibr" rid="B39">Bonet-Aleta et al. (2022a)</xref>, <xref ref-type="bibr" rid="B38">Bonet-Aleta et al. (2022b)</xref>
</td>
</tr>
<tr>
<td align="center">
</td>
<td align="center">Improve NP&#x2019;s properties</td>
<td rowspan="1" align="center">AuNPs</td>
<td align="center">-</td>
<td align="center">NPs uptake was improved using an adenovirus</td>
<td align="center">
<xref ref-type="bibr" rid="B127">Gonzalez-Pastor et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="center">
</td>
<td align="center">Drug delivery</td>
<td align="center"/>
<td align="center">Gemcitabine/Gapmers</td>
<td align="center">Delivery of both agents reduced the chemoresistence to gemcitabine in cancer cells</td>
<td align="center">
<xref ref-type="bibr" rid="B108">Garcia-Garrido et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="center">
</td>
<td rowspan="4" align="center">Drug delivery</td>
<td rowspan="4" align="center">AuNPs</td>
<td align="center">DOX</td>
<td align="center">A synergetic effect between chemo and photothermal therapy was observed reducing cell viability in cancer cells</td>
<td align="center">
<xref ref-type="bibr" rid="B78">Encinas-Basurto et al. (2018a)</xref>
</td>
</tr>
<tr>
<td align="center">
</td>
<td align="center">Docetaxel/DOX</td>
<td align="center">Combination of the chemotherapeutic properties of the drugs with the photothermal therapy of the NPs produced high cytotoxic effects in breast cancer cells</td>
<td align="center">
<xref ref-type="bibr" rid="B306">Villar-Alvarez et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="center">
</td>
<td align="center">Doxycicline/Fosbretabulin</td>
<td align="center">Co-delivery of the two drugs in combination with photothermal and photodynamic therapy showed promising results in an embryo xenograph model</td>
<td align="center">
<xref ref-type="bibr" rid="B216">Paris et al. (2020)</xref>
</td>
</tr>
<tr>
<td align="center">
</td>
<td align="center">DOX</td>
<td align="center">Controlled release of the drug in combination with photothermal therapy evidenced a synergistic effect in cancer cells</td>
<td align="center">
<xref ref-type="bibr" rid="B307">Villar-Alvarez et al. (2018)</xref>
</td>
</tr>
<tr>
<td align="center">
</td>
<td rowspan="2" align="center">Drug delivery</td>
<td rowspan="4" align="center">AuNPs</td>
<td align="center">DOX</td>
<td align="center">A nanosystem for the controlled release of the drug was developed</td>
<td align="center">
<xref ref-type="bibr" rid="B176">Martin-Saavedra et al. (2017)</xref>
</td>
</tr>
<tr>
<td align="center">
</td>
<td align="center">DOX/SN38</td>
<td align="center">Controlled drug release of both drugs showed a potent anti-tumoral activity as well as anti-neoplastic activity against cancer stem cells</td>
<td align="center">
<xref ref-type="bibr" rid="B156">Latorre et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="center">Cancer</td>
<td align="center">Biosynthesis of AuNPs with therapeutic properties</td>
<td rowspan="2" align="center">-</td>
<td align="center">NPs synthetized using an aqueous extract of <italic>Saccorhiza polyschides</italic> showed both, immunostimulant and anti-proliferative activities, on immune and tumor cells</td>
<td align="center">
<xref ref-type="bibr" rid="B123">Gonzalez-Ballesteros et al. (2021a)</xref>
</td>
</tr>
<tr>
<td align="center">
</td>
<td align="center">Green synthesis of AuNPs with therapeutic properties</td>
<td align="center">NPs synthetized using extracted carrageenan from red seaweed presented anti-oxidant and anti-tumoral activities</td>
<td align="center">
<xref ref-type="bibr" rid="B124">Gonzalez-Ballesteros et al. (2021b)</xref>
</td>
</tr>
<tr>
<td align="center">
</td>
<td align="center">miRNA delivery</td>
<td align="center">AuNPs</td>
<td align="center">Natural killer cells extracellular vesicle-miRNA</td>
<td align="center">Specific delivery of the NPs regulated the immune response representing a potential immunomodulatory approach for cancer treatment</td>
<td align="center">
<xref ref-type="bibr" rid="B73">Dosil et al. (2022)</xref>
</td>
</tr>
<tr>
<td align="center">
</td>
<td align="center">Drug delivery</td>
<td align="center">AuNPs</td>
<td align="center">DOX</td>
<td align="center">The therapeutic agent triggered by NIR light showed a reduction in the viability of cancer cells</td>
<td align="center">
<xref ref-type="bibr" rid="B138">Hernandez Montoto et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="center">
</td>
<td align="center">Drug delivery</td>
<td align="center">PLGA@Ag<sub>2</sub>S and PLGA@Ag<sub>2</sub>S@SPION</td>
<td align="center">Maslinic acid</td>
<td align="center">An efficient encapsulation and controlled release of the therapeutic agent was observed in cellular models</td>
<td align="center">
<xref ref-type="bibr" rid="B10">Alvear-Jimenez et al. (2022)</xref>
</td>
</tr>
<tr>
<td align="center">
</td>
<td align="center"/>
<td align="center">AgNPs and AuNPs</td>
<td align="center">Raltitrexed</td>
<td align="center">Drug modified NPs showed a strong inhibition on cancer cell viability</td>
<td align="center">
<xref ref-type="bibr" rid="B195">Morey et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="center">
</td>
<td align="center">Drug delivery</td>
<td align="center">Folate-targeted albumin-alginate NPs</td>
<td align="center">PTX</td>
<td align="center">Improved uptake of NPs by cells due to the overexpression of folate receptor</td>
<td align="center">
<xref ref-type="bibr" rid="B182">Martinez-Relimpio et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="center">
</td>
<td align="center">Treatment of different types of tumors</td>
<td align="center">AgNPs-LE AgNPs-PE</td>
<td align="center">
<italic>A. muricata</italic> extracts</td>
<td align="center">Lower concentrations were found to have a potential antitumor activity with a better therapeutic index for the treatment of different types of tumors</td>
<td align="center">
<xref ref-type="bibr" rid="B128">Gonzalez-Pedroza et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="center">
</td>
<td align="center">Macrophages polarization from M2 to M1 profiles</td>
<td align="center">Arginine based</td>
<td align="center">Toll-like receptor 3 agonist poly(I:C)</td>
<td align="center">Nanocomplexes enabled a safe delivery of the Poly (i:C) that induced pro-inflammatory state macrophages</td>
<td align="center">
<xref ref-type="bibr" rid="B58">Dacoba et al. (2020b)</xref>
</td>
</tr>
<tr>
<td align="center">
</td>
<td align="center">Intratumoral immunotherapy</td>
<td align="center">Polyethylenimine</td>
<td align="center">Toll-like receptor 3 agonist poly(I:C)</td>
<td align="center">Nanoplexed formulation of Poly I:C induced immunogenic cell death of tumoral cells</td>
<td align="center">
<xref ref-type="bibr" rid="B25">Aznar et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="center">
</td>
<td align="center">Improve tumor targeting</td>
<td align="center">Poly(lactic-co-glycolic acid)</td>
<td align="center">Allyl-isothiocyanate</td>
<td align="center">Antibody functionalized NP showed improved antitumoral properties than the free drug in cell co-cultures</td>
<td align="center">
<xref ref-type="bibr" rid="B79">Encinas-Basurto et al. (2018b)</xref>
</td>
</tr>
<tr>
<td align="center">
</td>
<td align="center">Develop microgels for drug delivery</td>
<td align="center">Poly(N-vinyl caprolactam)</td>
<td align="center">DOX</td>
<td align="center">Sustained release of DOX through clathrin dependent internalization</td>
<td align="center">
<xref ref-type="bibr" rid="B87">Etchenausia et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="center">
</td>
<td align="center">Improve treatment of unresectable cancer by controlled release</td>
<td align="center">Polyglutamic acid</td>
<td align="center">Gemcitabine</td>
<td align="center">Lasting control release of loaded drug more than 1 month and effective cell growth inhibition in resistant cancer cell lines</td>
<td align="center">
<xref ref-type="bibr" rid="B282">Staka et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="center">
</td>
<td align="center">Edelfosine oral administration</td>
<td rowspan="3" align="center">Solid lipid NPs (SLNs)</td>
<td align="center">Edelfosine</td>
<td align="center">NPs slowed down primary tumor growth and prevented metastatic spread. Combination with DOX did not show synergistic effects</td>
<td align="center">
<xref ref-type="bibr" rid="B126">Gonzalez-Fernandez et al. (2018)</xref>
</td>
</tr>
<tr>
<td align="center">
</td>
<td align="center">Biodistribution study of edelfosine oral, intravenous and intraperitoneal administration</td>
<td align="center">Edelfosine</td>
<td align="center">Biodistribution map of NPs after intravenous and intraperitounal administration showing that NPs presented quantifiable and constant levels in blood after intraperitoneal dose</td>
<td align="center">
<xref ref-type="bibr" rid="B154">Lasa-Saracibar et al. (2022)</xref>
</td>
</tr>
<tr>
<td align="center">Cancer</td>
<td align="center">Maslinic acid oral administration</td>
<td align="center">Maslinic acid</td>
<td align="center">NPs improved solubility of the therapeutic agent, yielding delivery across <italic>in vitro</italic> gut barrier models, being able to inhibit the growth of pancreatic cancer cells</td>
<td align="center">
<xref ref-type="bibr" rid="B3">Aguilera-Garrido et al. (2022)</xref>
</td>
</tr>
<tr>
<td align="center">
</td>
<td align="center">Improve the efficiency and the specificity of the SLN-loaded drug</td>
<td align="center"/>
<td align="center">Trans retinoic acid</td>
<td align="center">Phosphatidylethanolamine polyethylene glycol NPs improve active cellular internalization increasing the chemotoxic effect of the drug</td>
<td align="center">
<xref ref-type="bibr" rid="B13">Arana et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="center">
</td>
<td align="center">Induce cancer cell death by apoptosis</td>
<td align="center">Nanostructured lipid carriers (NLCs)</td>
<td align="center">Apo2L/TRAIL</td>
<td align="center">Nanoformulation development for apoptosis-inducing ligand with efficacy in sarcoma cell lines</td>
<td align="center">
<xref ref-type="bibr" rid="B100">Gallego-Lleyda et al. (2018)</xref>
</td>
</tr>
<tr>
<td align="center">
</td>
<td align="center">Increase the granulysin concentration at the site of contact with the target cell</td>
<td align="center">Liposomes</td>
<td align="center">Granulysin</td>
<td align="center">Granulysin cytotoxicity is increased when formulated with liposomes and acts through the mitochondrial apoptotic pathway</td>
<td align="center">
<xref ref-type="bibr" rid="B277">Soler-Agesta et al. (2022)</xref>
</td>
</tr>
<tr>
<td align="center">
</td>
<td align="center">Parenteral administration</td>
<td align="center">Quatsomes</td>
<td align="center">Myristalkonium chloride (MKC) and cholesterol</td>
<td align="center">Quatsomes are useful for biodistribution studies after intravenous administration and drug delivery applicability</td>
<td align="center">
<xref ref-type="bibr" rid="B303">Vargas-Nadal et al. (2020)</xref>
</td>
</tr>
<tr>
<td align="center">
</td>
<td align="center">miRNAs delivery</td>
<td align="center"/>
<td align="center">miRNAs</td>
<td align="center">Quatsomes protect miRNA and provide a pH sensitive delivery platform</td>
<td align="center">
<xref ref-type="bibr" rid="B37">Boloix et al. (2022)</xref>
</td>
</tr>
<tr>
<td align="center">
</td>
<td rowspan="2" align="center">Cellular transfection</td>
<td rowspan="2" align="center">Lipoplexes</td>
<td rowspan="2" align="center">siRNA</td>
<td align="center">Remarkable silencing activity was obtained without associated toxicity</td>
<td align="center">
<xref ref-type="bibr" rid="B254">Sanchez-Arribas et al. (2020a)</xref>
</td>
</tr>
<tr>
<td align="center">
</td>
<td align="center">Cationic lipids with a helper lipid are a safe and biocompatible gene silencing strategy</td>
<td align="center">
<xref ref-type="bibr" rid="B253">Sanchez-Arribas et al. (2020b)</xref>
</td>
</tr>
<tr>
<td align="center">Cancer (Triple negative breast cancer)</td>
<td align="center">Enhance the efficacy of first-line chemotherapeutics</td>
<td align="center">Polyglutamic acid</td>
<td align="center">DOX</td>
<td align="center">Effective reduction of lung and lymph node metastases in triple-negative breast cancer</td>
<td align="center">
<xref ref-type="bibr" rid="B75">Duro-Castano et al. (2021a)</xref>
</td>
</tr>
<tr>
<td align="center">Cancer (prostate)</td>
<td align="center">pH dependent and controlled release of drug</td>
<td align="center">Tert-Ser polyacetal</td>
<td align="center">PTX</td>
<td align="center">Sustained release of PTX (2 weeks) reducing systemic toxicities while conserving tumor growth inhibitory activity</td>
<td align="center">
<xref ref-type="bibr" rid="B93">Fernandez et al. (2022)</xref>
</td>
</tr>
<tr>
<td align="center">Cancer immunotherapy</td>
<td align="center">Delivery of two therapeutic agents for reverting MDSC-mediated immunosuppression</td>
<td align="center">Polyarginine</td>
<td align="center">RNAi and CCL2 chemokine</td>
<td align="center">Nanocapsules modulated monocyte differentiation into tumour-associated macrophages and reduced significantly C/EBP&#x3b2; mRNA levels</td>
<td align="center">
<xref ref-type="bibr" rid="B160">Ledo et al. (2019)</xref>
</td>
</tr>
<tr>
<td rowspan="2" align="center">Cancer (pancreatic)</td>
<td align="center">Development of targeted delivery chemotherapy</td>
<td align="center">Iron oxide NPs</td>
<td align="center">Gemcitabine and anti-CD47 antibody</td>
<td align="center">Improved results and delivery were shown after treatment with the multifunctional NPs</td>
<td align="center">
<xref ref-type="bibr" rid="B295">Trabulo et al. (2017)</xref>
</td>
</tr>
<tr>
<td align="center">MHT in mice model</td>
<td align="center">Iron Oxide (maghemite) NPs</td>
<td align="center">-</td>
<td align="center">Temperature rise during MHT can be controlled by modulating the field intensity in animal models</td>
<td align="center">
<xref ref-type="bibr" rid="B35">Beola et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="center">Cancer (sarcoma)</td>
<td align="center">Microswimmers with MHT capacity</td>
<td align="center">Manganese ferrite NPs</td>
<td align="center">-</td>
<td align="center">Microswimmers can be employed to enhance tissue penetration for specific cargo delivery</td>
<td align="center">
<xref ref-type="bibr" rid="B234">Ramos-Docampo et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="center">Cancer (breast)</td>
<td align="center">Enzyme prodrug therapy</td>
<td align="center">AuNPs</td>
<td align="center">Horseradish peroxidase</td>
<td align="center">This combination strategy evidenced high anti-tumoral activity in 3D tumor models</td>
<td align="center">
<xref ref-type="bibr" rid="B311">Vivo-Llorca et al. (2022)</xref>
</td>
</tr>
<tr>
<td align="center">Breast and Lung cancer</td>
<td align="center">Develop, characterize and assay Tripalm-NPs-PTX.</td>
<td align="center">Nanostructured lipid carriers (NLCs)</td>
<td align="center">PTX</td>
<td align="center">PTX tumor activity was increased in breast and lung cancer cells through glyceryl triplamitate NPs formulation</td>
<td align="center">
<xref ref-type="bibr" rid="B162">Leiva et al. (2017)</xref>
</td>
</tr>
<tr>
<td align="center">Brain cancer</td>
<td align="center">Hyperthermia control</td>
<td align="center">AuNPs</td>
<td align="center">-</td>
<td align="center">Hybrid probes were internalized in 3D tumor spheroids and can induced cell death through photothermal effects, while measuring the local temperature <italic>in situ</italic>
</td>
<td align="center">
<xref ref-type="bibr" rid="B232">Quintanilla et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="center">Glioblastoma</td>
<td align="center">Develop safer cationic NLCs using machine learning algorithms</td>
<td align="center">Nanostructured lipid carriers (NLCs)</td>
<td align="center">Atorvastatin Coumarin</td>
<td align="center">Two novel glycerol lipids were studied showing that GLY1 circumvents the intrinsic cytotoxicity of common surfactant CTAB and shows anticancer activity</td>
<td align="center">
<xref ref-type="bibr" rid="B32">Basso et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="center">Gastrointestinal stromal tumors</td>
<td align="center">Characterization of IMT-loaded NLCs</td>
<td align="center">Nanostructured lipid carriers (NLCs)</td>
<td align="center">Imatinib</td>
<td align="center">Imatinib loaded NPs were synthesized and characterized, showing a controlled release of the drug and thus being promising for tumor treatment</td>
<td align="center">
<xref ref-type="bibr" rid="B135">Gundogdu et al. (2022)</xref>
</td>
</tr>
<tr>
<td rowspan="3" align="center">Eye disease</td>
<td align="center">Gene therapy</td>
<td align="center">Solid lipid NPs (SLNs)</td>
<td align="center">IL-10</td>
<td align="center">SLNs formulations were safe after topical administration and hyaluronic acid based ones reached endothelial layer</td>
<td align="center">
<xref ref-type="bibr" rid="B304">Vicente-Pascual et al. (2020)</xref>
</td>
</tr>
<tr>
<td align="center">Production of IL-10 in corneal cells</td>
<td align="center">Solid lipid NPs (SLNs)</td>
<td align="center">mRNA-based nanomedicinal products</td>
<td align="center">SLNs presented a high transfection efficiency when formulated as eye drops</td>
<td align="center">
<xref ref-type="bibr" rid="B118">Gomez-Aguado et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="center">Downregulate metalloproteinase 9 (MPP-9)</td>
<td align="center">Solid lipid NPs (SLNs)</td>
<td align="center">Short-hairpin RNA (shRNA)</td>
<td align="center">NPs with non viral vectors downregulated MMP-9 expression in human corneal cells</td>
<td align="center">
<xref ref-type="bibr" rid="B293">Torrecilla et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="center">Fabry disease</td>
<td align="center">Delivery comparison by quatsomes and hybrid liposomes</td>
<td align="center">Quatsomes and liposomes</td>
<td align="center">&#x3b1;-galactosidase A</td>
<td align="center">Improved efficacy was observed with hybrid liposomes having a good <italic>in vitro</italic>/<italic>in vivo</italic> safety profile</td>
<td align="center">
<xref ref-type="bibr" rid="B292">Tomsen-Melero et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="center">Hearing loss</td>
<td align="center">Local administration</td>
<td align="center">Solid lipid NPs (SLNs)</td>
<td align="center">Dexamethasone and hydrocortisone</td>
<td align="center">Loaded NPs penetrated into auditory cells and protected them from cisplatin induced ototoxicity</td>
<td align="center">
<xref ref-type="bibr" rid="B48">Cervantes et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="center">Inflammatory bowel disease</td>
<td align="center">Oral drug delivery</td>
<td align="center">Solid lipid NPs (SLNs)</td>
<td align="center">Polyphenol oleuropein (OLE)</td>
<td align="center">NPs ameliorated inflammation in macrophages and in a mouse model of acute colitis</td>
<td align="center">
<xref ref-type="bibr" rid="B140">Huguet-Casquero et al. (2020)</xref>
</td>
</tr>
<tr>
<td align="center">Keratoconus</td>
<td align="center">Ocular drug delivery</td>
<td align="center">Solid lipid NPs (SLNs)</td>
<td align="center">Lactoferrin</td>
<td align="center">Successful preparation of lactoferrin SLNs with a controlled release pattern</td>
<td align="center">
<xref ref-type="bibr" rid="B302">Varela-Fernandez et al. (2022)</xref>
</td>
</tr>
<tr>
<td align="center">Obesity</td>
<td align="center">Liver lipopolysaccharide-binding protein (LBP) downregulation</td>
<td align="center">Solid lipid NPs (SLNs)</td>
<td align="center">Modified LBP siRNA</td>
<td align="center">Nanoformulated siRNA against liver LBP is a promising therapy for faty liver associated to obesity</td>
<td align="center">
<xref ref-type="bibr" rid="B157">Latorre et al. (2022)</xref>
</td>
</tr>
<tr>
<td align="center">-</td>
<td align="center">Increase EGFR gene expression</td>
<td align="center">Nanostructured lipid carriers (NLCs)</td>
<td align="center">Recombinant human epithelial growth factor (rhEGF)</td>
<td align="center">NLCs improved EGF expression enhancing the efficiency of explant-based methodologies for primary cell culture</td>
<td align="center">
<xref ref-type="bibr" rid="B49">Chato-Astrain et al. (2021)</xref>
</td>
</tr>
<tr>
<td rowspan="2" align="center">Respiratory diseases</td>
<td align="center">Delivery</td>
<td align="center">TNFR-Dex-MSN</td>
<td align="center">Dexamethasone</td>
<td align="center">A selective uptake by macrophages of the NPs was observed, demonstrating lung accumulation and reduction of the damage</td>
<td align="center">
<xref ref-type="bibr" rid="B107">Garcia-Fernandez et al. (2021a)</xref>, <xref ref-type="bibr" rid="B106">Garcia-Fernandez et al. (2021b)</xref>
</td>
</tr>
<tr>
<td align="center">Pulmonary and intramuscular administration</td>
<td align="center">Nanostructured lipid carriers (NLCs)</td>
<td align="center">Sodium colistimethate</td>
<td align="center">NLC enabled a dose reduction of the drug to obtain a similar <italic>in vivo</italic> effect without apparent toxicity</td>
<td align="center">
<xref ref-type="bibr" rid="B217">Pastor et al. (2019)</xref>
</td>
</tr>
<tr>
<td rowspan="2" align="center">Tissue regeneration (bone)</td>
<td align="center">Delivery</td>
<td align="center">MSN@PEI</td>
<td align="center">Osteostatin and siRNA</td>
<td align="center">Both therapeutic agents were efficiently delivered inside cells and consequently a synergistic effect in the increase in the osteogenic markers was observed</td>
<td align="center">
<xref ref-type="bibr" rid="B193">Mora-Raimundo et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="center">Induce osteogenesis and bone repair</td>
<td rowspan="3" align="center">MSNs</td>
<td rowspan="3" align="center">Ipriflavone</td>
<td align="center">Results showed that both, bone regeneration and angiogenesis, were promoted after injection in an animal model</td>
<td align="center">
<xref ref-type="bibr" rid="B14">Arcos et al. (2022)</xref>
</td>
</tr>
<tr>
<td align="center">Tissue regeneration (angiogenesis)</td>
<td align="center">Enhance angiogenesis</td>
<td align="center">NPs evidenced a great potential to enhance angiogenesis after intracellular uptake</td>
<td align="center">
<xref ref-type="bibr" rid="B47">Casarrubios et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="center">Tissue regeneration (periodontal)</td>
<td align="center">Periodontal augmentation</td>
<td align="center">NPs stimulated differentiation of pre-osteoblasts into mature osteoblasts after clathrin-dependent internalization</td>
<td align="center">
<xref ref-type="bibr" rid="B46">Casarrubios et al. (2020)</xref>
</td>
</tr>
<tr>
<td rowspan="4" align="center">Vaccine development</td>
<td align="center">Delivery</td>
<td align="center">MSNs</td>
<td align="center">Immunomodulatory and vesicle-associated proteins (Ag85B, LprG and LprA)</td>
<td align="center">The designed nanosystems have been extensively characterized and their their immunostimulatory capacity demonstrated</td>
<td align="center">
<xref ref-type="bibr" rid="B192">Montalvo-Quiros et al. (2020)</xref>
</td>
</tr>
<tr>
<td align="center">Improve targeting specific immune cells in the lymphatics</td>
<td align="center">Chitosan, polyarginine, and carboxymethyl-&#x3b2;-glucan</td>
<td align="center">-</td>
<td align="center">Lymphatic uptake of polymeric NPs is dependent on particle size and charge</td>
<td align="center">
<xref ref-type="bibr" rid="B55">Cordeiro et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="center">Development of intranasal vaccination against <italic>Mycobacterium tuberculosis</italic>
</td>
<td align="center">Nanocapsules with a polymeric shell</td>
<td align="center">Imiquimod and a fusion protein formed by two antigens of <italic>Mycobacterium tuberculosis</italic>
</td>
<td align="center">Inulin polyarginine produced an adequate IgA response <italic>in vivo</italic>
</td>
<td align="center">
<xref ref-type="bibr" rid="B69">Diego-Gonzalez et al. (2020)</xref>
</td>
</tr>
<tr>
<td align="center">Improve vaccine development</td>
<td align="center">Poly(&#x3b2;-amino esters)</td>
<td align="center">mRNA</td>
<td align="center">Detailed description of a simple production of mRNA polymeric NPs with a proof of concept immunization</td>
<td align="center">
<xref ref-type="bibr" rid="B94">Fornaguera et al. (2021)</xref>
</td>
</tr>
<tr>
<td rowspan="5" align="center">Neurodegenerative diseases</td>
<td align="center">Develop multimodal NPs for AD</td>
<td align="center">Polyglutamate</td>
<td align="center">Bisdemethoxycurcumin or Genistein</td>
<td align="center">Angiopep-2 conjugated NPs were efficiently delivered through the BBB and the treatment reduced &#x3b2;-amyloid peptides and rescued cognitive impairments in mice</td>
<td align="center">
<xref ref-type="bibr" rid="B74">Duro-Castano et al. (2021b)</xref>
</td>
</tr>
<tr>
<td align="center">miRNA delivery to the hippocampus</td>
<td align="center">Polyarginine</td>
<td align="center">Specific miRNA mimic, miR-132</td>
<td align="center">Successful production of a scalable nanoformulation that was efficiently delivered to the brain to exert its therapeutic action by nasal administration</td>
<td align="center">
<xref ref-type="bibr" rid="B251">Samaridou et al. (2020)</xref>
</td>
</tr>
<tr>
<td rowspan="2" align="center">Improve BBB permeability and pharmacokinetics of compounds</td>
<td rowspan="2" align="center">Poly(lactic-co-glycolic acid)</td>
<td align="center">PDE7 inhibitor</td>
<td align="center">Successful preparation of polymeric nanoparticle with efficient encapsulation and a sustained cargo release in mice brains after oral administration</td>
<td align="center">
<xref ref-type="bibr" rid="B208">Nozal et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="center">CDC7 inhibitor</td>
<td align="center">Successful preparation of polymeric nanoparticle with efficient encapsulation and permeability through the BBB</td>
<td align="center">
<xref ref-type="bibr" rid="B244">Rojas-Prats et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="center">Drug delivery across BBB</td>
<td align="center">Nanostructured lipid carriers (NLCs)</td>
<td align="center">Growth factors</td>
<td align="center">TAT-NLCs showed good BBB permeability <italic>in vitro</italic> and reduced the inflammatory response in human microglia</td>
<td align="center">
<xref ref-type="bibr" rid="B139">Hernando et al. (2022)</xref>
</td>
</tr>
<tr>
<td rowspan="2" align="center">Diabetes</td>
<td align="center">Oral delivery of insulin</td>
<td align="center">Polyarginine</td>
<td align="center">Insulin</td>
<td align="center">Enhanced epithelial accumulation of insulin that did increase insulin transport</td>
<td align="center">
<xref ref-type="bibr" rid="B205">Niu et al. (2018)</xref>
</td>
</tr>
<tr>
<td align="center">Provide an efficient oral peptide administration</td>
<td align="center">Poly(lactic-co-glycolic acid)</td>
<td align="center">Hydrophobically modified insulin</td>
<td align="center">Nanoemulsions internalized Caco-2 monolayers yielding to a moderate hypoglycemic response in diabetic rats</td>
<td align="center">
<xref ref-type="bibr" rid="B260">Santalices et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="center">Stroke</td>
<td align="center">Enhance BBB penetration</td>
<td align="center">Poly(lactic-co-glycolic acid)</td>
<td align="center">-</td>
<td align="center">Controlled brain delivery of polymeric NPs by endovascular administration and magnetic targeting</td>
<td align="center">
<xref ref-type="bibr" rid="B129">Grayston et al. (2022)</xref>
</td>
</tr>
<tr>
<td align="center">Ocular inflammaition</td>
<td align="center">Improve pharmacokinetic properties of licochalcone A</td>
<td align="center">Poly(lactic-co-glycolic acid)</td>
<td align="center">Licochalcone A</td>
<td align="center">Development of ocular inflammation targeted NPs with therapeutic efficacy <italic>in vivo</italic>
</td>
<td align="center">
<xref ref-type="bibr" rid="B99">Galindo et al. (2022)</xref>
</td>
</tr>
<tr>
<td align="center">Atherosclerosis</td>
<td align="center">Deliver miRNA and atorvastatin simultaneously</td>
<td align="center">Poly(lactic-co-glycolic acid)</td>
<td align="center">miRNA 124a and atorvastatin</td>
<td align="center">NPs delivered simultaneously miRNA and atorvastatin that significantly reduced proinflammatory cytokines and prevented the accumulation of low-density lipoproteins inside macrophage</td>
<td align="center">
<xref ref-type="bibr" rid="B159">Leal et al. (2022)</xref>
</td>
</tr>
<tr>
<td rowspan="2" align="center">Inflammation autoimmune diseases</td>
<td align="center">Obtain a synergistic anti-inflammatory effect</td>
<td align="center">1-vinylimidazole</td>
<td align="center">Ketoprofen and dexamethasone</td>
<td align="center">Synergistic anti-inflammatory effect of non-toxic polymeric NPs loaded with dexamethasone and naproxen. Coumarin loaded NPs showed to be rapidly uptaken by macrophages</td>
<td align="center">
<xref ref-type="bibr" rid="B85">Espinosa-Cano et al. (2020a)</xref>
</td>
</tr>
<tr>
<td align="center">Study the synergistic anti-inflammatory effect</td>
<td align="center">1-vinylimidazole and methacrylic derivative</td>
<td align="center">Dexamethasone and naproxen</td>
<td align="left"/>
<td align="center">
<xref ref-type="bibr" rid="B86">Espinosa-Cano et al. (2020b)</xref>
</td>
</tr>
<tr>
<td align="center">Acute ischemic stroke</td>
<td align="center">Optimize <italic>in vivo</italic> delivery specificity</td>
<td align="center">CaCO<sub>3</sub> cores stabilized by poly(vinylsulfonic acid)</td>
<td align="center">Thrombolytic serine protease</td>
<td align="center">Encapsulation of therapeutic agent precluded its inactivation promoting blood clots breakdown <italic>in vitro</italic>. Delivery upon ultrasound application was confirmed <italic>in vivo</italic>
</td>
<td align="center">
<xref ref-type="bibr" rid="B56">Correa-Paz et al. (2019)</xref>
</td>
</tr>
<tr>
<td rowspan="11" align="center">-</td>
<td align="center">To develop zwitterionic pDNA delivery systems</td>
<td align="center">Polyglutamic acid</td>
<td align="center">Plasmid DNA delivery</td>
<td align="center">Successful plasmid DNA complexes formation that yielded an effective transfection in N2a cells without apparent toxicity</td>
<td align="center">
<xref ref-type="bibr" rid="B204">Nino-Pariente et al. (2017)</xref>
</td>
</tr>
<tr>
<td align="center">Develop fuel-free propulsion NPs activatable by NIR</td>
<td align="center">Polyethylene and propylene glycol and ribose</td>
<td align="center">-</td>
<td align="center">Succesful development of NIR light powered carbonaceous nanobottles</td>
<td align="center">
<xref ref-type="bibr" rid="B316">Xuan et al. (2018)</xref>
</td>
</tr>
<tr>
<td align="center">Gene therapy</td>
<td align="center">AuNPs</td>
<td align="center">Plasmid DNA</td>
<td align="center">A novel strategy to control the release of plasmid DNA after sternal stimuli as irradiation was developed</td>
<td align="center">
<xref ref-type="bibr" rid="B252">Sanchez-Arribas et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="center">Multi-Hot-Spot magnetic inductive nanoheating</td>
<td align="center">Iron oxide (magnetite/maghemite) NPs</td>
<td align="center">-</td>
<td align="center">Creation of simultaneous and sequential multi hot spot conditions in a single pot</td>
<td align="center">
<xref ref-type="bibr" rid="B210">Ovejero et al. (2021b)</xref>
</td>
</tr>
<tr>
<td align="center">Nucleic acid delivery</td>
<td align="center">Solid lipid NPs (SLNs)</td>
<td align="center">Circular DNA and linear RNA</td>
<td align="center">Implementation of SLN formulation to efficiently transfect DNA and RNA</td>
<td align="center">
<xref ref-type="bibr" rid="B89">Fabregas et al. (2017)</xref>
</td>
</tr>
<tr>
<td align="center">Nucleic acid delivery</td>
<td align="center">Solid lipid NPs (SLNs)</td>
<td align="center">mRNA and pDNA</td>
<td align="center">Study of several SLNs for nucleic acid delivery analyzing stability and transfection efficieny</td>
<td align="center">
<xref ref-type="bibr" rid="B119">Gomez-Aguado et al. (2020)</xref>
</td>
</tr>
<tr>
<td align="center">Nucleic acid delivery (gene-silencing therapy)</td>
<td align="center">Solid lipid NPs (SLNs)</td>
<td align="center">siRNA</td>
<td align="center">Cholesteryl oleate SLNs represent a safe and efficient transfection tool for nonviral nucleic acid delivery</td>
<td align="center">
<xref ref-type="bibr" rid="B285">Sune-Pou et al. (2018)</xref>
</td>
</tr>
<tr>
<td align="center">Increase the cellular attachment</td>
<td rowspan="3" align="center">AuNPs</td>
<td rowspan="3" align="center">-</td>
<td align="center">Cellular adherence was increase enabling the thermoablating effect of AuNPs without cellular internalization</td>
<td align="center">
<xref ref-type="bibr" rid="B23">Artiga et al. (2018)</xref>
</td>
</tr>
<tr>
<td align="center">Control protein corona formation</td>
<td align="center">Protein corona formation was controlled and thus NPs cellular uptake increased</td>
<td align="center">
<xref ref-type="bibr" rid="B197">Mosquera et al. (2020)</xref>
</td>
</tr>
<tr>
<td align="center">Inhibition of enzymatic activities</td>
<td align="center">Local generation of plasmonic heat inhibited the horseradish peroxidase and the glucose oxidase which were coupled to AuNPs</td>
<td align="center">
<xref ref-type="bibr" rid="B290">Thompson et al. (2017)</xref>
</td>
</tr>
<tr>
<td align="center">pDNA delivery</td>
<td align="center">Lipoplexes</td>
<td align="center">pDNA</td>
<td align="center">Amphiphilic lipids and DOPE yieldied and efficient DNA transfection</td>
<td align="center">
<xref ref-type="bibr" rid="B181">Martinez-Negro et al. (2018)</xref>
</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>Indubitably, one of the most explored abilities of NPs is their role as nanocarriers. In fact, in the last years the delivery function continues to improve, reaching a finely tuned controlled release that can be achieved through nanoformulation, and be sensitive to changes in the NPs&#x2019; environment, i.e., temperature light, ultrasounds or pH (<xref ref-type="bibr" rid="B316">Xuan et al., 2018</xref>; <xref ref-type="bibr" rid="B70">Diez et al., 2021</xref>; <xref ref-type="bibr" rid="B183">Mayol et al., 2021</xref>; <xref ref-type="bibr" rid="B2">Aguilera-Correa et al., 2022a</xref>). Exquisitely controlled layer-by-layer design of NPs enables to control and achieve drug release with spatiotemporal resolution, improving currently available therapeutic options (<xref ref-type="bibr" rid="B56">Correa-Paz et al., 2019</xref>). In addition, targeting key pathological cells present in several diseases such as senescent cells through their high &#x3b2;-galactosidase activity was achieved through galacto-oligosaccharides encapsulated drugs, yielding a versatile strategy potentially effective for multiple pathologies (<xref ref-type="bibr" rid="B200">Munoz-Espin et al., 2018</xref>). This delivery function can be further improved with the combination of self-propelled materials, (<xref ref-type="bibr" rid="B234">Ramos-Docampo et al., 2019</xref>), or synergistic delivery of therapeutic agents as demonstrated by the delivery of siRNA and a peptidic drug with remarkable potential against osteoporosis (<xref ref-type="bibr" rid="B193">Mora-Raimundo et al., 2019</xref>). The field however still shows important challenges ahead as highlighted in the aimed insulin oral delivery (<xref ref-type="bibr" rid="B205">Niu et al., 2018</xref>) that did not translate into an increased systemic absorption of insulin despite achieving a high retention in enterocytes.</p>
<p>The delivery of therapeutic agents and oligonucleotides based on polymeric nanocomplexes that stabilize and shield RNA analogs enabled the delivery of poly(I:C) to effectively treat several cancers. The preclinical data motivated clinical trials coordinated from Spain in which BO-112 was administered alone or in combinations treatments and performed in several hospitals with positive clinical benefits for some patients (<xref ref-type="bibr" rid="B174">M&#xe1;rquez-Rodas et al., 2022</xref>), (NCT: 02828098) (<xref ref-type="bibr" rid="B289">Therapeutics, 2016</xref>), (NCT: 05265650) (<xref ref-type="bibr" rid="B52">Clinica Universidad de Navarra UdN, 2022a</xref>), (NCT: 04570332) (<xref ref-type="bibr" rid="B288">Therapeutics, 2020</xref>). Interestingly, the same poly(I:C) agent in combination with polysaccharide based NPs has been employed for the development of another challenging therapeutic area: the creation of the HIV vaccine. Hyaluronic and chitosan NPs decorated with conserved HIV peptides as antigens and loaded with poly(I:C) yielded in a strong activation af antigen presenting cells (<xref ref-type="bibr" rid="B60">Dacoba et al., 2019</xref>).</p>
<p>Another clinical trial has its aim at evaluating antibiotic-containing alginate NPs for the treatment of <italic>Pseudomonas aeruginosa</italic> infection and biofilm formation in bronchiectasis patients. These type of NPs have shown to be efficient in treating pulmonary infections (<xref ref-type="bibr" rid="B67">Dhand, 2018</xref>).</p>
<p>Protein NPs also show promising characteristics for the delivery of insulin which yielded in clinical translation. Specifically the preclinical results obtained with Zein NPs has motivated the design of a clinical trial to verify in humans whether they could provide an efficient glycemic control in diabetic and obese patients through and orally administered therapeutic insulin derivative (NCT: 05560412) (<xref ref-type="bibr" rid="B53">Clinica Universidad de Navarra UdN, 2022b</xref>).</p>
<p>Regarding clinical applications, organic NPs and biodegradable MSNs have a competitive advantage over other metallic NPs. However, the remarkable properties that the metallic NPs have motivate their research for fighting complex diseases (<xref ref-type="bibr" rid="B290">Thompson et al., 2017</xref>). Thus, the combination of several cores in Janus&#x2013;type NPs yields highly efficient conjugates that can not only combine complementary drugs or targeting agents but also synergistic effects simultaneously whith great potential to improve the treatment of several diseases (<xref ref-type="bibr" rid="B167">Lopez et al., 2017</xref>; <xref ref-type="bibr" rid="B83">Espinosa et al., 2020</xref>).</p>
<p>One of the hardest and more significant step in nanomedical development entails reaching clinical trials. This normally challenging road can have additional hurdles to achieve suitable nanoformulations. To translate nanomedicines into the clinic, multiple challenges should be taken into account to manufacture them under quality guidelines regulations (<xref ref-type="bibr" rid="B95">Foulkes et al., 2020</xref>). First, the results observed in research settings must be contextualized and standardized to prepare them for clinical translation. While small molecules are commonly evaluated for their efficacy, toxicity, and side effects, nanotherapies must also prove the biocompatibility for each of the components within the formulation. The use of specific nanomaterials for the development of personalized treatment requires in depth understanding of disease biology and the interaction between nanomaterials and the body. The potential of inorganic NPs in biomedicine is still in the preliminary stages of the clinic. Some important challenges in terms of biodistribution, pharmacokinetics, metabolism, biological barriers, safety, large-scale synthesis, patient heterogeneity or overall cost must be taken into account and optimized (<xref ref-type="bibr" rid="B223">Perez-Hernandez et al., 2017</xref>). In addition, several key parameters of the intrinsic NP-derived effects such as magnetic hyperthermia must be extensively studied and characterized to better understand its therapeutic operability and improve clinical translation (<xref ref-type="bibr" rid="B35">Beola et al., 2021</xref>; <xref ref-type="bibr" rid="B169">Luengo et al., 2022</xref>). On the objectives of the Spanish Scientific Network HIPERNANO stablished among different national groups was to consolidate the current scientific knowledge on hyperthermal therapies to enhance their practical implementation in clinical development (<xref ref-type="bibr" rid="B279">Spanish Scientific Network HiperNano, 2018</xref>). In addition, a key milestone was reached in 2022, where the first patient with pancreatic cancer was treated with magnetic hyperthermia in combination with the standard of care at Vall d&#x2019;Hebron hospital (<xref ref-type="bibr" rid="B207">NoCanTher Project, 2022</xref>). This pilot study will guide future interventions and shed light on the steps needed to bring nanomedicines to the clinic. From this experience, it is worth highlighting that it is essential to involve multiple stakeholders, from scientists to clinicians, at every level (e.g., nanotherapy and clinical study design) from the beginning of the project to increase the success of this kind of study (<xref ref-type="bibr" rid="B165">Liz-Marz&#xe1;n et al., 2022</xref>). Furthermore collaborative nets and workshops such as NanomedSpain, Nanbiosis, Ciber-bbn and NanoSpain enable to promote collaborative studies with this goal.</p>
<p>Finally, while in this review we have only focused on the therapeutic role of NPs, there is another substantial part of nanomedicine that involves the diagnosis of diseases and in which an extensive amount of research groups in Spain are engaged. Both methods to diagnose <italic>in vivo</italic> (<xref ref-type="bibr" rid="B314">Ximendes et al., 2021</xref>), (<xref ref-type="bibr" rid="B315">Ximendes et al., 2017</xref>), (<xref ref-type="bibr" rid="B221">Pellico et al., 2021</xref>), (<xref ref-type="bibr" rid="B261">Santos et al., 2020</xref>) and <italic>ex vivo</italic> (<xref ref-type="bibr" rid="B220">Pelaez et al., 2018</xref>), (<xref ref-type="bibr" rid="B163">Litti et al., 2021</xref>), (<xref ref-type="bibr" rid="B80">Enshaei et al., 2021</xref>) enabled by several nanoformulations have revolutionized current medical practices and will continue to improve the crucial ability to diagnose diseases efficiently. In addition, the continuous effort of researchers to understand and exquisitely characterize the fate of NPs in biological system is a crucial foundation for all this work (<xref ref-type="bibr" rid="B326">Carregal-Romero et al., 2021</xref>; <xref ref-type="bibr" rid="B18">Areny-Balaguero et al., 2022</xref>).</p>
</sec>
</body>
<back>
<sec id="s5">
<title>Author contributions</title>
<p>VP, PF-G, CPA, and MC contributed to the concept and design of the manuscript. VP, PF-G, CPA, JAB, and CT-B contributed to the writing. BS, AS, ST, AE, GS, and MC critically revised the manuscript and contributed to the writing. All authors contributed to the article and approved the submitted version.</p>
</sec>
<sec id="s6">
<title>Funding</title>
<p>This work has been partially supported by MCIN/AEI /10.13039/501100011033 and European Union NextGenerationEU/PRTR (PID2021-128340OA-I00, PID2020-119352RB-I00, PID2021-127033OB-C21 and RTI2018-101050-J-I00), Comunidad de Madrid (S2022/BMD-7403 RENIM-CM and Talento program 2018-T1/IND-1005), European Union&#x2019;s Horizon 2020 research and innovation programme (grant agreement No 685795), la Caixa Foundation LCF/PR/HA21/52350003, Asociaci&#x00F3;n Espa&#x00F1;ola Contra el C&#x00E1;ncer IDEAS21989THOM, MCIN/AEI/10.13039/501100011033 and &#x201c;ESF investing in your future&#x201d; (RYC2019-027489-I, RYC2020-029282-I). CTB thanks Ministerio de Educaci&#x00F3;n (FPU18/06310) for the predoctoral fellowship. IMDEA Nanociencia acknowledges support from the &#x2018;Severo Ochoa&#x2019; Programme for Centers of Excellence in R&#x26;D (MINECO, CEX2020-001039-S).</p>
</sec>
<ack>
<p>The authors want to thank Prof. Dr. S. Ortega-Gutierrez and Prof. Dr. M. L. L&#xf3;pez-Rodr&#xed;guez for the inspiration to start this review. Due to space restrictions, we made a selection of publications to be discussed in this review; we apologize to all of our colleagues whose work has not been cited here.</p>
</ack>
<sec sec-type="COI-statement" id="s7">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s8">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<fn-group>
<fn id="fn2">
<label>1</label>
<p>Hybrid here refers to nanostructures combining two types of inorganic materials in which both are clearly distinguishable (e.g., core-shell, aggregates/encapsulates of individual NPs of both materials) and both provide a relevant function for the application (i.e., are not used just as a coating or as a platform).</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aguilera-Correa</surname>
<given-names>J. J.</given-names>
</name>
<name>
<surname>Garcia-Alvarez</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Mediero</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Esteban</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Vallet-Regi</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Effect of gold nanostars plus amikacin against carbapenem-resistant <italic>Klebsiella pneumoniae</italic> biofilms</article-title>. <source>Biol. (Basel).</source> <volume>11</volume> (<issue>2</issue>), <fpage>162</fpage>. <pub-id pub-id-type="doi">10.3390/biology11020162</pub-id>
</citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aguilera-Correa</surname>
<given-names>J. J.</given-names>
</name>
<name>
<surname>Gisbert-Garzaran</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mediero</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Fernandez-Acenero</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>de-Pablo-Velasco</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Lozano</surname>
<given-names>D.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Antibiotic delivery from bone-targeted mesoporous silica nanoparticles for the treatment of osteomyelitis caused by methicillin-resistant <italic>Staphylococcus aureus</italic>
</article-title>. <source>Acta Biomater.</source> <volume>154</volume>, <fpage>608</fpage>&#x2013;<lpage>625</lpage>. <pub-id pub-id-type="doi">10.1016/j.actbio.2022.10.039</pub-id>
</citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aguilera-Garrido</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Arranz</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Galvez-Ruiz</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Marchal</surname>
<given-names>J. A.</given-names>
</name>
<name>
<surname>Galisteo-Gonzalez</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Giblin</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Solid lipid nanoparticles to improve bioaccessibility and permeability of orally administered maslinic acid</article-title>. <source>Drug Deliv.</source> <volume>29</volume> (<issue>1</issue>), <fpage>1971</fpage>&#x2013;<lpage>1982</lpage>. <pub-id pub-id-type="doi">10.1080/10717544.2022.2086937</pub-id>
</citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ahamed</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Alsalhi</surname>
<given-names>M. S.</given-names>
</name>
<name>
<surname>Siddiqui</surname>
<given-names>M. K.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Silver nanoparticle applications and human health</article-title>. <source>Clin. Chim. Acta</source> <volume>411</volume> (<issue>23-24</issue>), <fpage>1841</fpage>&#x2013;<lpage>1848</lpage>. <pub-id pub-id-type="doi">10.1016/j.cca.2010.08.016</pub-id>
</citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ahijado-Guzman</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Sanchez-Arribas</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Martinez-Negro</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gonzalez-Rubio</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Santiago-Varela</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pardo</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Intercellular trafficking of gold nanostars in uveal melanoma cells for plasmonic photothermal therapy</article-title>. <source>Nanomater. (Basel).</source> <volume>10</volume> (<issue>3</issue>), <fpage>590</fpage>. <pub-id pub-id-type="doi">10.3390/nano10030590</pub-id>
</citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aires</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Cadenas</surname>
<given-names>J. F.</given-names>
</name>
<name>
<surname>Guantes</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Cortajarena</surname>
<given-names>A. L.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>An experimental and computational framework for engineering multifunctional nanoparticles: Designing selective anticancer therapies</article-title>. <source>Nanoscale</source> <volume>9</volume> (<issue>36</issue>), <fpage>13760</fpage>&#x2013;<lpage>13771</lpage>. <pub-id pub-id-type="doi">10.1039/c7nr04475e</pub-id>
</citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alfranca</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Artiga</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Stepien</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Moros</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mitchell</surname>
<given-names>S. G.</given-names>
</name>
<name>
<surname>de la Fuente</surname>
<given-names>J. M.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Gold nanoprism-nanorod face off: Comparing the heating efficiency, cellular internalization and thermoablation capacity</article-title>. <source>Nanomedicine (Lond).</source> <volume>11</volume> (<issue>22</issue>), <fpage>2903</fpage>&#x2013;<lpage>2916</lpage>. <pub-id pub-id-type="doi">10.2217/nnm-2016-0257</pub-id>
</citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alfranca</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Beola</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Gutierrez</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Artiga</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>
<italic>In vivo</italic> comparison of the biodistribution and long-term fate of colloids - gold nanoprisms and nanorods - with minimum surface modification</article-title>. <source>Nanomedicine (Lond).</source> <volume>14</volume> (<issue>23</issue>), <fpage>3035</fpage>&#x2013;<lpage>3055</lpage>. <pub-id pub-id-type="doi">10.2217/nnm-2019-0253</pub-id>
</citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alipour</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Baneshi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hosseinkhani</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Mahmoudi</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Jabari Arabzadeh</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Akrami</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Recent progress in biomedical applications of RGD-based ligand: From precise cancer theranostics to biomaterial engineering: A systematic review</article-title>. <source>J. Biomed. Mater Res. A</source> <volume>108</volume> (<issue>4</issue>), <fpage>839</fpage>&#x2013;<lpage>850</lpage>. <pub-id pub-id-type="doi">10.1002/jbm.a.36862</pub-id>
</citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alvear-Jimenez</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Zabala Gutierrez</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Villaverde</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Lozano-Chamizo</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Guardia</surname>
<given-names>P.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Electrospraying as a technique for the controlled synthesis of biocompatible PLGA@Ag2S and PLGA@Ag2S@SPION nanocarriers with drug release capability</article-title>. <source>Pharmaceutics</source> <volume>14</volume> (<issue>1</issue>), <fpage>214</fpage>. <pub-id pub-id-type="doi">10.3390/pharmaceutics14010214</pub-id>
</citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ambrosone</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Matteis</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Serrano-Sevilla</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Tortiglione</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>De La Fuente</surname>
<given-names>J. M.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Glycogen synthase kinase 3&#x3b2; inhibitor delivered by chitosan nanocapsules promotes safe, fast, and efficient activation of Wnt signaling <italic>in vivo</italic>
</article-title>. <source>ACS Biomater. Sci. Eng.</source> <volume>6</volume> (<issue>5</issue>), <fpage>2893</fpage>&#x2013;<lpage>2903</lpage>. <pub-id pub-id-type="doi">10.1021/acsbiomaterials.9b01820</pub-id>
</citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Amendola</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Pilot</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Frasconi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Marago</surname>
<given-names>O. M.</given-names>
</name>
<name>
<surname>Iati</surname>
<given-names>M. A.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Surface plasmon resonance in gold nanoparticles: A review</article-title>. <source>J. Phys. Condens Matter</source> <volume>29</volume> (<issue>20</issue>), <fpage>203002</fpage>. <pub-id pub-id-type="doi">10.1088/1361-648x/aa60f3</pub-id>
</citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arana</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Bayon-Cordero</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Sarasola</surname>
<given-names>L. I.</given-names>
</name>
<name>
<surname>Berasategi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ruiz</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Alkorta</surname>
<given-names>I.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Solid lipid nanoparticles surface modification modulates cell internalization and improves chemotoxic treatment in an oral carcinoma cell line</article-title>. <source>Nanomater. (Basel)</source> <volume>9</volume> (<issue>3</issue>), <fpage>464</fpage>. <pub-id pub-id-type="doi">10.3390/nano9030464</pub-id>
</citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arcos</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Gomez-Cerezo</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Saiz-Pardo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>de Pablo</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Ortega</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Enciso</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Injectable mesoporous bioactive nanoparticles regenerate bone tissue under osteoporosis conditions</article-title>. <source>Acta Biomater.</source> <volume>151</volume>, <fpage>501</fpage>&#x2013;<lpage>511</lpage>. <pub-id pub-id-type="doi">10.1016/j.actbio.2022.07.067</pub-id>
</citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ardizzone</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Blasi</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Vona</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Rosspeintner</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Punzi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Altamura</surname>
<given-names>E.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Highly stable and red-emitting nanovesicles incorporating lipophilic diketopyrrolopyrroles for cell imaging</article-title>. <source>Chemistry</source> <volume>24</volume> (<issue>44</issue>), <fpage>11386</fpage>&#x2013;<lpage>11392</lpage>. <pub-id pub-id-type="doi">10.1002/chem.201801444</pub-id>
</citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ardizzone</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kurhuzenkau</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Illa-Tuset</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Faraudo</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Bondar</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hagan</surname>
<given-names>D.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Nanostructuring lipophilic dyes in water using stable Vesicles, quatsomes, as scaffolds and their use as probes for bioimaging</article-title>. <source>Small</source> <volume>14</volume> (<issue>16</issue>), <fpage>e1703851</fpage>. <pub-id pub-id-type="doi">10.1002/smll.201703851</pub-id>
</citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arenas-Vivo</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Amariei</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Aguado</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Rosal</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Horcajada</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>An Ag-loaded photoactive nano-metal organic framework as a promising biofilm treatment</article-title>. <source>Acta Biomater.</source> <volume>97</volume>, <fpage>490</fpage>&#x2013;<lpage>500</lpage>. <pub-id pub-id-type="doi">10.1016/j.actbio.2019.08.011</pub-id>
</citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Areny-Balaguero</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mekseriwattana</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Camprubi-Rimblas</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Stephany</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Roldan</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sole-Porta</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Fluorescent PLGA nanocarriers for pulmonary administration: Influence of the surface charge</article-title>. <source>Pharmaceutics</source> <volume>14</volume> (<issue>7</issue>), <fpage>1447</fpage>. <pub-id pub-id-type="doi">10.3390/pharmaceutics14071447</pub-id>
</citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ariza-Saenz</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Espina</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bolanos</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Calpena</surname>
<given-names>A. C.</given-names>
</name>
<name>
<surname>Gomara</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Haro</surname>
<given-names>I.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Penetration of polymeric nanoparticles loaded with an HIV-1 inhibitor peptide derived from GB virus C in a vaginal mucosa model</article-title>. <source>Eur. J. Pharm. Biopharm.</source> <volume>120</volume>, <fpage>98</fpage>&#x2013;<lpage>106</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejpb.2017.08.008</pub-id>
</citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ariza-Saenz</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Espina</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Calpena</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Gomara</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Perez-Pomeda</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Haro</surname>
<given-names>I.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Design, characterization, and biopharmaceutical behavior of nanoparticles loaded with an HIV-1 fusion inhibitor peptide</article-title>. <source>Mol. Pharm.</source> <volume>15</volume> (<issue>11</issue>), <fpage>5005</fpage>&#x2013;<lpage>5018</lpage>. <pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.8b00609</pub-id>
</citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arriortua</surname>
<given-names>O. K.</given-names>
</name>
<name>
<surname>Insausti</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lezama</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Gil de Muro</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Garaio</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>de la Fuente</surname>
<given-names>J. M.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>RGD-Functionalized Fe3O4 nanoparticles for magnetic hyperthermia</article-title>. <source>Colloids Surf. B Biointerfaces</source> <volume>165</volume>, <fpage>315</fpage>&#x2013;<lpage>324</lpage>. <pub-id pub-id-type="doi">10.1016/j.colsurfb.2018.02.031</pub-id>
</citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arroyo-Crespo</surname>
<given-names>J. J.</given-names>
</name>
<name>
<surname>Arminan</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Charbonnier</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Balzano-Nogueira</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Huertas-Lopez</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Marti</surname>
<given-names>C.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Tumor microenvironment-targeted poly-L-glutamic acid-based combination conjugate for enhanced triple negative breast cancer treatment</article-title>. <source>Biomaterials</source> <volume>186</volume>, <fpage>8</fpage>&#x2013;<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1016/j.biomaterials.2018.09.023</pub-id>
</citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Artiga</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Garcia-Embid</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>De Matteis</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Mitchell</surname>
<given-names>S. G.</given-names>
</name>
<name>
<surname>de la Fuente</surname>
<given-names>J. M.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Effective <italic>in vitro</italic> photokilling by cell-adhesive gold nanorods</article-title>. <source>Front. Chem.</source> <volume>6</volume>, <fpage>234</fpage>. <pub-id pub-id-type="doi">10.3389/fchem.2018.00234</pub-id>
</citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Astorga-Gamaza</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Vitali</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Borrajo</surname>
<given-names>M. L.</given-names>
</name>
<name>
<surname>Suarez-Lopez</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Jaime</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Bastus</surname>
<given-names>N.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Antibody cooperative adsorption onto AuNPs and its exploitation to force natural killer cells to kill HIV-infected T cells</article-title>. <source>Nano Today</source> <volume>36</volume>, <fpage>101056</fpage>. <pub-id pub-id-type="doi">10.1016/j.nantod.2020.101056</pub-id>
</citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aznar</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Planelles</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Perez-Olivares</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Molina</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Garasa</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Etxeberria</surname>
<given-names>I.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Immunotherapeutic effects of intratumoral nanoplexed poly I:C</article-title>. <source>J. Immunother. Cancer</source> <volume>7</volume> (<issue>1</issue>), <fpage>116</fpage>. <pub-id pub-id-type="doi">10.1186/s40425-019-0568-2</pub-id>
</citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baranyai</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Soria-Carrera</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Alleva</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mill&#xe1;n-Placer</surname>
<given-names>A. C.</given-names>
</name>
<name>
<surname>Luc&#xed;a</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mart&#xed;n-Rap&#xfa;n</surname>
<given-names>R.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Nanotechnology-based targeted drug delivery: An emerging tool to overcome tuberculosis</article-title>. <source>Adv. Ther.</source> <volume>4</volume> (<issue>1</issue>), <fpage>2000113</fpage>. <pub-id pub-id-type="doi">10.1002/adtp.202000113</pub-id>
</citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barbero</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Michelini</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Moriones</surname>
<given-names>O. H.</given-names>
</name>
<name>
<surname>Patarroyo</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Rosell</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Gusta</surname>
<given-names>M. F.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Role of common cell culture media supplements on citrate-stabilized gold nanoparticle protein corona formation, aggregation state, and the consequent impact on cellular uptake</article-title>. <source>Bioconjug Chem.</source> <volume>33</volume> (<issue>8</issue>), <fpage>1505</fpage>&#x2013;<lpage>1514</lpage>. <pub-id pub-id-type="doi">10.1021/acs.bioconjchem.2c00232</pub-id>
</citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barbero</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Moriones</surname>
<given-names>O. H.</given-names>
</name>
<name>
<surname>Bastus</surname>
<given-names>N. G.</given-names>
</name>
<name>
<surname>Puntes</surname>
<given-names>V.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Dynamic equilibrium in the cetyltrimethylammonium bromide-Au nanoparticle bilayer, and the consequent impact on the formation of the nanoparticle protein corona</article-title>. <source>Bioconjug Chem.</source> <volume>30</volume> (<issue>11</issue>), <fpage>2917</fpage>&#x2013;<lpage>2930</lpage>. <pub-id pub-id-type="doi">10.1021/acs.bioconjchem.9b00624</pub-id>
</citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barbero</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Russo</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Vitali</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Piella</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Salvo</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Borrajo</surname>
<given-names>M. L.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>formation of the protein corona: The interface between nanoparticles and the immune system</article-title>. <source>Semin. Immunol.</source> <volume>34</volume>, <fpage>52</fpage>&#x2013;<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1016/j.smim.2017.10.001</pub-id>
</citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barbosa</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Agrawal</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Rodriguez-Lorenzo</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Pastoriza-Santos</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Alvarez-Puebla</surname>
<given-names>R. A.</given-names>
</name>
<name>
<surname>Kornowski</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2010</year>). <article-title>Tuning size and sensing properties in colloidal gold nanostars</article-title>. <source>Langmuir</source> <volume>26</volume> (<issue>18</issue>), <fpage>14943</fpage>&#x2013;<lpage>14950</lpage>. <pub-id pub-id-type="doi">10.1021/la102559e</pub-id>
</citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bass</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Moore</surname>
<given-names>J. L.</given-names>
</name>
<name>
<surname>Coakley</surname>
<given-names>W. T.</given-names>
</name>
</person-group> (<year>1978</year>). <article-title>Lethality in mammalian cells due to hyperthermia under oxic and hypoxic conditions</article-title>. <source>Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med.</source> <volume>33</volume> (<issue>1</issue>), <fpage>57</fpage>&#x2013;<lpage>67</lpage>. <pub-id pub-id-type="doi">10.1080/09553007714551491</pub-id>
</citation>
</ref>
<ref id="B32">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Basso</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Mendes</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Silva</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Cova</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Luque-Michel</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Jorge</surname>
<given-names>A. F.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Sorting hidden patterns in nanoparticle performance for glioblastoma using machine learning algorithms</article-title>. <source>Int. J. Pharm.</source> <volume>592</volume>, <fpage>120095</fpage>. <pub-id pub-id-type="doi">10.1016/j.ijpharm.2020.120095</pub-id>
</citation>
</ref>
<ref id="B319">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Becerril-Castro</surname>
<given-names>I. B.</given-names>
</name>
<name>
<surname>Calderon</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Pazos-Perez</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Guerrini</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Schulz</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Feliu</surname>
<given-names>I.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Gold nanostars: Synthesis, optical and SERS analytical properties</article-title>. <source>Anal. Sens.</source> <volume>2</volume>, <fpage>e202200005</fpage>. <pub-id pub-id-type="doi">10.1002/anse.202200005</pub-id>
</citation>
</ref>
<ref id="B33">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beola</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Asin</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Fratila</surname>
<given-names>R. M.</given-names>
</name>
<name>
<surname>Herrero</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>de la Fuente</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Grazu</surname>
<given-names>V.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Dual role of magnetic nanoparticles as intracellular hotspots and extracellular matrix disruptors triggered by magnetic hyperthermia in 3D cell culture models</article-title>. <source>ACS Appl. Mater Interfaces</source> <volume>10</volume> (<issue>51</issue>), <fpage>44301</fpage>&#x2013;<lpage>44313</lpage>. <pub-id pub-id-type="doi">10.1021/acsami.8b18270</pub-id>
</citation>
</ref>
<ref id="B34">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beola</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Asin</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Roma-Rodrigues</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Fernandez-Afonso</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Fratila</surname>
<given-names>R. M.</given-names>
</name>
<name>
<surname>Serantes</surname>
<given-names>D.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>The intracellular number of magnetic nanoparticles modulates the apoptotic death pathway after magnetic hyperthermia treatment</article-title>. <source>ACS Appl. Mater Interfaces</source> <volume>12</volume> (<issue>39</issue>), <fpage>43474</fpage>&#x2013;<lpage>43487</lpage>. <pub-id pub-id-type="doi">10.1021/acsami.0c12900</pub-id>
</citation>
</ref>
<ref id="B35">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beola</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Grazu</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Fernandez-Afonso</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Fratila</surname>
<given-names>R. M.</given-names>
</name>
<name>
<surname>de Las Heras</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>de la Fuente</surname>
<given-names>J. M.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Critical parameters to improve pancreatic cancer treatment using magnetic hyperthermia: Field conditions, immune response, and particle biodistribution</article-title>. <source>ACS Appl. Mater Interfaces</source> <volume>13</volume> (<issue>11</issue>), <fpage>12982</fpage>&#x2013;<lpage>12996</lpage>. <pub-id pub-id-type="doi">10.1021/acsami.1c02338</pub-id>
</citation>
</ref>
<ref id="B36">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bernardos</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Piacenza</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Sancenon</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Hamidi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Maleki</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Turner</surname>
<given-names>R. J.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Mesoporous silica-based materials with bactericidal properties</article-title>. <source>Small</source> <volume>15</volume> (<issue>24</issue>), <fpage>e1900669</fpage>. <pub-id pub-id-type="doi">10.1002/smll.201900669</pub-id>
</citation>
</ref>
<ref id="B37">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boloix</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Feiner-Gracia</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Kober</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Repetto</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Pascarella</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Soriano</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Engineering pH-sensitive stable nanovesicles for delivery of MicroRNA therapeutics</article-title>. <source>Small</source> <volume>18</volume> (<issue>3</issue>), <fpage>e2101959</fpage>. <pub-id pub-id-type="doi">10.1002/smll.202101959</pub-id>
</citation>
</ref>
<ref id="B38">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bonet-Aleta</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Encinas-Gimenez</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Urriolabeitia</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Martin-Duque</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Hueso</surname>
<given-names>J. L.</given-names>
</name>
<name>
<surname>Santamaria</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Unveiling the interplay between homogeneous and heterogeneous catalytic mechanisms in copper-iron nanoparticles working under chemically relevant tumour conditions</article-title>. <source>Chem. Sci.</source> <volume>13</volume> (<issue>28</issue>), <fpage>8307</fpage>&#x2013;<lpage>8320</lpage>. <pub-id pub-id-type="doi">10.1039/d2sc01379g</pub-id>
</citation>
</ref>
<ref id="B39">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bonet-Aleta</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Sancho-Albero</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Calzada-Funes</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Irusta</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Martin-Duque</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Hueso</surname>
<given-names>J. L.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Glutathione-Triggered catalytic response of Copper-Iron mixed oxide Nanoparticles. Leveraging tumor microenvironment conditions for chemodynamic therapy</article-title>. <source>J. Colloid Interface Sci.</source> <volume>617</volume>, <fpage>704</fpage>&#x2013;<lpage>717</lpage>. <pub-id pub-id-type="doi">10.1016/j.jcis.2022.03.036</pub-id>
</citation>
</ref>
<ref id="B40">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Borzenkov</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pallavicini</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Chirico</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Photothermally active inorganic nanoparticles: From colloidal solutions to photothermally active printed surfaces and polymeric nanocomposite materials</article-title>. <source>Eur. J. Inorg. Chem.</source> <volume>2019</volume> (<issue>41</issue>), <fpage>4397</fpage>&#x2013;<lpage>4404</lpage>. <pub-id pub-id-type="doi">10.1002/ejic.201900836</pub-id>
</citation>
</ref>
<ref id="B41">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cabrera</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Coene</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Leliaert</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Artes-Ibanez</surname>
<given-names>E. J.</given-names>
</name>
<name>
<surname>Dupre</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Telling</surname>
<given-names>N. D.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Dynamical magnetic response of iron oxide nanoparticles inside live cells</article-title>. <source>ACS Nano</source> <volume>12</volume> (<issue>3</issue>), <fpage>2741</fpage>&#x2013;<lpage>2752</lpage>. <pub-id pub-id-type="doi">10.1021/acsnano.7b08995</pub-id>
</citation>
</ref>
<ref id="B42">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cacicedo</surname>
<given-names>M. L.</given-names>
</name>
<name>
<surname>Islan</surname>
<given-names>G. A.</given-names>
</name>
<name>
<surname>Leon</surname>
<given-names>I. E.</given-names>
</name>
<name>
<surname>Alvarez</surname>
<given-names>V. A.</given-names>
</name>
<name>
<surname>Chourpa</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Allard-Vannier</surname>
<given-names>E.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Bacterial cellulose hydrogel loaded with lipid nanoparticles for localized cancer treatment</article-title>. <source>Colloids Surf. B Biointerfaces</source> <volume>170</volume>, <fpage>596</fpage>&#x2013;<lpage>608</lpage>. <pub-id pub-id-type="doi">10.1016/j.colsurfb.2018.06.056</pub-id>
</citation>
</ref>
<ref id="B43">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cadete</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Olivera</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Besev</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Dhal</surname>
<given-names>P. K.</given-names>
</name>
<name>
<surname>Goncalves</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Almeida</surname>
<given-names>A. J.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Self-assembled hyaluronan nanocapsules for the intracellular delivery of anticancer drugs</article-title>. <source>Sci. Rep.</source> <volume>9</volume> (<issue>1</issue>), <fpage>11565</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-019-47995-8</pub-id>
</citation>
</ref>
<ref id="B44">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carrillo-Carrion</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Martinez</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Navarro Poupard</surname>
<given-names>M. F.</given-names>
</name>
<name>
<surname>Pelaz</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Polo</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Arenas-Vivo</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Aqueous stable gold nanostar/ZIF-8 nanocomposites for light-triggered release of active cargo inside living cells</article-title>. <source>Angew. Chem. Int. Ed. Engl.</source> <volume>58</volume> (<issue>21</issue>), <fpage>7078</fpage>&#x2013;<lpage>7082</lpage>. <pub-id pub-id-type="doi">10.1002/anie.201902817</pub-id>
</citation>
</ref>
<ref id="B45">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Casadome-Perales</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Matteis</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Alleva</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Infantes-Rodriguez</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Palomares-Perez</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Saito</surname>
<given-names>T.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Inhibition of p38 MAPK in the brain through nasal administration of p38 inhibitor loaded in chitosan nanocapsules</article-title>. <source>Nanomedicine (Lond)</source> <volume>14</volume> (<issue>18</issue>), <fpage>2409</fpage>&#x2013;<lpage>2422</lpage>. <pub-id pub-id-type="doi">10.2217/nnm-2018-0496</pub-id>
</citation>
</ref>
<ref id="B46">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Casarrubios</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Gomez-Cerezo</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Feito</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Vallet-Regi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Arcos</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Portoles</surname>
<given-names>M. T.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Ipriflavone-loaded mesoporous nanospheres with potential applications for periodontal treatment</article-title>. <source>Nanomater. (Basel)</source> <volume>10</volume> (<issue>12</issue>), <fpage>2573</fpage>. <pub-id pub-id-type="doi">10.3390/nano10122573</pub-id>
</citation>
</ref>
<ref id="B47">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Casarrubios</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Polo-Montalvo</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Serrano</surname>
<given-names>M. C.</given-names>
</name>
<name>
<surname>Feito</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Vallet-Regi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Arcos</surname>
<given-names>D.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Effects of ipriflavone-loaded mesoporous nanospheres on the differentiation of endothelial progenitor cells and their modulation by macrophages</article-title>. <source>Nanomater. (Basel)</source> <volume>11</volume> (<issue>5</issue>), <fpage>1102</fpage>. <pub-id pub-id-type="doi">10.3390/nano11051102</pub-id>
</citation>
</ref>
<ref id="B48">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cervantes</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Arana</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Murillo-Cuesta</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bruno</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Alkorta</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Varela-Nieto</surname>
<given-names>I.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Solid lipid nanoparticles loaded with glucocorticoids protect auditory cells from cisplatin-induced ototoxicity</article-title>. <source>J. Clin. Med.</source> <volume>8</volume> (<issue>9</issue>), <fpage>1464</fpage>. <pub-id pub-id-type="doi">10.3390/jcm8091464</pub-id>
</citation>
</ref>
<ref id="B49">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chato-Astrain</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Sanchez-Porras</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Garcia-Garcia</surname>
<given-names>O. D.</given-names>
</name>
<name>
<surname>Vairo</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Villar-Vidal</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Villullas</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Improvement of cell culture methods for the successful generation of human keratinocyte primary cell cultures using EGF-loaded nanostructured lipid carriers</article-title>. <source>Biomedicines</source> <volume>9</volume> (<issue>11</issue>), <fpage>1634</fpage>. <pub-id pub-id-type="doi">10.3390/biomedicines9111634</pub-id>
</citation>
</ref>
<ref id="B50">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chin</surname>
<given-names>K. C.</given-names>
</name>
<name>
<surname>Chong</surname>
<given-names>G. L.</given-names>
</name>
<name>
<surname>Poh</surname>
<given-names>C. K.</given-names>
</name>
<name>
<surname>Van</surname>
<given-names>L. H.</given-names>
</name>
<name>
<surname>Sow</surname>
<given-names>C. H.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2007</year>). <article-title>Large-scale synthesis of Fe3O4 nanosheets at low temperature</article-title>. <source>J. Phys. Chem. C</source> <volume>111</volume> (<issue>26</issue>), <fpage>9136</fpage>&#x2013;<lpage>9141</lpage>. <pub-id pub-id-type="doi">10.1021/jp070873g</pub-id>
</citation>
</ref>
<ref id="B51">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Christou</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Pearson</surname>
<given-names>J. R.</given-names>
</name>
<name>
<surname>Beltran</surname>
<given-names>A. M.</given-names>
</name>
<name>
<surname>Fernandez-Afonso</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Gutierrez</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>de la Fuente</surname>
<given-names>J. M.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Iron-gold nanoflowers: A promising tool for multimodal imaging and hyperthermia therapy</article-title>. <source>Pharmaceutics</source> <volume>14</volume> (<issue>3</issue>), <fpage>636</fpage>. <pub-id pub-id-type="doi">10.3390/pharmaceutics14030636</pub-id>
</citation>
</ref>
<ref id="B52">
<citation citation-type="web">
<collab>Clinica Universidad de Navarra UdN</collab> (<year>2022a</year>). <article-title>Study of BO-112 with radiotherapy and nivolumab for metastatic refractory NSCLC (noelia) clinicaltrials.gov2022</article-title>. <comment>Available from: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT05265650?term=BO-112&amp;draw=2&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT05265650?term&#x3d;BO-112&#x26;draw&#x3d;2&#x26;rank&#x3d;1</ext-link>
</comment>.</citation>
</ref>
<ref id="B53">
<citation citation-type="web">
<collab>Clinica Universidad de Navarra UdN</collab> (<year>2022b</year>). <article-title>Zein nanoparticles for glycemic control (GLUCOCAPS) clinicaltrials.gov2022</article-title>. <comment>Available from: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT05560412?term=zein&amp;cntry=ES&amp;draw=2&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT05560412?term&#x3d;zein&#x26;cntry&#x3d;ES&#x26;draw&#x3d;2&#x26;rank&#x3d;1</ext-link>
</comment>.</citation>
</ref>
<ref id="B54">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Colilla</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Vallet-Regi</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Targeted stimuli-responsive mesoporous silica nanoparticles for bacterial infection treatment</article-title>. <source>Int. J. Mol. Sci.</source> <volume>21</volume> (<issue>22</issue>), <fpage>8605</fpage>. <pub-id pub-id-type="doi">10.3390/ijms21228605</pub-id>
</citation>
</ref>
<ref id="B55">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cordeiro</surname>
<given-names>A. S.</given-names>
</name>
<name>
<surname>Crecente-Campo</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Bouzo</surname>
<given-names>B. L.</given-names>
</name>
<name>
<surname>Gonzalez</surname>
<given-names>S. F.</given-names>
</name>
<name>
<surname>de la Fuente</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Alonso</surname>
<given-names>M. J.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Engineering polymeric nanocapsules for an efficient drainage and biodistribution in the lymphatic system</article-title>. <source>J. Drug Target</source> <volume>27</volume> (<issue>5-6</issue>), <fpage>646</fpage>&#x2013;<lpage>658</lpage>. <pub-id pub-id-type="doi">10.1080/1061186x.2018.1561886</pub-id>
</citation>
</ref>
<ref id="B56">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Correa-Paz</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Navarro Poupard</surname>
<given-names>M. F.</given-names>
</name>
<name>
<surname>Polo</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Rodriguez-Perez</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Taboada</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Iglesias-Rey</surname>
<given-names>R.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>
<italic>In vivo</italic> ultrasound-activated delivery of recombinant tissue plasminogen activator from the cavity of sub-micrometric capsules</article-title>. <source>J. Control Release</source> <volume>308</volume>, <fpage>162</fpage>&#x2013;<lpage>171</lpage>. <pub-id pub-id-type="doi">10.1016/j.jconrel.2019.07.017</pub-id>
</citation>
</ref>
<ref id="B57">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Crecente-Campo</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Virgilio</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Morone</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Calvino-Sampedro</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Fernandez-Marino</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Olivera</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Design of polymeric nanocapsules to improve their lympho-targeting capacity</article-title>. <source>Nanomedicine (Lond).</source> <volume>14</volume> (<issue>23</issue>), <fpage>3013</fpage>&#x2013;<lpage>3033</lpage>. <pub-id pub-id-type="doi">10.2217/nnm-2019-0206</pub-id>
</citation>
</ref>
<ref id="B58">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dacoba</surname>
<given-names>T. G.</given-names>
</name>
<name>
<surname>Anfray</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Mainini</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Allavena</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Alonso</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Torres Andon</surname>
<given-names>F.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Arginine-based poly(I:C)-Loaded nanocomplexes for the polarization of macrophages toward M1-antitumoral effectors</article-title>. <source>Front. Immunol.</source> <volume>11</volume>, <fpage>1412</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2020.01412</pub-id>
</citation>
</ref>
<ref id="B59">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dacoba</surname>
<given-names>T. G.</given-names>
</name>
<name>
<surname>Olivera</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Torres</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Crecente-Campo</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Alonso</surname>
<given-names>M. J.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Modulating the immune system through nanotechnology</article-title>. <source>Semin. Immunol.</source> <volume>34</volume>, <fpage>78</fpage>&#x2013;<lpage>102</lpage>. <pub-id pub-id-type="doi">10.1016/j.smim.2017.09.007</pub-id>
</citation>
</ref>
<ref id="B60">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dacoba</surname>
<given-names>T. G.</given-names>
</name>
<name>
<surname>Omange</surname>
<given-names>R. W.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Crecente-Campo</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Alonso</surname>
<given-names>M. J.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Polysaccharide nanoparticles can efficiently modulate the immune response against an HIV peptide antigen</article-title>. <source>ACS Nano</source> <volume>13</volume> (<issue>5</issue>), <fpage>4947</fpage>&#x2013;<lpage>4959</lpage>. <pub-id pub-id-type="doi">10.1021/acsnano.8b07662</pub-id>
</citation>
</ref>
<ref id="B61">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dacoba</surname>
<given-names>T. G.</given-names>
</name>
<name>
<surname>Ruiz-Gaton</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Benito</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Klein</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Dupin</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Technological challenges in the preclinical development of an HIV nanovaccine candidate</article-title>. <source>Drug Deliv. Transl. Res.</source> <volume>10</volume> (<issue>3</issue>), <fpage>621</fpage>&#x2013;<lpage>634</lpage>. <pub-id pub-id-type="doi">10.1007/s13346-020-00721-8</pub-id>
</citation>
</ref>
<ref id="B62">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>de la Presa</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Luengo</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Multigner</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Costo</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Morales</surname>
<given-names>M. P.</given-names>
</name>
<name>
<surname>Rivero</surname>
<given-names>G.</given-names>
</name>
<etal/>
</person-group> (<year>2012</year>). <article-title>Study of heating efficiency as a function of concentration, size, and applied field in &#x3b3;-Fe2O3 nanoparticles</article-title>. <source>J. Phys. Chem. C</source> <volume>116</volume> (<issue>48</issue>), <fpage>25602</fpage>&#x2013;<lpage>25610</lpage>. <pub-id pub-id-type="doi">10.1021/jp310771p</pub-id>
</citation>
</ref>
<ref id="B63">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Luca</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Profita</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Cicero</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>&#x3c;p&#x26;gt;Nab-paclitaxel in pretreated metastatic breast cancer: Evaluation of activity, safety, and quality of life&#x26;lt;/p&#x26;gt;</article-title>. <source>Onco Targets Ther.</source> <volume>12</volume>, <fpage>1621</fpage>&#x2013;<lpage>1627</lpage>. <pub-id pub-id-type="doi">10.2147/ott.s191519</pub-id>
</citation>
</ref>
<ref id="B64">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Matteis</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Jary</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Luc&#xed;a</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Garc&#xed;a-Embid</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Serrano-Sevilla</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>P&#xe9;rez</surname>
<given-names>D.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>New active formulations against <italic>M. tuberculosis</italic>: Bedaquiline encapsulation in lipid nanoparticles and chitosan nanocapsules</article-title>. <source>Chem. Eng. J.</source> <volume>340</volume>, <fpage>181</fpage>&#x2013;<lpage>191</lpage>. <pub-id pub-id-type="doi">10.1016/j.cej.2017.12.110</pub-id>
</citation>
</ref>
<ref id="B65">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>DeDiego</surname>
<given-names>M. L.</given-names>
</name>
<name>
<surname>Portilla</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Daviu</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Lopez-Garcia</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Villamayor</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Mulens-Arias</surname>
<given-names>V.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Iron oxide and iron oxyhydroxide nanoparticles impair SARS-CoV-2 infection of cultured cells</article-title>. <source>J. Nanobiotechnology</source> <volume>20</volume> (<issue>1</issue>), <fpage>352</fpage>. <pub-id pub-id-type="doi">10.1186/s12951-022-01542-2</pub-id>
</citation>
</ref>
<ref id="B66">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Del Sol-Fernandez</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Portilla-Tundidor</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Gutierrez</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Odio</surname>
<given-names>O. F.</given-names>
</name>
<name>
<surname>Reguera</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Barber</surname>
<given-names>D. F.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Flower-like Mn-doped magnetic nanoparticles functionalized with &#x3b1;<sub>v</sub>&#x3b2;<sub>3</sub>-integrin-ligand to efficiently induce intracellular heat after alternating magnetic field exposition, triggering glioma cell death</article-title>. <source>ACS Appl. Mater Interfaces</source> <volume>11</volume> (<issue>30</issue>), <fpage>26648</fpage>&#x2013;<lpage>26663</lpage>. <pub-id pub-id-type="doi">10.1021/acsami.9b08318</pub-id>
</citation>
</ref>
<ref id="B67">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dhand</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>The rationale and evidence for use of inhaled antibiotics to control <italic>Pseudomonas aeruginosa</italic> infection in non-cystic fibrosis Bronchiectasis</article-title>. <source>J. Aerosol Med. Pulm. Drug Deliv.</source> <volume>31</volume> (<issue>3</issue>), <fpage>121</fpage>&#x2013;<lpage>138</lpage>. <pub-id pub-id-type="doi">10.1089/jamp.2017.1415</pub-id>
</citation>
</ref>
<ref id="B68">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dhiman</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Awasthi</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Sharma</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Kharkwal</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kulkarni</surname>
<given-names>G. T.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Lipid nanoparticles as carriers for bioactive delivery</article-title>. <source>Front. Chem.</source> <volume>9</volume>, <fpage>580118</fpage>. <pub-id pub-id-type="doi">10.3389/fchem.2021.580118</pub-id>
</citation>
</ref>
<ref id="B69">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Diego-Gonzalez</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Crecente-Campo</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Paul</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Reljic</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Alonso</surname>
<given-names>M. J.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Design of polymeric nanocapsules for intranasal vaccination against Mycobacterium tuberculosis: Influence of the polymeric shell and antigen positioning</article-title>. <source>Pharmaceutics</source> <volume>12</volume> (<issue>6</issue>), <fpage>489</fpage>. <pub-id pub-id-type="doi">10.3390/pharmaceutics12060489</pub-id>
</citation>
</ref>
<ref id="B70">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Diez</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Lucena-Sanchez</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Escudero</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Llopis-Lorente</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Villalonga</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Martinez-Manez</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Ultrafast directional Janus Pt-mesoporous silica nanomotors for smart drug delivery</article-title>. <source>ACS Nano</source> <volume>15</volume> (<issue>3</issue>), <fpage>4467</fpage>&#x2013;<lpage>4480</lpage>. <pub-id pub-id-type="doi">10.1021/acsnano.0c08404</pub-id>
</citation>
</ref>
<ref id="B322">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Di Silvio</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Silvestri</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lay</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Polito</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Moya</surname>
<given-names>S. E.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Impact of concanavalinA affinity in the intracellular fate of protein corona on Glucosamine Au nanoparticles</article-title>. <source>Scientific Reports</source> <volume>8</volume> (<issue>1</issue>), <fpage>9046</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-018-27418-w</pub-id>
</citation>
</ref>
<ref id="B71">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Do</surname>
<given-names>T. T. A.</given-names>
</name>
<name>
<surname>Grijalvo</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Imae</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Garcia-Celma</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Rodriguez-Abreu</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>A nanocellulose-based platform towards targeted chemo-photodynamic/photothermal cancer therapy</article-title>. <source>Carbohydr. Polym.</source> <volume>270</volume>, <fpage>118366</fpage>. <pub-id pub-id-type="doi">10.1016/j.carbpol.2021.118366</pub-id>
</citation>
</ref>
<ref id="B72">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dolai</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Mandal</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Jana</surname>
<given-names>N. R.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Nanoparticle size effects in biomedical applications</article-title>. <source>ACS Appl. Nano Mater.</source> <volume>4</volume> (<issue>7</issue>), <fpage>6471</fpage>&#x2013;<lpage>6496</lpage>. <pub-id pub-id-type="doi">10.1021/acsanm.1c00987</pub-id>
</citation>
</ref>
<ref id="B73">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dosil</surname>
<given-names>S. G.</given-names>
</name>
<name>
<surname>Lopez-Cobo</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Rodriguez-Galan</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Fernandez-Delgado</surname>
<given-names>I.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Natural killer (NK) cell-derived extracellular-vesicle shuttled microRNAs control T cell responses</article-title>. <source>Elife</source> <volume>11</volume>, <fpage>e76319</fpage>. <pub-id pub-id-type="doi">10.7554/elife.76319</pub-id>
</citation>
</ref>
<ref id="B74">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Duro-Castano</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Borras</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Herranz-Perez</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Blanco-Gandia</surname>
<given-names>M. C.</given-names>
</name>
<name>
<surname>Conejos-Sanchez</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Arminan</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Targeting Alzheimer&#x27;s disease with multimodal polypeptide-based nanoconjugates</article-title>. <source>Sci. Adv.</source> <volume>7</volume> (<issue>13</issue>), <fpage>eabf9180</fpage>. <pub-id pub-id-type="doi">10.1126/sciadv.abf9180</pub-id>
</citation>
</ref>
<ref id="B75">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Duro-Castano</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sousa-Herves</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Arminan</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Charbonnier</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Arroyo-Crespo</surname>
<given-names>J. J.</given-names>
</name>
<name>
<surname>Wedepohl</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Polyglutamic acid-based crosslinked doxorubicin nanogels as an anti-metastatic treatment for triple negative breast cancer</article-title>. <source>J. Control Release</source> <volume>332</volume>, <fpage>10</fpage>&#x2013;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1016/j.jconrel.2021.02.005</pub-id>
</citation>
</ref>
<ref id="B76">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Elming</surname>
<given-names>P. B.</given-names>
</name>
<name>
<surname>Sorensen</surname>
<given-names>B. S.</given-names>
</name>
<name>
<surname>Oei</surname>
<given-names>A. L.</given-names>
</name>
<name>
<surname>Franken</surname>
<given-names>N. A. P.</given-names>
</name>
<name>
<surname>Crezee</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Overgaard</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Hyperthermia: The optimal treatment to overcome radiation resistant hypoxia</article-title>. <source>Cancers (Basel)</source> <volume>11</volume> (<issue>1</issue>), <fpage>60</fpage>. <pub-id pub-id-type="doi">10.3390/cancers11010060</pub-id>
</citation>
</ref>
<ref id="B77">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Elsabahy</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wooley</surname>
<given-names>K. L.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Design of polymeric nanoparticles for biomedical delivery applications</article-title>. <source>Chem. Soc. Rev.</source> <volume>41</volume> (<issue>7</issue>), <fpage>2545</fpage>&#x2013;<lpage>2561</lpage>. <pub-id pub-id-type="doi">10.1039/c2cs15327k</pub-id>
</citation>
</ref>
<ref id="B78">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Encinas-Basurto</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Ibarra</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Juarez</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Pardo</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Barbosa</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Taboada</surname>
<given-names>P.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Hybrid folic acid-conjugated gold nanorods-loaded human serum albumin nanoparticles for simultaneous photothermal and chemotherapeutic therapy</article-title>. <source>Mater Sci. Eng. C Mater Biol. Appl.</source> <volume>91</volume>, <fpage>669</fpage>&#x2013;<lpage>678</lpage>. <pub-id pub-id-type="doi">10.1016/j.msec.2018.06.002</pub-id>
</citation>
</ref>
<ref id="B79">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Encinas-Basurto</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Juarez</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Valdez</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Burboa</surname>
<given-names>M. G.</given-names>
</name>
<name>
<surname>Barbosa</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Taboada</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Targeted drug delivery via human epidermal growth factor receptor for sustained release of allyl isothiocyanate</article-title>. <source>Curr. Top. Med. Chem.</source> <volume>18</volume> (<issue>14</issue>), <fpage>1252</fpage>&#x2013;<lpage>1260</lpage>. <pub-id pub-id-type="doi">10.2174/1568026618666180810150113</pub-id>
</citation>
</ref>
<ref id="B80">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Enshaei</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Puiggali-Jou</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Del Valle</surname>
<given-names>L. J.</given-names>
</name>
<name>
<surname>Turon</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Saperas</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Aleman</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Nanotheranostic interface based on antibiotic-loaded conducting polymer nanoparticles for real-time monitoring of bacterial growth inhibition</article-title>. <source>Adv. Healthc. Mater</source> <volume>10</volume> (<issue>7</issue>), <fpage>e2001636</fpage>. <pub-id pub-id-type="doi">10.1002/adhm.202001636</pub-id>
</citation>
</ref>
<ref id="B81">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Escudero-Duch</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Martin-Saavedra</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Prieto</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sanchez-Casanova</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lopez</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Sebastian</surname>
<given-names>V.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Gold nanoparticles for the <italic>in situ</italic> polymerization of near-infrared responsive hydrogels based on fibrin</article-title>. <source>Acta Biomater.</source> <volume>100</volume>, <fpage>306</fpage>&#x2013;<lpage>315</lpage>. <pub-id pub-id-type="doi">10.1016/j.actbio.2019.09.040</pub-id>
</citation>
</ref>
<ref id="B82">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Espinosa</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Castro</surname>
<given-names>G. R.</given-names>
</name>
<name>
<surname>Reguera</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Castellano</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Castillo</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Camarero</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Photoactivated nanoscale temperature gradient detection using X-ray absorption spectroscopy as a direct nanothermometry method</article-title>. <source>Nano Lett.</source> <volume>21</volume> (<issue>1</issue>), <fpage>769</fpage>&#x2013;<lpage>777</lpage>. <pub-id pub-id-type="doi">10.1021/acs.nanolett.0c04477</pub-id>
</citation>
</ref>
<ref id="B83">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Espinosa</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Reguera</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Curcio</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Munoz-Noval</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kuttner</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Van de Walle</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Janus magnetic-plasmonic nanoparticles for magnetically guided and thermally activated cancer therapy</article-title>. <source>Small</source> <volume>16</volume> (<issue>11</issue>), <fpage>e1904960</fpage>. <pub-id pub-id-type="doi">10.1002/smll.201904960</pub-id>
</citation>
</ref>
<ref id="B84">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Espinosa</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Silva</surname>
<given-names>A. K.</given-names>
</name>
<name>
<surname>Sanchez-Iglesias</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Grzelczak</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pechoux</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Desboeufs</surname>
<given-names>K.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Cancer cell internalization of gold nanostars impacts their photothermal efficiency <italic>in vitro</italic> and <italic>in vivo</italic>: Toward a plasmonic thermal fingerprint in tumoral environment</article-title>. <source>Adv. Healthc. Mater</source> <volume>5</volume> (<issue>9</issue>), <fpage>1040</fpage>&#x2013;<lpage>1048</lpage>. <pub-id pub-id-type="doi">10.1002/adhm.201501035</pub-id>
</citation>
</ref>
<ref id="B85">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Espinosa-Cano</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Aguilar</surname>
<given-names>M. R.</given-names>
</name>
<name>
<surname>Portilla</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Barber</surname>
<given-names>D. F.</given-names>
</name>
<name>
<surname>San Roman</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Anti-inflammatory polymeric nanoparticles based on ketoprofen and dexamethasone</article-title>. <source>Pharmaceutics</source> <volume>12</volume> (<issue>8</issue>), <fpage>723</fpage>. <pub-id pub-id-type="doi">10.3390/pharmaceutics12080723</pub-id>
</citation>
</ref>
<ref id="B86">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Espinosa-Cano</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Aguilar</surname>
<given-names>M. R.</given-names>
</name>
<name>
<surname>Portilla</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Barber</surname>
<given-names>D. F.</given-names>
</name>
<name>
<surname>San Roman</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Polymeric nanoparticles that combine dexamethasone and naproxen for the synergistic inhibition of Il12b transcription in macrophages</article-title>. <source>Macromol. Biosci.</source> <volume>20</volume> (<issue>7</issue>), <fpage>e2000002</fpage>. <pub-id pub-id-type="doi">10.1002/mabi.202000002</pub-id>
</citation>
</ref>
<ref id="B87">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Etchenausia</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Villar-Alvarez</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Forcada</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Save</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Taboada</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Evaluation of cationic core-shell thermoresponsive poly(N-vinylcaprolactam)-based microgels as potential drug delivery nanocarriers</article-title>. <source>Mater Sci. Eng. C Mater Biol. Appl.</source> <volume>104</volume>, <fpage>109871</fpage>. <pub-id pub-id-type="doi">10.1016/j.msec.2019.109871</pub-id>
</citation>
</ref>
<ref id="B88">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Etxebeste-Mitxeltorena</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Moreno</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Carvalheiro</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Calvo</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Navarro-Blasco</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Gonzalez-Penas</surname>
<given-names>E.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Oral efficacy of a diselenide compound loaded in nanostructured lipid carriers in a murine model of visceral leishmaniasis</article-title>. <source>ACS Infect. Dis.</source> <volume>7</volume> (<issue>12</issue>), <fpage>3197</fpage>&#x2013;<lpage>3209</lpage>. <pub-id pub-id-type="doi">10.1021/acsinfecdis.1c00394</pub-id>
</citation>
</ref>
<ref id="B89">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fabregas</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Prieto-Sanchez</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sune-Pou</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Boyero-Corral</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Tico</surname>
<given-names>J. R.</given-names>
</name>
<name>
<surname>Garcia-Montoya</surname>
<given-names>E.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Improved formulation of cationic solid lipid nanoparticles displays cellular uptake and biological activity of nucleic acids</article-title>. <source>Int. J. Pharm.</source> <volume>516</volume> (<issue>1-2</issue>), <fpage>39</fpage>&#x2013;<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijpharm.2016.11.026</pub-id>
</citation>
</ref>
<ref id="B90">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fabrizio</surname>
<given-names>E. D.</given-names>
</name>
<name>
<surname>Schl&#xfc;cker</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wenger</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Regmi</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Rigneault</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Calafiore</surname>
<given-names>G.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Roadmap on biosensing and photonics with advanced nano-optical methods</article-title>. <source>J. Opt.</source> <volume>18</volume> (<issue>6</issue>), <fpage>063003</fpage>. <pub-id pub-id-type="doi">10.1088/2040-8978/18/6/063003</pub-id>
</citation>
</ref>
<ref id="B91">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Falgas</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Pallares</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Serna</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Sanchez-Garcia</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Sierra</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Gallardo</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Selective delivery of T22-PE24-H6 to CXCR4(&#x2b;) diffuse large B-cell lymphoma cells leads to wide therapeutic index in a disseminated mouse model</article-title>. <source>Theranostics</source> <volume>10</volume> (<issue>12</issue>), <fpage>5169</fpage>&#x2013;<lpage>5180</lpage>. <pub-id pub-id-type="doi">10.7150/thno.43231</pub-id>
</citation>
</ref>
<ref id="B92">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fern&#xe1;ndez</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Holgado</surname>
<given-names>M. &#xc1;.</given-names>
</name>
<name>
<surname>Cayero-Otero</surname>
<given-names>M. D.</given-names>
</name>
<name>
<surname>Pineda</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Yepes</surname>
<given-names>L. M.</given-names>
</name>
<name>
<surname>Gaspar</surname>
<given-names>D. P.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Improved antileishmanial activity and cytotoxicity of a novel nanotherapy for N-iodomethyl-N,N-dimethyl-N-(6,6-diphenylhex-5-en-1-yl)ammonium iodide</article-title>. <source>J. Drug Deliv. Sci. Technol.</source> <volume>61</volume>, <fpage>101988</fpage>. <pub-id pub-id-type="doi">10.1016/j.jddst.2020.101988</pub-id>
</citation>
</ref>
<ref id="B93">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fernandez</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Movellan</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Foradada</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Gimenez</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Garcia-Aranda</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Mancilla</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>
<italic>In vivo</italic> antitumor and antimetastatic efficacy of a polyacetal&#x2010;based paclitaxel conjugate for prostate cancer therapy</article-title>. <source>Adv. Healthc. Mater</source> <volume>11</volume> (<issue>7</issue>), <fpage>e2101544</fpage>. <pub-id pub-id-type="doi">10.1002/adhm.202101544</pub-id>
</citation>
</ref>
<ref id="B94">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fornaguera</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Diaz-Caballero</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Garcia-Fernandez</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Olmo</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Stampa-Lopez Pinto</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Navalon-Lopez</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Synthesis and characterization of mRNA-loaded poly(beta aminoesters) nanoparticles for vaccination purposes</article-title>. <source>J. Vis. Exp.</source> <volume>2021</volume>, <fpage>174</fpage>.</citation>
</ref>
<ref id="B95">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Foulkes</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Man</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Thind</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yeung</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Joy</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hoskins</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>The regulation of nanomaterials and nanomedicines for clinical application: Current and future perspectives</article-title>. <source>Biomater. Sci.</source> <volume>8</volume> (<issue>17</issue>), <fpage>4653</fpage>&#x2013;<lpage>4664</lpage>. <pub-id pub-id-type="doi">10.1039/d0bm00558d</pub-id>
</citation>
</ref>
<ref id="B320">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qu</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Frame-guided synthesis of polymeric colloidal discs</article-title>. <source>J. Am. Chem. Soc.</source> <volume>143</volume> (<issue>4</issue>), <fpage>1790</fpage>&#x2013;<lpage>1797</lpage>. <pub-id pub-id-type="doi">10.1021/jacs.0c08627</pub-id>
</citation>
</ref>
<ref id="B321">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fleury</surname>
<given-names>J. B.</given-names>
</name>
<name>
<surname>Werner</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gu&#x00E9;vel</surname>
<given-names>X. L.</given-names>
</name>
<name>
<surname>Baulin</surname>
<given-names>V. A.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Protein corona modulates interaction of spiky nanoparticles with lipid bilayers</article-title>. <source>Journal of Colloid and Interface Science</source> <volume>603</volume>, <fpage>550</fpage>&#x2013;<lpage>558</lpage>. <pub-id pub-id-type="doi">10.1016/j.jcis.2021.06.047</pub-id>
</citation>
</ref>
<ref id="B96">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Fratila</surname>
<given-names>R. M.</given-names>
</name>
<name>
<surname>de la Fuente</surname>
<given-names>J. M.</given-names>
</name>
</person-group> (<year>2019</year>). &#x201c;<article-title>Introduction to hyperthermia</article-title>,&#x201d; in <source>Nanomaterials for magnetic and optical hyperthermia applications</source>. Editors <person-group person-group-type="editor">
<name>
<surname>Fratila</surname>
<given-names>R. M.</given-names>
</name>
<name>
<surname>De La Fuente</surname>
<given-names>J. M.</given-names>
</name>
</person-group> (<publisher-name>Elsevier</publisher-name>), <fpage>1</fpage>&#x2013;<lpage>10</lpage>.</citation>
</ref>
<ref id="B97">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frigaard</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Jensen</surname>
<given-names>J. L.</given-names>
</name>
<name>
<surname>Galtung</surname>
<given-names>H. K.</given-names>
</name>
<name>
<surname>Hiorth</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>The potential of chitosan in nanomedicine: An overview of the cytotoxicity of chitosan based nanoparticles</article-title>. <source>Front. Pharmacol.</source> <volume>13</volume>, <fpage>880377</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2022.880377</pub-id>
</citation>
</ref>
<ref id="B98">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fuentes-Garc&#xed;a</surname>
<given-names>J. A. C. A, A.</given-names>
</name>
<name>
<surname>de Castro</surname>
<given-names>C. E.</given-names>
</name>
<name>
<surname>Giacomelli</surname>
<given-names>F. C.</given-names>
</name>
<name>
<surname>Ibarra</surname>
<given-names>M. R.</given-names>
</name>
<name>
<surname>Bonvent</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Fabi&#xe1;n Goya</surname>
<given-names>G.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Sonochemical route for mesoporous silica-coated magnetic nanoparticles towards pH-triggered drug delivery system</article-title>. <source>J. Mater Res. Technol.</source> <volume>15</volume>, <fpage>52</fpage>&#x2013;<lpage>67</lpage>. <pub-id pub-id-type="doi">10.1016/j.jmrt.2021.08.014</pub-id>
</citation>
</ref>
<ref id="B99">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Galindo</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Sanchez-Lopez</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Gomara</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Espina</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ettcheto</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Cano</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Development of peptide targeted PLGA-PEGylated nanoparticles loading licochalcone-A for ocular inflammation</article-title>. <source>Pharmaceutics</source> <volume>14</volume> (<issue>2</issue>), <fpage>285</fpage>. <pub-id pub-id-type="doi">10.3390/pharmaceutics14020285</pub-id>
</citation>
</ref>
<ref id="B100">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gallego-Lleyda</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>De Miguel</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Anel</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Martinez-Lostao</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Lipid nanoparticles decorated with TNF-related aptosis-inducing ligand (TRAIL) are more cytotoxic than soluble recombinant TRAIL in sarcoma</article-title>. <source>Int. J. Mol. Sci.</source> <volume>19</volume> (<issue>5</issue>), <fpage>1449</fpage>. <pub-id pub-id-type="doi">10.3390/ijms19051449</pub-id>
</citation>
</ref>
<ref id="B101">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gallego-Yerga</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Benito</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Blanco-Fernandez</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Martinez-Negro</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Velaz</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Aicart</surname>
<given-names>E.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Plasmid-templated control of DNA-cyclodextrin nanoparticle morphology through molecular vector design for effective gene delivery</article-title>. <source>Chemistry</source> <volume>24</volume> (<issue>15</issue>), <fpage>3825</fpage>&#x2013;<lpage>3835</lpage>. <pub-id pub-id-type="doi">10.1002/chem.201705723</pub-id>
</citation>
</ref>
<ref id="B102">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Garc&#xed;a</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Gonz&#xe1;lez</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Harvey</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Izquierdo-Barba</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Vallet-Reg&#xed;</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Effective reduction of biofilm through photothermal therapy by gold core@shell based mesoporous silica nanoparticles</article-title>. <source>Microporous Mesoporous Mater.</source> <volume>328</volume>, <fpage>111489</fpage>. <pub-id pub-id-type="doi">10.1016/j.micromeso.2021.111489</pub-id>
</citation>
</ref>
<ref id="B103">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Garcia</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Fernandez-Pradas</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Llado</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Serra</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Zalvidea</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Kogan</surname>
<given-names>M. J.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>The combined use of gold nanoparticles and infrared radiation enables cytosolic protein delivery</article-title>. <source>Chemistry</source> <volume>27</volume> (<issue>14</issue>), <fpage>4670</fpage>&#x2013;<lpage>4675</lpage>. <pub-id pub-id-type="doi">10.1002/chem.202005000</pub-id>
</citation>
</ref>
<ref id="B104">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Garcia</surname>
<given-names>M. A.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Surface plasmons in metallic nanoparticles: Fundamentals and applications</article-title>. <source>J. Phys. D Appl. Phys.</source> <volume>44</volume> (<issue>28</issue>), <fpage>283001</fpage>. <pub-id pub-id-type="doi">10.1088/0022-3727/44/28/283001</pub-id>
</citation>
</ref>
<ref id="B105">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Garcia-Alvarez</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Vallet-Regi</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Hard and soft protein corona of nanomaterials: Analysis and relevance</article-title>. <source>Nanomater. (Basel).</source> <volume>11</volume> (<issue>4</issue>), <fpage>888</fpage>. <pub-id pub-id-type="doi">10.3390/nano11040888</pub-id>
</citation>
</ref>
<ref id="B106">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Garcia-Fernandez</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sancenon</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Martinez-Manez</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Mesoporous silica nanoparticles for pulmonary drug delivery</article-title>. <source>Adv. Drug Deliv. Rev.</source> <volume>177</volume>, <fpage>113953</fpage>. <pub-id pub-id-type="doi">10.1016/j.addr.2021.113953</pub-id>
</citation>
</ref>
<ref id="B107">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Garcia-Fernandez</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sancho</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bisbal</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Amoros</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Marcos</surname>
<given-names>M. D.</given-names>
</name>
<name>
<surname>Orzaez</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Targeted-lung delivery of dexamethasone using gated mesoporous silica nanoparticles. A new therapeutic approach for acute lung injury treatment</article-title>. <source>J. Control Release</source> <volume>337</volume>, <fpage>14</fpage>&#x2013;<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1016/j.jconrel.2021.07.010</pub-id>
</citation>
</ref>
<ref id="B108">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Garcia-Garrido</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Cordani</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Somoza</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Modified gold nanoparticles to overcome the chemoresistance to gemcitabine in mutant p53 cancer cells</article-title>. <source>Pharmaceutics</source> <volume>13</volume> (<issue>12</issue>), <fpage>2067</fpage>. <pub-id pub-id-type="doi">10.3390/pharmaceutics13122067</pub-id>
</citation>
</ref>
<ref id="B109">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Garcia-Lojo</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Nunez-Sanchez</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gomez-Grana</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Grzelczak</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pastoriza-Santos</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Perez-Juste</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Plasmonic supercrystals</article-title>. <source>Acc. Chem. Res.</source> <volume>52</volume> (<issue>7</issue>), <fpage>1855</fpage>&#x2013;<lpage>1864</lpage>. <pub-id pub-id-type="doi">10.1021/acs.accounts.9b00213</pub-id>
</citation>
</ref>
<ref id="B110">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Garcia-Soriano</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Amaro</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Lafuente-Gomez</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Milan-Rois</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Somoza</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Navio</surname>
<given-names>C.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>The influence of cation incorporation and leaching in the properties of Mn-doped nanoparticles for biomedical applications</article-title>. <source>J. Colloid Interface Sci.</source> <volume>578</volume>, <fpage>510</fpage>&#x2013;<lpage>521</lpage>. <pub-id pub-id-type="doi">10.1016/j.jcis.2020.06.011</pub-id>
</citation>
</ref>
<ref id="B111">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Garcia-Soriano</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Milan-Rois</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Lafuente-Gomez</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Navio</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Gutierrez</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Cusso</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Iron oxide-manganese oxide nanoparticles with tunable morphology and switchable MRI contrast mode triggered by intracellular conditions</article-title>. <source>J. Colloid Interface Sci.</source> <volume>613</volume>, <fpage>447</fpage>&#x2013;<lpage>460</lpage>. <pub-id pub-id-type="doi">10.1016/j.jcis.2022.01.070</pub-id>
</citation>
</ref>
<ref id="B112">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gaspar</surname>
<given-names>D. P.</given-names>
</name>
<name>
<surname>Gaspar</surname>
<given-names>M. M.</given-names>
</name>
<name>
<surname>Eleuterio</surname>
<given-names>C. V.</given-names>
</name>
<name>
<surname>Grenha</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Blanco</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Goncalves</surname>
<given-names>L. M. D.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Microencapsulated solid lipid nanoparticles as a hybrid platform for pulmonary antibiotic delivery</article-title>. <source>Mol. Pharm.</source> <volume>14</volume> (<issue>9</issue>), <fpage>2977</fpage>&#x2013;<lpage>2990</lpage>. <pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.7b00169</pub-id>
</citation>
</ref>
<ref id="B113">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gatoo</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Naseem</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Arfat</surname>
<given-names>M. Y.</given-names>
</name>
<name>
<surname>Dar</surname>
<given-names>A. M.</given-names>
</name>
<name>
<surname>Qasim</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Zubair</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Physicochemical properties of nanomaterials: Implication in associated toxic manifestations</article-title>. <source>Biomed. Res. Int.</source> <volume>2014</volume>, <fpage>1</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1155/2014/498420</pub-id>
</citation>
</ref>
<ref id="B114">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gavil&#xe1;n</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kowalski</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Heinke</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Sugunan</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sommertune</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Var&#xf3;n</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Colloidal flower-shaped iron oxide nanoparticles: Synthesis strategies and coatings</article-title>. <source>Part. Part. Syst. Charact.</source> <volume>34</volume> (<issue>7</issue>), <fpage>1700094</fpage>. <pub-id pub-id-type="doi">10.1002/ppsc.201700094</pub-id>
</citation>
</ref>
<ref id="B324">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gerke</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zabala Gutierrez</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>M&#x00E9;ndez-Gonz&#x00E1;lez</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Cruz</surname>
<given-names>M. C. I.</given-names>
</name>
<name>
<surname>Mulero</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Jaque</surname>
<given-names>D.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Clickable albumin nanoparticles for pretargeted drug delivery toward PD-L1 overexpressing tumors in combination immunotherapy</article-title>. <source>Bioconjugate Chemistry</source> <volume>33</volume> (<issue>5</issue>), <fpage>821</fpage>&#x2013;<lpage>828</lpage>. <pub-id pub-id-type="doi">10.1021/acs.bioconjchem.2c00087</pub-id>
</citation>
</ref>
<ref id="B115">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Giner-Casares</surname>
<given-names>J. J.</given-names>
</name>
<name>
<surname>Henriksen-Lacey</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Coronado-Puchau</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Liz-Marz&#xe1;n</surname>
<given-names>L. M.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Inorganic nanoparticles for biomedicine: Where materials scientists meet medical research</article-title>. <source>Mater. Today</source> <volume>19</volume> (<issue>1</issue>), <fpage>19</fpage>&#x2013;<lpage>28</lpage>. <pub-id pub-id-type="doi">10.1016/j.mattod.2015.07.004</pub-id>
</citation>
</ref>
<ref id="B116">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gisbert-Garzaran</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lozano</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Vallet-Regi</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Mesoporous silica nanoparticles for targeting subcellular organelles</article-title>. <source>Int. J. Mol. Sci.</source> <volume>21</volume> (<issue>24</issue>), <fpage>9696</fpage>. <pub-id pub-id-type="doi">10.3390/ijms21249696</pub-id>
</citation>
</ref>
<ref id="B117">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goesmann</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Feldmann</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Cover picture: Nanoparticulate functional materials (angew. Chem. Int. Ed. 8/2010)</article-title>. <source>Angew. Chem. Int. Ed.</source> <volume>49</volume> (<issue>8</issue>), <fpage>1333</fpage>. <pub-id pub-id-type="doi">10.1002/anie.200907226</pub-id>
</citation>
</ref>
<ref id="B118">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gomez-Aguado</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Rodriguez-Castejon</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Beraza-Millor</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Vicente-Pascual</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Rodriguez-Gascon</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Garelli</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>mRNA-based nanomedicinal products to address corneal inflammation by interleukin-10 supplementation</article-title>. <source>Pharmaceutics</source> <volume>13</volume> (<issue>9</issue>), <fpage>1472</fpage>. <pub-id pub-id-type="doi">10.3390/pharmaceutics13091472</pub-id>
</citation>
</ref>
<ref id="B119">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gomez-Aguado</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Rodriguez-Castejon</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Vicente-Pascual</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Rodriguez-Gascon</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Pozo-Rodriguez</surname>
<given-names>A. D.</given-names>
</name>
<name>
<surname>Solinis Aspiazu</surname>
<given-names>M. A.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Nucleic acid delivery by solid lipid nanoparticles containing switchable lipids: Plasmid DNA vs. Messenger RNA</article-title>. <source>Mol.</source> <volume>25</volume> (<issue>24</issue>), <fpage>5995</fpage>. <pub-id pub-id-type="doi">10.3390/molecules25245995</pub-id>
</citation>
</ref>
<ref id="B120">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gomez-Grana</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Perez-Ameneiro</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Vecino</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Pastoriza-Santos</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Perez-Juste</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Cruz</surname>
<given-names>J. M.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Biogenic synthesis of metal nanoparticles using a biosurfactant extracted from corn and their antimicrobial properties</article-title>. <source>Nanomater. (Basel)</source> <volume>7</volume> (<issue>6</issue>), <fpage>139</fpage>. <pub-id pub-id-type="doi">10.3390/nano7060139</pub-id>
</citation>
</ref>
<ref id="B121">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gonzalez-Aramundiz</surname>
<given-names>J. V.</given-names>
</name>
<name>
<surname>Peleteiro</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gonzalez-Fernandez</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Alonso</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Csaba</surname>
<given-names>N. S.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Protamine nanocapsules for the development of thermostable adjuvanted nanovaccines</article-title>. <source>Mol. Pharm.</source> <volume>15</volume> (<issue>12</issue>), <fpage>5653</fpage>&#x2013;<lpage>5664</lpage>. <pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.8b00852</pub-id>
</citation>
</ref>
<ref id="B122">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gonzalez-Aramundiz</surname>
<given-names>J. V.</given-names>
</name>
<name>
<surname>Presas</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Dalmau-Mena</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Martinez-Pulgarin</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Alonso</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Escribano</surname>
<given-names>J. M.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Rational design of protamine nanocapsules as antigen delivery carriers</article-title>. <source>J. Control Release</source> <volume>245</volume>, <fpage>62</fpage>&#x2013;<lpage>69</lpage>. <pub-id pub-id-type="doi">10.1016/j.jconrel.2016.11.012</pub-id>
</citation>
</ref>
<ref id="B123">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gonzalez-Ballesteros</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Diego-Gonzalez</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Lastra-Valdor</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Grimaldi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Cavazza</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bigi</surname>
<given-names>F.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Saccorhiza polyschides used to synthesize gold and silver nanoparticles with enhanced antiproliferative and immunostimulant activity</article-title>. <source>Mater Sci. Eng. C Mater Biol. Appl.</source> <volume>123</volume>, <fpage>111960</fpage>. <pub-id pub-id-type="doi">10.1016/j.msec.2021.111960</pub-id>
</citation>
</ref>
<ref id="B124">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gonzalez-Ballesteros</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Torres</surname>
<given-names>M. D.</given-names>
</name>
<name>
<surname>Florez-Fernandez</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Diego-Gonzalez</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Simon-Vazquez</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Rodriguez-Arguelles</surname>
<given-names>M. C.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Eco-friendly extraction of Mastocarpus stellatus carrageenan for the synthesis of gold nanoparticles with improved biological activity</article-title>. <source>Int. J. Biol. Macromol.</source> <volume>183</volume>, <fpage>1436</fpage>&#x2013;<lpage>1449</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijbiomac.2021.05.115</pub-id>
</citation>
</ref>
<ref id="B125">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gonzalez-Fernandez</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lozano-Iturbe</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Menendez</surname>
<given-names>M. F.</given-names>
</name>
<name>
<surname>Ordiales</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Fernandez-Vega</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Merayo</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>A promising antifungal and antiamoebic effect of silver nanorings, a novel type of AgNP</article-title>. <source>Antibiot. (Basel)</source> <volume>11</volume> (<issue>8</issue>), <fpage>1054</fpage>. <pub-id pub-id-type="doi">10.3390/antibiotics11081054</pub-id>
</citation>
</ref>
<ref id="B126">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gonzalez-Fernandez</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>H. K.</given-names>
</name>
<name>
<surname>Patino-Garcia</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Heymann</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Blanco-Prieto</surname>
<given-names>M. J.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Oral administration of edelfosine encapsulated lipid nanoparticles causes regression of lung metastases in pre-clinical models of osteosarcoma</article-title>. <source>Cancer Lett.</source> <volume>430</volume>, <fpage>193</fpage>&#x2013;<lpage>200</lpage>. <pub-id pub-id-type="doi">10.1016/j.canlet.2018.05.030</pub-id>
</citation>
</ref>
<ref id="B127">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gonzalez-Pastor</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Hernandez</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Gimeno</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>de Martino</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Man</surname>
<given-names>Y. K. S.</given-names>
</name>
<name>
<surname>Hallden</surname>
<given-names>G.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Coating an adenovirus with functionalized gold nanoparticles favors uptake, intracellular trafficking and anti-cancer therapeutic efficacy</article-title>. <source>Acta Biomater.</source> <volume>134</volume>, <fpage>593</fpage>&#x2013;<lpage>604</lpage>. <pub-id pub-id-type="doi">10.1016/j.actbio.2021.07.047</pub-id>
</citation>
</ref>
<ref id="B128">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gonzalez-Pedroza</surname>
<given-names>M. G.</given-names>
</name>
<name>
<surname>Argueta-Figueroa</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Garcia-Contreras</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Jimenez-Martinez</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Martinez-Martinez</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Navarro-Marchal</surname>
<given-names>S. A.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Silver nanoparticles from Annona muricata peel and leaf extracts as a potential potent, biocompatible and low cost antitumor tool</article-title>. <source>Biocompatible Low Cost Antitumor Tool. Nanomater. (Basel).</source> <volume>11</volume> (<issue>5</issue>), <fpage>1273</fpage>. <pub-id pub-id-type="doi">10.3390/nano11051273</pub-id>
</citation>
</ref>
<ref id="B129">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grayston</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Garcia-Gabilondo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Arrue</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kopcansky</surname>
<given-names>P.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Endovascular administration of magnetized nanocarriers targeting brain delivery after stroke</article-title>. <source>J. Cereb. Blood Flow. Metab.</source> <volume>42</volume> (<issue>2</issue>), <fpage>237</fpage>&#x2013;<lpage>252</lpage>. <pub-id pub-id-type="doi">10.1177/0271678x211028816</pub-id>
</citation>
</ref>
<ref id="B130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grimaudo</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Concheiro</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Alvarez-Lorenzo</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Crosslinked hyaluronan electrospun nanofibers for ferulic acid ocular delivery</article-title>. <source>Pharmaceutics</source> <volume>12</volume> (<issue>3</issue>), <fpage>274</fpage>. <pub-id pub-id-type="doi">10.3390/pharmaceutics12030274</pub-id>
</citation>
</ref>
<ref id="B131">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grzelak</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Teles</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Roher</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Grayston</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Rosell</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Gich</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Bioevaluation of magnetic mesoporous silica rods: Cytotoxicity, cell uptake and biodistribution in zebrafish and rodents</article-title>. <source>RSC Adv.</source> <volume>12</volume> (<issue>49</issue>), <fpage>31878</fpage>&#x2013;<lpage>31888</lpage>. <pub-id pub-id-type="doi">10.1039/d2ra05750f</pub-id>
</citation>
</ref>
<ref id="B132">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guasch</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Hoffmann</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Diemer</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Riahinezhad</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Neubauer</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kessler</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Combining adhesive nanostructured surfaces and costimulatory signals to increase T cell activation</article-title>. <source>Nano Lett.</source> <volume>18</volume> (<issue>9</issue>), <fpage>5899</fpage>&#x2013;<lpage>5904</lpage>. <pub-id pub-id-type="doi">10.1021/acs.nanolett.8b02588</pub-id>
</citation>
</ref>
<ref id="B133">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guisasola</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Asin</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Beola</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>de la Fuente</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Baeza</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Vallet-Regi</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Beyond traditional hyperthermia: <italic>In vivo</italic> cancer treatment with magnetic-responsive mesoporous silica nanocarriers</article-title>. <source>ACS Appl. Mater Interfaces</source> <volume>10</volume> (<issue>15</issue>), <fpage>12518</fpage>&#x2013;<lpage>12525</lpage>. <pub-id pub-id-type="doi">10.1021/acsami.8b02398</pub-id>
</citation>
</ref>
<ref id="B134">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guisasola</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Baeza</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>As&#xed;n</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>de la Fuente</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Vallet-Reg&#xed;</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Heating at the nanoscale through drug-delivery devices: Fabrication and synergic effects in cancer treatment with nanoparticles</article-title>. <source>Small Methods</source> <volume>2</volume> (<issue>9</issue>), <fpage>1800007</fpage>. <pub-id pub-id-type="doi">10.1002/smtd.201800007</pub-id>
</citation>
</ref>
<ref id="B135">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gundogdu</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Demir</surname>
<given-names>E. S.</given-names>
</name>
<name>
<surname>Ekinci</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ozgenc</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Ilem-Ozdemir</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Senyigit</surname>
<given-names>Z.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>An innovative formulation based on nanostructured lipid carriers for imatinib delivery: Pre-formulation, cellular uptake and cytotoxicity studies</article-title>. <source>Nanomater. (Basel).</source> <volume>12</volume> (<issue>2</issue>), <fpage>250</fpage>. <pub-id pub-id-type="doi">10.3390/nano12020250</pub-id>
</citation>
</ref>
<ref id="B136">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hendiger</surname>
<given-names>E. B.</given-names>
</name>
<name>
<surname>Padzik</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sifaoui</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Reyes-Batlle</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lopez-Arencibia</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Rizo-Liendo</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Silver nanoparticles as a novel potential preventive agent against Acanthamoeba keratitis</article-title>. <source>Pathogens</source> <volume>9</volume> (<issue>5</issue>), <fpage>350</fpage>. <pub-id pub-id-type="doi">10.3390/pathogens9050350</pub-id>
</citation>
</ref>
<ref id="B137">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hendiger</surname>
<given-names>E. B.</given-names>
</name>
<name>
<surname>Padzik</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sifaoui</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Reyes-Batlle</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lopez-Arencibia</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Zyskowska</surname>
<given-names>D.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Silver nanoparticles conjugated with contact lens solutions may reduce the risk of Acanthamoeba keratitis</article-title>. <source>Pathogens</source> <volume>10</volume> (<issue>5</issue>), <fpage>583</fpage>. <pub-id pub-id-type="doi">10.3390/pathogens10050583</pub-id>
</citation>
</ref>
<ref id="B138">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hernandez Montoto</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Llopis-Lorente</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Gorbe</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Terr&#xe9;s</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Cao-Milan</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Diaz de Grenu</surname>
<given-names>B.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Janus gold nanostars-mesoporous silica nanoparticles for NIR-light-triggered drug delivery</article-title>. <source>Chemistry</source> <volume>25</volume> (<issue>36</issue>), <fpage>8471</fpage>&#x2013;<lpage>8478</lpage>. <pub-id pub-id-type="doi">10.1002/chem.201900750</pub-id>
</citation>
</ref>
<ref id="B139">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hernando</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Nikolakopoulou</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Voulgaris</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Hernandez</surname>
<given-names>R. M.</given-names>
</name>
<name>
<surname>Igartua</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Herland</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Dual effect of TAT functionalized DHAH lipid nanoparticles with neurotrophic factors in human BBB and microglia cultures</article-title>. <source>Fluids Barriers CNS</source> <volume>19</volume> (<issue>1</issue>), <fpage>22</fpage>. <pub-id pub-id-type="doi">10.1186/s12987-022-00315-1</pub-id>
</citation>
</ref>
<ref id="B140">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huguet-Casquero</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Gainza</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Pedraz</surname>
<given-names>J. L.</given-names>
</name>
<name>
<surname>Beloqui</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Oral delivery of oleuropein-loaded lipid nanocarriers alleviates inflammation and oxidative stress in acute colitis</article-title>. <source>Int. J. Pharm.</source> <volume>586</volume>, <fpage>119515</fpage>. <pub-id pub-id-type="doi">10.1016/j.ijpharm.2020.119515</pub-id>
</citation>
</ref>
<ref id="B141">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Inchaurraga</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Martinez-Lopez</surname>
<given-names>A. L.</given-names>
</name>
<name>
<surname>Martin-Arbella</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Irache</surname>
<given-names>J. M.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Zein-based nanoparticles for the oral delivery of insulin</article-title>. <source>Drug Deliv. Transl. Res.</source> <volume>10</volume> (<issue>6</issue>), <fpage>1601</fpage>&#x2013;<lpage>1611</lpage>. <pub-id pub-id-type="doi">10.1007/s13346-020-00796-3</pub-id>
</citation>
</ref>
<ref id="B142">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iturrioz-Rodriguez</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Correa-Duarte</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Fanarraga</surname>
<given-names>M. L.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>&#x3c;p&#x26;gt;Controlled drug delivery systems for cancer based on mesoporous silica nanoparticles&#x26;lt;/p&#x26;gt;</article-title>. <source>Int. J. Nanomedicine</source> <volume>14</volume>, <fpage>3389</fpage>&#x2013;<lpage>3401</lpage>. <pub-id pub-id-type="doi">10.2147/ijn.s198848</pub-id>
</citation>
</ref>
<ref id="B143">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iturrioz-Rodriguez</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Gonzalez-Dominguez</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Gonzalez-Lavado</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Marin-Caba</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Vaz</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Perez-Lorenzo</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>A biomimetic escape strategy for cytoplasm invasion by synthetic particles</article-title>. <source>Angew. Chem. Int. Ed. Engl.</source> <volume>56</volume> (<issue>44</issue>), <fpage>13924</fpage>&#x2013;<lpage>13928</lpage>. <pub-id pub-id-type="doi">10.1002/ange.201707769</pub-id>
</citation>
</ref>
<ref id="B144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jaque</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Martinez Maestro</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>del Rosal</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Haro-Gonzalez</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Benayas</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Plaza</surname>
<given-names>J. L.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>Nanoparticles for photothermal therapies</article-title>. <source>Nanoscale</source> <volume>6</volume> (<issue>16</issue>), <fpage>9494</fpage>&#x2013;<lpage>9530</lpage>. <pub-id pub-id-type="doi">10.1039/c4nr00708e</pub-id>
</citation>
</ref>
<ref id="B145">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jia</surname>
<given-names>C. J.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>L. D.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>X. D.</given-names>
</name>
<name>
<surname>Heyderman</surname>
<given-names>L. J.</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>Z. G.</given-names>
</name>
<etal/>
</person-group> (<year>2008</year>). <article-title>Large-scale synthesis of single-crystalline iron oxide magnetic nanorings</article-title>. <source>J. Am. Chem. Soc.</source> <volume>130</volume> (<issue>50</issue>), <fpage>16968</fpage>&#x2013;<lpage>16977</lpage>. <pub-id pub-id-type="doi">10.1021/ja805152t</pub-id>
</citation>
</ref>
<ref id="B146">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jimenez-Falcao</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>de Luis</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Garcia-Fernandez</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Llopis-Lorente</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Diez</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Sanchez</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Glucose-responsive enzyme-controlled mesoporous nanomachine with a layer-by-layer supramolecular architecture</article-title>. <source>ACS Appl. Bio Mater</source> <volume>2</volume> (<issue>8</issue>), <fpage>3321</fpage>&#x2013;<lpage>3328</lpage>. <pub-id pub-id-type="doi">10.1021/acsabm.9b00338</pub-id>
</citation>
</ref>
<ref id="B147">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jindal</surname>
<given-names>A. B.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>The effect of particle shape on cellular interaction and drug delivery applications of micro- and nanoparticles</article-title>. <source>Int. J. Pharm.</source> <volume>532</volume> (<issue>1</issue>), <fpage>450</fpage>&#x2013;<lpage>465</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijpharm.2017.09.028</pub-id>
</citation>
</ref>
<ref id="B148">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jornet-Martinez</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Hakobyan</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Argente-Garcia</surname>
<given-names>A. I.</given-names>
</name>
<name>
<surname>Molins-Legua</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Campins-Falco</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Nylon-supported plasmonic assay based on the aggregation of silver nanoparticles: <italic>In situ</italic> determination of hydrogen sulfide-like compounds in breath samples as a proof of concept</article-title>. <source>ACS Sens.</source> <volume>4</volume> (<issue>8</issue>), <fpage>2164</fpage>&#x2013;<lpage>2172</lpage>. <pub-id pub-id-type="doi">10.1021/acssensors.9b01019</pub-id>
</citation>
</ref>
<ref id="B149">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khan</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Saeed</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Khan</surname>
<given-names>I.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Nanoparticles: Properties, applications and toxicities</article-title>. <source>Arabian J. Chem.</source> <volume>12</volume> (<issue>7</issue>), <fpage>908</fpage>&#x2013;<lpage>931</lpage>. <pub-id pub-id-type="doi">10.1016/j.arabjc.2017.05.011</pub-id>
</citation>
</ref>
<ref id="B150">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>Y. I.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Hyeon</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Recent development of inorganic nanoparticles for biomedical imaging</article-title>. <source>ACS Cent. Sci.</source> <volume>4</volume> (<issue>3</issue>), <fpage>324</fpage>&#x2013;<lpage>336</lpage>. <pub-id pub-id-type="doi">10.1021/acscentsci.7b00574</pub-id>
</citation>
</ref>
<ref id="B151">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>W. J.</given-names>
</name>
<name>
<surname>Kwon</surname>
<given-names>Y. J.</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>C. H.</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>S. K.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>K. O.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Insulin smart drug delivery nanoparticles of aminophenylboronic acid-POSS molecule at neutral pH</article-title>. <source>Sci. Rep.</source> <volume>11</volume> (<issue>1</issue>), <fpage>21894</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-021-01216-3</pub-id>
</citation>
</ref>
<ref id="B152">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kolosnjaj-Tabi</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Marangon</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Nicolas-Boluda</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Silva</surname>
<given-names>A. K. A.</given-names>
</name>
<name>
<surname>Gazeau</surname>
<given-names>F.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Nanoparticle-based hyperthermia, a local treatment modulating the tumor extracellular matrix</article-title>. <source>Pharmacol. Res.</source> <volume>126</volume>, <fpage>123</fpage>&#x2013;<lpage>137</lpage>. <pub-id pub-id-type="doi">10.1016/j.phrs.2017.07.010</pub-id>
</citation>
</ref>
<ref id="B153">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lafuente-Gomez</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Fontana</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Dhanjani</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Garcia-Soriano</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Correia</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Synergistic immunomodulatory effect in macrophages mediated by magnetic nanoparticles modified with miRNAs</article-title>. <source>Nanoscale</source> <volume>14</volume> (<issue>31</issue>), <fpage>11129</fpage>&#x2013;<lpage>11138</lpage>. <pub-id pub-id-type="doi">10.1039/d2nr01767a</pub-id>
</citation>
</ref>
<ref id="B154">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lasa-Saracibar</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>El Moukhtari</surname>
<given-names>S. H.</given-names>
</name>
<name>
<surname>Tsotakos</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Xanthopoulos</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Loudos</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Bouziotis</surname>
<given-names>P.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>
<italic>In vivo</italic> biodistribution of edelfosine-loaded lipid nanoparticles radiolabeled with Technetium-99 m: Comparison of administration routes in mice</article-title>. <source>Eur. J. Pharm. Biopharm.</source> <volume>175</volume>, <fpage>1</fpage>&#x2013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejpb.2022.04.007</pub-id>
</citation>
</ref>
<ref id="B155">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Latorre</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Latorre</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Castellanos</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lafuente-Gomez</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Diaz</surname>
<given-names>C. R.</given-names>
</name>
<name>
<surname>Crespo-Barreda</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Albumin-based nanostructures for uveal melanoma treatment</article-title>. <source>Nanomedicine</source> <volume>35</volume>, <fpage>102391</fpage>. <pub-id pub-id-type="doi">10.1016/j.nano.2021.102391</pub-id>
</citation>
</ref>
<ref id="B156">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Latorre</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Latorre</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Castellanos</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Rodriguez Diaz</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Lazaro-Carrillo</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Aguado</surname>
<given-names>T.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Multifunctional albumin-stabilized gold nanoclusters for the reduction of cancer stem cells</article-title>. <source>Cancers (Basel)</source> <volume>11</volume> (<issue>7</issue>), <fpage>969</fpage>. <pub-id pub-id-type="doi">10.3390/cancers11070969</pub-id>
</citation>
</ref>
<ref id="B157">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Latorre</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Diaz-Trelles</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Comas</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Gavalda-Navarro</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Milbank</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Dragano</surname>
<given-names>N.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Downregulation of hepatic lipopolysaccharide binding protein improves lipogenesis-induced liver lipid accumulation</article-title>. <source>Mol. Ther. Nucleic Acids</source> <volume>29</volume>, <fpage>599</fpage>&#x2013;<lpage>613</lpage>. <pub-id pub-id-type="doi">10.1016/j.omtn.2022.08.003</pub-id>
</citation>
</ref>
<ref id="B158">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lazaro-Carrillo</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Calero</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Aires</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Simoes</surname>
<given-names>B. M.</given-names>
</name>
<name>
<surname>Latorre</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Tailored functionalized magnetic nanoparticles to target breast cancer cells including cancer stem-like cells</article-title>. <source>Cancers (Basel)</source> <volume>12</volume> (<issue>6</issue>), <fpage>1397</fpage>. <pub-id pub-id-type="doi">10.3390/cancers12061397</pub-id>
</citation>
</ref>
<ref id="B159">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leal</surname>
<given-names>B. H.</given-names>
</name>
<name>
<surname>Velasco</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Cambon</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Pardo</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Fernandez-Vega</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Arellano</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Combined therapeutics for atherosclerosis treatment using polymeric nanovectors</article-title>. <source>Pharmaceutics</source> <volume>14</volume> (<issue>2</issue>), <fpage>258</fpage>. <pub-id pub-id-type="doi">10.3390/pharmaceutics14020258</pub-id>
</citation>
</ref>
<ref id="B160">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ledo</surname>
<given-names>A. M.</given-names>
</name>
<name>
<surname>Sasso</surname>
<given-names>M. S.</given-names>
</name>
<name>
<surname>Bronte</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Marigo</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Boyd</surname>
<given-names>B. J.</given-names>
</name>
<name>
<surname>Garcia-Fuentes</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Co-delivery of RNAi and chemokine by polyarginine nanocapsules enables the modulation of myeloid-derived suppressor cells</article-title>. <source>J. Control Release</source> <volume>295</volume>, <fpage>60</fpage>&#x2013;<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1016/j.jconrel.2018.12.041</pub-id>
</citation>
</ref>
<ref id="B161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Son</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Jeon</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Immunogenic effect of hyperthermia on enhancing radiotherapeutic efficacy</article-title>. <source>Int. J. Mol. Sci.</source> <volume>19</volume> (<issue>9</issue>), <fpage>2795</fpage>. <pub-id pub-id-type="doi">10.3390/ijms19092795</pub-id>
</citation>
</ref>
<ref id="B162">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leiva</surname>
<given-names>M. C.</given-names>
</name>
<name>
<surname>Ortiz</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Contreras-Caceres</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Perazzoli</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Mayevych</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Lopez-Romero</surname>
<given-names>J. M.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Tripalmitin nanoparticle formulations significantly enhance paclitaxel antitumor activity against breast and lung cancer cells <italic>in vitro</italic>
</article-title>. <source>Sci. Rep.</source> <volume>7</volume> (<issue>1</issue>), <fpage>13506</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-017-13816-z</pub-id>
</citation>
</ref>
<ref id="B163">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Litti</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Trivini</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ferraro</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Reguera</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>3D printed microfluidic device for magnetic trapping and SERS quantitative evaluation of environmental and biomedical analytes</article-title>. <source>ACS Appl. Mater Interfaces</source> <volume>13</volume> (<issue>29</issue>), <fpage>34752</fpage>&#x2013;<lpage>34761</lpage>. <pub-id pub-id-type="doi">10.1021/acsami.1c09771</pub-id>
</citation>
</ref>
<ref id="B164">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>X.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Synthesis of self-assembled hyaluronan based nanoparticles and their applications in targeted imaging and therapy</article-title>. <source>Carbohydr. Res.</source> <volume>511</volume>, <fpage>108500</fpage>. <pub-id pub-id-type="doi">10.1016/j.carres.2022.108500</pub-id>
</citation>
</ref>
<ref id="B165">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liz-Marz&#xe1;n</surname>
<given-names>L. M.</given-names>
</name>
<name>
<surname>Nel</surname>
<given-names>A. E.</given-names>
</name>
<name>
<surname>Brinker</surname>
<given-names>C. J.</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>W. C. W.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>What do we mean when we say nanomedicine?</article-title> <source>ACS Nano</source> <volume>16</volume> (<issue>9</issue>), <fpage>13257</fpage>&#x2013;<lpage>13259</lpage>. <pub-id pub-id-type="doi">10.1021/acsnano.2c08675</pub-id>
</citation>
</ref>
<ref id="B166">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Llinas</surname>
<given-names>M. C.</given-names>
</name>
<name>
<surname>Martinez-Edo</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Cascante</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Porcar</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Borros</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sanchez-Garcia</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Preparation of a mesoporous silica-based nano-vehicle for dual DOX/CPT pH-triggered delivery</article-title>. <source>Drug Deliv.</source> <volume>25</volume> (<issue>1</issue>), <fpage>1137</fpage>&#x2013;<lpage>1146</lpage>. <pub-id pub-id-type="doi">10.1080/10717544.2018.1472678</pub-id>
</citation>
</ref>
<ref id="B167">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lopez</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Villegas</surname>
<given-names>M. R.</given-names>
</name>
<name>
<surname>Rodriguez</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Villaverde</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Lozano</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Baeza</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Janus mesoporous silica nanoparticles for dual targeting of tumor cells and mitochondria</article-title>. <source>ACS Appl. Mater Interfaces</source> <volume>9</volume> (<issue>32</issue>), <fpage>26697</fpage>&#x2013;<lpage>26706</lpage>. <pub-id pub-id-type="doi">10.1021/acsami.7b06906</pub-id>
</citation>
</ref>
<ref id="B168">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lozano-Pedraza</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Plaza-Mayoral</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Espinosa</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sot</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Serrano</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Salas</surname>
<given-names>G.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Assessing the parameters modulating optical losses of iron oxide nanoparticles under near infrared irradiation</article-title>. <source>Nanoscale Adv.</source> <volume>3</volume> (<issue>22</issue>), <fpage>6490</fpage>&#x2013;<lpage>6502</lpage>. <pub-id pub-id-type="doi">10.1039/d1na00601k</pub-id>
</citation>
</ref>
<ref id="B169">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Luengo</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Diaz-Riascos</surname>
<given-names>Z. V.</given-names>
</name>
<name>
<surname>Garcia-Soriano</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Teran</surname>
<given-names>F. J.</given-names>
</name>
<name>
<surname>Artes-Ibanez</surname>
<given-names>E. J.</given-names>
</name>
<name>
<surname>Ibarrola</surname>
<given-names>O.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Fine control of <italic>in vivo</italic> magnetic hyperthermia using iron oxide nanoparticles with different coatings and degree of aggregation</article-title>. <source>Pharmaceutics</source> <volume>14</volume> (<issue>8</issue>), <fpage>1526</fpage>. <pub-id pub-id-type="doi">10.3390/pharmaceutics14081526</pub-id>
</citation>
</ref>
<ref id="B170">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Luengo</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Sot</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Salas</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Combining Ag and gamma-Fe2O3 properties to produce effective antibacterial nanocomposites</article-title>. <source>Colloids Surf. B Biointerfaces</source> <volume>194</volume>, <fpage>111178</fpage>. <pub-id pub-id-type="doi">10.1016/j.colsurfb.2020.111178</pub-id>
</citation>
</ref>
<ref id="B171">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Manzano</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Vallet-Regi</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Mesoporous silica nanoparticles in nanomedicine applications</article-title>. <source>J. Mater Sci. Mater Med.</source> <volume>29</volume> (<issue>5</issue>), <fpage>65</fpage>. <pub-id pub-id-type="doi">10.1007/s10856-018-6069-x</pub-id>
</citation>
</ref>
<ref id="B172">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Manzano</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Vallet-Regi</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Ultrasound responsive mesoporous silica nanoparticles for biomedical applications</article-title>. <source>Chem. Commun. (Camb)</source> <volume>55</volume> (<issue>19</issue>), <fpage>2731</fpage>&#x2013;<lpage>2740</lpage>. <pub-id pub-id-type="doi">10.1039/c8cc09389j</pub-id>
</citation>
</ref>
<ref id="B173">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marciello</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Rossi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Caramella</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Remunan-Lopez</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Freeze-dried cylinders carrying chitosan nanoparticles for vaginal peptide delivery</article-title>. <source>Carbohydr. Polym.</source> <volume>170</volume>, <fpage>43</fpage>&#x2013;<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1016/j.carbpol.2017.04.051</pub-id>
</citation>
</ref>
<ref id="B174">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>M&#xe1;rquez-Rodas</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Dutriaux</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Saiag</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>de la Cruz Merino</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Castanon &#xc1;lvarez</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Robert</surname>
<given-names>C.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Abstract CT014: Efficacy of intratumoral BO-112 with systemic pembrolizumab in patients with advanced melanoma refractory to anti-PD-1-based therapy: Final results of SPOTLIGHT203 phase 2 study</article-title>. <source>Cancer Res.</source> <volume>82</volume>, <fpage>CT014</fpage>. <pub-id pub-id-type="doi">10.1158/1538-7445.am2022-ct014</pub-id>
</citation>
</ref>
<ref id="B175">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martin-Rapun</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>De Matteis</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Ambrosone</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Garcia-Embid</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gutierrez</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>de la Fuente</surname>
<given-names>J. M.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Targeted nanoparticles for the treatment of alzheimer&#x27;s disease</article-title>. <source>Curr. Pharm. Des.</source> <volume>23</volume> (<issue>13</issue>), <fpage>1927</fpage>&#x2013;<lpage>1952</lpage>. <pub-id pub-id-type="doi">10.2174/1381612822666161226151011</pub-id>
</citation>
</ref>
<ref id="B176">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martin-Saavedra</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Ruiz-Hernandez</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Escudero-Duch</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Prieto</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Arruebo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sadeghi</surname>
<given-names>N.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Lipogels responsive to near-infrared light for the triggered release of therapeutic agents</article-title>. <source>Acta Biomater.</source> <volume>61</volume>, <fpage>54</fpage>&#x2013;<lpage>65</lpage>. <pub-id pub-id-type="doi">10.1016/j.actbio.2017.08.010</pub-id>
</citation>
</ref>
<ref id="B177">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martinez-Carmona</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Izquierdo-Barba</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Colilla</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Vallet-Regi</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Concanavalin A-targeted mesoporous silica nanoparticles for infection treatment</article-title>. <source>Acta Biomater.</source> <volume>96</volume>, <fpage>547</fpage>&#x2013;<lpage>556</lpage>. <pub-id pub-id-type="doi">10.1016/j.actbio.2019.07.001</pub-id>
</citation>
</ref>
<ref id="B178">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martinez-Carmona</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lozano</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Colilla</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Vallet-Regi</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Lectin-conjugated pH-responsive mesoporous silica nanoparticles for targeted bone cancer treatment</article-title>. <source>Acta Biomater.</source> <volume>65</volume>, <fpage>393</fpage>&#x2013;<lpage>404</lpage>. <pub-id pub-id-type="doi">10.1016/j.actbio.2017.11.007</pub-id>
</citation>
</ref>
<ref id="B179">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martinez-Edo</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Xue</surname>
<given-names>E. Y.</given-names>
</name>
<name>
<surname>Ha</surname>
<given-names>S. Y. Y.</given-names>
</name>
<name>
<surname>Ponton</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Gonzalez-Delgado</surname>
<given-names>J. A.</given-names>
</name>
<name>
<surname>Borros</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Nanoparticles for triple drug release for combined chemo- and photodynamic therapy</article-title>. <source>Chemistry</source> <volume>27</volume> (<issue>59</issue>), <fpage>14610</fpage>&#x2013;<lpage>14618</lpage>. <pub-id pub-id-type="doi">10.1002/chem.202101842</pub-id>
</citation>
</ref>
<ref id="B180">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martinez-Lopez</surname>
<given-names>A. L.</given-names>
</name>
<name>
<surname>Gonzalez-Navarro</surname>
<given-names>C. J.</given-names>
</name>
<name>
<surname>Vizmanos</surname>
<given-names>J. L.</given-names>
</name>
<name>
<surname>Irache</surname>
<given-names>J. M.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Zein-based nanocarriers for the oral delivery of insulin. <italic>in vivo</italic> evaluation in <italic>Caenorhabditis elegans</italic>
</article-title>. <source>Drug Deliv. Transl. Res.</source> <volume>11</volume> (<issue>2</issue>), <fpage>647</fpage>&#x2013;<lpage>658</lpage>. <pub-id pub-id-type="doi">10.1007/s13346-021-00919-4</pub-id>
</citation>
</ref>
<ref id="B181">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martinez-Negro</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Guerrero-Martinez</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Garcia-Rio</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Domenech</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Aicart</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Tros de Ilarduya</surname>
<given-names>C.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Multidisciplinary approach to the transfection of plasmid DNA by a nonviral nanocarrier based on a gemini-bolaamphiphilic hybrid lipid</article-title>. <source>ACS Omega</source> <volume>3</volume> (<issue>1</issue>), <fpage>208</fpage>&#x2013;<lpage>217</lpage>. <pub-id pub-id-type="doi">10.1021/acsomega.7b01657</pub-id>
</citation>
</ref>
<ref id="B182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martinez-Relimpio</surname>
<given-names>A. M.</given-names>
</name>
<name>
<surname>Benito</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Perez-Izquierdo</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Teijon</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Olmo</surname>
<given-names>R. M.</given-names>
</name>
<name>
<surname>Blanco</surname>
<given-names>M. D.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Paclitaxel-loaded folate-targeted albumin-alginate nanoparticles crosslinked with ethylenediamine. Synthesis and <italic>in vitro</italic> characterization</article-title>. <source>Polym. (Basel)</source> <volume>13</volume> (<issue>13</issue>), <fpage>2083</fpage>. <pub-id pub-id-type="doi">10.3390/polym13132083</pub-id>
</citation>
</ref>
<ref id="B183">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mayol</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Diez</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Sanchez</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>de la Torre</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Villalonga</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lucena-Sanchez</surname>
<given-names>E.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>A glutathione disulfide-sensitive Janus nanomachine controlled by an enzymatic AND logic gate for smart delivery</article-title>. <source>Nanoscale</source> <volume>13</volume> (<issue>44</issue>), <fpage>18616</fpage>&#x2013;<lpage>18625</lpage>. <pub-id pub-id-type="doi">10.1039/d0nr08282a</pub-id>
</citation>
</ref>
<ref id="B184">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mazario</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Herrasti</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Morales</surname>
<given-names>M. P.</given-names>
</name>
<name>
<surname>Menendez</surname>
<given-names>N.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Synthesis and characterization of CoFe2O4 ferrite nanoparticles obtained by an electrochemical method</article-title>. <source>Nanotechnology</source> <volume>23</volume> (<issue>35</issue>), <fpage>355708</fpage>. <pub-id pub-id-type="doi">10.1088/0957-4484/23/35/355708</pub-id>
</citation>
</ref>
<ref id="B185">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>McGillicuddy</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Murray</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Kavanagh</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Morrison</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Fogarty</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Cormican</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Silver nanoparticles in the environment: Sources, detection and ecotoxicology</article-title>. <source>Sci. Total Environ.</source> <volume>575</volume>, <fpage>231</fpage>&#x2013;<lpage>246</lpage>. <pub-id pub-id-type="doi">10.1016/j.scitotenv.2016.10.041</pub-id>
</citation>
</ref>
<ref id="B186">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mejias</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Hernandez Flores</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Talelli</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Tajada-Herraiz</surname>
<given-names>J. L.</given-names>
</name>
<name>
<surname>Brollo</surname>
<given-names>M. E. F.</given-names>
</name>
<name>
<surname>Portilla</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Cell-promoted nanoparticle aggregation decreases nanoparticle-induced hyperthermia under an alternating magnetic field independently of nanoparticle coating, core size, and subcellular localization</article-title>. <source>ACS Appl. Mater Interfaces</source> <volume>11</volume> (<issue>1</issue>), <fpage>340</fpage>&#x2013;<lpage>355</lpage>. <pub-id pub-id-type="doi">10.1021/acsami.8b18451</pub-id>
</citation>
</ref>
<ref id="B323">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mendez-Gonzalez</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Lifante</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zabala Gutierrez</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Marin</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Ximendes</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Sanz-de Diego</surname>
<given-names>E.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Optomagnetic nanofluids for controlled brain hyperthermia: a critical study</article-title>. <source>Nanoscale</source> <volume>14</volume> (<issue>43</issue>), <fpage>16208</fpage>&#x2013;<lpage>16219</lpage>. <pub-id pub-id-type="doi">10.1039/d2nr03413a</pub-id>
</citation>
</ref>
<ref id="B187">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Milan Rois</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Latorre</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Rodriguez Diaz</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Del Moral</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Somoza</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Reprogramming cells for synergistic combination therapy with nanotherapeutics against uveal melanoma</article-title>. <source>Biomimetics (Basel)</source> <volume>3</volume> (<issue>4</issue>), <fpage>28</fpage>. <pub-id pub-id-type="doi">10.3390/biomimetics3040028</pub-id>
</citation>
</ref>
<ref id="B188">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miron-Barroso</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Domenech</surname>
<given-names>E. B.</given-names>
</name>
<name>
<surname>Trigueros</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Nanotechnology-based strategies to overcome current barriers in gene delivery</article-title>. <source>Int. J. Mol. Sci.</source> <volume>22</volume> (<issue>16</issue>), <fpage>8537</fpage>. <pub-id pub-id-type="doi">10.3390/ijms22168537</pub-id>
</citation>
</ref>
<ref id="B189">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mitxelena-Iribarren</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Hisey</surname>
<given-names>C. L.</given-names>
</name>
<name>
<surname>Errazquin-Irigoyen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gonzalez-Fernandez</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Imbuluzqueta</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Mujika</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Effectiveness of nanoencapsulated methotrexate against osteosarcoma cells: <italic>In vitro</italic> cytotoxicity under dynamic conditions</article-title>. <source>Biomed. Microdevices</source> <volume>19</volume> (<issue>2</issue>), <fpage>35</fpage>. <pub-id pub-id-type="doi">10.1007/s10544-017-0177-0</pub-id>
</citation>
</ref>
<ref id="B190">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mitxelena-Iribarren</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Lizarbe-Sancha</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Campisi</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Arana</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Mujika</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Different microfluidic environments for <italic>in vitro</italic> testing of lipid nanoparticles against osteosarcoma</article-title>. <source>Bioeng. (Basel)</source> <volume>8</volume> (<issue>6</issue>), <fpage>77</fpage>. <pub-id pub-id-type="doi">10.3390/bioengineering8060077</pub-id>
</citation>
</ref>
<ref id="B191">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Montalvo-Quiros</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gomez-Grana</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Vallet-Regi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Prados-Rosales</surname>
<given-names>R. C.</given-names>
</name>
<name>
<surname>Gonzalez</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Luque-Garcia</surname>
<given-names>J. L.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Mesoporous silica nanoparticles containing silver as novel antimycobacterial agents against <italic>Mycobacterium tuberculosis</italic>
</article-title>. <source>Colloids Surf. B Biointerfaces</source> <volume>197</volume>, <fpage>111405</fpage>. <pub-id pub-id-type="doi">10.1016/j.colsurfb.2020.111405</pub-id>
</citation>
</ref>
<ref id="B192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Montalvo-Quiros</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Vallet-Regi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Palacios</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Anguita</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Prados-Rosales</surname>
<given-names>R. C.</given-names>
</name>
<name>
<surname>Gonzalez</surname>
<given-names>B.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Mesoporous silica nanoparticles as a potential platform for vaccine development against tuberculosis</article-title>. <source>Tuberc. Pharm.</source> <volume>12</volume> (<issue>12</issue>), <fpage>1218</fpage>. <pub-id pub-id-type="doi">10.3390/pharmaceutics12121218</pub-id>
</citation>
</ref>
<ref id="B325">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Montero</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>P&#x00E9;rez</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Benito</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Teij&#x00F3;n</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Teij&#x00F3;n</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Olmo</surname>
<given-names>R.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Biocompatibility studies of intravenously administered ionic-crosslinked chitosan-BSA nanoparticles as vehicles for antitumour drugs</article-title>. <source>International Journal of Pharmaceutics</source> <volume>554</volume>, <fpage>337</fpage>&#x2013;<lpage>351</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijpharm.2018.11.027</pub-id>
</citation>
</ref>
<ref id="B193">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mora-Raimundo</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Lozano</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Manzano</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Vallet-Regi</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Nanoparticles to knockdown osteoporosis-related gene and promote osteogenic marker expression for osteoporosis treatment</article-title>. <source>ACS Nano</source> <volume>13</volume> (<issue>5</issue>), <fpage>5451</fpage>&#x2013;<lpage>5464</lpage>. <pub-id pub-id-type="doi">10.1021/acsnano.9b00241</pub-id>
</citation>
</ref>
<ref id="B194">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moran</surname>
<given-names>H. B. T.</given-names>
</name>
<name>
<surname>Turley</surname>
<given-names>J. L.</given-names>
</name>
<name>
<surname>Andersson</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lavelle</surname>
<given-names>E. C.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Immunomodulatory properties of chitosan polymers</article-title>. <source>Biomaterials</source> <volume>184</volume>, <fpage>1</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.biomaterials.2018.08.054</pub-id>
</citation>
</ref>
<ref id="B195">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morey</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Llinas</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Bueno-Costa</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Leon</surname>
<given-names>A. J.</given-names>
</name>
<name>
<surname>Pina</surname>
<given-names>M. N.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Raltitrexed-modified gold and silver nanoparticles for targeted cancer therapy: Cytotoxicity behavior <italic>in vitro</italic> on A549 and HCT-116 human cancer cells</article-title>. <source>Mater. (Basel)</source> <volume>14</volume> (<issue>3</issue>), <fpage>534</fpage>. <pub-id pub-id-type="doi">10.3390/ma14030534</pub-id>
</citation>
</ref>
<ref id="B196">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moros</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Idiago-Lopez</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Asin</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Moreno-Antolin</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Beola</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Grazu</surname>
<given-names>V.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Triggering antitumoural drug release and gene expression by magnetic hyperthermia</article-title>. <source>Adv. Drug Deliv. Rev.</source> <volume>138</volume>, <fpage>326</fpage>&#x2013;<lpage>343</lpage>. <pub-id pub-id-type="doi">10.1016/j.addr.2018.10.004</pub-id>
</citation>
</ref>
<ref id="B197">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mosquera</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Garcia</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Henriksen-Lacey</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Martinez-Calvo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Dhanjani</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mascarenas</surname>
<given-names>J. L.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Reversible control of protein corona formation on gold nanoparticles using host-guest interactions</article-title>. <source>ACS Nano</source> <volume>14</volume> (<issue>5</issue>), <fpage>5382</fpage>&#x2013;<lpage>5391</lpage>. <pub-id pub-id-type="doi">10.1021/acsnano.9b08752</pub-id>
</citation>
</ref>
<ref id="B198">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mulens-Arias</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Rojas</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Sanz-Ortega</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Portilla</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Perez-Yague</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Barber</surname>
<given-names>D. F.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Polyethylenimine-coated superparamagnetic iron oxide nanoparticles impair <italic>in vitro</italic> and <italic>in vivo</italic> angiogenesis</article-title>. <source>Nanomedicine</source> <volume>21</volume>, <fpage>102063</fpage>. <pub-id pub-id-type="doi">10.1016/j.nano.2019.102063</pub-id>
</citation>
</ref>
<ref id="B199">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mulvihill</surname>
<given-names>J. J.</given-names>
</name>
<name>
<surname>Cunnane</surname>
<given-names>E. M.</given-names>
</name>
<name>
<surname>Ross</surname>
<given-names>A. M.</given-names>
</name>
<name>
<surname>Duskey</surname>
<given-names>J. T.</given-names>
</name>
<name>
<surname>Tosi</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Grabrucker</surname>
<given-names>A. M.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Drug delivery across the blood-brain barrier: Recent advances in the use of nanocarriers</article-title>. <source>Nanomedicine (Lond).</source> <volume>15</volume> (<issue>2</issue>), <fpage>205</fpage>&#x2013;<lpage>214</lpage>. <pub-id pub-id-type="doi">10.2217/nnm-2019-0367</pub-id>
</citation>
</ref>
<ref id="B200">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Munoz-Espin</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Rovira</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Galiana</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Gimenez</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Lozano-Torres</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Paez-Ribes</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>A versatile drug delivery system targeting senescent cells</article-title>. <source>EMBO Mol. Med.</source> <volume>10</volume> (<issue>9</issue>), <fpage>e9355</fpage>. <pub-id pub-id-type="doi">10.15252/emmm.201809355</pub-id>
</citation>
</ref>
<ref id="B201">
<citation citation-type="web">
<person-group person-group-type="author">
<name>
<surname>Nanoscience</surname>
<given-names>I.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>NoCanTher project 2020</article-title>. <comment>Available from: <ext-link ext-link-type="uri" xlink:href="http://www.nocanther-project.eu/">http://www.nocanther-project.eu/</ext-link>.</comment>
</citation>
</ref>
<ref id="B202">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Navarro-Palomares</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Garcia-Hevia</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Padin-Gonzalez</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Banobre-Lopez</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Villegas</surname>
<given-names>J. C.</given-names>
</name>
<name>
<surname>Valiente</surname>
<given-names>R.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Targeting nanomaterials to head and neck cancer cells using a fragment of the Shiga toxin as a potent natural ligand</article-title>. <source>Cancers (Basel).</source> <volume>13</volume> (<issue>19</issue>), <fpage>4920</fpage>. <pub-id pub-id-type="doi">10.3390/cancers13194920</pub-id>
</citation>
</ref>
<ref id="B203">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nicu</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Ciolacu</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Ciolacu</surname>
<given-names>D. E.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Advanced functional materials based on nanocellulose for pharmaceutical/medical applications</article-title>. <source>Pharmaceutics</source> <volume>13</volume> (<issue>8</issue>), <fpage>1125</fpage>. <pub-id pub-id-type="doi">10.3390/pharmaceutics13081125</pub-id>
</citation>
</ref>
<ref id="B204">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nino-Pariente</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Arminan</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Reinhard</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Scholz</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Kos</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Wagner</surname>
<given-names>E.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Design of poly-l-glutamate-based complexes for pDNA delivery</article-title>. <source>Macromol. Biosci.</source> <volume>17</volume> (<issue>10</issue>). <pub-id pub-id-type="doi">10.1002/mabi.201700245</pub-id>
</citation>
</ref>
<ref id="B205">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Niu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Samaridou</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Jaumain</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Coene</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ullio</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Shrestha</surname>
<given-names>N.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>PEG-PGA enveloped octaarginine-peptide nanocomplexes: An oral peptide delivery strategy</article-title>. <source>J. Control Release</source> <volume>276</volume>, <fpage>125</fpage>&#x2013;<lpage>139</lpage>. <pub-id pub-id-type="doi">10.1016/j.jconrel.2018.03.004</pub-id>
</citation>
</ref>
<ref id="B206">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Niu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Tedesco</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Benetti</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Mabondzo</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Montagner</surname>
<given-names>I. M.</given-names>
</name>
<name>
<surname>Marigo</surname>
<given-names>I.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Rational design of polyarginine nanocapsules intended to help peptides overcoming intestinal barriers</article-title>. <source>J. Control Release</source> <volume>263</volume>, <fpage>4</fpage>&#x2013;<lpage>17</lpage>. <pub-id pub-id-type="doi">10.1016/j.jconrel.2017.02.024</pub-id>
</citation>
</ref>
<ref id="B207">
<citation citation-type="web">
<collab>NoCanTher Project</collab> (<year>2022</year>). <article-title>First patient is enrolled in the NoCanTher&#x2019;s clinical study 2022</article-title>. <comment>Available from: <ext-link ext-link-type="uri" xlink:href="http://www.nocanther-project.eu/index.php/news/70-first-patient-is-enrolled-in-the-nocanther-s-clinical-study">http://www.nocanther-project.eu/index.php/news/70-first-patient-is-enrolled-in-the-nocanther-s-clinical-study</ext-link>.</comment>
</citation>
</ref>
<ref id="B208">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nozal</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Rojas-Prats</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Maestro</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Gil</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Perez</surname>
<given-names>D. I.</given-names>
</name>
<name>
<surname>Martinez</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Improved controlled release and brain penetration of the small molecule S14 using PLGA nanoparticles</article-title>. <source>Int. J. Mol. Sci.</source> <volume>22</volume> (<issue>6</issue>), <fpage>3206</fpage>. <pub-id pub-id-type="doi">10.3390/ijms22063206</pub-id>
</citation>
</ref>
<ref id="B209">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ortgies</surname>
<given-names>D. H.</given-names>
</name>
<name>
<surname>de la Cueva</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Del Rosal</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Sanz-Rodriguez</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Fernandez</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Iglesias-de la Cruz</surname>
<given-names>M. C.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>
<italic>In vivo</italic> deep tissue fluorescence and magnetic imaging employing hybrid nanostructures</article-title>. <source>ACS Appl. Mater Interfaces</source> <volume>8</volume> (<issue>2</issue>), <fpage>1406</fpage>&#x2013;<lpage>1414</lpage>. <pub-id pub-id-type="doi">10.1021/acsami.5b10617</pub-id>
</citation>
</ref>
<ref id="B210">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ovejero</surname>
<given-names>J. G.</given-names>
</name>
<name>
<surname>Armenia</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Serantes</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Veintemillas-Verdaguer</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zeballos</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Lopez-Gallego</surname>
<given-names>F.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Selective magnetic nanoheating: Combining iron oxide nanoparticles for multi-hot-spot induction and sequential regulation</article-title>. <source>Nano Lett.</source> <volume>21</volume> (<issue>17</issue>), <fpage>7213</fpage>&#x2013;<lpage>7220</lpage>. <pub-id pub-id-type="doi">10.1021/acs.nanolett.1c02178</pub-id>
</citation>
</ref>
<ref id="B211">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ovejero</surname>
<given-names>J. G.</given-names>
</name>
<name>
<surname>Spizzo</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Morales</surname>
<given-names>M. P.</given-names>
</name>
<name>
<surname>Del Bianco</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Mixing iron oxide nanoparticles with different shape and size for tunable magneto-heating performance</article-title>. <source>Nanoscale</source> <volume>13</volume> (<issue>11</issue>), <fpage>5714</fpage>&#x2013;<lpage>5729</lpage>. <pub-id pub-id-type="doi">10.1039/d0nr09121a</pub-id>
</citation>
</ref>
<ref id="B212">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Padzik</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hendiger</surname>
<given-names>E. B.</given-names>
</name>
<name>
<surname>Chomicz</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Grodzik</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Szmidt</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Grobelny</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Tannic acid-modified silver nanoparticles as a novel therapeutic agent against Acanthamoeba</article-title>. <source>Parasitol. Res.</source> <volume>117</volume> (<issue>11</issue>), <fpage>3519</fpage>&#x2013;<lpage>3525</lpage>. <pub-id pub-id-type="doi">10.1007/s00436-018-6049-6</pub-id>
</citation>
</ref>
<ref id="B213">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pallares</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Nunez</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Sanchez-Garcia</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Falgas</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Serna</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Unzueta</surname>
<given-names>U.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Antineoplastic effect of a diphtheria toxin-based nanoparticle targeting acute myeloid leukemia cells overexpressing CXCR4</article-title>. <source>J. Control Release</source> <volume>335</volume>, <fpage>117</fpage>&#x2013;<lpage>129</lpage>. <pub-id pub-id-type="doi">10.1016/j.jconrel.2021.05.014</pub-id>
</citation>
</ref>
<ref id="B214">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pallares</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Unzueta</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Falgas</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sanchez-Garcia</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Serna</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Gallardo</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>An Auristatin nanoconjugate targeting CXCR4&#x2b; leukemic cells blocks acute myeloid leukemia dissemination</article-title>. <source>J. Hematol. Oncol.</source> <volume>13</volume> (<issue>1</issue>), <fpage>36</fpage>. <pub-id pub-id-type="doi">10.1186/s13045-020-00863-9</pub-id>
</citation>
</ref>
<ref id="B215">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pardo</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Pelaz</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Gallo</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ba&#xf1;obre-L&#xf3;pez</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Parak</surname>
<given-names>W. J.</given-names>
</name>
<name>
<surname>Barbosa</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Synthesis, characterization, and evaluation of superparamagnetic doped ferrites as potential therapeutic nanotools</article-title>. <source>Chem. Mater.</source> <volume>32</volume> (<issue>6</issue>), <fpage>2220</fpage>&#x2013;<lpage>2231</lpage>. <pub-id pub-id-type="doi">10.1021/acs.chemmater.9b04848</pub-id>
</citation>
</ref>
<ref id="B216">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Paris</surname>
<given-names>J. L.</given-names>
</name>
<name>
<surname>Villaverde</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Gomez-Grana</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Vallet-Regi</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Nanoparticles for multimodal antivascular therapeutics: Dual drug release, photothermal and photodynamic therapy</article-title>. <source>Acta Biomater.</source> <volume>101</volume>, <fpage>459</fpage>&#x2013;<lpage>468</lpage>. <pub-id pub-id-type="doi">10.1016/j.actbio.2019.11.004</pub-id>
</citation>
</ref>
<ref id="B217">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pastor</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Basas</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Vairo</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Gainza</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Moreno-Sastre</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gomis</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Safety and effectiveness of sodium colistimethate-loaded nanostructured lipid carriers (SCM-NLC) against <italic>P. aeruginosa</italic>: <italic>In vitro</italic> and <italic>in vivo</italic> studies following pulmonary and intramuscular administration</article-title>. <source>Nanomedicine</source> <volume>18</volume>, <fpage>101</fpage>&#x2013;<lpage>111</lpage>. <pub-id pub-id-type="doi">10.1016/j.nano.2019.02.014</pub-id>
</citation>
</ref>
<ref id="B218">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Paterson</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>S. A.</given-names>
</name>
<name>
<surname>Wark</surname>
<given-names>A. W.</given-names>
</name>
<name>
<surname>de la RicaGold</surname>
<given-names>R. S.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Gold suprashells: Enhanced photothermal nanoheaters with multiple localized surface plasmon resonances for broadband surface-enhanced Raman scattering</article-title>. <source>J. Phys. Chem. C</source> <volume>121</volume> (<issue>13</issue>), <fpage>7404</fpage>&#x2013;<lpage>7411</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jpcc.6b12792</pub-id>
</citation>
</ref>
<ref id="B219">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Paul</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Sharma</surname>
<given-names>C. P.</given-names>
</name>
</person-group> (<year>2020</year>). &#x201c;<article-title>13 - inorganic nanoparticles for targeted drug delivery</article-title>,&#x201d; in <source>Biointegration of medical implant materials</source>. Editor <person-group person-group-type="editor">
<name>
<surname>Sharma</surname>
<given-names>C. P.</given-names>
</name>
</person-group> <edition>Second Edition</edition> (<publisher-name>Woodhead Publishing</publisher-name>), <fpage>333</fpage>&#x2013;<lpage>373</lpage>.</citation>
</ref>
<ref id="B220">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pelaez</surname>
<given-names>E. C.</given-names>
</name>
<name>
<surname>Estevez</surname>
<given-names>M. C.</given-names>
</name>
<name>
<surname>Portela</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Salvador</surname>
<given-names>J. P.</given-names>
</name>
<name>
<surname>Marco</surname>
<given-names>M. P.</given-names>
</name>
<name>
<surname>Lechuga</surname>
<given-names>L. M.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Nanoplasmonic biosensor device for the monitoring of acenocoumarol therapeutic drug in plasma</article-title>. <source>Biosens. Bioelectron.</source> <volume>119</volume>, <fpage>149</fpage>&#x2013;<lpage>155</lpage>. <pub-id pub-id-type="doi">10.1016/j.bios.2018.08.011</pub-id>
</citation>
</ref>
<ref id="B221">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pellico</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Fernandez-Barahona</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Ruiz-Cabello</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Gutierrez</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Munoz-Hernando</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sanchez-Guisado</surname>
<given-names>M. J.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>HAP-multitag, a PET and positive MRI contrast nanotracer for the longitudinal characterization of vascular calcifications in atherosclerosis</article-title>. <source>ACS Appl. Mater Interfaces</source> <volume>13</volume> (<issue>38</issue>), <fpage>45279</fpage>&#x2013;<lpage>45290</lpage>. <pub-id pub-id-type="doi">10.1021/acsami.1c13417</pub-id>
</citation>
</ref>
<ref id="B222">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pena-Gonzalez</surname>
<given-names>C. E.</given-names>
</name>
<name>
<surname>Pedziwiatr-Werbicka</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Shcharbin</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Guerrero-Beltran</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Abashkin</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Loznikova</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Gold nanoparticles stabilized by cationic carbosilane dendrons: Synthesis and biological properties</article-title>. <source>Dalton Trans.</source> <volume>46</volume> (<issue>27</issue>), <fpage>8736</fpage>&#x2013;<lpage>8745</lpage>. <pub-id pub-id-type="doi">10.1039/c6dt03791g</pub-id>
</citation>
</ref>
<ref id="B223">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Perez-Hernandez</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Moros</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Stepien</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Del Pino</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Menao</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>de Las Heras</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Multiparametric analysis of anti-proliferative and apoptotic effects of gold nanoprisms on mouse and human primary and transformed cells, biodistribution and toxicity <italic>in vivo</italic>
</article-title>. <source>Part Fibre Toxicol.</source> <volume>14</volume> (<issue>1</issue>), <fpage>41</fpage>. <pub-id pub-id-type="doi">10.1186/s12989-017-0222-4</pub-id>
</citation>
</ref>
<ref id="B224">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Perez-Tanoira</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Fernandez-Arias</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Potel</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Carballo-Fernandez</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Perez-Castro</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Boutinguiza</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Silver nanoparticles produced by laser ablation and Re-irradiation are effective preventing peri-implantitis multispecies biofilm formation</article-title>. <source>Int. J. Mol. Sci.</source> <volume>23</volume> (<issue>19</issue>), <fpage>12027</fpage>. <pub-id pub-id-type="doi">10.3390/ijms231912027</pub-id>
</citation>
</ref>
<ref id="B225">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Plaza-Ga</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Manzaneda-Gonzalez</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Kisovec</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Almendro-Vedia</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Munoz-Ubeda</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Anderluh</surname>
<given-names>G.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>pH-triggered endosomal escape of pore-forming Listeriolysin O toxin-coated gold nanoparticles</article-title>. <source>J. Nanobiotechnology</source> <volume>17</volume> (<issue>1</issue>), <fpage>108</fpage>. <pub-id pub-id-type="doi">10.1186/s12951-019-0543-6</pub-id>
</citation>
</ref>
<ref id="B226">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Polo</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>del Pino</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Pardo</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Taboada</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Pelaz</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2018</year>). &#x201c;<article-title>Magnetic nanoparticles for cancer therapy and bioimaging</article-title>,&#x201d; in <source>Nanooncology: Engineering nanomaterials for cancer therapy and diagnosis</source>. Editors <person-group person-group-type="editor">
<name>
<surname>Gon&#xe7;alves</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Tobias</surname>
<given-names>G.</given-names>
</name>
</person-group> (<publisher-loc>Cham</publisher-loc>: <publisher-name>Springer International Publishing</publisher-name>), <fpage>239</fpage>&#x2013;<lpage>279</lpage>.</citation>
</ref>
<ref id="B227">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Portela</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Calvo-Lozano</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Estevez</surname>
<given-names>M. C.</given-names>
</name>
<name>
<surname>Medina Escuela</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lechuga</surname>
<given-names>L. M.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Optical nanogap antennas as plasmonic biosensors for the detection of miRNA biomarkers</article-title>. <source>J. Mater Chem. B</source> <volume>8</volume> (<issue>19</issue>), <fpage>4310</fpage>&#x2013;<lpage>4317</lpage>. <pub-id pub-id-type="doi">10.1039/d0tb00307g</pub-id>
</citation>
</ref>
<ref id="B228">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Poyatos-Racionero</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Gonzalez-Alvarez</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Sanchez-Moreno</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Sitia</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Gatto</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Pompa</surname>
<given-names>P. P.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Lactose-Gated mesoporous silica particles for intestinal controlled delivery of essential oil components: An <italic>in vitro</italic> and <italic>in vivo</italic> study</article-title>. <source>Pharmaceutics</source> <volume>13</volume> (<issue>7</issue>), <fpage>982</fpage>. <pub-id pub-id-type="doi">10.3390/pharmaceutics13070982</pub-id>
</citation>
</ref>
<ref id="B229">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Prajapati</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Garcia-Garrido</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Somoza</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Albumin-based nanoparticles for the delivery of doxorubicin in breast cancer</article-title>. <source>Cancers (Basel)</source> <volume>13</volume> (<issue>12</issue>), <fpage>3011</fpage>. <pub-id pub-id-type="doi">10.3390/cancers13123011</pub-id>
</citation>
</ref>
<ref id="B230">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Prajapati</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Somoza</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Albumin nanostructures for nucleic acid delivery in cancer: Current trend, emerging issues, and possible solutions</article-title>. <source>Cancers (Basel).</source> <volume>13</volume> (<issue>14</issue>), <fpage>3454</fpage>. <pub-id pub-id-type="doi">10.3390/cancers13143454</pub-id>
</citation>
</ref>
<ref id="B231">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qaiser</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kiani</surname>
<given-names>M. H.</given-names>
</name>
<name>
<surname>Parveen</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Sarfraz</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Shahnaz</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Rahdar</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Design and synthesis of multifunctional polymeric micelles for targeted delivery in <italic>Helicobacter pylori</italic> infection</article-title>. <source>J. Mol. Liq.</source> <volume>363</volume>, <fpage>119802</fpage>. <pub-id pub-id-type="doi">10.1016/j.molliq.2022.119802</pub-id>
</citation>
</ref>
<ref id="B232">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Quintanilla</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Garcia</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>de Lazaro</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Garcia-Alvarez</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Henriksen-Lacey</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Vranic</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Thermal monitoring during photothermia: Hybrid probes for simultaneous plasmonic heating and near-infrared optical nanothermometry</article-title>. <source>Theranostics</source> <volume>9</volume> (<issue>24</issue>), <fpage>7298</fpage>&#x2013;<lpage>7312</lpage>. <pub-id pub-id-type="doi">10.7150/thno.38091</pub-id>
</citation>
</ref>
<ref id="B233">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ramirez-Jimenez</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Artiga</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mitchell</surname>
<given-names>S. G.</given-names>
</name>
<name>
<surname>Martin-Rapun</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>de la Fuente</surname>
<given-names>J. M.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Surfactant-free synthesis and scalable purification of triangular gold nanoprisms with low non-specific cellular uptake</article-title>. <source>Nanomater. (Basel)</source> <volume>10</volume> (<issue>3</issue>), <fpage>539</fpage>. <pub-id pub-id-type="doi">10.3390/nano10030539</pub-id>
</citation>
</ref>
<ref id="B234">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ramos-Docampo</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Fernandez-Medina</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Taipaleenmaki</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Hovorka</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Salgueirino</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Stadler</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Microswimmers with heat delivery capacity for 3D cell spheroid penetration</article-title>. <source>ACS Nano</source> <volume>13</volume> (<issue>10</issue>), <fpage>12192</fpage>&#x2013;<lpage>12205</lpage>. <pub-id pub-id-type="doi">10.1021/acsnano.9b06869</pub-id>
</citation>
</ref>
<ref id="B235">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reboredo</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Gonzalez-Navarro</surname>
<given-names>C. J.</given-names>
</name>
<name>
<surname>Martinez-Oharriz</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Martinez-Lopez</surname>
<given-names>A. L.</given-names>
</name>
<name>
<surname>Irache</surname>
<given-names>J. M.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Preparation and evaluation of PEG-coated zein nanoparticles for oral drug delivery purposes</article-title>. <source>Int. J. Pharm.</source> <volume>597</volume>, <fpage>120287</fpage>. <pub-id pub-id-type="doi">10.1016/j.ijpharm.2021.120287</pub-id>
</citation>
</ref>
<ref id="B236">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Redolfi Riva</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Pastoriza-Santos</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Lak</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Pellegrino</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Perez-Juste</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Mattoli</surname>
<given-names>V.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Plasmonic/magnetic nanocomposites: Gold nanorods-functionalized silica coated magnetic nanoparticles</article-title>. <source>J. Colloid Interface Sci.</source> <volume>502</volume>, <fpage>201</fpage>&#x2013;<lpage>209</lpage>. <pub-id pub-id-type="doi">10.1016/j.jcis.2017.04.089</pub-id>
</citation>
</ref>
<ref id="B237">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reidy</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Haase</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Luch</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Dawson</surname>
<given-names>K. A.</given-names>
</name>
<name>
<surname>Lynch</surname>
<given-names>I.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Mechanisms of silver nanoparticle release, transformation and toxicity: A critical review of current knowledge and recommendations for future studies and applications</article-title>. <source>Mater. (Basel)</source> <volume>6</volume> (<issue>6</issue>), <fpage>2295</fpage>&#x2013;<lpage>2350</lpage>. <pub-id pub-id-type="doi">10.3390/ma6062295</pub-id>
</citation>
</ref>
<ref id="B238">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Relano-Rodriguez</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Espinar-Buitrago</surname>
<given-names>M. S.</given-names>
</name>
<name>
<surname>Martin-Canadilla</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Gomez-Ramirez</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Jimenez</surname>
<given-names>J. L.</given-names>
</name>
<name>
<surname>Munoz-Fernandez</surname>
<given-names>M. A.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Nanotechnology against human cytomegalovirus <italic>in vitro</italic>: Polyanionic carbosilane dendrimers as antiviral agents</article-title>. <source>J. Nanobiotechnology</source> <volume>19</volume> (<issue>1</issue>), <fpage>65</fpage>. <pub-id pub-id-type="doi">10.1186/s12951-021-00809-4</pub-id>
</citation>
</ref>
<ref id="B239">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rincon-Iglesias</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Rodrigo</surname>
<given-names>I. L. B. B.</given-names>
</name>
<name>
<surname>Serea</surname>
<given-names>E. S. A.</given-names>
</name>
<name>
<surname>Plazaola</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Lanceros-Mendez</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Core-shell Fe(3)O(4)@Au nanorod-loaded gels for tunable and anisotropic magneto- and photothermia</article-title>. <source>ACS Appl. Mater Interfaces</source> <volume>14</volume> (<issue>5</issue>), <fpage>7130</fpage>&#x2013;<lpage>7140</lpage>. <pub-id pub-id-type="doi">10.1021/acsami.1c20990</pub-id>
</citation>
</ref>
<ref id="B240">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ritz</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Schottler</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kotman</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Baier</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Musyanovych</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kuharev</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>Protein corona of nanoparticles: Distinct proteins regulate the cellular uptake</article-title>. <source>Biomacromolecules</source> <volume>16</volume> (<issue>4</issue>), <fpage>1311</fpage>&#x2013;<lpage>1321</lpage>. <pub-id pub-id-type="doi">10.1021/acs.biomac.5b00108</pub-id>
</citation>
</ref>
<ref id="B241">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roca</surname>
<given-names>A. G.</given-names>
</name>
<name>
<surname>Gutierrez</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Gavilan</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Fortes Brollo</surname>
<given-names>M. E.</given-names>
</name>
<name>
<surname>Veintemillas-Verdaguer</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Morales</surname>
<given-names>M. D. P.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Design strategies for shape-controlled magnetic iron oxide nanoparticles</article-title>. <source>Adv. Drug Deliv. Rev.</source> <volume>138</volume>, <fpage>68</fpage>&#x2013;<lpage>104</lpage>. <pub-id pub-id-type="doi">10.1016/j.addr.2018.12.008</pub-id>
</citation>
</ref>
<ref id="B242">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rocha</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Rodriguez</surname>
<given-names>E. M.</given-names>
</name>
<name>
<surname>Vanetsev</surname>
<given-names>A. S.</given-names>
</name>
<name>
<surname>Rahn</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sammelselg</surname>
<given-names>V.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Subtissue imaging and thermal monitoring of gold nanorods through joined encapsulation with Nd-doped infrared-emitting nanoparticles</article-title>. <source>Small</source> <volume>12</volume> (<issue>39</issue>), <fpage>5394</fpage>&#x2013;<lpage>5400</lpage>. <pub-id pub-id-type="doi">10.1002/smll.201600866</pub-id>
</citation>
</ref>
<ref id="B243">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rodriguez</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Ramos-Soriano</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Perkins</surname>
<given-names>J. R.</given-names>
</name>
<name>
<surname>Mascaraque</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Torres</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Gomez</surname>
<given-names>F.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Glycosylated nanostructures in sublingual immunotherapy induce long-lasting tolerance in LTP allergy mouse model</article-title>. <source>Sci. Rep.</source> <volume>9</volume> (<issue>1</issue>), <fpage>4043</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-019-40114-7</pub-id>
</citation>
</ref>
<ref id="B244">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rojas-Prats</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Tosat-Bitrian</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Martinez-Gonzalez</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Nozal</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Perez</surname>
<given-names>D. I.</given-names>
</name>
<name>
<surname>Martinez</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Increasing brain permeability of PHA-767491, a cell division cycle 7 kinase inhibitor, with biodegradable polymeric nanoparticles</article-title>. <source>Pharmaceutics</source> <volume>13</volume> (<issue>2</issue>), <fpage>180</fpage>. <pub-id pub-id-type="doi">10.3390/pharmaceutics13020180</pub-id>
</citation>
</ref>
<ref id="B245">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Romero</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Moya</surname>
<given-names>S. E.</given-names>
</name>
</person-group> (<year>2012</year>). &#x201c;<article-title>Chapter 4 - synthesis of organic nanoparticles</article-title>,&#x201d; in <source>Frontiers of nanoscience</source>. Editors <person-group person-group-type="editor">
<name>
<surname>de la Fuente</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Grazu</surname>
<given-names>V.</given-names>
</name>
</person-group> (<publisher-name>Elsevier</publisher-name>), <volume>4</volume>, <fpage>115</fpage>&#x2013;<lpage>141</lpage>.</citation>
</ref>
<ref id="B246">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rubia-Rodriguez</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Santana-Otero</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Spassov</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Tombacz</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Johansson</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>De La Presa</surname>
<given-names>P.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Whither magnetic hyperthermia?</article-title> <source>A Tentat. Roadmap. Mater. (Basel)</source> <volume>14</volume> (<issue>4</issue>), <fpage>706</fpage>. <pub-id pub-id-type="doi">10.3390/ma14040706</pub-id>
</citation>
</ref>
<ref id="B247">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rubia-Rodriguez</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Zilberti</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Arduino</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bottauscio</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Chiampi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ortega</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>
<italic>In silico</italic> assessment of collateral eddy current heating in biocompatible implants subjected to magnetic hyperthermia treatments</article-title>. <source>Int. J. Hyperth.</source> <volume>38</volume> (<issue>1</issue>), <fpage>846</fpage>&#x2013;<lpage>861</lpage>. <pub-id pub-id-type="doi">10.1080/02656736.2021.1909758</pub-id>
</citation>
</ref>
<ref id="B248">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rubio-Canalejas</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Baelo</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Herbera</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Blanco-Cabra</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Vukomanovic</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Torrents</surname>
<given-names>E.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>3D spatial organization and improved antibiotic treatment of a Pseudomonas aeruginosa-Staphylococcus aureus wound biofilm by nanoparticle enzyme delivery</article-title>. <source>Front. Microbiol.</source> <volume>13</volume>, <fpage>959156</fpage>. <pub-id pub-id-type="doi">10.3389/fmicb.2022.959156</pub-id>
</citation>
</ref>
<ref id="B249">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sabio</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Sosa</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Delgado-Lopez</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Dominguez-Vera</surname>
<given-names>J. M.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Two-sided antibacterial cellulose combining probiotics and silver nanoparticles</article-title>. <source>Molecules</source> <volume>26</volume> (<issue>10</issue>), <fpage>2848</fpage>. <pub-id pub-id-type="doi">10.3390/molecules26102848</pub-id>
</citation>
</ref>
<ref id="B250">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saha</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Agasti</surname>
<given-names>S. S.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Rotello</surname>
<given-names>V. M.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Gold nanoparticles in chemical and biological sensing</article-title>. <source>Chem. Rev.</source> <volume>112</volume> (<issue>5</issue>), <fpage>2739</fpage>&#x2013;<lpage>2779</lpage>. <pub-id pub-id-type="doi">10.1021/cr2001178</pub-id>
</citation>
</ref>
<ref id="B251">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Samaridou</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Walgrave</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Salta</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Alvarez</surname>
<given-names>D. M.</given-names>
</name>
<name>
<surname>Castro-Lopez</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Loza</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Nose-to-brain delivery of enveloped RNA - cell permeating peptide nanocomplexes for the treatment of neurodegenerative diseases</article-title>. <source>Biomaterials</source> <volume>230</volume>, <fpage>119657</fpage>. <pub-id pub-id-type="doi">10.1016/j.biomaterials.2019.119657</pub-id>
</citation>
</ref>
<ref id="B252">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sanchez-Arribas</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Diaz-Nunez</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Osio Barcina</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Aicart</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Junquera</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Guerrero-Martinez</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Controlled pDNA release in gemini cationic lipoplexes by femtosecond laser irradiation of gold nanostars</article-title>. <source>Nanomater. (Basel)</source> <volume>11</volume> (<issue>6</issue>), <fpage>1498</fpage>. <pub-id pub-id-type="doi">10.3390/nano11061498</pub-id>
</citation>
</ref>
<ref id="B253">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sanchez-Arribas</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Martinez-Negro</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Villar</surname>
<given-names>E. M.</given-names>
</name>
<name>
<surname>Perez</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Aicart</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Taboada</surname>
<given-names>P.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Biocompatible nanovector of siRNA consisting of arginine-based cationic lipid for gene knockdown in cancer cells</article-title>. <source>ACS Appl. Mater Interfaces</source> <volume>12</volume> (<issue>31</issue>), <fpage>34536</fpage>&#x2013;<lpage>34547</lpage>. <pub-id pub-id-type="doi">10.1021/acsami.0c06273</pub-id>
</citation>
</ref>
<ref id="B254">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sanchez-Arribas</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Martinez-Negro</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Villar</surname>
<given-names>E. M.</given-names>
</name>
<name>
<surname>Perez</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Osio Barcina</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Aicart</surname>
<given-names>E.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Protein expression knockdown in cancer cells induced by a gemini cationic lipid nanovector with histidine-based polar heads</article-title>. <source>Pharmaceutics</source> <volume>12</volume> (<issue>9</issue>), <fpage>791</fpage>. <pub-id pub-id-type="doi">10.3390/pharmaceutics12090791</pub-id>
</citation>
</ref>
<ref id="B255">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sanchez-Garcia</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Sala</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Serna</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Alamo</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Parlade</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Alba-Castellon</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>A refined cocktailing of pro-apoptotic nanoparticles boosts anti-tumor activity</article-title>. <source>Acta Biomater.</source> <volume>113</volume>, <fpage>584</fpage>&#x2013;<lpage>596</lpage>. <pub-id pub-id-type="doi">10.1016/j.actbio.2020.06.033</pub-id>
</citation>
</ref>
<ref id="B256">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sanchez-Garcia</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Serna</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Alamo</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Sala</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Cespedes</surname>
<given-names>M. V.</given-names>
</name>
<name>
<surname>Roldan</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Self-assembling toxin-based nanoparticles as self-delivered antitumoral drugs</article-title>. <source>J. Control Release</source> <volume>274</volume>, <fpage>81</fpage>&#x2013;<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1016/j.jconrel.2018.01.031</pub-id>
</citation>
</ref>
<ref id="B257">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sanchez-Lopez</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Gomara</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Haro</surname>
<given-names>I.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Nanotechnology-based platforms for vaginal delivery of peptide microbicides</article-title>. <source>Curr. Med. Chem.</source> <volume>28</volume> (<issue>22</issue>), <fpage>4356</fpage>&#x2013;<lpage>4379</lpage>. <pub-id pub-id-type="doi">10.2174/0929867328666201209095753</pub-id>
</citation>
</ref>
<ref id="B258">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sans-Serramitjana</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Jorba</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Fuste</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Pedraz</surname>
<given-names>J. L.</given-names>
</name>
<name>
<surname>Vinuesa</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Vinas</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Free and nanoencapsulated tobramycin: Effects on planktonic and biofilm forms of Pseudomonas</article-title>. <source>Microorganisms</source> <volume>5</volume> (<issue>3</issue>), <fpage>35</fpage>. <pub-id pub-id-type="doi">10.3390/microorganisms5030035</pub-id>
</citation>
</ref>
<ref id="B259">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sans-Serramitjana</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Jorba</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pedraz</surname>
<given-names>J. L.</given-names>
</name>
<name>
<surname>Vinuesa</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Vinas</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Determination of the spatiotemporal dependence of &#x3c;em&#x26;gt;<italic>Pseudomonas aeruginosa</italic>&#x26;lt;/em&#x26;gt; biofilm viability after treatment with NLC-colistin</article-title>. <source>Int. J. Nanomedicine</source> <volume>12</volume>, <fpage>4409</fpage>&#x2013;<lpage>4413</lpage>. <pub-id pub-id-type="doi">10.2147/ijn.s138763</pub-id>
</citation>
</ref>
<ref id="B260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Santalices</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Vazquez-Vazquez</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Santander-Ortega</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Lozano</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Araujo</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Sarmento</surname>
<given-names>B.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>A nanoemulsion/micelles mixed nanosystem for the oral administration of hydrophobically modified insulin</article-title>. <source>Drug Deliv. Transl. Res.</source> <volume>11</volume> (<issue>2</issue>), <fpage>524</fpage>&#x2013;<lpage>545</lpage>. <pub-id pub-id-type="doi">10.1007/s13346-021-00920-x</pub-id>
</citation>
</ref>
<ref id="B261">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Santos</surname>
<given-names>H. D. A.</given-names>
</name>
<name>
<surname>Zabala Gutierrez</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Lifante</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ximendes</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Laurenti</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Ultrafast photochemistry produces superbright short-wave infrared dots for low-dose <italic>in vivo</italic> imaging</article-title>. <source>Nat. Commun.</source> <volume>11</volume> (<issue>1</issue>), <fpage>2933</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-020-16333-2</pub-id>
</citation>
</ref>
<ref id="B262">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sanz</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Calatayud</surname>
<given-names>M. P.</given-names>
</name>
<name>
<surname>Torres</surname>
<given-names>T. E.</given-names>
</name>
<name>
<surname>Fanarraga</surname>
<given-names>M. L.</given-names>
</name>
<name>
<surname>Ibarra</surname>
<given-names>M. R.</given-names>
</name>
<name>
<surname>Goya</surname>
<given-names>G. F.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Magnetic hyperthermia enhances cell toxicity with respect to exogenous heating</article-title>. <source>Biomaterials</source> <volume>114</volume>, <fpage>62</fpage>&#x2013;<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1016/j.biomaterials.2016.11.008</pub-id>
</citation>
</ref>
<ref id="B263">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sanz-Ortega</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Portilla</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Perez-Yague</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Barber</surname>
<given-names>D. F.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Magnetic targeting of adoptively transferred tumour-specific nanoparticle-loaded CD8(&#x2b;) T cells does not improve their tumour infiltration in a mouse model of cancer but promotes the retention of these cells in tumour-draining lymph nodes</article-title>. <source>J. Nanobiotechnology</source> <volume>17</volume> (<issue>1</issue>), <fpage>87</fpage>. <pub-id pub-id-type="doi">10.1186/s12951-019-0520-0</pub-id>
</citation>
</ref>
<ref id="B264">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sanz-Ortega</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Rojas</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Marcos</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Portilla</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Stein</surname>
<given-names>J. V.</given-names>
</name>
<name>
<surname>Barber</surname>
<given-names>D. F.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>T cells loaded with magnetic nanoparticles are retained in peripheral lymph nodes by the application of a magnetic field</article-title>. <source>J. Nanobiotechnology</source> <volume>17</volume> (<issue>1</issue>), <fpage>14</fpage>. <pub-id pub-id-type="doi">10.1186/s12951-019-0440-z</pub-id>
</citation>
</ref>
<ref id="B265">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sanz-Ortega</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Rojas</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Portilla</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Perez-Yague</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Barber</surname>
<given-names>D. F.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Magnetic nanoparticles attached to the NK cell surface for tumor targeting in adoptive transfer therapies does not affect cellular effector functions</article-title>. <source>Front. Immunol.</source> <volume>10</volume>, <fpage>2073</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2019.02073</pub-id>
</citation>
</ref>
<ref id="B266">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sapareto</surname>
<given-names>S. A.</given-names>
</name>
<name>
<surname>Dewey</surname>
<given-names>W. C.</given-names>
</name>
</person-group> (<year>1984</year>). <article-title>Thermal dose determination in cancer therapy</article-title>. <source>Int. J. Radiat. Oncol. Biol. Phys.</source> <volume>10</volume> (<issue>6</issue>), <fpage>787</fpage>&#x2013;<lpage>800</lpage>. <pub-id pub-id-type="doi">10.1016/0360-3016(84)90379-1</pub-id>
</citation>
</ref>
<ref id="B267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saravani</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Sargazi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Saravani</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Rabbani</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Rahdar</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Taboada</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Newly crocin-coated magnetite nanoparticles induce apoptosis and decrease VEGF expression in breast carcinoma cells</article-title>. <source>J. Drug Deliv. Sci. Technol.</source> <volume>60</volume>, <fpage>101987</fpage>. <pub-id pub-id-type="doi">10.1016/j.jddst.2020.101987</pub-id>
</citation>
</ref>
<ref id="B268">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sartaj</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Qamar</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Qizilbash</surname>
<given-names>F. F.</given-names>
</name>
<name>
<surname>Annu</surname>
<given-names>Md S.</given-names>
</name>
<name>
<surname>Alhakamy</surname>
<given-names>N. A.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Polymeric nanoparticles: Exploring the current drug development and therapeutic insight of breast cancer treatment and recommendations</article-title>. <source>Polym. (Basel)</source> <volume>13</volume> (<issue>24</issue>), <fpage>4400</fpage>. <pub-id pub-id-type="doi">10.3390/polym13244400</pub-id>
</citation>
</ref>
<ref id="B269">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sayed</surname>
<given-names>F. N.</given-names>
</name>
<name>
<surname>Polshettiwar</surname>
<given-names>V.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Facile and sustainable synthesis of shaped iron oxide nanoparticles: Effect of iron precursor salts on the shapes of iron oxides</article-title>. <source>Sci. Rep.</source> <volume>5</volume>, <fpage>9733</fpage>. <pub-id pub-id-type="doi">10.1038/srep09733</pub-id>
</citation>
</ref>
<ref id="B270">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Serrano-Sevilla</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Artiga</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mitchell</surname>
<given-names>S. G.</given-names>
</name>
<name>
<surname>De Matteis</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>de la Fuente</surname>
<given-names>J. M.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Natural polysaccharides for siRNA delivery: Nanocarriers based on chitosan, hyaluronic acid, and their derivatives</article-title>. <source>Molecules</source> <volume>24</volume> (<issue>14</issue>), <fpage>2570</fpage>. <pub-id pub-id-type="doi">10.3390/molecules24142570</pub-id>
</citation>
</ref>
<ref id="B271">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sharma</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Jeevanandam</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Synthesis of self-assembled prismatic iron oxide nanoparticles by a novel thermal decomposition route</article-title>. <source>RSC Adv.</source> <volume>3</volume> (<issue>1</issue>), <fpage>189</fpage>&#x2013;<lpage>200</lpage>. <pub-id pub-id-type="doi">10.1039/c2ra22004k</pub-id>
</citation>
</ref>
<ref id="B272">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shi</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>W.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Effects of polyethylene glycol on the surface of nanoparticles for targeted drug delivery</article-title>. <source>Nanoscale</source> <volume>13</volume> (<issue>24</issue>), <fpage>10748</fpage>&#x2013;<lpage>10764</lpage>. <pub-id pub-id-type="doi">10.1039/d1nr02065j</pub-id>
</citation>
</ref>
<ref id="B273">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shokrani</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Shokrani</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sajadi</surname>
<given-names>S. M.</given-names>
</name>
<name>
<surname>Khodadadi Yazdi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Seidi</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Jouyandeh</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Polysaccharide-based nanocomposites for biomedical applications: A critical review</article-title>. <source>Nanoscale Horiz.</source> <volume>7</volume>, <fpage>1136</fpage>&#x2013;<lpage>1160</lpage>. <pub-id pub-id-type="doi">10.1039/d2nh00214k</pub-id>
</citation>
</ref>
<ref id="B274">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Silvan</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Zorraquin-Pena</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Gonzalez de Llano</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Moreno-Arribas</surname>
<given-names>M. V.</given-names>
</name>
<name>
<surname>Martinez-Rodriguez</surname>
<given-names>A. J.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Antibacterial activity of glutathione-stabilized silver nanoparticles against Campylobacter multidrug-resistant strains</article-title>. <source>Front. Microbiol.</source> <volume>9</volume>, <fpage>458</fpage>. <pub-id pub-id-type="doi">10.3389/fmicb.2018.00458</pub-id>
</citation>
</ref>
<ref id="B275">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Simeonidis</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Morales</surname>
<given-names>M. P.</given-names>
</name>
<name>
<surname>Marciello</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Angelakeris</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>de la Presa</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Lazaro-Carrillo</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>
<italic>In-situ</italic> particles reorientation during magnetic hyperthermia application: Shape matters twice</article-title>. <source>Sci. Rep.</source> <volume>6</volume>, <fpage>38382</fpage>. <pub-id pub-id-type="doi">10.1038/srep38382</pub-id>
</citation>
</ref>
<ref id="B276">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Soenen</surname>
<given-names>S. J.</given-names>
</name>
<name>
<surname>Parak</surname>
<given-names>W. J.</given-names>
</name>
<name>
<surname>Rejman</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Manshian</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>(Intra)cellular stability of inorganic nanoparticles: Effects on cytotoxicity, particle functionality, and biomedical applications</article-title>. <source>Chem. Rev.</source> <volume>115</volume> (<issue>5</issue>), <fpage>2109</fpage>&#x2013;<lpage>2135</lpage>. <pub-id pub-id-type="doi">10.1021/cr400714j</pub-id>
</citation>
</ref>
<ref id="B277">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Soler-Agesta</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Guerrero-Ochoa</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Marco-Brualla</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ibanez-Perez</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Marzo</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Martinez-Lostao</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Conjugation of the 9-kDa isoform of granulysin with liposomes potentiates its cytotoxicity</article-title>. <source>Int. J. Mol. Sci.</source> <volume>23</volume> (<issue>15</issue>), <fpage>8705</fpage>. <pub-id pub-id-type="doi">10.3390/ijms23158705</pub-id>
</citation>
</ref>
<ref id="B278">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Soprano</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Alvarez</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Pelaz</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Del Pino</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Polo</surname>
<given-names>E.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Plasmonic cell-derived nanocomposites for light-controlled cargo release inside living cells</article-title>. <source>Adv. Biosyst.</source> <volume>4</volume> (<issue>3</issue>), <fpage>e1900260</fpage>. <pub-id pub-id-type="doi">10.1002/adbi.201900260</pub-id>
</citation>
</ref>
<ref id="B279">
<citation citation-type="book">
<collab>Spanish Scientific Network HiperNano</collab> (<year>2018</year>). <source>Spanish scientific Network HiperNano (RED2018-102626-T)</source>.</citation>
</ref>
<ref id="B280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sperling</surname>
<given-names>R. A.</given-names>
</name>
<name>
<surname>Rivera Gil</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Zanella</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Parak</surname>
<given-names>W. J.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Biological applications of gold nanoparticles</article-title>. <source>Chem. Soc. Rev.</source> <volume>37</volume> (<issue>9</issue>), <fpage>1896</fpage>&#x2013;<lpage>1908</lpage>. <pub-id pub-id-type="doi">10.1039/b712170a</pub-id>
</citation>
</ref>
<ref id="B281">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Spilde</surname>
<given-names>M. N.</given-names>
</name>
<name>
<surname>Northup</surname>
<given-names>D. E.</given-names>
</name>
<name>
<surname>Boston</surname>
<given-names>P. J.</given-names>
</name>
<name>
<surname>Schelble</surname>
<given-names>R. T.</given-names>
</name>
<name>
<surname>Dano</surname>
<given-names>K. E.</given-names>
</name>
<name>
<surname>Crossey</surname>
<given-names>L. J.</given-names>
</name>
<etal/>
</person-group> (<year>2005</year>). <article-title>Geomicrobiology of cave ferromanganese deposits: A field and laboratory investigation</article-title>. <source>Geomicrobiol. J.</source> <volume>22</volume> (<issue>3-4</issue>), <fpage>99</fpage>&#x2013;<lpage>116</lpage>. <pub-id pub-id-type="doi">10.1080/01490450590945889</pub-id>
</citation>
</ref>
<ref id="B282">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Staka</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Cadete</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Surikutchi</surname>
<given-names>B. T.</given-names>
</name>
<name>
<surname>Abuzaid</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Bradshaw</surname>
<given-names>T. D.</given-names>
</name>
<name>
<surname>Alonso</surname>
<given-names>M. J.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>A novel low molecular weight nanocomposite hydrogel formulation for intra-tumoural delivery of anti-cancer drugs</article-title>. <source>Int. J. Pharm.</source> <volume>565</volume>, <fpage>151</fpage>&#x2013;<lpage>161</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijpharm.2019.04.070</pub-id>
</citation>
</ref>
<ref id="B283">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stepien</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Moros</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Perez-Hernandez</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Monge</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gutierrez</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Fratila</surname>
<given-names>R. M.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Effect of surface chemistry and associated protein corona on the long-term biodegradation of iron oxide nanoparticles <italic>in vivo</italic>
</article-title>. <source>ACS Appl. Mater Interfaces</source> <volume>10</volume> (<issue>5</issue>), <fpage>4548</fpage>&#x2013;<lpage>4560</lpage>. <pub-id pub-id-type="doi">10.1021/acsami.7b18648</pub-id>
</citation>
</ref>
<ref id="B284">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Storozhylova</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Crecente-Campo</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Cabaleiro</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Lugo</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Dussouy</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Sim&#xf5;es</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>An <italic>in situ</italic> hyaluronic acid-fibrin hydrogel containing drug-loaded nanocapsules for intra-articular treatment of inflammatory joint diseases</article-title>. <source>Regen. Eng. Transl. Med.</source> <volume>6</volume> (<issue>2</issue>), <fpage>201</fpage>&#x2013;<lpage>216</lpage>. <pub-id pub-id-type="doi">10.1007/s40883-020-00154-2</pub-id>
</citation>
</ref>
<ref id="B285">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sune-Pou</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Prieto-Sanchez</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>El Yousfi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Boyero-Corral</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Nardi-Ricart</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Nofrerias-Roig</surname>
<given-names>I.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Cholesteryl oleate-loaded cationic solid lipid nanoparticles as carriers for efficient gene-silencing therapy</article-title>. <source>Int. J. Nanomedicine</source> <volume>13</volume>, <fpage>3223</fpage>&#x2013;<lpage>3233</lpage>. <pub-id pub-id-type="doi">10.2147/ijn.s158884</pub-id>
</citation>
</ref>
<ref id="B326">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carregal-Romero</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Groult</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ca&#x00F1;adas</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>A-Gonzalez</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>LechugaVieco</surname>
<given-names>A. V.</given-names>
</name>
<name>
<surname>Garc&#x00ED;a-Fojeda</surname>
<given-names>B.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Delayed alveolar clearance of nanoparticles through control of coating composition and interaction with lung surfactant protein A</article-title>. <source>Materials Science and Engineering: C</source> <volume>134</volume>, <fpage>112551</fpage>. <pub-id pub-id-type="doi">10.1016/j.msec.2021.112551</pub-id>
</citation>
</ref>
<ref id="B286">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Teijeiro-Valino</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Novoa-Carballal</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Borrajo</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Vidal</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Alonso-Nocelo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>de la Fuente Freire</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>A multifunctional drug nanocarrier for efficient anticancer therapy</article-title>. <source>J. Control Release</source> <volume>294</volume>, <fpage>154</fpage>&#x2013;<lpage>164</lpage>. <pub-id pub-id-type="doi">10.1016/j.jconrel.2018.12.002</pub-id>
</citation>
</ref>
<ref id="B287">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tenchov</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Bird</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Curtze</surname>
<given-names>A. E.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Q.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Lipid nanoparticles-from liposomes to mRNA vaccine delivery, a landscape of research diversity and advancement</article-title>. <source>ACS Nano</source> <volume>15</volume>, <fpage>16982</fpage>&#x2013;<lpage>17015</lpage>. <pub-id pub-id-type="doi">10.1021/acsnano.1c04996</pub-id>
</citation>
</ref>
<ref id="B288">
<citation citation-type="web">
<person-group person-group-type="author">
<name>
<surname>Therapeutics</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>BO-112 with pembrolizumab in unresectable malignant melanoma (SPOTLIGHT203) clinicaltrials.gov2020</article-title>. <comment>Available from: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04570332">https://clinicaltrials.gov/ct2/show/NCT04570332</ext-link>.</comment>
</citation>
</ref>
<ref id="B289">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Therapeutics</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2016</year>). <source>Exploratory study of BO-112 in adult patients with aggressive solid tumors clinicaltrials gov</source>. <comment>[Available from: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02828098">https://clinicaltrials.gov/ct2/show/NCT02828098</ext-link>.</comment>
</citation>
</ref>
<ref id="B290">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thompson</surname>
<given-names>S. A.</given-names>
</name>
<name>
<surname>Paterson</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Azab</surname>
<given-names>M. M.</given-names>
</name>
<name>
<surname>Wark</surname>
<given-names>A. W.</given-names>
</name>
<name>
<surname>de la Rica</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Light-triggered inactivation of enzymes with photothermal nanoheaters</article-title>. <source>Small</source> <volume>13</volume> (<issue>15</issue>), <fpage>1603195</fpage>. <pub-id pub-id-type="doi">10.1002/smll.201603195</pub-id>
</citation>
</ref>
<ref id="B291">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thwala</surname>
<given-names>L. N.</given-names>
</name>
<name>
<surname>Delgado</surname>
<given-names>D. P.</given-names>
</name>
<name>
<surname>Leone</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Marigo</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Benetti</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Chenlo</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Protamine nanocapsules as carriers for oral peptide delivery</article-title>. <source>J. Control Release</source> <volume>291</volume>, <fpage>157</fpage>&#x2013;<lpage>168</lpage>. <pub-id pub-id-type="doi">10.1016/j.jconrel.2018.10.022</pub-id>
</citation>
</ref>
<ref id="B292">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tomsen-Melero</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Passemard</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Garcia-Aranda</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Diaz-Riascos</surname>
<given-names>Z. V.</given-names>
</name>
<name>
<surname>Gonzalez-Rioja</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Nedergaard Pedersen</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Impact of chemical composition on the nanostructure and biological activity of alpha-galactosidase-loaded nanovesicles for fabry disease treatment</article-title>. <source>ACS Appl. Mater Interfaces</source> <volume>13</volume> (<issue>7</issue>), <fpage>7825</fpage>&#x2013;<lpage>7838</lpage>. <pub-id pub-id-type="doi">10.1021/acsami.0c16871</pub-id>
</citation>
</ref>
<ref id="B293">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Torrecilla</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Gomez-Aguado</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Vicente-Pascual</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Del Pozo-Rodriguez</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Solinis</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Rodriguez-Gascon</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>MMP-9 downregulation with lipid nanoparticles for inhibiting corneal neovascularization by gene silencing</article-title>. <source>Nanomater. (Basel)</source> <volume>9</volume> (<issue>4</issue>), <fpage>631</fpage>. <pub-id pub-id-type="doi">10.3390/nano9040631</pub-id>
</citation>
</ref>
<ref id="B294">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tortiglione</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>de la Fuente</surname>
<given-names>J. M.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Synthesis of gold nanoparticles for gene silencing</article-title>. <source>Methods Mol. Biol.</source> <volume>1974</volume>, <fpage>203</fpage>&#x2013;<lpage>214</lpage>. <pub-id pub-id-type="doi">10.1007/978-1-4939-9220-1_15</pub-id>
</citation>
</ref>
<ref id="B295">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Trabulo</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Aires</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Aicher</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Heeschen</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Cortajarena</surname>
<given-names>A. L.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Multifunctionalized iron oxide nanoparticles for selective targeting of pancreatic cancer cells</article-title>. <source>Biochim. Biophys. Acta Gen. Subj.</source> <volume>1861</volume> (<issue>6</issue>), <fpage>1597</fpage>&#x2013;<lpage>1605</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbagen.2017.01.035</pub-id>
</citation>
</ref>
<ref id="B296">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vairo</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Basas</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Pastor</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Palau</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gomis</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Almirante</surname>
<given-names>B.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>
<italic>In vitro</italic> and <italic>in vivo</italic> antimicrobial activity of sodium colistimethate and amikacin-loaded nanostructured lipid carriers (NLC)</article-title>. <source>Nanomedicine</source> <volume>29</volume>, <fpage>102259</fpage>. <pub-id pub-id-type="doi">10.1016/j.nano.2020.102259</pub-id>
</citation>
</ref>
<ref id="B297">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vallet-Regi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Colilla</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Izquierdo-Barba</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Manzano</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Mesoporous silica nanoparticles for drug delivery: Current insights</article-title>. <source>Molecules</source> <volume>23</volume> (<issue>1</issue>), <fpage>47</fpage>. <pub-id pub-id-type="doi">10.3390/molecules23010047</pub-id>
</citation>
</ref>
<ref id="B298">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vallet-Regi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gonzalez</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Izquierdo-Barba</surname>
<given-names>I.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Nanomaterials as promising alternative in the infection treatment</article-title>. <source>Int. J. Mol. Sci.</source> <volume>20</volume> (<issue>15</issue>), <fpage>3806</fpage>. <pub-id pub-id-type="doi">10.3390/ijms20153806</pub-id>
</citation>
</ref>
<ref id="B299">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vallet-Regi</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Our contributions to applications of mesoporous silica nanoparticles</article-title>. <source>Acta Biomater.</source> <volume>137</volume>, <fpage>44</fpage>&#x2013;<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1016/j.actbio.2021.10.011</pub-id>
</citation>
</ref>
<ref id="B300">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vallet-Regi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>R&#xe1;mila</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>del Real</surname>
<given-names>R. P.</given-names>
</name>
<name>
<surname>P&#xe9;rez-Pariente</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2001</year>). <article-title>A new property of MCM-41: Drug delivery system</article-title>. <source>Chem. Mater.</source> <volume>13</volume> (<issue>2</issue>), <fpage>308</fpage>&#x2013;<lpage>311</lpage>. <pub-id pub-id-type="doi">10.1021/cm0011559</pub-id>
</citation>
</ref>
<ref id="B301">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vallet-Regi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Schuth</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Lozano</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Colilla</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Manzano</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Engineering mesoporous silica nanoparticles for drug delivery: Where are we after two decades?</article-title> <source>Chem. Soc. Rev.</source> <volume>51</volume> (<issue>13</issue>), <fpage>5365</fpage>&#x2013;<lpage>5451</lpage>. <pub-id pub-id-type="doi">10.1039/d1cs00659b</pub-id>
</citation>
</ref>
<ref id="B302">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Varela-Fernandez</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Garcia-Otero</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Diaz-Tome</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Regueiro</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Lopez-Lopez</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gonzalez-Barcia</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Lactoferrin-loaded nanostructured lipid carriers (NLCs) as a new formulation for optimized ocular drug delivery</article-title>. <source>Eur. J. Pharm. Biopharm.</source> <volume>172</volume>, <fpage>144</fpage>&#x2013;<lpage>156</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejpb.2022.02.010</pub-id>
</citation>
</ref>
<ref id="B303">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vargas-Nadal</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Munoz-Ubeda</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Alamo</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Mitjans</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Cespedes</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Kober</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>MKC-quatsomes: A stable nanovesicle platform for bio-imaging and drug-delivery applications</article-title>. <source>Nanomedicine</source> <volume>24</volume>, <fpage>102136</fpage>. <pub-id pub-id-type="doi">10.1016/j.nano.2019.102136</pub-id>
</citation>
</ref>
<ref id="B304">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vicente-Pascual</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gomez-Aguado</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Rodriguez-Castejon</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Rodriguez-Gascon</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Muntoni</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Battaglia</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Topical administration of SLN-based gene therapy for the treatment of corneal inflammation by de novo IL-10 production</article-title>. <source>Pharmaceutics</source> <volume>12</volume> (<issue>6</issue>), <fpage>584</fpage>. <pub-id pub-id-type="doi">10.3390/pharmaceutics12060584</pub-id>
</citation>
</ref>
<ref id="B305">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vilaboa</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Bore</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Martin-Saavedra</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Bayford</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Winfield</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Firth-Clark</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>New inhibitor targeting human transcription factor HSF1: Effects on the heat shock response and tumor cell survival</article-title>. <source>Nucleic Acids Res.</source> <volume>45</volume> (<issue>10</issue>), <fpage>5797</fpage>&#x2013;<lpage>5817</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkx194</pub-id>
</citation>
</ref>
<ref id="B306">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Villar-Alvarez</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Cambon</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Pardo</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Arellano</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Marcos</surname>
<given-names>A. V.</given-names>
</name>
<name>
<surname>Pelaz</surname>
<given-names>B.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Combination of light-driven co-delivery of chemodrugs and plasmonic-induced heat for cancer therapeutics using hybrid protein nanocapsules</article-title>. <source>J. Nanobiotechnology</source> <volume>17</volume> (<issue>1</issue>), <fpage>106</fpage>. <pub-id pub-id-type="doi">10.1186/s12951-019-0538-3</pub-id>
</citation>
</ref>
<ref id="B307">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Villar-Alvarez</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Cambon</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Pardo</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mosquera</surname>
<given-names>V. X.</given-names>
</name>
<name>
<surname>Bouzas-Mosquera</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Topete</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Gold nanorod-based nanohybrids for combinatorial therapeutics</article-title>. <source>ACS Omega</source> <volume>3</volume> (<issue>10</issue>), <fpage>12633</fpage>&#x2013;<lpage>12647</lpage>. <pub-id pub-id-type="doi">10.1021/acsomega.8b01591</pub-id>
</citation>
</ref>
<ref id="B308">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Villaverde</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>G&#xf3;mez-Gra&#xf1;a</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Guisasola</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Garc&#xed;a</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Hanske</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Liz-Marz&#xe1;n</surname>
<given-names>L. M.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Targeted chemo-photothermal therapy: A nanomedicine approximation to selective melanoma treatment</article-title>. <source>Part. Part. Syst. Charact.</source> <volume>35</volume> (<issue>7</issue>), <fpage>1800148</fpage>. <pub-id pub-id-type="doi">10.1002/ppsc.201800148</pub-id>
</citation>
</ref>
<ref id="B309">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Villegas</surname>
<given-names>M. R.</given-names>
</name>
<name>
<surname>Baeza</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Vallet-Regi</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Nanotechnological strategies for protein delivery</article-title>. <source>Molecules</source> <volume>23</volume> (<issue>5</issue>), <fpage>1008</fpage>. <pub-id pub-id-type="doi">10.3390/molecules23051008</pub-id>
</citation>
</ref>
<ref id="B310">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vinuesa</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Herraez</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Oliver</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Elizondo</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Acarregui</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Esquisabel</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Benznidazole nanoformulates: A chance to improve therapeutics for Chagas disease</article-title>. <source>Am. J. Trop. Med. Hyg.</source> <volume>97</volume> (<issue>5</issue>), <fpage>1469</fpage>&#x2013;<lpage>1476</lpage>. <pub-id pub-id-type="doi">10.4269/ajtmh.17-0044</pub-id>
</citation>
</ref>
<ref id="B311">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vivo-Llorca</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Morella-Aucejo</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Garcia-Fernandez</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Diez</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Llopis-Lorente</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Orzaez</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Horseradish peroxidase-functionalized gold nanoconjugates for breast cancer treatment based on enzyme prodrug therapy</article-title>. <source>Int. J. Nanomedicine</source> <volume>17</volume>, <fpage>409</fpage>&#x2013;<lpage>422</lpage>. <pub-id pub-id-type="doi">10.2147/ijn.s323802</pub-id>
</citation>
</ref>
<ref id="B312">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Volta-Duran</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Serna</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Sanchez-Garcia</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Avino</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sanchez</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Lopez-Laguna</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Design and engineering of tumor-targeted, dual-acting cytotoxic nanoparticles</article-title>. <source>Acta Biomater.</source> <volume>119</volume>, <fpage>312</fpage>&#x2013;<lpage>322</lpage>. <pub-id pub-id-type="doi">10.1016/j.actbio.2020.11.018</pub-id>
</citation>
</ref>
<ref id="B313">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wolfram</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ferrari</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Clinical cancer nanomedicine</article-title>. <source>Nano Today</source> <volume>25</volume>, <fpage>85</fpage>&#x2013;<lpage>98</lpage>. <pub-id pub-id-type="doi">10.1016/j.nantod.2019.02.005</pub-id>
</citation>
</ref>
<ref id="B314">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ximendes</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Marin</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ruiz</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Gomez-Cerezo</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Rodriguez-Sevilla</surname>
<given-names>P.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Infrared-emitting multimodal nanostructures for controlled <italic>in vivo</italic> magnetic hyperthermia</article-title>. <source>Adv. Mater</source> <volume>33</volume> (<issue>30</issue>), <fpage>e2100077</fpage>. <pub-id pub-id-type="doi">10.1002/adma.202100077</pub-id>
</citation>
</ref>
<ref id="B315">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ximendes</surname>
<given-names>E. C.</given-names>
</name>
<name>
<surname>Rocha</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Sales</surname>
<given-names>T. O.</given-names>
</name>
<name>
<surname>Fern&#xe1;ndez</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Sanz-Rodr&#xed;guez</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Mart&#xed;n</surname>
<given-names>I. R.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>
<italic>In vivo</italic> subcutaneous thermal video recording by supersensitive infrared nanothermometers</article-title>. <source>Adv. Funct. Mater.</source> <volume>27</volume> (<issue>38</issue>), <fpage>1702249</fpage>. <pub-id pub-id-type="doi">10.1002/adfm.201702249</pub-id>
</citation>
</ref>
<ref id="B316">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xuan</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mestre</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Sanchez</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Noncontinuous super-diffusive dynamics of a light-activated nanobottle motor</article-title>. <source>Angew. Chem. Int. Ed. Engl.</source> <volume>57</volume> (<issue>23</issue>), <fpage>6954</fpage>&#x2013;<lpage>6958</lpage>. <pub-id pub-id-type="doi">10.1002/ange.201801910</pub-id>
</citation>
</ref>
<ref id="B317">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zamora-Perez</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Pelaz</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Tsoutsi</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Soliman</surname>
<given-names>M. G.</given-names>
</name>
<name>
<surname>Parak</surname>
<given-names>W. J.</given-names>
</name>
<name>
<surname>Rivera-Gil</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Hyperspectral-enhanced dark field analysis of individual and collective photo-responsive gold-copper sulfide nanoparticles</article-title>. <source>Nanoscale</source> <volume>13</volume> (<issue>31</issue>), <fpage>13256</fpage>&#x2013;<lpage>13272</lpage>. <pub-id pub-id-type="doi">10.1039/d0nr08256b</pub-id>
</citation>
</ref>
<ref id="B318">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>S. M.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Controlled phase and tunable magnetism in ordered iron oxide nanotube arrays prepared by atomic layer deposition</article-title>. <source>Sci. Rep.</source> <volume>6</volume>, <fpage>18401</fpage>. <pub-id pub-id-type="doi">10.1038/srep18401</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>